MeSH term
Frequency | Condition_Probility | *Cleavage Stage, Ovum | 3 | 2.0 |
Embryo Transfer/*standards | 3 | 2.0 |
Female | 5869 | 6.0 |
Humans | 14250 | 6.0 |
Meta-Analysis | 4 | 2.0 |
Pregnancy | 317 | 5.0 |
Pregnancy Outcome | 32 | 11.0 |
Pregnancy Rate | 3 | 2.0 |
Pregnancy, Multiple | 4 | 2.0 |
Randomized Controlled Trials | 57 | 13.0 |
Review Literature | 4 | 3.0 |
Acute Disease | 153 | 6.0 |
Adult | 5729 | 10.0 |
Bone Marrow Transplantation/*statistics & numerical data | 6 | 6.0 |
Comparative Study | 1588 | 5.0 |
Cord Blood Stem Cell Transplantation/*statistics & numerical data | 6 | 7.0 |
Fetal Blood/transplantation | 6 | 7.0 |
Leukemia/*therapy | 8 | 6.0 |
Patient Selection | 23 | 11.0 |
Animals | 2318 | 3.0 |
*Computational Biology | 2 | 3.0 |
Oligonucleotide Array Sequence Analysis | 7 | 0.0 |
Follow-Up Studies | 637 | 18.0 |
France | 25 | 8.0 |
*Neoplasms | 2 | 11.0 |
Population Surveillance | 32 | 19.0 |
Seasons | 7 | 5.0 |
United States/epidemiology | 68 | 18.0 |
*Evidence-Based Medicine | 3 | 17.0 |
Quality Control | 31 | 15.0 |
Norway | 2 | 1.0 |
Blood Glucose/metabolism | 5 | 0.0 |
*Exercise | 4 | 2.0 |
Incidence | 252 | 20.0 |
Male | 6361 | 7.0 |
Middle Aged | 3899 | 8.0 |
Reference Values | 203 | 4.0 |
Risk Factors | 671 | 11.0 |
Smoking/adverse effects | 16 | 5.0 |
*Smoking Cessation | 3 | 7.0 |
Weight Loss | 26 | 18.0 |
Albumins/metabolism | 5 | 3.0 |
Albuminuria/*prevention & control | 4 | 4.0 |
Antihypertensive Agents/*therapeutic use | 4 | 1.0 |
Diabetes Mellitus, Type 2/complications/*drug therapy | 4 | 4.0 |
Hypertension/complications/*drug therapy | 4 | 3.0 |
Indoles/*therapeutic use | 5 | 3.0 |
Renin-Angiotensin System/*drug effects | 4 | 3.0 |
Aged | 1701 | 5.0 |
Cardiac Output, Low/*mortality | 4 | 7.0 |
Coronary Arteriosclerosis/mortality | 4 | 7.0 |
Risk | 43 | 4.0 |
Surgical Procedures, Elective/*mortality | 4 | 7.0 |
Time Factors | 842 | 8.0 |
Amino Acid Sequence | 787 | 3.0 |
Binding Sites | 207 | 2.0 |
Crystallization | 13 | 5.0 |
Crystallography, X-Ray | 17 | 2.0 |
Glycosylation | 70 | 7.0 |
Ligands | 118 | 4.0 |
Models, Biological | 118 | 3.0 |
Models, Molecular | 117 | 4.0 |
Molecular Sequence Data | 1115 | 3.0 |
Polysaccharides/analysis | 2 | 25.0 |
Protein Binding | 207 | 2.0 |
Protein Structure, Quaternary/drug effects | 3 | 30.0 |
Receptors, Virus/chemistry/metabolism | 2 | 50.0 |
Research Support, Non-U.S. Gov't | 7412 | 5.0 |
Research Support, U.S. Gov't, P.H.S. | 3739 | 6.0 |
Viral Envelope Proteins/*chemistry/metabolism | 2 | 66.0 |
Virion/chemistry/metabolism | 2 | 40.0 |
Disease Outbreaks | 9 | 15.0 |
Housing | 2 | 15.0 |
Maryland/epidemiology | 3 | 23.0 |
Aged, 80 and over | 358 | 3.0 |
Fatal Outcome | 79 | 13.0 |
Tomography, X-Ray Computed | 61 | 8.0 |
Antineoplastic Agents/*pharmacology/therapeutic use | 4 | 4.0 |
DNA Adducts | 3 | 4.0 |
DNA Damage | 13 | 1.0 |
DNA Repair | 3 | 0.0 |
Drug Delivery Systems | 5 | 5.0 |
Drug Resistance, Neoplasm | 5 | 0.0 |
Gene Expression | 177 | 2.0 |
Neoplasms/drug therapy/genetics | 3 | 9.0 |
Platinum Compounds/*pharmacology/therapeutic use | 3 | 11.0 |
Biopsy | 220 | 13.0 |
*Gene Expression | 20 | 1.0 |
*Lymphocytes, Tumor-Infiltrating | 4 | 25.0 |
Anxiety Disorders/*classification/psychology/therapy | 4 | 44.0 |
Child | 908 | 6.0 |
Alleles | 68 | 0.0 |
Pharmacogenetics | 3 | 2.0 |
Variation (Genetics) | 64 | 3.0 |
Mutation | 194 | 2.0 |
Peptides/*pharmacology | 4 | 1.0 |
Adolescent | 1391 | 7.0 |
Anti-Retroviral Agents/*therapeutic use | 9 | 64.0 |
Antiretroviral Therapy, Highly Active/*utilization | 4 | 100.0 |
Child, Preschool | 662 | 7.0 |
Infant | 563 | 9.0 |
Jamaica | 2 | 9.0 |
Prospective Studies | 848 | 20.0 |
Severity of Illness Index | 130 | 10.0 |
*Treatment Outcome | 3 | 12.0 |
Antiretroviral Therapy, Highly Active | 258 | 85.0 |
Cohort Studies | 791 | 30.0 |
*Databases, Factual | 3 | 5.0 |
Retrospective Studies | 623 | 17.0 |
Carcinoma, Hepatocellular/etiology/*metabolism/pathology | 2 | 18.0 |
Liver Neoplasms/etiology/*metabolism/pathology | 2 | 18.0 |
Proto-Oncogene Proteins c-myc/*metabolism | 2 | 2.0 |
Tumor Markers, Biological/*metabolism | 2 | 0.0 |
*Disease Transmission, Vertical | 69 | 69.0 |
Lung/radiography | 7 | 26.0 |
Phylogeny | 51 | 3.0 |
Reverse Transcriptase Polymerase Chain Reaction | 127 | 1.0 |
CD4-Positive T-Lymphocytes/immunology | 577 | 68.0 |
CD8-Positive T-Lymphocytes/immunology | 295 | 61.0 |
Case-Control Studies | 334 | 6.0 |
Cell Polarity | 7 | 5.0 |
Cells, Cultured | 1107 | 6.0 |
Cytokines/*immunology | 18 | 19.0 |
Diabetes Mellitus, Type 1/*immunology | 15 | 21.0 |
Flow Cytometry | 1217 | 18.0 |
Lymphocyte Activation | 833 | 26.0 |
Mitogens/pharmacology | 54 | 20.0 |
Statistics, Nonparametric | 114 | 11.0 |
T-Lymphocytes/*immunology | 616 | 27.0 |
HIV Infections/*complications | 238 | 87.0 |
Plasmapheresis | 3 | 8.0 |
Platelet Count | 24 | 5.0 |
Prognosis | 487 | 7.0 |
Survival Analysis | 309 | 14.0 |
Treatment Outcome | 596 | 17.0 |
AIDS Vaccines/administration & dosage/adverse effects/*therapeutic use | 2 | 100.0 |
Acquired Immunodeficiency Syndrome/*immunology/*therapy | 6 | 100.0 |
Administration, Oral | 90 | 9.0 |
Appetite | 2 | 25.0 |
Body Weight | 40 | 6.0 |
CD4 Lymphocyte Count | 2171 | 94.0 |
RNA, Viral/blood | 451 | 88.0 |
Thailand | 30 | 20.0 |
Vaccination | 59 | 35.0 |
Viral Load | 843 | 87.0 |
Viremia | 41 | 87.0 |
Aging/*immunology/*physiology | 2 | 100.0 |
Bicycling/physiology | 2 | 18.0 |
CD4-Positive T-Lymphocytes/*immunology | 537 | 69.0 |
Cross-Sectional Studies | 256 | 21.0 |
*Immunocompetence | 7 | 46.0 |
Interleukin-2/biosynthesis | 127 | 29.0 |
Lymphocyte Subsets | 119 | 61.0 |
Physical Endurance/*immunology | 2 | 50.0 |
Running/physiology | 5 | 31.0 |
Bone Marrow Cells/pathology | 2 | 3.0 |
Clone Cells | 218 | 20.0 |
Fusion Proteins, bcr-abl/*genetics | 2 | 2.0 |
Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 18 | 54.0 |
Immunophenotyping | 688 | 23.0 |
RNA, Messenger/analysis | 112 | 3.0 |
Receptors, Antigen, T-Cell, gamma-delta/*analysis | 21 | 52.0 |
Antibodies, Viral/blood | 54 | 47.0 |
*HIV Infections | 13 | 76.0 |
*HIV Seropositivity | 24 | 80.0 |
Influenza/*prevention & control | 3 | 75.0 |
Italy | 28 | 4.0 |
*Vaccination | 19 | 35.0 |
Antigens, CD/*analysis | 119 | 15.0 |
B-Lymphocytes/*immunology | 90 | 10.0 |
CD8-Positive T-Lymphocytes/*immunology | 182 | 56.0 |
Cell Communication | 29 | 10.0 |
Chlamydia Infections/*immunology | 5 | 41.0 |
Dendritic Cells | 5 | 33.0 |
Immunocompetence | 22 | 52.0 |
Phenotype | 561 | 6.0 |
Cell Division | 209 | 4.0 |
Epithelial Cells/physiology | 3 | 4.0 |
HLA-DR Antigens/analysis | 183 | 28.0 |
Hepatitis C/blood/*complications | 3 | 60.0 |
Immunoenzyme Techniques | 183 | 5.0 |
Ki-67 Antigen/analysis | 10 | 3.0 |
Lymphocyte Count | 434 | 63.0 |
Proliferating Cell Nuclear Antigen/analysis | 3 | 1.0 |
S100 Proteins/analysis | 8 | 4.0 |
Acquired Immunodeficiency Syndrome/*blood | 24 | 58.0 |
Antigens, CD4/*blood | 27 | 61.0 |
CD4-Positive T-Lymphocytes/*cytology | 37 | 82.0 |
Flow Cytometry/methods | 70 | 27.0 |
HIV Seropositivity/*blood | 20 | 71.0 |
CD4-Positive T-Lymphocytes/cytology | 53 | 77.0 |
CD8-Positive T-Lymphocytes/cytology | 35 | 89.0 |
International Cooperation | 7 | 8.0 |
Reproducibility of Results | 100 | 6.0 |
Antigens, CD3/blood | 20 | 64.0 |
Antigens, CD4/blood | 38 | 63.0 |
Flow Cytometry/instrumentation/methods/standards | 2 | 100.0 |
HIV Seropositivity/blood | 15 | 65.0 |
Specimen Handling | 17 | 17.0 |
Temperature | 34 | 3.0 |
Antigens, CD4/biosynthesis | 64 | 77.0 |
Lasers | 7 | 6.0 |
Light | 12 | 5.0 |
Scattering, Radiation | 10 | 8.0 |
Antigens, CD45/*biosynthesis | 3 | 33.0 |
Antibodies, Monoclonal | 337 | 13.0 |
Flow Cytometry/*methods | 68 | 30.0 |
Immunophenotyping/*methods | 29 | 41.0 |
T-Lymphocyte Subsets/*cytology | 12 | 46.0 |
Antigens, CD4/analysis | 310 | 76.0 |
Antigens, CD8/analysis | 159 | 65.0 |
T-Lymphocytes/*cytology | 30 | 33.0 |
Chemokines, CC/metabolism | 3 | 6.0 |
DNA, Viral/blood | 69 | 85.0 |
Disease Susceptibility | 43 | 5.0 |
HIV Infections/virology | 37 | 52.0 |
HIV-1/*pathogenicity/physiology | 19 | 61.0 |
Leukocytes, Mononuclear/*virology | 24 | 70.0 |
Pan troglodytes | 20 | 16.0 |
Proviruses | 8 | 47.0 |
SIV/*pathogenicity/physiology | 3 | 100.0 |
Simian Acquired Immunodeficiency Syndrome/virology | 6 | 75.0 |
Species Specificity | 93 | 3.0 |
Virus Replication | 349 | 41.0 |
Antigens, CD3/immunology | 83 | 30.0 |
CD4-Positive T-Lymphocytes/cytology/immunology | 39 | 76.0 |
Cell Line | 1067 | 5.0 |
Chemokines, CC/biosynthesis | 2 | 12.0 |
Chemotaxis, Leukocyte/immunology | 11 | 18.0 |
Hay Fever/blood/*immunology/pathology | 2 | 100.0 |
Lung/*immunology | 14 | 33.0 |
Receptors, Chemokine/*biosynthesis/genetics | 2 | 6.0 |
Skin/*immunology | 22 | 20.0 |
Antigens, CD/analysis | 408 | 24.0 |
Antigens, CD14/analysis | 12 | 10.0 |
Antigens, CD19/analysis | 23 | 26.0 |
Antigens, CD3/analysis | 111 | 44.0 |
Antigens, CD45/analysis | 92 | 36.0 |
Arthritis, Rheumatoid/*immunology | 32 | 14.0 |
Fluorescent Antibody Technique | 235 | 9.0 |
In Vitro | 425 | 6.0 |
Interferon Type II/analysis | 26 | 28.0 |
Colposcopy | 6 | 30.0 |
Mass Screening | 7 | 3.0 |
Sensitivity and Specificity | 163 | 5.0 |
Vaginal Smears | 8 | 12.0 |
Anti-HIV Agents/*therapeutic use | 420 | 94.0 |
*Antiretroviral Therapy, Highly Active | 273 | 89.0 |
Drug Resistance/*genetics | 5 | 10.0 |
HIV Infections/*drug therapy/mortality | 26 | 92.0 |
Infant, Newborn | 295 | 6.0 |
Pilot Projects | 142 | 23.0 |
Reverse Transcriptase Inhibitors/*therapeutic use | 103 | 93.0 |
Uganda | 16 | 59.0 |
Anti-HIV Agents/*administration & dosage/pharmacology | 3 | 100.0 |
CD4-Positive T-Lymphocytes/cytology/*drug effects | 9 | 81.0 |
CD8-Positive T-Lymphocytes/cytology/*drug effects | 5 | 100.0 |
Double-Blind Method | 287 | 17.0 |
Drug Therapy, Combination | 604 | 42.0 |
HIV Infections/blood/*drug therapy/immunology | 30 | 96.0 |
Hematocrit | 17 | 4.0 |
*Viral Load | 151 | 91.0 |
Causality | 8 | 20.0 |
Confounding Factors (Epidemiology) | 8 | 12.0 |
HIV Infections/*drug therapy/immunology | 104 | 97.0 |
HIV-1/*drug effects | 74 | 54.0 |
*Models, Statistical | 28 | 45.0 |
Zidovudine/*therapeutic use | 140 | 91.0 |
Chromatin/metabolism | 2 | 0.0 |
Cross-Linking Reagents | 37 | 10.0 |
*Gene Expression Regulation | 27 | 1.0 |
Macromolecular Substances | 43 | 2.0 |
Mice | 1115 | 3.0 |
Mice, Transgenic | 153 | 5.0 |
Mutation/genetics | 13 | 1.0 |
Protein Structure, Tertiary | 76 | 1.0 |
Protein Subunits | 4 | 1.0 |
Thymus Gland/cytology/immunology/metabolism | 4 | 33.0 |
Transcription Factors/genetics/metabolism | 3 | 0.0 |
Acquired Immunodeficiency Syndrome/*complications/*drug therapy | 3 | 100.0 |
English Abstract | 978 | 8.0 |
Survival Rate | 227 | 10.0 |
*Immunotherapy | 32 | 20.0 |
Interleukin-2/*therapeutic use | 36 | 35.0 |
Life Tables | 22 | 13.0 |
*Lymphocyte Count | 37 | 77.0 |
*Lymphocyte Subsets | 67 | 77.0 |
Neoplasm Metastasis | 16 | 1.0 |
Hemophilia A/*complications | 32 | 82.0 |
*Knee Joint | 2 | 20.0 |
*Knee Prosthesis | 2 | 25.0 |
Prosthesis Failure | 6 | 11.0 |
Reoperation | 8 | 6.0 |
Treatment Failure | 77 | 28.0 |
Abortion, Habitual/*immunology | 4 | 16.0 |
Cytotoxicity, Immunologic | 212 | 22.0 |
Histocompatibility Antigens Class I/analysis | 21 | 22.0 |
Histocompatibility Antigens Class II/analysis | 27 | 13.0 |
Killer Cells, Natural/immunology | 153 | 36.0 |
Lymphocyte Subsets/immunology | 80 | 57.0 |
Blood Donors | 37 | 18.0 |
CD4-Positive T-Lymphocytes/drug effects/*immunology | 28 | 70.0 |
Cross-Over Studies | 24 | 3.0 |
Drug Administration Schedule | 179 | 21.0 |
*Immunity, Cellular | 39 | 29.0 |
Killer Cells, Natural/drug effects/immunology | 14 | 45.0 |
T-Lymphocytes, Helper-Inducer/drug effects/immunology | 2 | 20.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 39 | 8.0 |
Cyclophosphamide/*therapeutic use | 10 | 35.0 |
Doxorubicin/*therapeutic use | 6 | 25.0 |
HIV-1/physiology | 62 | 68.0 |
Prednisolone/*therapeutic use | 6 | 27.0 |
Vincristine/*therapeutic use | 4 | 50.0 |
AIDS-Related Opportunistic Infections/blood/*immunology | 4 | 80.0 |
Acquired Immunodeficiency Syndrome/*immunology | 133 | 58.0 |
Antigens, CD/blood | 57 | 24.0 |
Antigens, CD18/blood | 2 | 25.0 |
Cell Division/drug effects | 97 | 2.0 |
Cytokines/blood | 38 | 18.0 |
HIV-1 | 119 | 66.0 |
Lymphokines/blood | 2 | 3.0 |
N-Formylmethionine Leucyl-Phenylalanine/pharmacology | 9 | 3.0 |
Neutrophils/drug effects/immunology | 3 | 18.0 |
T-Lymphocytes/drug effects/*immunology/pathology | 4 | 80.0 |
CD4-Positive T-Lymphocytes/metabolism/pathology | 3 | 75.0 |
CD8-Positive T-Lymphocytes/metabolism/pathology | 2 | 66.0 |
Cell Count | 108 | 11.0 |
Membrane Glycoproteins/*metabolism | 19 | 3.0 |
Serine Endopeptidases/*metabolism | 6 | 6.0 |
Amphotericin B/therapeutic use | 12 | 75.0 |
Antifungal Agents/therapeutic use | 20 | 68.0 |
Cryptococcus neoformans/isolation & purification | 3 | 60.0 |
Fluconazole/therapeutic use | 9 | 64.0 |
Flucytosine/therapeutic use | 4 | 66.0 |
Antigens, CD4/*metabolism | 304 | 95.0 |
Disease Progression | 626 | 23.0 |
Macaca mulatta | 91 | 20.0 |
Membrane Glycoproteins/genetics/*metabolism | 5 | 3.0 |
SIV/genetics/*pathogenicity | 4 | 50.0 |
Surface Plasmon Resonance | 8 | 4.0 |
*Variation (Genetics) | 40 | 3.0 |
Viral Envelope Proteins/genetics/*metabolism | 6 | 23.0 |
Antibodies, Viral/immunology | 19 | 24.0 |
*Hematopoietic Stem Cell Transplantation | 34 | 8.0 |
Herpesvirus 3, Human/*immunology | 8 | 44.0 |
Immunoglobulin G/immunology | 36 | 10.0 |
Interferon Type II/immunology | 16 | 18.0 |
Lymphoma/immunology/therapy | 2 | 66.0 |
Proportional Hazards Models | 199 | 29.0 |
Transplantation, Autologous/immunology | 3 | 60.0 |
Tumor Necrosis Factor-alpha/immunology | 13 | 12.0 |
Vaccines, Inactivated/administration & dosage/*immunology | 2 | 100.0 |
Cell Adhesion/immunology | 14 | 8.0 |
Cell Adhesion Molecules/*metabolism | 20 | 7.0 |
L-Selectin/*metabolism | 5 | 21.0 |
Lymphocyte Subsets/immunology/*metabolism | 2 | 28.0 |
Stress, Psychological/*immunology | 7 | 77.0 |
Anti-HIV Agents/therapeutic use | 205 | 89.0 |
Hepatitis C/*complications/immunology | 3 | 75.0 |
Hepatitis C Antibodies/blood | 2 | 15.0 |
HIV Seropositivity/*complications | 64 | 95.0 |
Neoplasm Staging | 76 | 3.0 |
Registries | 20 | 8.0 |
Concanavalin A/pharmacology | 41 | 19.0 |
Dose-Response Relationship, Drug | 189 | 3.0 |
Interleukin-2/pharmacology | 111 | 20.0 |
Lectins/pharmacology | 7 | 18.0 |
Lipopolysaccharides/pharmacology | 26 | 2.0 |
*Panax | 4 | 30.0 |
Plant Lectins | 5 | 10.0 |
U937 Cells | 16 | 3.0 |
Antigen-Presenting Cells/immunology | 76 | 27.0 |
Antigens, Differentiation/metabolism | 13 | 10.0 |
Cytokines/metabolism | 49 | 11.0 |
Homeostasis | 15 | 3.0 |
Immune Tolerance | 79 | 28.0 |
*Immunoconjugates | 25 | 7.0 |
Models, Immunological | 43 | 20.0 |
Rats | 196 | 1.0 |
Receptors, Interleukin-2/*metabolism | 22 | 29.0 |
T-Lymphocytes, Suppressor-Effector/*immunology | 45 | 45.0 |
Thymus Gland/cytology/immunology | 24 | 57.0 |
Transforming Growth Factor beta/metabolism | 3 | 1.0 |
DNA, Neoplasm/genetics | 4 | 0.0 |
Diagnosis, Differential | 131 | 6.0 |
Frontal Bone/pathology | 2 | 66.0 |
Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor/genetics | 5 | 41.0 |
Killer Cells, Natural/*pathology | 11 | 37.0 |
Nose Neoplasms/*pathology | 2 | 40.0 |
Polymerase Chain Reaction | 446 | 3.0 |
Tumor Markers, Biological/analysis | 27 | 3.0 |
Area Under Curve | 24 | 5.0 |
Capsules | 7 | 16.0 |
HIV Infections/blood | 7 | 63.0 |
Tablets, Enteric-Coated | 2 | 40.0 |
Therapeutic Equivalency | 2 | 8.0 |
Adjuvants, Immunologic/*pharmacology/therapeutic use | 3 | 21.0 |
Antigens/immunology | 25 | 17.0 |
Antigens, CD80/immunology | 6 | 9.0 |
Antigens, Surface/immunology | 44 | 23.0 |
Cell Death/immunology | 7 | 21.0 |
Cell Survival/immunology | 15 | 27.0 |
Cytokines/antagonists & inhibitors | 2 | 18.0 |
DNA-Binding Proteins/immunology | 3 | 13.0 |
Interleukin-10/biosynthesis | 21 | 17.0 |
Macrophage Activation/immunology | 5 | 13.0 |
Membrane Glycoproteins/immunology | 26 | 14.0 |
*Nuclear Proteins | 27 | 1.0 |
T-Lymphocytes/immunology | 351 | 25.0 |
T-Lymphocytes, Helper-Inducer/immunology | 100 | 52.0 |
Th2 Cells/immunology | 37 | 23.0 |
CD4-CD8 Ratio | 535 | 84.0 |
Chagas Disease/*immunology | 7 | 41.0 |
Chile | 2 | 3.0 |
Chronic Disease | 201 | 11.0 |
AIDS-Related Opportunistic Infections/*drug therapy/immunology | 8 | 100.0 |
Antiviral Agents/*therapeutic use | 87 | 66.0 |
Cytomegalovirus Retinitis/*drug therapy/immunology | 4 | 100.0 |
Visual Acuity | 8 | 5.0 |
*Apoptosis | 101 | 6.0 |
CD4-Positive T-Lymphocytes/*pathology | 33 | 100.0 |
Protease Inhibitors/*therapeutic use | 12 | 48.0 |
Antigens, Bacterial/immunology | 28 | 25.0 |
Antigens, Viral | 7 | 31.0 |
*Blood Donors | 22 | 20.0 |
Cytokines/analysis | 21 | 29.0 |
Cytomegalovirus/*immunology | 15 | 23.0 |
Enterotoxins/immunology | 11 | 20.0 |
Interferon Type II/analysis/biosynthesis | 5 | 62.0 |
Tumor Necrosis Factor-alpha/analysis/biosynthesis | 5 | 25.0 |
CD4-Positive T-Lymphocytes/*immunology/metabolism | 32 | 58.0 |
HIV-1/*immunology | 315 | 63.0 |
Immunoblotting | 38 | 1.0 |
Oxidation-Reduction | 17 | 1.0 |
Succinimides/chemistry | 2 | 25.0 |
Analysis of Variance | 121 | 5.0 |
Antibodies, Viral/*isolation & purification | 3 | 60.0 |
Blood Pressure | 2 | 0.0 |
*CD4 Lymphocyte Count | 235 | 97.0 |
HIV/*immunology | 69 | 65.0 |
HIV Infections/*epidemiology | 19 | 82.0 |
*Nutritional Status | 25 | 31.0 |
Prevalence | 210 | 16.0 |
Urban Population | 19 | 18.0 |
Zambia/epidemiology | 2 | 40.0 |
Cell Differentiation | 186 | 5.0 |
Clonal Anergy | 12 | 32.0 |
Disease Models, Animal | 117 | 5.0 |
HIV Infections/*immunology | 330 | 73.0 |
Membrane Glycoproteins/physiology | 9 | 5.0 |
Simian Acquired Immunodeficiency Syndrome/immunology | 5 | 62.0 |
T-Lymphocytes, Cytotoxic/*immunology | 129 | 24.0 |
Virus Diseases/*immunology | 6 | 33.0 |
Androstadienes/pharmacology | 3 | 1.0 |
Antibodies, Monoclonal/pharmacology | 83 | 11.0 |
Antigen-Presenting Cells/*immunology | 31 | 20.0 |
B-Lymphocytes/immunology | 173 | 24.0 |
Basophils/immunology | 2 | 10.0 |
Cell Adhesion Molecules/immunology | 13 | 19.0 |
Clone Cells/immunology | 41 | 26.0 |
Egtazic Acid/pharmacology | 6 | 5.0 |
Histocompatibility Antigens Class II/*immunology | 40 | 23.0 |
Immune Tolerance/immunology | 14 | 29.0 |
Lymphocyte Activation/*immunology | 109 | 25.0 |
Lymphocyte Function-Associated Antigen-1/immunology | 5 | 17.0 |
Macrophages/immunology | 63 | 21.0 |
Mice, Inbred BALB C | 227 | 7.0 |
Organ Specificity | 18 | 1.0 |
Rats, Inbred Lew | 32 | 12.0 |
Receptors, Antigen, T-Cell/*immunology | 64 | 35.0 |
Spleen/cytology/immunology | 14 | 21.0 |
T-Lymphocyte Subsets/*immunology | 314 | 57.0 |
Tumor Cells, Cultured/immunology | 13 | 15.0 |
Antigens, CD/*immunology | 42 | 9.0 |
Hemodynamic Processes/physiology | 3 | 5.0 |
Oxygen/*metabolism | 3 | 2.0 |
Apoptosis/*drug effects | 31 | 3.0 |
Ethanol/*pharmacology | 2 | 1.0 |
HIV/*pathogenicity | 8 | 72.0 |
AIDS-Related Opportunistic Infections/epidemiology/*prevention & control | 5 | 100.0 |
*HIV-1 | 715 | 73.0 |
Poisson Distribution | 5 | 22.0 |
Poverty | 4 | 19.0 |
South Africa/epidemiology | 10 | 18.0 |
CD4-Positive T-Lymphocytes/*cytology/immunology | 18 | 78.0 |
CD8-Positive T-Lymphocytes/*cytology/immunology | 9 | 81.0 |
Major Histocompatibility Complex | 36 | 15.0 |
Receptors, Antigen, T-Cell, alpha-beta/genetics | 32 | 47.0 |
Receptors, Interleukin-2 | 25 | 21.0 |
Thymus Gland/*cytology/immunology | 13 | 65.0 |
Graft Rejection/*immunology | 26 | 33.0 |
Infusions, Intravenous | 51 | 7.0 |
Interferon Type II/administration & dosage | 3 | 21.0 |
Kidney Transplantation/immunology | 7 | 12.0 |
Monocytes/*immunology | 53 | 13.0 |
Transplantation, Homologous/immunology | 12 | 28.0 |
Arteriosclerosis/immunology | 3 | 50.0 |
Hyperplasia | 14 | 3.0 |
Temporal Arteritis/genetics/immunology/*physiopathology | 2 | 100.0 |
Tunica Intima/pathology | 2 | 7.0 |
HIV Infections/complications/*epidemiology | 3 | 75.0 |
Multivariate Analysis | 179 | 13.0 |
Socioeconomic Factors | 30 | 17.0 |
CD4-Positive T-Lymphocytes | 228 | 87.0 |
*Herpesvirus 8, Human | 5 | 41.0 |
Predictive Value of Tests | 213 | 10.0 |
Sarcoma, Kaposi/*virology | 5 | 45.0 |
CD4-Positive T-Lymphocytes/immunology/*virology | 17 | 73.0 |
CD8-Positive T-Lymphocytes/immunology/*virology | 4 | 80.0 |
Epitopes, T-Lymphocyte/immunology | 24 | 25.0 |
Phosphoproteins/*immunology | 2 | 16.0 |
Viral Matrix Proteins/*immunology | 2 | 12.0 |
Chi-Square Distribution | 58 | 8.0 |
Confidence Intervals | 53 | 15.0 |
Epithelial Cells/metabolism/*virology | 2 | 66.0 |
HIV-1/*physiology | 266 | 56.0 |
Receptors, CCR5/analysis | 16 | 32.0 |
Receptors, CXCR4/*analysis | 3 | 23.0 |
Base Sequence | 534 | 2.0 |
*Cell Adhesion Molecules | 21 | 9.0 |
HIV-1/*metabolism | 138 | 59.0 |
Lectins/genetics/*metabolism | 2 | 40.0 |
*Lectins, C-Type | 16 | 9.0 |
Receptors, Chemokine/genetics/*metabolism | 6 | 12.0 |
Receptors, Virus/genetics/*metabolism | 8 | 25.0 |
SIV/metabolism | 3 | 42.0 |
Sequence Alignment | 55 | 1.0 |
Viral Proteins/*metabolism | 6 | 9.0 |
Antibodies/immunology | 16 | 4.0 |
Antigens, CD4/metabolism | 247 | 79.0 |
Cell Membrane/virology | 9 | 56.0 |
HIV-1/*pathogenicity | 55 | 61.0 |
Monocytes/*virology | 11 | 47.0 |
Precipitin Tests | 90 | 3.0 |
AIDS-Related Opportunistic Infections/epidemiology/*microbiology | 4 | 80.0 |
Community-Acquired Infections/epidemiology/microbiology | 2 | 100.0 |
Cross Infection/epidemiology/microbiology | 2 | 100.0 |
Drug Resistance | 27 | 4.0 |
HIV Infections/drug therapy | 26 | 63.0 |
Italy/epidemiology | 36 | 16.0 |
Adjuvants, Immunologic/*therapeutic use | 28 | 35.0 |
Cytokines/biosynthesis | 101 | 19.0 |
Hepatitis B Surface Antigens/immunology | 3 | 12.0 |
Hepatitis B e Antigens/blood | 4 | 50.0 |
Hepatitis B virus/genetics/*isolation & purification | 2 | 50.0 |
T-Lymphocytes/*drug effects/immunology | 24 | 26.0 |
Thymosin/*analogs & derivatives/*therapeutic use | 2 | 100.0 |
Bone Marrow/*pathology | 9 | 6.0 |
Leukemia, B-Cell, Chronic/*pathology | 4 | 23.0 |
Remission, Spontaneous | 14 | 19.0 |
T-Lymphocytes/*pathology | 31 | 44.0 |
Giant Cells/pathology | 5 | 31.0 |
Thyroiditis, Autoimmune/*complications | 2 | 28.0 |
Anti-HIV Agents/*pharmacology | 51 | 37.0 |
HIV-1/*drug effects/physiology | 49 | 56.0 |
Macrophage Colony-Stimulating Factor/*biosynthesis | 2 | 40.0 |
Virus Replication/*drug effects | 50 | 32.0 |
Zidovudine/*pharmacology | 12 | 46.0 |
Cell Fractionation | 10 | 3.0 |
Cell Line, Transformed | 107 | 6.0 |
HLA-D Antigens/immunology/metabolism | 2 | 50.0 |
Hybridomas | 21 | 14.0 |
Immunity, Natural/genetics | 8 | 12.0 |
Leukocytes, Mononuclear/enzymology/immunology/metabolism | 2 | 66.0 |
*Lymphocyte Activation/genetics | 8 | 29.0 |
Multigene Family/immunology | 2 | 8.0 |
Recombinant Proteins/immunology/metabolism | 10 | 22.0 |
Tumor Cells, Cultured | 371 | 2.0 |
Antibodies, Monoclonal/*pharmacology/therapeutic use | 3 | 16.0 |
Antigens, CD3/pharmacology | 4 | 25.0 |
Antigens, CD4/*immunology | 279 | 89.0 |
Immunosuppressive Agents/*pharmacology/therapeutic use | 2 | 22.0 |
MAP Kinase Signaling System/immunology | 3 | 15.0 |
Mitogen-Activated Protein Kinase 3 | 5 | 0.0 |
Phosphorylation | 180 | 2.0 |
Protein-Tyrosine Kinase/*antagonists & inhibitors/metabolism | 2 | 4.0 |
Antigens, CD/metabolism | 90 | 10.0 |
Carrier Proteins/metabolism | 8 | 1.0 |
Immunohistochemistry | 483 | 3.0 |
Lymphocytes, Tumor-Infiltrating/immunology | 13 | 35.0 |
Membrane Proteins/metabolism | 29 | 5.0 |
*Proteins | 25 | 5.0 |
RNA-Binding Proteins/metabolism | 4 | 4.0 |
Serine Endopeptidases/metabolism | 4 | 3.0 |
T-Lymphocytes/*cytology/immunology | 23 | 48.0 |
Animals, Newborn | 16 | 2.0 |
Antiviral Agents/therapeutic use | 80 | 76.0 |
DNA, Viral/analysis | 139 | 43.0 |
HIV-2/*pathogenicity | 5 | 83.0 |
HIV Infections/diagnosis/*immunology | 6 | 100.0 |
*Immunocompromised Host | 30 | 66.0 |
Risk Assessment | 46 | 5.0 |
Vaccination/adverse effects | 3 | 50.0 |
Autoimmunity | 31 | 23.0 |
Enzyme-Linked Immunosorbent Assay | 283 | 7.0 |
Immunoglobulin G/*immunology | 16 | 16.0 |
Interferon Type II/blood | 28 | 23.0 |
Interleukin-4/blood | 11 | 23.0 |
Sex Factors | 100 | 6.0 |
Stroke Volume | 4 | 6.0 |
T-Lymphocyte Subsets/immunology | 206 | 55.0 |
Ventricular Function, Left/physiology | 3 | 17.0 |
B-Lymphocytes | 35 | 19.0 |
Premedication | 2 | 10.0 |
T-Lymphocytes | 68 | 27.0 |
Tumor Markers, Biological/blood | 3 | 1.0 |
AIDS-Related Opportunistic Infections/prevention & control | 17 | 85.0 |
*Acquired Immunodeficiency Syndrome | 5 | 71.0 |
Health Status | 18 | 20.0 |
*Quality of Life | 34 | 34.0 |
*Questionnaires | 7 | 20.0 |
Corticotropin/*diagnostic use | 2 | 40.0 |
HIV Infections/*blood/mortality | 3 | 100.0 |
Hydrocortisone/*blood | 14 | 9.0 |
Intensive Care Units | 6 | 10.0 |
Antibodies, Monoclonal/*immunology | 109 | 14.0 |
Carbohydrate Sequence | 17 | 5.0 |
*Epitope Mapping | 5 | 9.0 |
Glycoside Hydrolases/metabolism | 3 | 9.0 |
HIV Antibodies/*immunology | 63 | 64.0 |
HIV Envelope Protein gp120/chemistry/genetics/*immunology | 3 | 60.0 |
HIV-1/immunology | 45 | 59.0 |
Neutralization Tests | 163 | 34.0 |
Sequence Analysis, DNA | 58 | 1.0 |
AIDS Vaccines/*immunology | 16 | 53.0 |
Immunization, Secondary | 15 | 42.0 |
Interferon Type II/metabolism | 47 | 20.0 |
SAIDS Vaccines/*immunology | 3 | 60.0 |
SIV/genetics/*immunology/physiology | 3 | 75.0 |
Simian Acquired Immunodeficiency Syndrome/*prevention & control | 5 | 83.0 |
Vaccines, DNA/*immunology | 9 | 33.0 |
Vaccinia virus/genetics/*immunology | 3 | 75.0 |
CD8-Positive T-Lymphocytes/*pathology | 11 | 78.0 |
HIV Seropositivity/*complications/immunology | 15 | 93.0 |
Algorithms | 26 | 6.0 |
CD4-Positive T-Lymphocytes/metabolism | 69 | 53.0 |
CD8-Positive T-Lymphocytes/metabolism | 38 | 50.0 |
Cell Adhesion | 67 | 4.0 |
Cell Separation | 152 | 14.0 |
Dendritic Cells/*metabolism | 9 | 14.0 |
Epitopes | 91 | 10.0 |
Interferon Type II/pharmacology | 24 | 4.0 |
Leukocytes, Mononuclear/metabolism | 23 | 10.0 |
Monocytes/metabolism | 22 | 6.0 |
Peptides/*chemistry | 2 | 4.0 |
Software | 14 | 4.0 |
Administration, Inhalation | 21 | 12.0 |
Anti-Inflammatory Agents/*therapeutic use | 10 | 28.0 |
Forced Expiratory Volume/drug effects/physiology | 2 | 40.0 |
Glucocorticoids/*therapeutic use | 7 | 18.0 |
London | 7 | 29.0 |
Lung/pathology | 15 | 15.0 |
CD4-Positive T-Lymphocytes/*immunology/pathology | 16 | 64.0 |
CD8-Positive T-Lymphocytes/*immunology/pathology | 8 | 61.0 |
Clone Cells/immunology/pathology | 5 | 38.0 |
Complementarity Determining Regions/analysis | 2 | 100.0 |
Immunosuppressive Agents/pharmacology/therapeutic use | 4 | 50.0 |
Receptors, Antigen, T-Cell, alpha-beta/analysis | 22 | 46.0 |
Blood Cells | 6 | 17.0 |
CD4-Positive T-Lymphocytes/immunology/*pathology | 11 | 100.0 |
T-Lymphocyte Subsets/immunology/pathology | 13 | 61.0 |
Thymus Gland/pathology | 5 | 21.0 |
Blood Circulation | 2 | 10.0 |
*Chemotaxis, Leukocyte | 11 | 14.0 |
Immunoglobulin Variable Region | 9 | 37.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 459 | 4.0 |
T-Lymphocyte Subsets/cytology/immunology/metabolism | 6 | 50.0 |
CD4-Positive T-Lymphocytes/immunology/*metabolism | 17 | 50.0 |
Calcium/*metabolism | 21 | 3.0 |
Cytokines/*biosynthesis | 70 | 17.0 |
Receptors, Antigen, T-Cell/immunology/*physiology | 7 | 87.0 |
CD4-Positive T-Lymphocytes/cytology/drug effects/immunology | 4 | 66.0 |
Interferon Type II/*biosynthesis | 42 | 26.0 |
Interleukin-10/*biosynthesis | 6 | 9.0 |
Interleukin-12/*biosynthesis | 8 | 22.0 |
Leukocytes, Mononuclear/cytology/drug effects/immunology | 4 | 25.0 |
Tuberculin/pharmacology | 6 | 40.0 |
Acquired Immunodeficiency Syndrome/*drug therapy/immunology | 32 | 78.0 |
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use | 8 | 16.0 |
Combined Modality Therapy | 113 | 9.0 |
HIV/metabolism | 7 | 46.0 |
*Phytotherapy | 20 | 20.0 |
Romania | 3 | 17.0 |
*Immunoglobulin M | 5 | 17.0 |
Tuberculosis/*complications/immunology/pathology | 2 | 100.0 |
Hematopoietic Stem Cell Mobilization/*methods | 2 | 3.0 |
Leukemia, Myeloid, Chronic/*therapy | 2 | 14.0 |
Antigens, CD34/analysis | 15 | 2.0 |
Gestational Age | 23 | 2.0 |
Granulocyte Colony Stimulating Factor, Recombinant/pharmacology | 2 | 18.0 |
Lymphocyte Culture Test, Mixed | 104 | 16.0 |
Mice, Inbred C57BL | 209 | 5.0 |
Recombinant Proteins/pharmacology | 102 | 5.0 |
Stem Cell Factor/pharmacology | 2 | 1.0 |
T-Lymphocytes, Cytotoxic/immunology | 113 | 28.0 |
Liver/immunology/*pathology | 3 | 33.0 |
Lymphocytes/immunology/*pathology | 6 | 54.0 |
Lymphocytes/immunology/metabolism/*pathology | 2 | 100.0 |
Antigens, CD56/analysis | 13 | 19.0 |
Antineoplastic Agents/*therapeutic use | 21 | 5.0 |
CD8-Positive T-Lymphocytes | 58 | 84.0 |
Cladribine/*therapeutic use | 5 | 55.0 |
Immunosuppressive Agents/*therapeutic use | 29 | 23.0 |
Leukemia, Hairy Cell/*drug therapy/immunology | 3 | 75.0 |
Lymphocytes/*immunology | 97 | 24.0 |
Recurrence | 134 | 10.0 |
Remission Induction | 75 | 13.0 |
Anti-Asthmatic Agents/*therapeutic use | 5 | 50.0 |
Anti-Inflammatory Agents/administration & dosage/*therapeutic use | 2 | 22.0 |
Antibody Formation/drug effects | 9 | 18.0 |
Asthma/drug therapy/*immunology | 7 | 87.0 |
Epitopes/analysis | 24 | 9.0 |
Immunity, Cellular/drug effects | 22 | 36.0 |
Leukocyte Count | 693 | 44.0 |
Steroids | 7 | 29.0 |
Adenocarcinoma/*immunology | 2 | 5.0 |
Antioxidants/*administration & dosage | 2 | 12.0 |
*Dietary Supplements | 9 | 15.0 |
Immunity, Cellular | 245 | 37.0 |
Interleukin-2/*biosynthesis | 25 | 17.0 |
Th1 Cells/*immunology | 38 | 28.0 |
Graft vs Host Disease/immunology | 9 | 29.0 |
Immunization | 64 | 16.0 |
Leukocytes, Mononuclear/*transplantation | 2 | 33.0 |
Polymorphism, Genetic | 43 | 0.0 |
Postoperative Period | 22 | 7.0 |
Transplantation Chimera | 8 | 22.0 |
Transplantation, Isogeneic | 6 | 21.0 |
Anthropometry | 17 | 7.0 |
Anti-HIV Agents/*adverse effects/therapeutic use | 19 | 86.0 |
Germany/epidemiology | 9 | 8.0 |
HIV Infections/*complications/drug therapy | 45 | 95.0 |
Logistic Models | 95 | 13.0 |
Protease Inhibitors/adverse effects/therapeutic use | 3 | 75.0 |
Quality of Life | 44 | 26.0 |
ROC Curve | 7 | 3.0 |
Reverse Transcriptase Inhibitors/adverse effects/therapeutic use | 13 | 100.0 |
Stavudine/adverse effects/therapeutic use | 8 | 88.0 |
Antiretroviral Therapy, Highly Active/*methods | 30 | 96.0 |
CD4-Positive T-Lymphocytes/drug effects | 45 | 88.0 |
HIV Infections/*drug therapy/immunology/virology | 133 | 96.0 |
HIV Protease Inhibitors/*administration & dosage | 13 | 100.0 |
Reverse Transcriptase Inhibitors/*administration & dosage | 14 | 100.0 |
CD4-Positive T-Lymphocytes/drug effects/immunology | 31 | 73.0 |
CD8-Positive T-Lymphocytes/drug effects/immunology | 16 | 69.0 |
HIV Protease Inhibitors/*administration & dosage/adverse effects | 6 | 100.0 |
Indinavir/*administration & dosage/adverse effects | 2 | 100.0 |
Reverse Transcriptase Inhibitors/administration & dosage/adverse effects | 3 | 100.0 |
Ritonavir/*administration & dosage/adverse effects | 3 | 100.0 |
Anti-HIV Agents/*administration & dosage | 63 | 95.0 |
Australia/epidemiology | 16 | 25.0 |
Regression Analysis | 164 | 10.0 |
Reverse Transcriptase Inhibitors/administration & dosage | 7 | 100.0 |
Antiretroviral Therapy, Highly Active/*adverse effects | 26 | 96.0 |
HIV Infections/blood/drug therapy/*immunology | 10 | 90.0 |
Interferon Type II/blood/immunology | 2 | 66.0 |
CD4-Positive T-Lymphocytes/cytology/drug effects/*immunology | 9 | 69.0 |
Cytokines/biosynthesis/blood | 2 | 22.0 |
DNA, Viral/chemistry/genetics | 5 | 50.0 |
HIV Infections/drug therapy/*immunology/virology | 32 | 82.0 |
HIV-1/genetics/growth & development/*immunology | 5 | 100.0 |
Longitudinal Studies | 252 | 29.0 |
Interleukin-2/immunology | 22 | 20.0 |
Interleukin-4/immunology | 17 | 29.0 |
Interleukin-7/immunology | 2 | 40.0 |
Lymphocytes/cytology/immunology | 4 | 17.0 |
Lymphokines/*immunology | 3 | 9.0 |
Receptors, Antigen, T-Cell/immunology | 66 | 34.0 |
Receptors, Antigen, T-Cell, alpha-beta/*immunology | 17 | 32.0 |
Receptors, Antigen, T-Cell, gamma-delta/immunology | 12 | 54.0 |
Receptors, Interleukin-2/immunology | 25 | 39.0 |
Signal Transduction/immunology | 55 | 16.0 |
Anti-Infective Agents/therapeutic use | 23 | 62.0 |
Antineoplastic Agents/therapeutic use | 10 | 3.0 |
Clinical Trials | 75 | 8.0 |
Africa | 9 | 10.0 |
Antigens, Protozoan/*immunology | 10 | 25.0 |
CD4-Positive T-Lymphocytes/*immunology/physiology | 3 | 75.0 |
Cell Division/immunology | 64 | 22.0 |
Cytokines/biosynthesis/immunology | 6 | 33.0 |
Peptides/immunology | 26 | 19.0 |
Protozoan Proteins/*immunology | 4 | 30.0 |
Age Distribution | 41 | 13.0 |
Biopsy, Needle | 34 | 8.0 |
Disease-Free Survival | 40 | 4.0 |
HIV Seronegativity | 98 | 71.0 |
HIV Seropositivity | 99 | 75.0 |
Probability | 50 | 8.0 |
Sex Distribution | 34 | 12.0 |
Gene Frequency | 40 | 0.0 |
Genotype | 171 | 1.0 |
HIV Antibodies/analysis | 34 | 79.0 |
HIV Infections/*prevention & control | 18 | 69.0 |
Hepatitis C Antibodies/analysis | 3 | 42.0 |
Homozygote | 16 | 0.0 |
Receptors, CCR5/*genetics | 26 | 16.0 |
AIDS-Related Opportunistic Infections/*diagnosis/epidemiology | 4 | 100.0 |
Texas/epidemiology | 12 | 40.0 |
Ganciclovir/therapeutic use | 15 | 65.0 |
Virus Activation | 19 | 36.0 |
Cytomegalovirus Retinitis/*complications/drug therapy/immunology | 2 | 100.0 |
Antibodies, Blocking/pharmacology | 9 | 10.0 |
CD8-Positive T-Lymphocytes/cytology/immunology | 20 | 71.0 |
Cell Movement/immunology | 15 | 15.0 |
Chemotaxis, Leukocyte/*immunology | 5 | 10.0 |
Cytokines/pharmacology | 29 | 7.0 |
Diffusion Chambers, Culture | 2 | 8.0 |
Immunologic Memory | 114 | 38.0 |
Integrin alpha4beta1 | 8 | 9.0 |
Interphase/immunology | 17 | 36.0 |
Synovial Fluid/immunology/metabolism | 2 | 66.0 |
T-Lymphocyte Subsets/*cytology/*immunology | 3 | 50.0 |
Tumor Necrosis Factor-alpha/*physiology | 8 | 2.0 |
Umbilical Veins | 5 | 1.0 |
Antigens, CD4/biosynthesis/immunology | 4 | 100.0 |
Cell-Free System/immunology | 3 | 17.0 |
Chemokines, CC/physiology | 2 | 15.0 |
Culture Media, Conditioned/pharmacology | 3 | 1.0 |
Down-Regulation/immunology | 16 | 16.0 |
HIV-1/*immunology/isolation & purification | 21 | 77.0 |
Immune Sera/pharmacology | 9 | 9.0 |
Molecular Chaperones/physiology | 2 | 28.0 |
Solubility | 152 | 10.0 |
Tumor Necrosis Factor-alpha/physiology | 11 | 7.0 |
Adoptive Transfer | 18 | 23.0 |
Aging/genetics/immunology | 2 | 66.0 |
Antibodies, Monoclonal/biosynthesis | 2 | 7.0 |
Autoantigens/*immunology/metabolism | 5 | 83.0 |
Cell Differentiation/immunology | 53 | 16.0 |
Cyclophosphamide/administration & dosage | 34 | 15.0 |
Epitopes, T-Lymphocyte/*immunology | 11 | 18.0 |
Injections, Intraperitoneal | 7 | 4.0 |
Islets of Langerhans/*immunology | 8 | 22.0 |
Mice, Inbred NOD | 25 | 11.0 |
Mice, SCID | 78 | 10.0 |
Spleen/cytology/transplantation | 2 | 100.0 |
Transgenes/immunology | 8 | 28.0 |
Receptor-CD3 Complex, Antigen, T-Cell/*physiology | 9 | 40.0 |
Transfection | 311 | 2.0 |
Blood Transfusion/adverse effects | 15 | 40.0 |
Cytokines/immunology | 40 | 27.0 |
DNA, Viral/isolation & purification | 14 | 56.0 |
Monocytes/immunology | 50 | 13.0 |
Renal Dialysis/*adverse effects | 5 | 3.0 |
Antigens, CD/*blood/genetics | 2 | 28.0 |
RNA, Messenger/blood/genetics | 2 | 11.0 |
Antigens, CD56/*immunology | 7 | 50.0 |
In Situ Hybridization | 74 | 2.0 |
Killer Cells, Natural/*immunology | 65 | 13.0 |
Receptors, Antigen, T-Cell, gamma-delta/genetics | 7 | 28.0 |
Skin Neoplasms/genetics/*immunology/pathology | 3 | 42.0 |
Immunity, Cellular/*physiology | 11 | 57.0 |
Immunotherapy/*methods | 18 | 13.0 |
Molecular Biology | 2 | 0.0 |
HIV Infections/*drug therapy | 188 | 81.0 |
Blood-Brain Barrier | 4 | 6.0 |
Brain/*blood supply | 4 | 12.0 |
Endothelium, Vascular/*virology | 3 | 75.0 |
Membrane Microdomains/*metabolism | 3 | 6.0 |
Microcirculation | 10 | 3.0 |
Microscopy, Confocal | 26 | 2.0 |
Mitogen-Activated Protein Kinases/metabolism | 8 | 0.0 |
Signal Transduction | 165 | 2.0 |
*Down-Regulation | 41 | 13.0 |
Histocompatibility Antigens Class I/*metabolism | 17 | 17.0 |
Leukocytes, Mononuclear/virology | 51 | 48.0 |
Macaca nemestrina | 18 | 58.0 |
SIV/genetics/*pathogenicity/physiology | 2 | 66.0 |
Antibody Formation/*physiology | 4 | 36.0 |
Immunoglobulins/analysis | 41 | 16.0 |
*Drug Resistance, Viral | 7 | 70.0 |
Protease Inhibitors | 3 | 17.0 |
AIDS-Related Opportunistic Infections/*prevention & control | 46 | 100.0 |
Anti-Infective Agents/*therapeutic use | 15 | 62.0 |
HIV Infections/*complications/drug therapy/immunology | 13 | 100.0 |
Pneumonia, Pneumocystis/*prevention & control | 26 | 96.0 |
Trimethoprim-Sulfamethoxazole Combination/*therapeutic use | 13 | 86.0 |
Cryptosporidium/isolation & purification | 4 | 100.0 |
Patient Compliance | 60 | 39.0 |
Giant Cells/virology | 22 | 56.0 |
HIV Infections/drug therapy/*transmission/virology | 3 | 75.0 |
HIV-1/*genetics | 86 | 27.0 |
Pregnancy Complications, Infectious/drug therapy/*virology | 3 | 100.0 |
Zidovudine/therapeutic use | 161 | 86.0 |
African Americans/statistics & numerical data | 2 | 28.0 |
United States | 97 | 11.0 |
Fetal Blood/*immunology | 7 | 8.0 |
Lymphocyte Activation/immunology | 156 | 29.0 |
Thymus Gland/*immunology | 26 | 45.0 |
HIV Protease Inhibitors/*therapeutic use | 106 | 93.0 |
Indinavir/*therapeutic use | 33 | 97.0 |
Neutrophils/pathology | 7 | 12.0 |
HIV Infections/*immunology/*virology | 23 | 92.0 |
HIV Protease Inhibitors/therapeutic use | 63 | 96.0 |
Reverse Transcriptase Inhibitors/therapeutic use | 91 | 94.0 |
HIV Infections/drug therapy/*virology | 17 | 89.0 |
RNA, Viral/*blood | 122 | 88.0 |
ADP-ribosyl Cyclase | 37 | 8.0 |
*Antigens, CD | 61 | 8.0 |
Antigens, CD14/metabolism | 7 | 5.0 |
CD4-Positive T-Lymphocytes/immunology/*physiology | 7 | 53.0 |
HLA-DR Antigens/*metabolism | 14 | 23.0 |
Lymphopenia | 4 | 57.0 |
Monocytes/*immunology/virology | 4 | 44.0 |
NAD+ Nucleosidase/metabolism | 4 | 14.0 |
CD4-Positive T-Lymphocytes/immunology/metabolism/virology | 5 | 50.0 |
*Immunologic Memory | 60 | 43.0 |
T-Lymphocyte Subsets/*immunology/metabolism/*virology | 2 | 100.0 |
Dendritic Cells/immunology/virology | 3 | 60.0 |
HIV/genetics/isolation & purification/physiology | 2 | 100.0 |
HIV Infections/*blood/*immunology/virology | 3 | 100.0 |
Immunoglobulin G/blood/immunology | 5 | 12.0 |
RNA, Viral/analysis | 162 | 58.0 |
Tumor Necrosis Factor-alpha/metabolism | 23 | 3.0 |
Antigens, CD8 | 204 | 75.0 |
HIV Seropositivity/genetics/immunology | 4 | 80.0 |
HIV-1/genetics/immunology/*physiology | 10 | 83.0 |
Receptors, CCR5/genetics/*metabolism | 9 | 22.0 |
AIDS-Related Opportunistic Infections/*epidemiology/microbiology | 4 | 100.0 |
Gram-Negative Bacteria/isolation & purification | 2 | 33.0 |
Gram-Positive Bacteria/isolation & purification | 2 | 40.0 |
HIV Infections/*complications/epidemiology | 14 | 87.0 |
Spain/epidemiology | 29 | 19.0 |
Argentina/epidemiology | 2 | 13.0 |
*Computer Simulation | 7 | 10.0 |
Electric Conductivity | 2 | 1.0 |
Membrane Potentials | 2 | 0.0 |
*Models, Molecular | 8 | 6.0 |
Protein Conformation | 169 | 5.0 |
Protein Structure, Secondary | 27 | 2.0 |
Glucocorticoids/*pharmacology | 11 | 7.0 |
Th1 Cells/*drug effects | 2 | 50.0 |
Antigens, CD/*blood | 27 | 16.0 |
Biological Markers/blood | 98 | 7.0 |
Dermatitis, Atopic/*immunology | 11 | 26.0 |
Enterotoxins/pharmacology | 12 | 19.0 |
Immunoglobulin E/*blood | 7 | 13.0 |
Lymphocytes/metabolism | 17 | 7.0 |
Muromonab-CD3/pharmacology | 19 | 26.0 |
Neutrophils/*metabolism | 3 | 1.0 |
Oxygen Consumption | 5 | 2.0 |
Phytohemagglutinins/pharmacology | 122 | 22.0 |
Superantigens/pharmacology | 6 | 24.0 |
Adjuvants, Immunologic | 10 | 19.0 |
Caspases/*genetics | 2 | 9.0 |
Influenza Vaccines/*administration & dosage/immunology | 2 | 100.0 |
HIV Infections/*complications/virology | 7 | 100.0 |
HIV-1/metabolism/pathogenicity/*physiology | 3 | 100.0 |
Retroviridae Proteins/*metabolism | 8 | 88.0 |
T-Lymphocytes/*virology | 22 | 42.0 |
African Continental Ancestry Group | 20 | 7.0 |
Europe | 27 | 9.0 |
European Continental Ancestry Group | 21 | 3.0 |
HIV Infections/*genetics/*physiopathology | 2 | 66.0 |
Haplotypes | 25 | 1.0 |
Polymorphism, Single Nucleotide | 2 | 0.0 |
Proteins/*genetics | 3 | 0.0 |
Cross Reactions/immunology | 7 | 14.0 |
Guinea Pigs | 14 | 1.0 |
Mycobacterium tuberculosis/*immunology | 22 | 33.0 |
Receptors, Antigen, T-Cell, gamma-delta/*immunology | 19 | 38.0 |
Specific Pathogen-Free Organisms | 8 | 9.0 |
T-Lymphocytes/cytology/*immunology | 46 | 34.0 |
Tuberculosis, Pulmonary/*immunology/microbiology | 2 | 40.0 |
AIDS Vaccines/*adverse effects | 2 | 100.0 |
Risk-Taking | 10 | 37.0 |
Host-Parasite Relations/*immunology | 2 | 100.0 |
Macrophages/immunology/parasitology | 2 | 100.0 |
Mycobacterium/immunology | 5 | 38.0 |
Mycobacterium Infections/*immunology | 3 | 42.0 |
AIDS-Related Opportunistic Infections/*diagnosis/parasitology | 2 | 100.0 |
Histocompatibility Testing | 24 | 2.0 |
*Kidney Transplantation | 21 | 4.0 |
*Bone Marrow Transplantation | 31 | 8.0 |
Calcimycin/pharmacology | 7 | 2.0 |
Calcium/metabolism | 80 | 5.0 |
Cell Proliferation/drug effects | 2 | 2.0 |
*Immunosuppression | 11 | 14.0 |
Thymidine/metabolism | 11 | 3.0 |
*Leukemic Infiltration | 6 | 54.0 |
Skin/*pathology | 15 | 16.0 |
Body Weight/*physiology | 2 | 6.0 |
HIV Infections/complications/*metabolism | 2 | 66.0 |
*Health Behavior | 2 | 15.0 |
Life Style | 11 | 8.0 |
Questionnaires | 79 | 14.0 |
Antibodies, Monoclonal/chemistry | 6 | 6.0 |
Calcium Signaling | 6 | 7.0 |
Cell-Free System | 8 | 2.0 |
Coculture Techniques | 92 | 13.0 |
Gels | 2 | 2.0 |
HIV-1/*drug effects/genetics/growth & development | 2 | 100.0 |
Rabbits | 78 | 2.0 |
Cognition Disorders/etiology | 3 | 23.0 |
Endocrine System/drug effects | 2 | 20.0 |
*Environmental Exposure | 3 | 4.0 |
Environmental Pollutants/*poisoning | 2 | 22.0 |
Food Contamination | 3 | 10.0 |
*Occupational Exposure | 9 | 6.0 |
Polychlorinated Biphenyls/*poisoning | 2 | 28.0 |
Skin Diseases/etiology | 2 | 25.0 |
Leukocytes, Mononuclear/immunology/metabolism | 6 | 14.0 |
Skin Tests | 48 | 24.0 |
*Antibody-Dependent Cell Cytotoxicity | 11 | 23.0 |
*Antibody-Dependent Enhancement | 2 | 100.0 |
HIV Antibodies/*blood/immunology | 5 | 100.0 |
HIV Envelope Protein gp120/immunology | 64 | 78.0 |
HIV Envelope Protein gp41/immunology | 13 | 59.0 |
HIV Infections/*immunology/*prevention & control | 2 | 100.0 |
Calcium Signaling/drug effects | 4 | 8.0 |
Cyclodextrins/pharmacology | 3 | 10.0 |
Macrophage Inflammatory Protein-1/*metabolism | 2 | 9.0 |
Protein Binding/drug effects | 26 | 7.0 |
Protein Conformation/drug effects | 3 | 5.0 |
Receptors, CCR5/chemistry/*metabolism | 6 | 54.0 |
T-Lymphocytes/chemistry/metabolism | 2 | 40.0 |
*beta-Cyclodextrins | 3 | 7.0 |
Cloning, Molecular | 114 | 1.0 |
DNA Primers | 98 | 2.0 |
HIV Infections/*virology | 54 | 54.0 |
HIV-1/genetics/*pathogenicity | 11 | 57.0 |
HIV Infections/blood/*virology | 6 | 54.0 |
HIV-1/*isolation & purification/physiology | 9 | 90.0 |
*Virus Replication | 106 | 37.0 |
Antigens, CD4/genetics/*physiology | 12 | 92.0 |
*Chimera | 4 | 12.0 |
HIV/*physiology | 57 | 78.0 |
Microglia/*virology | 4 | 80.0 |
Papio | 11 | 6.0 |
RNA, Messenger/genetics | 56 | 2.0 |
Receptors, Chemokine/genetics/*physiology | 3 | 27.0 |
SIV/*physiology | 13 | 48.0 |
London/epidemiology | 22 | 68.0 |
Medical Records | 15 | 21.0 |
Didanosine/*therapeutic use | 38 | 97.0 |
Neutropenia/chemically induced | 13 | 34.0 |
Binding Sites/physiology | 4 | 2.0 |
Binding, Competitive/physiology | 2 | 6.0 |
HIV Envelope Protein gp120/*metabolism | 133 | 83.0 |
Macrophages/virology | 34 | 45.0 |
Receptors, CCR5/*metabolism | 60 | 40.0 |
Anti-HIV Agents/administration & dosage/*therapeutic use | 45 | 93.0 |
Didanosine/administration & dosage/therapeutic use | 8 | 100.0 |
Nevirapine/administration & dosage/*therapeutic use | 7 | 100.0 |
Spain | 23 | 6.0 |
Stavudine/administration & dosage/therapeutic use | 6 | 100.0 |
B-Lymphocytes/metabolism | 16 | 8.0 |
Blotting, Northern | 64 | 1.0 |
Bone Marrow Cells/metabolism | 2 | 2.0 |
DNA, Complementary/metabolism | 4 | 0.0 |
DNA-Binding Proteins/biosynthesis | 5 | 5.0 |
Hematopoiesis/*physiology | 3 | 3.0 |
Lymphocytes/*metabolism | 20 | 12.0 |
*Receptors, Cell Surface | 4 | 1.0 |
Retroviridae | 3 | 4.0 |
T-Lymphocytes/metabolism | 41 | 14.0 |
Transcription Factors/metabolism | 7 | 0.0 |
Transcription, Genetic | 91 | 1.0 |
Up-Regulation | 65 | 2.0 |
Antigens, CD/immunology | 116 | 24.0 |
Antigens, CD2/*immunology | 2 | 5.0 |
Cytoplasm/immunology | 11 | 11.0 |
Down-Regulation | 166 | 8.0 |
Isoenzymes/metabolism | 10 | 1.0 |
Mitogen-Activated Protein Kinases/*metabolism | 5 | 0.0 |
Phospholipases A/metabolism | 2 | 3.0 |
Protein Kinase C/metabolism | 15 | 3.0 |
Adaptor Proteins, Vesicular Transport | 12 | 17.0 |
Antigens, CD4/chemistry | 8 | 80.0 |
Antigens, CD8/biosynthesis | 19 | 54.0 |
COS Cells | 39 | 1.0 |
Endocytosis | 38 | 9.0 |
Gene Products, nef/*metabolism | 17 | 62.0 |
Jurkat Cells | 124 | 9.0 |
Kinetics | 282 | 3.0 |
Plasmids/metabolism | 11 | 0.0 |
Protein Biosynthesis | 25 | 1.0 |
Recombinant Fusion Proteins/metabolism | 25 | 1.0 |
HIV-1/genetics/*pathogenicity/physiology | 12 | 75.0 |
Macrophages/immunology/*virology | 9 | 69.0 |
B-Lymphocytes/*pathology | 3 | 6.0 |
Herpesvirus 4, Human/isolation & purification/physiology | 2 | 66.0 |
Tumor Markers, Biological/metabolism | 13 | 3.0 |
Anti-HIV Agents/adverse effects/*therapeutic use | 43 | 93.0 |
Drug Resistance, Microbial | 71 | 42.0 |
HIV Infections/*drug therapy/virology | 70 | 87.0 |
Indinavir/adverse effects/*therapeutic use | 9 | 100.0 |
Lamivudine/adverse effects/*therapeutic use | 10 | 100.0 |
Reverse Transcriptase Inhibitors/adverse effects/*therapeutic use | 19 | 100.0 |
Stavudine/adverse effects/*therapeutic use | 7 | 100.0 |
Zidovudine/adverse effects/*therapeutic use | 32 | 96.0 |
HIV Infections/blood/*drug therapy/virology | 9 | 100.0 |
*HIV-1/genetics/isolation & purification | 24 | 96.0 |
Nelfinavir/*therapeutic use | 10 | 100.0 |
Culture Techniques | 14 | 3.0 |
Graft Rejection/*etiology | 3 | 23.0 |
Receptors, Antigen, T-Cell, alpha-beta/genetics/*immunology | 7 | 38.0 |
Transplantation Immunology | 15 | 23.0 |
Transplantation, Homologous | 74 | 11.0 |
AIDS-Related Opportunistic Infections/*epidemiology/immunology | 7 | 100.0 |
HIV Infections/*transmission | 26 | 47.0 |
Mexico/epidemiology | 3 | 10.0 |
Fibroblasts/pathology | 3 | 4.0 |
Fibrosis | 4 | 2.0 |
Fluorescent Antibody Technique, Direct | 20 | 19.0 |
Kidney/pathology | 7 | 4.0 |
Kidney Transplantation/*pathology | 4 | 36.0 |
AIDS Dementia Complex/*virology | 3 | 50.0 |
Brain/virology | 3 | 23.0 |
Giant Cells/physiology | 8 | 47.0 |
HIV-1/isolation & purification/*pathogenicity | 3 | 75.0 |
Monocytes/virology | 10 | 35.0 |
Organ Culture Techniques | 22 | 5.0 |
Virulence | 33 | 14.0 |
Antigens, CD3/metabolism | 60 | 36.0 |
Antigens, CD95/metabolism | 16 | 11.0 |
*Apoptosis/drug effects | 7 | 6.0 |
Receptors, Antigen, T-Cell/metabolism | 47 | 27.0 |
Reverse Transcriptase Inhibitors/*pharmacology | 3 | 23.0 |
Carrier State/virology | 2 | 50.0 |
Gene Products, nef/genetics/*metabolism | 23 | 74.0 |
HIV Infections/immunology/*virology | 27 | 77.0 |
*HIV Long-Term Survivors | 11 | 57.0 |
Japan | 21 | 1.0 |
Protein-Tyrosine Kinase/metabolism | 41 | 4.0 |
Proto-Oncogene Proteins/metabolism | 18 | 1.0 |
Antigens, CD4/*genetics | 58 | 100.0 |
Gene Products, rev/genetics | 2 | 25.0 |
Receptors, CXCR4/*genetics | 6 | 23.0 |
Recombinant Fusion Proteins/genetics | 3 | 1.0 |
*Transduction, Genetic | 4 | 5.0 |
Anti-HIV Agents/economics/*therapeutic use | 2 | 50.0 |
Antigens, CD56/*analysis | 8 | 25.0 |
Bone Marrow/pathology | 28 | 7.0 |
Leukemia, Myelomonocytic, Acute/*pathology | 2 | 22.0 |
Lymph Nodes/pathology | 36 | 12.0 |
Skin/pathology | 32 | 12.0 |
Skin Neoplasms/*immunology/*pathology | 4 | 80.0 |
HIV Infections/*complications/immunology | 66 | 95.0 |
Retreatment | 2 | 11.0 |
Biological Markers/analysis | 66 | 7.0 |
Duodenum/*immunology | 5 | 62.0 |
Food Hypersensitivity/*immunology | 3 | 27.0 |
Immunoglobulin A/analysis | 21 | 12.0 |
Interferon Type II/*analysis | 5 | 35.0 |
Interleukin-4/*analysis | 4 | 44.0 |
Intestinal Mucosa/immunology | 18 | 35.0 |
AIDS-Related Opportunistic Infections/*diagnosis/drug therapy | 9 | 90.0 |
Acquired Immunodeficiency Syndrome/*complications/*immunology | 2 | 100.0 |
Cote d'Ivoire | 20 | 74.0 |
Erythromycin/therapeutic use | 2 | 66.0 |
Burkina Faso/epidemiology | 3 | 75.0 |
HIV Infections/complications/*diagnosis | 5 | 71.0 |
Herpes Zoster/complications/epidemiology | 3 | 100.0 |
Antigens, CD3/biosynthesis | 19 | 33.0 |
*Cell Adhesion | 15 | 9.0 |
*Image Processing, Computer-Assisted | 2 | 4.0 |
Inflammation | 31 | 7.0 |
Myocardium/*pathology | 5 | 12.0 |
*Antigens, CD56 | 4 | 66.0 |
HIV-1/*immunology/physiology | 28 | 82.0 |
Killer Cells, Natural/immunology/*virology | 2 | 100.0 |
Receptors, CXCR4/analysis | 11 | 31.0 |
Antigen Presentation/*immunology | 14 | 15.0 |
Antigens, Differentiation, B-Lymphocyte/immunology | 8 | 15.0 |
Autoantigens/*immunology | 16 | 9.0 |
*Lectins | 13 | 7.0 |
Antigens, Differentiation/immunology | 29 | 27.0 |
Biological Markers | 209 | 12.0 |
Cell Cycle | 41 | 3.0 |
Immunologic Memory/physiology | 5 | 41.0 |
Synovial Fluid/immunology | 9 | 23.0 |
T-Lymphocytes/*immunology/pathology | 22 | 40.0 |
African Americans | 11 | 10.0 |
HIV Infections/*diagnosis | 10 | 62.0 |
Reverse Transcriptase Inhibitors/administration & dosage/therapeutic use | 12 | 92.0 |
Antibodies, Monoclonal/immunology | 275 | 16.0 |
Apoptosis/*immunology | 42 | 23.0 |
HIV Infections/drug therapy/*immunology | 51 | 76.0 |
In Situ Nick-End Labeling | 19 | 3.0 |
Interferon Type II/*biosynthesis/immunology | 5 | 38.0 |
Interleukin-2/*biosynthesis/immunology | 2 | 28.0 |
T-Lymphocytes/*metabolism | 64 | 16.0 |
Genetic Predisposition to Disease | 15 | 0.0 |
*Heterozygote | 8 | 2.0 |
Homosexuality, Male | 83 | 84.0 |
Receptors, Chemokine/*genetics | 11 | 11.0 |
*Body Composition | 9 | 8.0 |
Densitometry, X-Ray | 8 | 5.0 |
HIV Infections/*drug therapy/physiopathology | 13 | 100.0 |
Reverse Transcriptase Inhibitors/administration & dosage/*therapeutic use | 14 | 100.0 |
Cell Adhesion Molecules/*immunology | 7 | 13.0 |
Cyclosporine/*therapeutic use | 7 | 24.0 |
Langerhans Cells/*immunology | 9 | 22.0 |
Skin/immunology | 21 | 22.0 |
AIDS Vaccines/immunology/*therapeutic use | 3 | 100.0 |
*Viral Proteins | 14 | 7.0 |
Antigens, CD95/analysis | 6 | 18.0 |
CD4-Positive T-Lymphocytes/physiology | 29 | 56.0 |
*Granulocytes | 3 | 33.0 |
HIV/genetics | 27 | 67.0 |
*Leukapheresis | 8 | 22.0 |
Tumor Necrosis Factor-alpha/antagonists & inhibitors | 4 | 6.0 |
Acquired Immunodeficiency Syndrome/*drug therapy/immunology/virology | 29 | 96.0 |
CD4-Positive T-Lymphocytes/*virology | 60 | 73.0 |
HIV-1/*isolation & purification | 72 | 80.0 |
HLA-DR Antigens/*analysis | 32 | 18.0 |
Chromosome Aberrations | 19 | 3.0 |
Dendritic Cells/*pathology | 6 | 16.0 |
Gene Rearrangement | 18 | 3.0 |
Genes, myc | 5 | 1.0 |
Herpesvirus 4, Human/isolation & purification | 17 | 29.0 |
Karyotyping | 61 | 3.0 |
Lymphocytes/*pathology | 15 | 30.0 |
Lymphoma, Lymphoblastic/*pathology | 4 | 100.0 |
Receptors, Antigen, T-Cell/analysis | 56 | 54.0 |
Skin Neoplasms/*pathology | 14 | 14.0 |
Tumor Markers, Biological | 10 | 2.0 |
HIV Envelope Protein gp120/metabolism | 118 | 77.0 |
*Lymphocyte Activation | 327 | 24.0 |
Mice, Knockout | 76 | 2.0 |
Sequence Deletion | 32 | 1.0 |
AIDS-Related Opportunistic Infections/radiography | 3 | 100.0 |
Cell Adhesion/drug effects | 11 | 2.0 |
Cell Adhesion Molecules/chemistry | 2 | 14.0 |
Drug Evaluation, Preclinical | 4 | 2.0 |
Endothelium, Vascular/cytology/drug effects | 2 | 3.0 |
Structure-Activity Relationship | 137 | 4.0 |
Africa, Western | 10 | 47.0 |
Canada | 4 | 2.0 |
*HIV-2 | 22 | 88.0 |
Salvage Therapy | 15 | 20.0 |
CD4-Positive T-Lymphocytes/*drug effects/immunology | 17 | 85.0 |
Disease Transmission, Vertical | 61 | 70.0 |
Lymphocytes/immunology | 75 | 18.0 |
Neopterin/blood | 12 | 44.0 |
Recombinant Proteins/adverse effects/therapeutic use | 6 | 19.0 |
Great Britain | 16 | 6.0 |
CD4-Positive T-Lymphocytes/*drug effects | 29 | 90.0 |
HIV Infections/*drug therapy/immunology/pathology | 3 | 100.0 |
Apoptosis | 91 | 5.0 |
Interleukin-2/pharmacology/therapeutic use | 3 | 60.0 |
Proto-Oncogene Proteins c-bcl-2/biosynthesis/*physiology | 2 | 40.0 |
Receptors, Interleukin-2/*physiology | 2 | 9.0 |
Drug Resistance, Viral | 34 | 64.0 |
HIV Infections/drug therapy/immunology/*therapy | 4 | 100.0 |
HIV-1/*drug effects/isolation & purification | 3 | 42.0 |
Karnofsky Performance Status | 9 | 50.0 |
Proviruses/isolation & purification | 14 | 77.0 |
Tumor Necrosis Factor-alpha/analysis | 35 | 8.0 |
Anti-HIV Agents/pharmacology/therapeutic use | 7 | 70.0 |
DNA, Viral/*blood | 29 | 78.0 |
HIV Infections/blood/drug therapy/*virology | 7 | 100.0 |
HIV-1/genetics/isolation & purification/*physiology | 13 | 72.0 |
Lymphocyte Activation/drug effects | 142 | 25.0 |
Viremia/drug therapy/*virology | 3 | 100.0 |
HIV Infections/*psychology/therapy | 2 | 66.0 |
Health Status Indicators | 8 | 38.0 |
Interviews | 7 | 16.0 |
*Mental Health | 2 | 50.0 |
Lamivudine/therapeutic use | 40 | 90.0 |
Nelfinavir/therapeutic use | 12 | 100.0 |
Antigens, CD/analysis/immunology | 9 | 18.0 |
Antigens, Surface/*analysis/immunology | 6 | 33.0 |
Asthma/*immunology/*pathology | 2 | 100.0 |
Centrifugation, Density Gradient | 11 | 3.0 |
Anti-HIV Agents/*adverse effects | 10 | 62.0 |
HIV-1/*classification | 4 | 100.0 |
Blood Transfusion | 16 | 8.0 |
Epoetin Alfa/therapeutic use | 2 | 66.0 |
HIV Infections/blood/*complications/mortality | 3 | 100.0 |
Hemoglobins/analysis | 30 | 10.0 |
Cytokines/*therapeutic use | 2 | 11.0 |
HIV Infections/immunology/*therapy | 20 | 100.0 |
Immunotherapy | 64 | 19.0 |
Multicenter Studies | 33 | 27.0 |
*Medicine, African Traditional | 3 | 100.0 |
Odds Ratio | 73 | 6.0 |
Zimbabwe/epidemiology | 9 | 60.0 |
Gene Expression Regulation | 65 | 2.0 |
Genes, MHC Class II/*immunology | 2 | 10.0 |
Immune System/*immunology | 6 | 85.0 |
Trans-Activators/*immunology | 2 | 16.0 |
Apoptosis/immunology | 25 | 25.0 |
Cell Survival | 50 | 4.0 |
Homeostasis/immunology | 2 | 20.0 |
T-Lymphocytes, Helper-Inducer/*immunology | 93 | 46.0 |
Blotting, Western | 137 | 2.0 |
Candidiasis, Oral/complications | 8 | 100.0 |
HIV Infections/complications/*immunology | 48 | 94.0 |
Immunoglobulin A/*blood | 8 | 29.0 |
Immunoglobulin M/*blood | 4 | 11.0 |
Leukoplakia, Hairy/complications | 2 | 100.0 |
Saliva/*immunology | 2 | 11.0 |
HIV Infections/*complications/mortality | 9 | 100.0 |
AIDS-Related Opportunistic Infections/*diagnosis/pathology | 4 | 100.0 |
Antibody Affinity | 19 | 11.0 |
Binding, Competitive | 118 | 6.0 |
Cell Fusion | 86 | 36.0 |
Cell Membrane/immunology | 25 | 10.0 |
Cross Reactions | 50 | 6.0 |
Gene Products, env/immunology | 18 | 60.0 |
HIV Envelope Protein gp120/*immunology | 90 | 73.0 |
Immunoglobulins, Fab/*immunology | 4 | 15.0 |
Peptide Library | 8 | 6.0 |
Receptors, CCR5/*immunology | 5 | 27.0 |
CD8-Positive T-Lymphocytes/*cytology | 13 | 68.0 |
Cell Differentiation/drug effects/*physiology | 2 | 3.0 |
Cell Nucleus/*metabolism | 3 | 0.0 |
DNA/metabolism | 7 | 0.0 |
Sequence Homology, Amino Acid | 91 | 1.0 |
Tetradecanoylphorbol Acetate/pharmacology | 127 | 7.0 |
Antigens, CD4/biosynthesis/chemistry | 2 | 100.0 |
CD4-Positive T-Lymphocytes/pathology | 65 | 87.0 |
CD8-Positive T-Lymphocytes/pathology | 35 | 79.0 |
Eosinophils/pathology | 6 | 17.0 |
Intestinal Mucosa/metabolism/pathology | 2 | 6.0 |
Immunohistochemistry/methods | 23 | 3.0 |
Macrophages/metabolism | 16 | 5.0 |
RNA, Messenger/metabolism | 55 | 1.0 |
Rats, Sprague-Dawley | 18 | 0.0 |
Receptors, CXCR4/*metabolism | 52 | 32.0 |
Receptors, Chemokine/*metabolism | 23 | 16.0 |
Receptors, HIV/metabolism | 19 | 59.0 |
CD4-Positive T-Lymphocytes/*cytology/*immunology/metabolism | 4 | 50.0 |
*Cytotoxicity, Immunologic/genetics | 3 | 25.0 |
Interferon Type II/biosynthesis | 119 | 25.0 |
Receptors, Tumor Necrosis Factor/biosynthesis | 3 | 17.0 |
Blotting, Southern | 74 | 2.0 |
*Cell Division | 2 | 1.0 |
Clone Cells/pathology | 6 | 10.0 |
Cytokines/*biosynthesis/pharmacology | 2 | 33.0 |
Prostatic Neoplasms | 2 | 3.0 |
Anti-Infective Agents/*administration & dosage | 2 | 100.0 |
Bronchoalveolar Lavage | 4 | 16.0 |
Mutation/drug effects | 3 | 37.0 |
Trimethoprim-Sulfamethoxazole Combination/*administration & dosage | 2 | 100.0 |
Adenoviridae/*immunology | 4 | 50.0 |
*Age Factors | 2 | 25.0 |
Antibodies, Viral/analysis | 22 | 21.0 |
Kidney Transplantation | 5 | 4.0 |
Postoperative Complications/prevention & control | 3 | 10.0 |
Gene Products, env/genetics/*immunology | 3 | 50.0 |
Genetic Vectors | 79 | 5.0 |
HIV Antibodies/immunology | 40 | 64.0 |
HIV Envelope Protein gp120/genetics/immunology | 11 | 73.0 |
HIV Envelope Protein gp160/genetics/immunology | 2 | 66.0 |
HIV-1/genetics/*immunology | 40 | 58.0 |
Vaccines, DNA/genetics/*immunology | 2 | 28.0 |
Cell Survival/drug effects | 35 | 3.0 |
Dexamethasone/pharmacology | 10 | 2.0 |
Tumor Necrosis Factor-alpha/pharmacology | 34 | 2.0 |
Biological Response Modifiers/pharmacology/*therapeutic use | 2 | 28.0 |
CD4-Positive T-Lymphocytes/*drug effects/metabolism | 7 | 77.0 |
CD8-Positive T-Lymphocytes/*drug effects/metabolism | 2 | 100.0 |
Disability Evaluation | 3 | 8.0 |
Down-Regulation/*drug effects | 10 | 18.0 |
T-Lymphocyte Subsets/*drug effects/metabolism | 2 | 50.0 |
Age Factors | 213 | 8.0 |
Baltimore | 5 | 62.0 |
Health Services Accessibility/*economics | 2 | 100.0 |
Hospitals, University | 10 | 28.0 |
Medicaid/statistics & numerical data | 2 | 100.0 |
Antibodies, Monoclonal/administration & dosage/*pharmacology | 2 | 25.0 |
*Antigens, Neoplasm | 9 | 4.0 |
CD4-Positive T-Lymphocytes/drug effects/pathology | 5 | 100.0 |
*Drug Resistance, Neoplasm | 3 | 1.0 |
Lymphocyte Activation/genetics | 20 | 20.0 |
Cell Movement | 54 | 6.0 |
*Cell Transformation, Neoplastic | 3 | 0.0 |
Tongue/pathology | 2 | 33.0 |
Genes, Viral/*genetics | 3 | 15.0 |
HIV/*genetics | 24 | 41.0 |
*Mutation | 45 | 1.0 |
DNA, Viral/*analysis | 33 | 35.0 |
Papillomavirus, Human/*genetics | 2 | 2.0 |
Adrenal Cortex Hormones/therapeutic use | 12 | 17.0 |
Antiretroviral Therapy, Highly Active/methods | 10 | 83.0 |
Comorbidity | 40 | 16.0 |
Disease Transmission, Vertical/prevention & control | 10 | 76.0 |
Receptors, IgG/biosynthesis | 3 | 10.0 |
HIV Infections/*blood/drug therapy/immunology | 5 | 71.0 |
HIV Core Protein p24/*immunology | 10 | 76.0 |
HIV Infections/blood/*immunology | 44 | 72.0 |
Leukocytes, Mononuclear/cytology/immunology | 7 | 15.0 |
Lymphocytes/cytology/*immunology | 5 | 31.0 |
AIDS Vaccines/*immunology/therapeutic use | 3 | 100.0 |
Antigens, CD4/immunology | 153 | 76.0 |
HIV Antigens/immunology | 29 | 72.0 |
HIV Infections/blood/*immunology/*therapy | 2 | 100.0 |
Immunoglobulin G/blood | 70 | 24.0 |
Antibody Specificity | 103 | 7.0 |
Fusobacterium nucleatum/*immunology | 3 | 60.0 |
Immunity | 18 | 27.0 |
Porphyromonas gingivalis/*immunology | 9 | 42.0 |
Didanosine/therapeutic use | 41 | 87.0 |
Poland/epidemiology | 4 | 7.0 |
Stavudine/therapeutic use | 15 | 78.0 |
Candidiasis/epidemiology/etiology | 2 | 100.0 |
Esophagitis/epidemiology/etiology | 2 | 100.0 |
HIV | 5 | 38.0 |
Hospitalization | 28 | 23.0 |
Pneumonia, Pneumocystis/epidemiology/etiology | 2 | 100.0 |
Cell Nucleus/metabolism | 7 | 0.0 |
Proliferating Cell Nuclear Antigen/metabolism | 2 | 0.0 |
Antigens, Viral/*genetics/immunology | 2 | 50.0 |
Cytoplasm/chemistry | 2 | 1.0 |
Epitopes/genetics/immunology | 2 | 5.0 |
Leukocytes, Mononuclear/chemistry | 3 | 11.0 |
Peptide Fragments/immunology | 32 | 14.0 |
SIV/genetics/*immunology | 3 | 37.0 |
Simian Acquired Immunodeficiency Syndrome/*immunology/virology | 4 | 80.0 |
Antigens, CD4/*metabolism/pharmacology | 2 | 66.0 |
Drug Synergism | 38 | 2.0 |
HIV Envelope Protein gp41/chemistry/*metabolism | 4 | 66.0 |
HIV Infections/prevention & control | 7 | 46.0 |
HIV-1/*drug effects/metabolism | 9 | 64.0 |
Recombinant Proteins/metabolism/pharmacology | 4 | 3.0 |
T-Lymphocytes/virology | 35 | 51.0 |
AIDS-Related Opportunistic Infections/immunology | 12 | 92.0 |
*Clonal Deletion | 3 | 100.0 |
Genes, T-Cell Receptor beta | 6 | 50.0 |
HIV Seropositivity/*immunology | 76 | 78.0 |
Immunoglobulin Variable Region/genetics | 11 | 9.0 |
Pneumocystis/*immunology | 5 | 62.0 |
Antigens/administration & dosage | 3 | 17.0 |
CD4-Positive T-Lymphocytes/cytology/*immunology | 45 | 73.0 |
DNA-Binding Proteins/genetics | 11 | 1.0 |
Ovalbumin/immunology | 13 | 26.0 |
Receptors, Antigen, T-Cell/genetics | 22 | 26.0 |
Receptors, Interleukin-4/genetics | 2 | 18.0 |
Th2 Cells/cytology/*immunology | 3 | 25.0 |
CD4-Positive T-Lymphocytes/*immunology/metabolism/virology | 2 | 50.0 |
Epitopes, T-Lymphocyte/genetics | 3 | 75.0 |
Hepacivirus/genetics/*immunology | 2 | 33.0 |
HIV Seronegativity/*immunology | 28 | 84.0 |
Lymphocyte Depletion | 67 | 41.0 |
Th1 Cells/immunology | 43 | 25.0 |
HIV Infections/*diagnosis/epidemiology | 4 | 100.0 |
*Population Surveillance | 8 | 22.0 |
San Francisco | 11 | 73.0 |
Anti-HIV Agents/administration & dosage/therapeutic use | 13 | 86.0 |
Capsules/administration & dosage | 2 | 100.0 |
Drug Interactions | 44 | 3.0 |
HIV-1/isolation & purification/physiology | 8 | 88.0 |
Ritonavir/*administration & dosage/pharmacokinetics | 2 | 100.0 |
Aging | 9 | 2.0 |
*Bone Density | 2 | 1.0 |
HIV Infections/*physiopathology | 18 | 64.0 |
HIV Infections/*drug therapy/*immunology/virology | 29 | 87.0 |
Antigens, CD15 | 7 | 23.0 |
E-Selectin/metabolism | 3 | 6.0 |
Immunoglobulins/*analysis | 7 | 7.0 |
Intercellular Adhesion Molecule-1/*metabolism | 4 | 7.0 |
Mucoproteins/*analysis | 2 | 50.0 |
Receptors, Lymphocyte Homing/*metabolism | 3 | 9.0 |
B-Lymphocytes/cytology/metabolism | 2 | 11.0 |
Histocompatibility Antigens Class II/metabolism | 22 | 27.0 |
Immune System/*cytology | 2 | 50.0 |
Leukocytes/*cytology/metabolism | 2 | 40.0 |
Monocytes/cytology/metabolism | 2 | 7.0 |
Neuroglia/cytology/metabolism | 2 | 11.0 |
Swine/*immunology | 4 | 12.0 |
T-Lymphocytes/cytology/metabolism | 4 | 15.0 |
Cytokines/biosynthesis/*blood | 3 | 33.0 |
Monocytes/metabolism/pathology | 2 | 40.0 |
Th2 Cells/metabolism/pathology | 2 | 66.0 |
HIV-1/drug effects/*physiology | 21 | 52.0 |
Antibodies, Monoclonal/metabolism | 36 | 11.0 |
Antigens, CD28/*metabolism | 12 | 11.0 |
Genes, MHC Class I | 5 | 4.0 |
Membrane Proteins/*physiology | 7 | 5.0 |
Receptors, Antigen, T-Cell/*metabolism | 41 | 28.0 |
*Receptors, Immunologic | 3 | 1.0 |
T-Lymphocyte Subsets/classification/*immunology | 5 | 55.0 |
T-Lymphocytes, Cytotoxic/classification/*immunology | 6 | 40.0 |
*Photopheresis | 3 | 33.0 |
Sezary Syndrome/*drug therapy | 2 | 100.0 |
Skin Neoplasms/*drug therapy | 6 | 31.0 |
Lung Neoplasms/immunology/*therapy | 2 | 33.0 |
*Drug Resistance, Viral/genetics | 6 | 100.0 |
*HIV-1/drug effects/genetics | 6 | 100.0 |
AIDS-Related Opportunistic Infections/physiopathology | 4 | 100.0 |
Zimbabwe | 4 | 15.0 |
HIV Infections/*blood/drug therapy | 10 | 83.0 |
Prolactin/*blood | 4 | 0.0 |
Drug Resistance, Viral/genetics | 14 | 77.0 |
HIV Protease Inhibitors/adverse effects/*therapeutic use | 19 | 100.0 |
*HIV-1/drug effects/genetics/immunology | 2 | 100.0 |
Ritonavir/adverse effects/*therapeutic use | 7 | 100.0 |
*Salvage Therapy | 12 | 57.0 |
Sulfonamides/adverse effects/*therapeutic use | 2 | 100.0 |
HIV Infections/*drug therapy/immunology/prevention & control | 2 | 100.0 |
Hydroxyurea/*therapeutic use | 6 | 85.0 |
Bronchoalveolar Lavage Fluid/cytology | 25 | 21.0 |
Bronchoscopy | 21 | 34.0 |
Lymphocytosis/*complications/immunology | 3 | 75.0 |
Pulmonary Alveoli/pathology | 3 | 12.0 |
Respiratory Function Tests | 24 | 15.0 |
Antigens, CD4/analysis/metabolism | 3 | 100.0 |
Antigens, Differentiation, T-Lymphocyte/metabolism | 30 | 27.0 |
Exons | 10 | 0.0 |
Genes, bcl-2 | 2 | 1.0 |
Nucleic Acid Hybridization | 32 | 2.0 |
Thymus Gland/cytology/growth & development/*immunology | 2 | 100.0 |
Antigens, Differentiation, B-Lymphocyte/metabolism | 6 | 10.0 |
Electrophoresis, Polyacrylamide Gel | 49 | 1.0 |
Epithelial Cells/metabolism | 2 | 0.0 |
Histocompatibility Antigens Class II/*metabolism | 12 | 22.0 |
*Drosophila Proteins | 3 | 0.0 |
Immunity, Natural | 24 | 10.0 |
Infection/*immunology | 3 | 14.0 |
Membrane Glycoproteins/*physiology | 13 | 4.0 |
Receptors, Cell Surface/*physiology | 9 | 4.0 |
Antigen-Presenting Cells/*physiology | 7 | 20.0 |
Receptors, Antigen, T-Cell/physiology | 38 | 27.0 |
Antigens, CD95/immunology | 16 | 30.0 |
Cell Division/drug effects/immunology | 8 | 13.0 |
Lymphocyte Activation/*drug effects | 80 | 24.0 |
Phytohemagglutinins/immunology | 20 | 40.0 |
Protease Inhibitors/pharmacology | 8 | 3.0 |
Antigens, CD28/analysis | 9 | 24.0 |
Antineoplastic Combined Chemotherapy Protocols/*pharmacology | 2 | 4.0 |
Breast Neoplasms/*drug therapy/immunology | 2 | 100.0 |
CD8-Positive T-Lymphocytes/*drug effects/immunology | 2 | 40.0 |
Cell Separation/methods | 21 | 13.0 |
Hematopoietic Stem Cell Transplantation | 9 | 5.0 |
Immune Tolerance/*drug effects | 6 | 33.0 |
T-Lymphocyte Subsets/drug effects | 16 | 84.0 |
Antigen Presentation | 63 | 20.0 |
Asthma/*immunology | 18 | 21.0 |
Hypersensitivity, Immediate/*immunology | 4 | 14.0 |
Cluster Analysis | 7 | 3.0 |
Immunocompromised Host/*immunology | 11 | 61.0 |
*Tomography, X-Ray Computed | 9 | 9.0 |
*Asian Continental Ancestry Group | 5 | 7.0 |
Body Composition | 25 | 10.0 |
Korea/epidemiology | 4 | 6.0 |
*Cell Lineage | 3 | 12.0 |
DNA-Binding Proteins/deficiency/genetics | 7 | 31.0 |
Gene Deletion | 36 | 1.0 |
Receptors, Antigen, T-Cell/*immunology/metabolism | 2 | 22.0 |
Th1 Cells/cytology/immunology/metabolism | 2 | 25.0 |
Trans-Activators/metabolism | 4 | 0.0 |
Cell Adhesion Molecules/*chemistry/*metabolism | 2 | 40.0 |
Protein Structure, Quaternary | 4 | 2.0 |
Proteomics | 2 | 6.0 |
Spectrometry, Mass, Electrospray Ionization | 3 | 3.0 |
Aging/immunology | 15 | 27.0 |
Nutritional Status | 34 | 25.0 |
*Peritoneal Dialysis | 4 | 6.0 |
Antigens, CD4/*immunology/metabolism | 22 | 95.0 |
Binding Sites, Antibody | 38 | 12.0 |
Dose-Response Relationship, Immunologic | 71 | 13.0 |
Erythrocytes/immunology | 13 | 5.0 |
Horses | 7 | 4.0 |
Immune Tolerance/*immunology | 8 | 17.0 |
Immunization Schedule | 11 | 39.0 |
Injections, Intravenous | 50 | 8.0 |
Injections, Subcutaneous | 42 | 13.0 |
*Lymphocyte Depletion | 28 | 35.0 |
Papio/*immunology | 2 | 100.0 |
Sheep | 15 | 2.0 |
Cell Line, Tumor | 25 | 0.0 |
Cell Membrane/immunology/virology | 3 | 60.0 |
Disease Susceptibility/immunology | 17 | 24.0 |
Giant Cells/immunology/virology | 3 | 50.0 |
Green Fluorescent Proteins | 22 | 2.0 |
Luminescent Proteins/genetics | 6 | 3.0 |
Transduction, Genetic | 26 | 6.0 |
Transgenes | 8 | 2.0 |
Vesicular stomatitis-Indiana virus/genetics/immunology | 2 | 100.0 |
Virus Replication/immunology | 29 | 54.0 |
Drug Combinations | 31 | 5.0 |
Extracellular Matrix/enzymology/immunology | 2 | 66.0 |
Interleukin-16/*physiology | 2 | 100.0 |
Receptors, Chemokine/*physiology | 10 | 24.0 |
Up-Regulation/immunology | 23 | 14.0 |
Antibody Formation | 103 | 23.0 |
Neoplasms/*immunology | 17 | 16.0 |
*CD4-Positive T-Lymphocytes | 102 | 97.0 |
*CD8-Positive T-Lymphocytes | 18 | 85.0 |
Long-Term Care | 6 | 11.0 |
Graft Rejection | 16 | 10.0 |
Immunosuppressive Agents/therapeutic use | 32 | 15.0 |
Liver Failure/*complications/*surgery | 2 | 100.0 |
Antigens, CD40/immunology | 9 | 16.0 |
Antilymphocyte Serum/therapeutic use | 3 | 14.0 |
CD40 Ligand/immunology | 2 | 18.0 |
Clonal Deletion | 6 | 46.0 |
*Immune Tolerance | 45 | 26.0 |
Immunosuppression/*methods | 7 | 29.0 |
*Models, Immunological | 22 | 52.0 |
T-Lymphocyte Subsets/drug effects/immunology | 14 | 73.0 |
Transplantation, Homologous/*immunology | 3 | 11.0 |
Fluoresceins | 14 | 22.0 |
Gene Products, vpr/metabolism | 2 | 40.0 |
HIV Core Protein p24/metabolism | 25 | 62.0 |
*Lactams | 2 | 66.0 |
*Membrane Fusion | 16 | 43.0 |
Substrate Specificity | 23 | 1.0 |
*HIV-1/physiology | 15 | 83.0 |
Receptors, CCR5/*antagonists & inhibitors | 3 | 8.0 |
Virus Replication/drug effects | 103 | 43.0 |
Chromosomes, Human, Pair 22 | 2 | 1.0 |
Measles/*immunology | 4 | 44.0 |
CD4 Lymphocyte Count/*methods | 20 | 100.0 |
CD4-CD8 Ratio/*methods | 8 | 100.0 |
HIV Seropositivity/*blood/immunology | 6 | 100.0 |
Antigens, CD3/genetics | 5 | 35.0 |
Gene Therapy/*methods | 17 | 4.0 |
Models, Genetic | 13 | 0.0 |
Recombinant Proteins/metabolism | 71 | 2.0 |
Reactive Oxygen Species/metabolism | 9 | 2.0 |
Cell Culture Techniques | 26 | 5.0 |
Cytokines/immunology/*secretion | 2 | 50.0 |
*Homeostasis | 3 | 5.0 |
DNA-Binding Proteins/metabolism | 14 | 0.0 |
Genes, Reporter | 19 | 0.0 |
HIV Long Terminal Repeat | 26 | 19.0 |
HIV-1/genetics/*metabolism | 21 | 31.0 |
Hela Cells | 249 | 4.0 |
NF-kappa B/*metabolism | 9 | 1.0 |
Trans-Activation (Genetics) | 11 | 0.0 |
Acquired Immunodeficiency Syndrome/*drug therapy/genetics/immunology | 2 | 100.0 |
HIV Protease/genetics | 18 | 75.0 |
HIV-1 Reverse Transcriptase/genetics | 29 | 78.0 |
Receptors, CCR5/genetics | 20 | 31.0 |
Receptors, Chemokine/genetics | 6 | 12.0 |
Immunoglobulin G/biosynthesis/classification | 2 | 66.0 |
Safety | 28 | 19.0 |
CD4-Positive T-Lymphocytes/*metabolism | 49 | 54.0 |
Clinical Trials/statistics & numerical data | 6 | 42.0 |
HIV Protease Inhibitors/blood/therapeutic use | 2 | 100.0 |
Antitubercular Agents/therapeutic use | 18 | 62.0 |
Chemoprevention | 9 | 21.0 |
Carcinoembryonic Antigen/*immunology | 2 | 11.0 |
Neoplasms/*immunology/*therapy | 4 | 28.0 |
Histocompatibility Antigens Class II/*chemistry/immunology | 2 | 100.0 |
Interleukin-10/metabolism | 10 | 15.0 |
Interleukin-2/metabolism | 34 | 23.0 |
Splenectomy/*adverse effects | 4 | 33.0 |
CD4-Positive T-Lymphocytes/*immunology/secretion | 5 | 50.0 |
Cytokines/secretion | 12 | 15.0 |
HIV Long-Term Survivors | 10 | 58.0 |
HIV Seronegativity/immunology | 35 | 63.0 |
HIV Seropositivity/blood/immunology | 9 | 75.0 |
T-Lymphocyte Subsets/*immunology/secretion | 8 | 66.0 |
Viremia/blood/immunology | 2 | 50.0 |
HIV Infections/drug therapy/epidemiology/*immunology | 4 | 100.0 |
British Columbia/epidemiology | 4 | 57.0 |
Cause of Death | 31 | 17.0 |
Data Collection | 7 | 8.0 |
Patient Compliance/*statistics & numerical data | 6 | 54.0 |
AIDS-Related Opportunistic Infections/*virology | 11 | 100.0 |
Adrenal Cortex Hormones/adverse effects/therapeutic use | 2 | 66.0 |
Foscarnet/therapeutic use | 8 | 100.0 |
Vision Disorders/etiology | 3 | 17.0 |
Drug Resistance, Multiple, Viral/*genetics | 7 | 100.0 |
HIV Protease Inhibitors/pharmacology/therapeutic use | 3 | 100.0 |
HIV-1/*drug effects/enzymology/genetics | 6 | 66.0 |
RNA, Viral/blood/genetics | 11 | 84.0 |
Reverse Transcriptase Inhibitors/pharmacology/therapeutic use | 3 | 60.0 |
Selection (Genetics) | 9 | 6.0 |
Sweden/epidemiology | 5 | 4.0 |
AIDS-Related Opportunistic Infections/*epidemiology/etiology | 2 | 100.0 |
Antigens, Fungal/blood | 3 | 100.0 |
Pneumococcal Vaccines | 9 | 75.0 |
Seroepidemiologic Studies | 28 | 27.0 |
Uganda/epidemiology | 12 | 48.0 |
Netherlands/epidemiology | 13 | 12.0 |
Plasma/virology | 6 | 85.0 |
Viremia/epidemiology/*virology | 2 | 100.0 |
Escherichia coli/isolation & purification | 2 | 25.0 |
Senegal/epidemiology | 7 | 58.0 |
Antigens, CD/biosynthesis | 41 | 12.0 |
*Cell Differentiation | 8 | 3.0 |
Goats | 5 | 5.0 |
Transplantation, Heterologous | 25 | 2.0 |
Antigens, CD/*metabolism | 51 | 8.0 |
Apoptosis/physiology | 9 | 2.0 |
Cell Culture Techniques/methods | 12 | 5.0 |
Cell Transplantation | 5 | 5.0 |
*Culture Media, Serum-Free | 2 | 22.0 |
Receptors, Interleukin-2/metabolism | 45 | 24.0 |
Cytokines/*metabolism | 26 | 9.0 |
Leukocytes/*immunology | 22 | 16.0 |
Membrane Glycoproteins/analysis | 23 | 8.0 |
Interferon-alpha/*therapeutic use | 20 | 31.0 |
Liver Transplantation | 7 | 12.0 |
Ribavirin/*therapeutic use | 10 | 71.0 |
Chromosome Mapping | 23 | 0.0 |
Genes, bcl-2/genetics | 2 | 5.0 |
Linkage Disequilibrium | 4 | 0.0 |
Lymphocyte Subsets/cytology/*metabolism | 2 | 66.0 |
*Quantitative Trait, Heritable | 2 | 4.0 |
T-Lymphocytes/cytology/*metabolism | 6 | 20.0 |
HIV Infections/complications/*drug therapy/mortality | 6 | 100.0 |
Michigan/epidemiology | 3 | 33.0 |
*Holistic Health | 2 | 100.0 |
Thailand/epidemiology | 16 | 30.0 |
Vitamin A/*administration & dosage | 3 | 100.0 |
*Research Design | 4 | 33.0 |
Sample Size | 4 | 12.0 |
Cell Membrane/chemistry/*metabolism | 2 | 11.0 |
Lymphocytes/cytology/metabolism | 2 | 8.0 |
Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase | 2 | 6.0 |
Polysaccharides/*metabolism | 3 | 13.0 |
CD4-Positive T-Lymphocytes/drug effects/*metabolism | 6 | 60.0 |
CD8-Positive T-Lymphocytes/drug effects/*metabolism | 2 | 100.0 |
HLA-DR Antigens/*biosynthesis | 6 | 20.0 |
Interleukin-12/pharmacology | 5 | 10.0 |
Interleukin-4/pharmacology | 31 | 9.0 |
Interleukins/*pharmacology | 10 | 13.0 |
Drugs, Chinese Herbal/*therapeutic use | 24 | 30.0 |
Calcium Signaling/immunology | 3 | 13.0 |
Fetal Blood/cytology/immunology | 6 | 17.0 |
HIV Infections/immunology/prevention & control | 4 | 80.0 |
HIV-1/growth & development/*immunology | 4 | 66.0 |
Immunity, Natural/immunology | 6 | 25.0 |
Stem Cells/cytology/immunology | 4 | 22.0 |
CD4-Positive T-Lymphocytes/immunology/metabolism | 32 | 47.0 |
CD8-Positive T-Lymphocytes/immunology/metabolism | 26 | 61.0 |
Cell Differentiation/genetics/immunology | 19 | 25.0 |
Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 28 | 35.0 |
Genes, MHC Class II/physiology | 3 | 23.0 |
Mice, Inbred DBA | 27 | 8.0 |
Peptide Fragments/genetics/immunology/metabolism | 2 | 25.0 |
T-Lymphocyte Subsets/*cytology/immunology/*metabolism | 2 | 50.0 |
Thymus Gland/*cytology/immunology/*metabolism | 2 | 33.0 |
*Antigens, CD34 | 5 | 7.0 |
Graft Survival/immunology | 7 | 13.0 |
Hematopoietic Stem Cells/cytology/*immunology | 5 | 10.0 |
Macrophage-1 Antigen/metabolism | 6 | 8.0 |
Mice, Inbred Strains | 36 | 4.0 |
Models, Animal | 14 | 5.0 |
Antigens, Differentiation, T-Lymphocyte/analysis | 148 | 43.0 |
Antigens, Fungal/immunology | 8 | 38.0 |
Candida albicans/immunology | 14 | 32.0 |
Cells, Cultured/immunology | 2 | 15.0 |
Environmental Exposure | 4 | 2.0 |
Hypersensitivity, Delayed/*immunology | 16 | 47.0 |
Intradermal Tests | 8 | 34.0 |
Neopterin/*urine | 2 | 100.0 |
Receptors, Interleukin-2/analysis | 97 | 37.0 |
Exercise/*physiology | 22 | 5.0 |
HIV-1/pathogenicity/*physiology | 13 | 48.0 |
Immunologic Memory/*immunology | 13 | 40.0 |
Influenza A Virus, Human/*immunology | 4 | 13.0 |
Influenza Vaccines/administration & dosage/*immunology | 4 | 80.0 |
Lung/virology | 2 | 22.0 |
Gene Expression/*drug effects | 2 | 0.0 |
Membrane Fusion/*drug effects | 17 | 58.0 |
Receptors, CXCR4/*biosynthesis | 7 | 22.0 |
Acquired Immunodeficiency Syndrome/*immunology/virology | 4 | 57.0 |
Dietary Supplements | 7 | 9.0 |
Vagina/virology | 8 | 100.0 |
Vitamin A Deficiency/immunology | 2 | 100.0 |
Acquired Immunodeficiency Syndrome/*drug therapy/immunology/transmission | 2 | 100.0 |
CD4-Positive T-Lymphocytes/*chemistry | 11 | 68.0 |
Receptors, CCR5/*analysis | 5 | 26.0 |
Immunoglobulins/*biosynthesis | 8 | 18.0 |
Intestines/*microbiology | 2 | 12.0 |
Body Weight/physiology | 3 | 4.0 |
Intestinal Absorption/*physiology | 3 | 12.0 |
Fluorescein-5-isothiocyanate | 29 | 21.0 |
Fluorescent Dyes | 38 | 9.0 |
Human Growth Hormone/blood | 2 | 3.0 |
Killer Cells, Natural | 25 | 59.0 |
Phycoerythrin | 10 | 50.0 |
Psychiatric Status Rating Scales | 16 | 7.0 |
Antigens, CD1/*immunology | 2 | 5.0 |
Antigens, CD14/immunology | 9 | 16.0 |
Dendritic Cells/immunology | 32 | 22.0 |
Killer Cells, Natural/*immunology/virology | 2 | 40.0 |
Receptors, Antigen, T-Cell, alpha-beta/immunology | 21 | 33.0 |
Receptors, CXCR4/immunology | 2 | 33.0 |
Receptors, Chemokine/immunology | 3 | 9.0 |
Anti-Bacterial Agents/therapeutic use | 24 | 23.0 |
DNA-Binding Proteins/physiology | 4 | 1.0 |
*JNK Mitogen-Activated Protein Kinases | 2 | 2.0 |
Lymphocytes/*physiology | 13 | 15.0 |
*Signal Transduction | 64 | 3.0 |
Th1 Cells/physiology | 4 | 25.0 |
Th2 Cells/physiology | 3 | 30.0 |
Trans-Activators/physiology | 4 | 2.0 |
Antigens, CD4/*chemistry/genetics/*metabolism | 9 | 100.0 |
Circular Dichroism | 11 | 2.0 |
Peptides/metabolism | 6 | 2.0 |
*Protein Structure, Secondary | 12 | 8.0 |
Adjuvants, Immunologic/administration & dosage/*therapeutic use | 4 | 44.0 |
Antiviral Agents/administration & dosage/*therapeutic use | 12 | 75.0 |
Thymus Extracts/therapeutic use | 2 | 100.0 |
HIV Seropositivity/diagnosis | 8 | 72.0 |
Hospitals, Teaching | 3 | 42.0 |
South Africa | 16 | 10.0 |
HIV-1/genetics/*physiology | 44 | 40.0 |
Placenta/cytology/*virology | 2 | 100.0 |
Receptors, CXCR4/metabolism | 57 | 36.0 |
Receptors, Chemokine/metabolism | 15 | 13.0 |
Dexamethasone/administration & dosage | 5 | 17.0 |
Doxorubicin/administration & dosage | 26 | 14.0 |
Thrombocytopenia/chemically induced | 3 | 15.0 |
Vincristine/administration & dosage | 26 | 16.0 |
Antigens, CD45/metabolism | 27 | 32.0 |
HIV Infections/immunology/virology | 17 | 65.0 |
Microglia/virology | 2 | 40.0 |
Th2 Cells/metabolism | 12 | 28.0 |
Interleukin-10/analysis | 10 | 29.0 |
Plasmodium falciparum/*immunology | 4 | 9.0 |
Hepacivirus/*genetics | 3 | 12.0 |
HLA-DR Antigens/genetics | 12 | 3.0 |
Hepatitis C/*immunology | 5 | 31.0 |
Interleukin-5/biosynthesis | 13 | 38.0 |
Cervical Intraepithelial Neoplasia/complications/*drug therapy | 2 | 100.0 |
HIV Infections/complications/*drug therapy | 35 | 92.0 |
Practice Guidelines | 22 | 27.0 |
HIV Infections/immunology/*physiopathology | 10 | 83.0 |
Menopause/*immunology | 4 | 80.0 |
Outpatients | 4 | 17.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 57 | 11.0 |
HIV-1/isolation & purification | 34 | 80.0 |
DNA, Viral | 36 | 22.0 |
HIV Infections/*immunology/virology | 40 | 63.0 |
HIV-1/isolation & purification/pathogenicity/*physiology | 2 | 66.0 |
Cytokines/*analysis | 12 | 14.0 |
Gene Expression/immunology | 15 | 17.0 |
Interleukin-4/analysis | 13 | 33.0 |
Necrosis | 26 | 7.0 |
*Antigen Presentation | 28 | 17.0 |
Infection/immunology | 4 | 13.0 |
Neoplasms/immunology | 3 | 5.0 |
HIV Infections/*drug therapy/metabolism | 3 | 60.0 |
Receptors, CCR5/antagonists & inhibitors | 4 | 44.0 |
Receptors, CXCR4/antagonists & inhibitors | 4 | 36.0 |
Receptors, Chemokine/*antagonists & inhibitors | 2 | 11.0 |
Cancer Vaccines/*pharmacology | 2 | 100.0 |
Cattle | 29 | 1.0 |
Interleukin-2/*pharmacology | 34 | 13.0 |
Lung Neoplasms/secondary | 3 | 3.0 |
Neoplasm Proteins/immunology | 2 | 5.0 |
Neoplasm Transplantation | 20 | 1.0 |
*Organ Transplantation | 5 | 22.0 |
Antigens, Differentiation/*metabolism | 10 | 8.0 |
HIV Infections/immunology/*physiopathology/virology | 3 | 75.0 |
HIV-1/isolation & purification/*physiology | 12 | 60.0 |
NAD+ Nucleosidase/*metabolism | 2 | 8.0 |
Polymorphism, Single-Stranded Conformational | 11 | 0.0 |
Receptor-CD3 Complex, Antigen, T-Cell/*genetics | 3 | 75.0 |
Syndrome | 41 | 2.0 |
*HIV Seronegativity | 35 | 94.0 |
Enzyme-Linked Immunosorbent Assay/methods | 18 | 6.0 |
Immunoglobulin A/*blood/immunology | 2 | 100.0 |
SIV/genetics/*physiology | 6 | 85.0 |
Amino Acid Substitution | 17 | 1.0 |
HIV Envelope Protein gp120/chemistry/*genetics | 4 | 57.0 |
HIV-1/classification/*genetics | 8 | 38.0 |
Peptide Fragments/chemistry/*genetics | 2 | 40.0 |
Cytomegalovirus Infections/*immunology/virology | 5 | 100.0 |
Kidney Transplantation/*adverse effects | 4 | 6.0 |
T-Lymphocytes, Suppressor-Effector/immunology | 90 | 57.0 |
HIV Envelope Protein gp120/metabolism/*pharmacology | 8 | 88.0 |
Mutagenesis, Site-Directed | 65 | 2.0 |
Interleukin-4/metabolism | 21 | 21.0 |
Major Histocompatibility Complex/*immunology | 11 | 28.0 |
Mice, Inbred CBA | 25 | 7.0 |
Postpartum Period/*immunology | 4 | 80.0 |
Spleen/metabolism | 6 | 4.0 |
Protein Processing, Post-Translational | 32 | 4.0 |
T-Lymphocytes/immunology/metabolism | 28 | 22.0 |
Ubiquitin/*metabolism | 2 | 1.0 |
src Homology Domains | 8 | 1.0 |
CD4-Positive T-Lymphocytes/metabolism/*virology | 9 | 52.0 |
*Cytopathogenic Effect, Viral | 6 | 54.0 |
DNA, Complementary/genetics | 15 | 0.0 |
Plasmids/genetics | 11 | 2.0 |
Proviruses/genetics | 28 | 42.0 |
Retroviridae/genetics | 16 | 4.0 |
Ribonuclease P | 2 | 8.0 |
Protease Inhibitors/therapeutic use | 13 | 68.0 |
*Attitude of Health Personnel | 2 | 15.0 |
HIV Infections/*drug therapy/*psychology | 3 | 100.0 |
Health Knowledge, Attitudes, Practice | 3 | 9.0 |
*Patient Compliance | 27 | 60.0 |
Patient Participation | 5 | 62.0 |
Tumor Necrosis Factor-alpha/biosynthesis | 42 | 8.0 |
Chemotherapy, Adjuvant | 9 | 4.0 |
Florida/epidemiology | 4 | 40.0 |
Mastectomy | 3 | 4.0 |
Radiotherapy, Adjuvant | 4 | 4.0 |
HIV/immunology | 37 | 66.0 |
HIV Infections/*immunology/pathology | 21 | 65.0 |
Lymph Nodes/immunology/pathology | 17 | 40.0 |
Lymphopenia/etiology/immunology | 2 | 66.0 |
Receptors, HIV/immunology | 6 | 60.0 |
Mycobacterium tuberculosis/immunology | 5 | 17.0 |
Plasmodium falciparum/immunology | 5 | 23.0 |
Receptors, Antigen, T-Cell, gamma-delta/*metabolism | 8 | 50.0 |
Autoantigens | 9 | 29.0 |
Histocompatibility Antigens Class II | 7 | 15.0 |
Molecular Mimicry | 9 | 12.0 |
Autoantigens/immunology | 13 | 9.0 |
Autoimmune Diseases/immunology/*pathology | 4 | 80.0 |
Brain/pathology | 12 | 3.0 |
CD4-Positive T-Lymphocytes/immunology/pathology | 25 | 73.0 |
Chemotaxis, Leukocyte | 30 | 16.0 |
Cytokines/physiology | 16 | 8.0 |
Macrophage Activation | 14 | 8.0 |
Magnetic Resonance Imaging | 46 | 4.0 |
Magnetic Resonance Spectroscopy | 16 | 3.0 |
Multiple Sclerosis/immunology/*pathology | 2 | 33.0 |
Myelin Proteins/immunology | 2 | 7.0 |
AIDS-Related Opportunistic Infections/diagnosis/*immunology | 4 | 100.0 |
*CD4-CD8 Ratio | 61 | 92.0 |
Heterosexuality | 11 | 55.0 |
Mouth Mucosa/microbiology | 2 | 28.0 |
Statistics | 33 | 7.0 |
Substance Abuse, Intravenous | 31 | 81.0 |
Antigens, CD3/*immunology | 29 | 27.0 |
Length of Stay | 11 | 13.0 |
Neoplasm Recurrence, Local | 13 | 3.0 |
Postoperative Complications | 11 | 7.0 |
Receptors, Cell Surface/*immunology | 7 | 8.0 |
Adoptive Transfer/*methods | 3 | 60.0 |
Antigens, CD34 | 28 | 4.0 |
CD4-Positive T-Lymphocytes/immunology/*transplantation | 4 | 100.0 |
Cryopreservation | 10 | 9.0 |
Genes, tat | 5 | 17.0 |
DNA-Binding Proteins/*physiology | 3 | 0.0 |
Gene Expression Regulation/*physiology | 3 | 0.0 |
Promoter Regions (Genetics) | 30 | 0.0 |
Trans-Activators/*physiology | 2 | 0.0 |
Antibodies, Monoclonal/adverse effects/*therapeutic use | 10 | 26.0 |
Molecular Structure | 29 | 4.0 |
Peptide Fragments/chemistry/genetics/metabolism | 3 | 4.0 |
Receptors, HIV/*metabolism | 38 | 59.0 |
Serine/chemistry | 3 | 2.0 |
Solutions | 3 | 1.0 |
Thermodynamics | 12 | 3.0 |
Acquired Immunodeficiency Syndrome/drug therapy/*mortality | 4 | 100.0 |
Computer Simulation | 19 | 5.0 |
*Proportional Hazards Models | 6 | 50.0 |
*Survival Analysis | 11 | 73.0 |
Lymphoma, T-Cell/drug therapy/metabolism/*pathology | 2 | 100.0 |
Prednisone/administration & dosage | 20 | 24.0 |
Antigens, CD40/*metabolism | 3 | 6.0 |
Antigens, CD95/*metabolism | 13 | 11.0 |
CHO Cells | 61 | 2.0 |
Caspases/metabolism | 8 | 1.0 |
Down-Regulation/drug effects | 10 | 3.0 |
Gene Expression Regulation, Neoplastic/drug effects | 5 | 1.0 |
*Gene Therapy | 10 | 2.0 |
Hamsters | 104 | 2.0 |
*Intracellular Signaling Peptides and Proteins | 5 | 0.0 |
Membrane Glycoproteins/genetics/metabolism | 2 | 2.0 |
Lymphocytes, Tumor-Infiltrating/*immunology | 22 | 32.0 |
Autoantibodies/*blood | 16 | 5.0 |
Cadherins/immunology | 2 | 15.0 |
Skin Diseases, Vesiculobullous/*immunology | 3 | 13.0 |
Absorption | 2 | 1.0 |
Anti-Bacterial Agents/pharmacology | 8 | 6.0 |
Antibodies, Monoclonal/analysis | 12 | 14.0 |
Antigens, CD40/analysis | 3 | 12.0 |
CD8-Positive T-Lymphocytes/immunology/*metabolism | 10 | 62.0 |
Carrier Proteins/*metabolism | 3 | 0.0 |
Chimeric Proteins/metabolism | 15 | 7.0 |
Phosphorylation/drug effects | 8 | 0.0 |
Tunicamycin/pharmacology | 8 | 10.0 |
Antineoplastic Agents/*pharmacology | 10 | 1.0 |
Transplantation Conditioning | 4 | 7.0 |
*Whole-Body Irradiation | 2 | 12.0 |
Adjuvants, Immunologic/*pharmacology | 22 | 13.0 |
Antigens/metabolism | 4 | 6.0 |
CD4-Positive T-Lymphocytes/*cytology/*immunology | 8 | 88.0 |
Histocompatibility Antigens/metabolism | 3 | 33.0 |
Membrane Glycoproteins/metabolism | 37 | 6.0 |
Homosexuality | 84 | 57.0 |
Taiwan/epidemiology | 3 | 2.0 |
*Antibody Formation | 15 | 15.0 |
Antigens, Surface/analysis | 103 | 24.0 |
Immunoglobulins/immunology | 8 | 17.0 |
Stress/*immunology | 2 | 33.0 |
Anti-HIV Agents/*administration & dosage/adverse effects | 21 | 95.0 |
Dideoxynucleosides/*administration & dosage/adverse effects | 2 | 100.0 |
Lamivudine/*administration & dosage/adverse effects | 3 | 100.0 |
Nelfinavir/*administration & dosage/adverse effects | 2 | 100.0 |
Reverse Transcriptase Inhibitors/*administration & dosage/adverse effects | 6 | 100.0 |
Zidovudine/*administration & dosage/adverse effects | 16 | 94.0 |
Cost-Benefit Analysis | 17 | 14.0 |
HIV Antibodies/blood | 53 | 73.0 |
HIV Core Protein p24/immunology | 26 | 74.0 |
Administration, Cutaneous | 10 | 10.0 |
Anti-Infective Agents/administration & dosage/*therapeutic use | 2 | 66.0 |
Hepatitis C/*complications/*surgery | 2 | 100.0 |
*Liver Transplantation | 9 | 6.0 |
Antigen Presentation/immunology | 12 | 15.0 |
Intercellular Adhesion Molecule-1/immunology | 6 | 14.0 |
Leukocytes, Mononuclear/immunology | 78 | 28.0 |
Macrophages/*immunology | 28 | 11.0 |
Tuberculosis, Pulmonary/*immunology | 15 | 38.0 |
Antigens, CD30/blood | 2 | 40.0 |
Interferon Type II/*immunology | 7 | 17.0 |
Interleukin-5/immunology | 2 | 12.0 |
RNA, Messenger/blood | 7 | 13.0 |
Receptors, CCR5/immunology | 7 | 36.0 |
Receptors, Immunologic/immunology | 21 | 20.0 |
AIDS-Related Opportunistic Infections/*drug therapy/virology | 3 | 100.0 |
Hepatitis C, Chronic/complications/*drug therapy/virology | 2 | 100.0 |
Interferon Alfa-2b/*therapeutic use | 17 | 42.0 |
Actins/metabolism | 9 | 1.0 |
Antigens, CD4/biosynthesis/metabolism | 4 | 80.0 |
Cytoplasm/metabolism | 28 | 3.0 |
Cytoskeleton/metabolism | 3 | 1.0 |
HIV/*metabolism | 25 | 67.0 |
HIV Infections/transmission | 12 | 85.0 |
Leukocytes, Mononuclear/metabolism/virology | 3 | 37.0 |
Microscopy, Electron | 118 | 5.0 |
Trypsin/pharmacology | 8 | 5.0 |
Postpartum Period/immunology | 4 | 66.0 |
Pregnancy/*immunology | 7 | 13.0 |
Pregnancy Complications, Infectious/*immunology | 15 | 71.0 |
Antigens, CD4/immunology/*metabolism | 28 | 100.0 |
Colorectal Neoplasms/immunology/*metabolism/pathology | 2 | 66.0 |
Gene Expression Regulation/immunology | 15 | 9.0 |
Killer Cells, Natural/immunology/*metabolism/pathology | 3 | 75.0 |
T-Lymphocytes/immunology/*metabolism/pathology | 4 | 57.0 |
*Directly Observed Therapy | 2 | 66.0 |
Ritonavir/blood/*therapeutic use | 4 | 100.0 |
Interleukin-2/therapeutic use | 11 | 27.0 |
Anti-HIV Agents/adverse effects/*blood/therapeutic use | 2 | 100.0 |
Drug Monitoring | 11 | 23.0 |
Alanine Transaminase/analysis | 2 | 25.0 |
Pyrimidinones/*therapeutic use | 3 | 100.0 |
Ritonavir/*therapeutic use | 18 | 94.0 |
Drug Resistance, Multiple, Viral | 3 | 75.0 |
AIDS Vaccines/*therapeutic use | 15 | 100.0 |
HIV Infections/*drug therapy/immunology/*virology | 10 | 90.0 |
Antigens, Bacterial/immunology/metabolism | 2 | 28.0 |
Lymphoid Tissue/*immunology | 9 | 33.0 |
Ovalbumin/immunology/metabolism | 2 | 40.0 |
Recombinant Fusion Proteins/immunology/metabolism | 3 | 14.0 |
Streptococcus pyogenes/immunology | 2 | 25.0 |
Fetal Blood/*cytology/immunology | 2 | 8.0 |
Genes, T-Cell Receptor beta/immunology | 2 | 100.0 |
Lung Diseases, Interstitial/*immunology | 5 | 62.0 |
Receptors, Chemokine/*analysis | 5 | 13.0 |
Sjogren's Syndrome/*immunology | 8 | 27.0 |
CD4-Positive T-Lymphocytes/immunology/*metabolism/*virology | 2 | 100.0 |
DNA, Viral/metabolism | 9 | 10.0 |
Virus Integration | 14 | 22.0 |
Virus Latency | 15 | 25.0 |
Atrophy | 8 | 5.0 |
Lymph Nodes/virology | 11 | 73.0 |
Reassortant Viruses/genetics/*pathogenicity | 2 | 66.0 |
Spleen/virology | 3 | 50.0 |
AIDS Vaccines/*administration & dosage/immunology | 2 | 50.0 |
Mouth Mucosa | 3 | 15.0 |
HIV Envelope Protein gp41/*metabolism | 15 | 83.0 |
Viral Fusion Proteins/*metabolism | 8 | 66.0 |
Base Composition | 3 | 1.0 |
HLA-DQ Antigens/biosynthesis/*genetics/immunology | 2 | 100.0 |
Haplotypes/*immunology | 2 | 8.0 |
L Cells (Cell Line) | 14 | 6.0 |
Stem Cells/cytology | 3 | 4.0 |
CD8-Positive T-Lymphocytes/*metabolism | 19 | 52.0 |
Interleukin-1/metabolism | 6 | 2.0 |
Radioligand Assay | 4 | 0.0 |
Complement 3d/metabolism | 2 | 9.0 |
Lymphocyte Subsets/*immunology | 81 | 64.0 |
Maternal-Fetal Exchange | 21 | 16.0 |
Antigens, CD45/immunology | 27 | 42.0 |
Interleukin-10/immunology | 6 | 21.0 |
T-Lymphocytes/*immunology/*pathology | 4 | 50.0 |
Acquired Immunodeficiency Syndrome/etiology/*immunology | 5 | 50.0 |
Antigens, CD28/biosynthesis/*immunology | 2 | 50.0 |
HLA-DR Antigens/biosynthesis/*immunology | 2 | 66.0 |
Allergens/immunology | 11 | 16.0 |
Neutrophils/immunology | 22 | 12.0 |
Tuberculin/immunology | 10 | 17.0 |
Candida/isolation & purification | 4 | 28.0 |
Eosinophils/immunology | 19 | 35.0 |
Hemolysis | 4 | 1.0 |
Immunoglobulin E/blood | 17 | 12.0 |
Mouth/*microbiology | 4 | 26.0 |
HIV Infections/*drug therapy/epidemiology | 4 | 100.0 |
HIV-1/drug effects | 17 | 41.0 |
Indinavir/adverse effects/therapeutic use | 4 | 100.0 |
Lamivudine/adverse effects/therapeutic use | 8 | 100.0 |
Nelfinavir/adverse effects/therapeutic use | 3 | 100.0 |
Zidovudine/adverse effects/therapeutic use | 12 | 85.0 |
HIV-1/metabolism | 21 | 44.0 |
Leukocytes, Mononuclear/*immunology/physiology | 2 | 40.0 |
Receptors, CCR5/metabolism | 59 | 39.0 |
Receptors, CXCR4/immunology/metabolism | 5 | 50.0 |
*Genetic Vectors | 23 | 6.0 |
Hepacivirus/*immunology | 5 | 16.0 |
Hepatitis Antibodies/blood | 3 | 25.0 |
Recombinant Proteins/administration & dosage/genetics/immunology | 2 | 66.0 |
Vaccines, Synthetic | 4 | 33.0 |
HIV Core Protein p24/biosynthesis | 25 | 55.0 |
HIV-1/isolation & purification/*metabolism | 9 | 56.0 |
Heterocyclic Compounds/pharmacology | 5 | 20.0 |
Receptors, Cytokine/metabolism | 5 | 5.0 |
*Receptors, G-Protein-Coupled | 20 | 7.0 |
Receptors, Peptide/metabolism | 3 | 9.0 |
*Receptors, Virus | 7 | 29.0 |
Chimeric Proteins/immunology | 4 | 12.0 |
Diabetes Mellitus, Type 1/*immunology/therapy | 2 | 100.0 |
Histocompatibility Antigens Class II/immunology | 55 | 30.0 |
Interleukin-10/pharmacology | 6 | 8.0 |
Didanosine/*administration & dosage | 9 | 100.0 |
Lamivudine/*administration & dosage | 10 | 83.0 |
Oxazines/*administration & dosage | 3 | 100.0 |
HIV Protease/*genetics | 8 | 88.0 |
Chemokines, CXC/metabolism | 13 | 16.0 |
Proteasome Endopeptidase Complex | 9 | 1.0 |
Receptors, CCR5/*physiology | 11 | 26.0 |
Receptors, CXCR4/*physiology | 10 | 20.0 |
Flow Cytometry/*standards | 5 | 38.0 |
Immunophenotyping/*standards | 8 | 66.0 |
Saudi Arabia | 3 | 7.0 |
Antigens, Surface/metabolism | 13 | 10.0 |
Ionophores/*pharmacology | 3 | 15.0 |
Protein Transport/drug effects | 2 | 3.0 |
Antigens, Viral/pharmacology | 6 | 85.0 |
CD4-Positive T-Lymphocytes/immunology/secretion | 2 | 100.0 |
Cell Communication/immunology | 11 | 13.0 |
Influenza Vaccines/*immunology | 8 | 40.0 |
Intercellular Adhesion Molecule-1/analysis | 23 | 21.0 |
Interferon Type II/biosynthesis/*secretion | 2 | 66.0 |
Killer Cells, Natural/*cytology | 7 | 30.0 |
Host-Parasite Relations | 3 | 8.0 |
Immunosuppressive Agents/pharmacology | 26 | 15.0 |
*Lymphocyte Activation/drug effects | 23 | 21.0 |
Sheep/*immunology | 2 | 15.0 |
HIV Infections/*drug therapy/*immunology | 47 | 87.0 |
*Gene Deletion | 8 | 0.0 |
Giant Cells/*physiology | 4 | 57.0 |
HIV-1/isolation & purification/*pathogenicity/*physiology | 3 | 100.0 |
Heteroduplex Analysis | 4 | 5.0 |
Emotions | 2 | 9.0 |
Oxazines/adverse effects/*therapeutic use | 6 | 100.0 |
Disease Transmission, Vertical/*prevention & control | 23 | 88.0 |
HIV Infections/*prevention & control/transmission | 4 | 100.0 |
Mothers | 4 | 4.0 |
Questionnaires/*standards | 2 | 28.0 |
Rural Population | 5 | 5.0 |
Antigens, CD56 | 20 | 28.0 |
B-Lymphocytes/cytology | 14 | 17.0 |
HIV-1/drug effects/genetics/*immunology | 4 | 100.0 |
Killer Cells, Natural/cytology | 13 | 52.0 |
Receptors, IgG | 27 | 19.0 |
Antigens, CD28/immunology | 28 | 19.0 |
Antigens, Differentiation/*biosynthesis | 2 | 6.0 |
Clonal Anergy/*immunology | 6 | 25.0 |
Receptors, CCR5/biosynthesis | 11 | 27.0 |
Receptors, Interleukin-2/biosynthesis | 29 | 27.0 |
*Up-Regulation | 5 | 2.0 |
HLA-DR Antigens/metabolism | 23 | 16.0 |
HIV Infections/*blood/drug therapy/*virology | 2 | 100.0 |
HIV-1/genetics/*isolation & purification | 40 | 85.0 |
Autoimmune Diseases/chemically induced/immunology | 2 | 66.0 |
Rats, Inbred BN | 5 | 10.0 |
Rats, Inbred Strains | 15 | 1.0 |
Receptors, Interleukin-2/immunology/metabolism | 3 | 42.0 |
T-Lymphocyte Subsets/drug effects/immunology/physiology | 2 | 66.0 |
Thymectomy | 14 | 46.0 |
Antigens, CD8/*metabolism | 20 | 60.0 |
Antioxidants/*pharmacology | 6 | 4.0 |
Kidney Failure, Chronic/*immunology/therapy | 4 | 44.0 |
*Membranes, Artificial | 6 | 7.0 |
Enzyme Inhibitors/*therapeutic use | 3 | 3.0 |
*Kidney Transplantation/statistics & numerical data | 2 | 100.0 |
Lactic Acid/blood | 2 | 4.0 |
*Leukocyte Count | 37 | 56.0 |
Cytokines/genetics/metabolism | 3 | 9.0 |
T-Lymphocytes/metabolism/*physiology | 2 | 15.0 |
*Disease Models, Animal | 18 | 5.0 |
Interferon Type II/*genetics | 7 | 13.0 |
Lymph Nodes/immunology | 31 | 31.0 |
Cocaine/*pharmacology | 2 | 18.0 |
HIV-1/*drug effects/growth & development | 10 | 71.0 |
Anti-HIV Agents/pharmacology/*therapeutic use | 25 | 78.0 |
Nevirapine/pharmacology/therapeutic use | 2 | 100.0 |
Pyrimidinones/pharmacology/*therapeutic use | 2 | 100.0 |
Reverse Transcriptase Inhibitors/pharmacology/*therapeutic use | 11 | 84.0 |
Ritonavir/pharmacology/*therapeutic use | 2 | 100.0 |
Genes, pol | 9 | 50.0 |
RNA, Viral/*analysis | 25 | 49.0 |
Acquired Immunodeficiency Syndrome/immunology/*transmission | 4 | 100.0 |
CD4-Positive T-Lymphocytes/virology | 41 | 60.0 |
Chemokines/biosynthesis | 8 | 20.0 |
*Sexual Behavior | 14 | 58.0 |
Antigens, CD3/analysis/biosynthesis | 2 | 100.0 |
Antigens, CD8/analysis/biosynthesis | 2 | 100.0 |
Gene Rearrangement, T-Lymphocyte/immunology | 2 | 66.0 |
RNA, Viral/analysis/biosynthesis | 3 | 60.0 |
Serologic Tests | 11 | 13.0 |
*Antiretroviral Therapy, Highly Active/adverse effects | 11 | 100.0 |
Creatinine/blood | 5 | 1.0 |
HIV Infections/complications/*drug therapy/physiopathology | 4 | 100.0 |
Antiviral Agents/administration & dosage/therapeutic use | 6 | 66.0 |
HIV Infections/*complications/drug therapy/epidemiology | 2 | 100.0 |
Hepacivirus/*physiology | 2 | 9.0 |
Giant Cells/drug effects | 12 | 85.0 |
HIV Core Protein p24/drug effects | 7 | 100.0 |
Chimeric Proteins/genetics/metabolism | 6 | 7.0 |
HIV Envelope Protein gp120/*chemistry/genetics/*metabolism | 6 | 50.0 |
HIV-1/genetics/immunology/*pathogenicity | 3 | 60.0 |
Antibodies, Monoclonal/immunology/metabolism | 7 | 17.0 |
Conserved Sequence | 20 | 1.0 |
*Frameshift Mutation | 2 | 1.0 |
HIV Antibodies/*immunology/metabolism | 5 | 83.0 |
HIV Envelope Protein gp120/chemistry/genetics/metabolism | 3 | 100.0 |
Membrane Fusion | 62 | 46.0 |
Gene Products, env/*metabolism | 21 | 75.0 |
Macrophages/*virology | 24 | 41.0 |
Receptors, CCR5 | 25 | 50.0 |
Simian Acquired Immunodeficiency Syndrome/immunology/virology | 3 | 60.0 |
Apoptosis/*drug effects/immunology | 3 | 23.0 |
Enzyme Activation | 62 | 1.0 |
Proto-Oncogene Proteins c-bcl-2/metabolism | 13 | 2.0 |
Receptors, Tumor Necrosis Factor, Type I | 7 | 2.0 |
Receptors, Tumor Necrosis Factor, Type II | 11 | 4.0 |
Signal Transduction/drug effects/immunology | 5 | 10.0 |
Antigens, CD4/analysis/*immunology | 14 | 87.0 |
Dendritic Cells/immunology/pathology | 7 | 36.0 |
Neoplasm Invasiveness/immunology | 2 | 40.0 |
HIV Envelope Protein gp41/metabolism | 18 | 72.0 |
Interleukin-12/biosynthesis | 10 | 10.0 |
Interleukin-4/biosynthesis | 48 | 33.0 |
Interleukins/*biosynthesis | 3 | 12.0 |
Smoking/*adverse effects | 6 | 2.0 |
Th1 Cells/metabolism | 7 | 26.0 |
Antigens, CD45 | 94 | 43.0 |
Lung Diseases/immunology | 5 | 50.0 |
Lymphoid Tissue | 2 | 18.0 |
Cytokines/biosynthesis/genetics | 6 | 9.0 |
Cytotoxicity Tests, Immunologic | 64 | 15.0 |
Microscopy, Fluorescence | 42 | 2.0 |
RNA, Messenger/biosynthesis | 43 | 2.0 |
Hemophilia A/drug therapy/*immunology | 3 | 42.0 |
Interferon Type II/secretion | 19 | 18.0 |
Interleukin-10/secretion | 7 | 21.0 |
Isoantigens/*immunology | 11 | 14.0 |
Spleen/immunology | 27 | 15.0 |
AIDS-Related Opportunistic Infections/drug therapy/*virology | 2 | 100.0 |
Hepatitis B virus/drug effects | 2 | 100.0 |
Lamivudine/*therapeutic use | 34 | 97.0 |
Mutagenesis | 35 | 3.0 |
Netherlands | 9 | 5.0 |
Artifacts | 4 | 7.0 |
DNA Primers/chemistry | 21 | 1.0 |
Micromanipulation | 2 | 11.0 |
*Microsatellite Repeats | 8 | 3.0 |
*Polymorphism, Genetic | 28 | 0.0 |
Antigens, CD4/biosynthesis/*metabolism | 4 | 100.0 |
Cell Membrane/drug effects | 2 | 5.0 |
Detergents/pharmacology | 5 | 4.0 |
HL-60 Cells | 11 | 1.0 |
Lymphocyte Specific Protein Tyrosine Kinase p56(lck)/*metabolism | 16 | 40.0 |
Octoxynol/pharmacology | 5 | 9.0 |
AIDS-Related Opportunistic Infections/*immunology | 23 | 79.0 |
Tuberculosis/*immunology | 10 | 33.0 |
HIV Infections/drug therapy/*physiopathology | 6 | 100.0 |
Lymphocyte Subsets/*classification/immunology | 2 | 66.0 |
Occupational Exposure/*adverse effects | 9 | 9.0 |
Polycyclic Hydrocarbons, Aromatic/*adverse effects | 2 | 18.0 |
Anti-HIV Agents/administration & dosage/*pharmacology | 4 | 66.0 |
Hemophilia A/complications/*virology | 3 | 100.0 |
HIV Infections/immunology/*prevention & control | 5 | 71.0 |
*Body Weight | 6 | 9.0 |
Diet Records | 5 | 20.0 |
Dietary Fats/administration & dosage | 4 | 4.0 |
Dietary Proteins/administration & dosage | 3 | 8.0 |
Energy Intake/*physiology | 2 | 15.0 |
Minority Groups | 3 | 42.0 |
Nutrition Assessment | 3 | 12.0 |
Ionomycin | 7 | 30.0 |
Knee Joint/*immunology | 2 | 66.0 |
Leukocytes, Mononuclear/drug effects/immunology | 8 | 17.0 |
Osteoarthritis/*immunology | 2 | 18.0 |
T-Lymphocytes/drug effects/*immunology | 39 | 26.0 |
Antibodies, Monoclonal/diagnostic use | 136 | 16.0 |
Leukocytes/*drug effects | 4 | 33.0 |
Lymphocytes/drug effects | 9 | 13.0 |
Monocytes/drug effects | 5 | 9.0 |
Urban Population/statistics & numerical data | 4 | 40.0 |
Antigens, CD20/biosynthesis | 2 | 11.0 |
Antigens, CD40/biosynthesis | 4 | 14.0 |
Antigens, CD80/biosynthesis | 3 | 5.0 |
Antigens, Differentiation, B-Lymphocyte/biosynthesis | 9 | 31.0 |
B-Lymphocytes/*microbiology | 4 | 40.0 |
Endoscopy | 5 | 14.0 |
Histocompatibility Antigens Class II/biosynthesis | 9 | 20.0 |
Membrane Glycoproteins/biosynthesis | 15 | 9.0 |
T-Lymphocytes/*microbiology | 19 | 61.0 |
Endometriosis/*immunology | 3 | 33.0 |
Extracellular Matrix Proteins/*immunology | 2 | 33.0 |
Infertility, Female/*immunology | 2 | 25.0 |
Antigens, CD/*genetics | 7 | 2.0 |
Asparaginase/administration & dosage | 3 | 14.0 |
Bone Marrow Transplantation | 19 | 7.0 |
*Killer Cells, Natural | 7 | 31.0 |
Membrane Glycoproteins/*genetics | 3 | 0.0 |
Antigens, CD57/*analysis | 2 | 22.0 |
Blood Sedimentation | 7 | 4.0 |
Interleukin-4/analysis/biosynthesis | 3 | 75.0 |
Cytomegalovirus Infections/*epidemiology | 3 | 60.0 |
Herpesvirus 6, Human/*genetics/pathogenicity | 2 | 100.0 |
Antigens, CD26/metabolism | 2 | 15.0 |
Antiviral Agents/*metabolism | 3 | 25.0 |
Peptides/*metabolism | 6 | 3.0 |
Africa, Southern/epidemiology | 2 | 100.0 |
*Genes, nef | 28 | 93.0 |
*Genes, rev | 5 | 62.0 |
*Genes, tat | 3 | 10.0 |
HIV Infections/epidemiology/*virology | 4 | 50.0 |
*HIV Long Terminal Repeat | 14 | 15.0 |
Giant Cells | 32 | 54.0 |
HIV-1/isolation & purification/metabolism/*physiology | 2 | 66.0 |
Condoms | 3 | 100.0 |
Hispanic Americans | 9 | 14.0 |
*Models, Biological | 23 | 11.0 |
Antibodies, Monoclonal/administration & dosage/*therapeutic use | 3 | 21.0 |
Arthritis, Rheumatoid/immunology/*therapy | 12 | 54.0 |
Photopheresis/*methods | 2 | 66.0 |
*Drug Monitoring | 4 | 20.0 |
HIV Infections/blood/*drug therapy | 36 | 90.0 |
HIV Infections/*blood/*complications/immunology | 3 | 100.0 |
Immune Sera/immunology | 11 | 6.0 |
*Membrane Glycoproteins | 25 | 2.0 |
SIV/genetics/immunology/*physiology | 2 | 66.0 |
*Sequence Deletion | 3 | 0.0 |
*Viral Envelope Proteins | 10 | 22.0 |
Antigens, CD4/*biosynthesis/genetics | 13 | 92.0 |
Antigens, CD8/*biosynthesis/genetics | 3 | 75.0 |
Gene Expression Regulation/drug effects | 20 | 2.0 |
Tetradecanoylphorbol Acetate/*pharmacology | 34 | 11.0 |
Thymus Gland/cytology/*immunology | 13 | 41.0 |
Alanine Transaminase/blood | 27 | 14.0 |
Liver/pathology | 14 | 7.0 |
Substance Abuse, Intravenous/complications | 38 | 82.0 |
Drug Tolerance | 23 | 19.0 |
HIV Infections/*complications/immunology/virology | 14 | 100.0 |
Interleukin-6/blood | 21 | 4.0 |
Receptors, Interleukin-6/blood | 3 | 16.0 |
Tretinoin/administration & dosage/adverse effects/*therapeutic use | 2 | 100.0 |
Dideoxynucleosides/*therapeutic use | 13 | 92.0 |
HIV-1/*drug effects/*genetics | 3 | 75.0 |
Oxazines/*therapeutic use | 5 | 100.0 |
Sulfonamides/*therapeutic use | 3 | 42.0 |
HIV Infections/complications/*drug therapy/immunology/virology | 4 | 100.0 |
HIV-1/drug effects/isolation & purification | 9 | 81.0 |
Switzerland | 12 | 16.0 |
HIV-1/*drug effects/genetics | 20 | 66.0 |
CD4-Positive T-Lymphocytes/*drug effects/*immunology | 3 | 60.0 |
CD4-Positive T-Lymphocytes/drug effects/*virology | 2 | 100.0 |
HIV Infections/drug therapy/immunology/virology | 4 | 80.0 |
HIV-1/drug effects/genetics/*physiology | 8 | 61.0 |
Adjuvants, Immunologic/therapeutic use | 16 | 36.0 |
Ritonavir/therapeutic use | 27 | 93.0 |
Epitope Mapping | 27 | 10.0 |
Gene Products, gag/genetics/*immunology | 3 | 60.0 |
HIV Antigens/genetics | 4 | 57.0 |
HLA-A Antigens | 2 | 0.0 |
Body Composition/*drug effects | 4 | 30.0 |
Electric Impedance | 7 | 12.0 |
Enteral Nutrition | 3 | 12.0 |
*Food, Formulated | 4 | 21.0 |
Acquired Immunodeficiency Syndrome/*drug therapy/psychology | 2 | 50.0 |
AIDS-Related Opportunistic Infections/drug therapy/*immunology | 7 | 87.0 |
HIV Infections/drug therapy/immunology | 12 | 92.0 |
Substance Abuse, Intravenous/*complications | 34 | 97.0 |
*Evolution, Molecular | 9 | 2.0 |
Genes, env | 29 | 50.0 |
*HIV-1/genetics/immunology | 14 | 87.0 |
Tuberculosis, Pulmonary/complications | 4 | 50.0 |
Interleukin-2/administration & dosage/*therapeutic use | 15 | 55.0 |
RNA, Viral/blood/drug effects | 5 | 100.0 |
Macrophage Inflammatory Protein-1/*biosynthesis | 4 | 57.0 |
RANTES/*biosynthesis | 3 | 25.0 |
Receptors, CCR5/*biosynthesis | 9 | 37.0 |
Antigens, CD26/*metabolism | 4 | 18.0 |
Baculoviridae | 5 | 9.0 |
Peritoneal Cavity/*pathology | 2 | 28.0 |
Peritoneal Dialysis, Continuous Ambulatory | 2 | 4.0 |
Aftercare | 2 | 28.0 |
Patient Compliance/*psychology/statistics & numerical data | 3 | 100.0 |
Liver/*pathology | 5 | 9.0 |
Antigens, CD28/metabolism | 15 | 15.0 |
Antigens, Surface/biosynthesis | 5 | 8.0 |
Clone Cells/drug effects/immunology/metabolism | 2 | 33.0 |
HIV Envelope Protein gp120/*chemistry/*metabolism | 7 | 87.0 |
Recombinant Proteins/chemistry/genetics/metabolism | 3 | 0.0 |
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 7 | 2.0 |
Anti-HIV Agents/adverse effects/therapeutic use | 12 | 92.0 |
Nuclear Family | 5 | 2.0 |
HIV Seropositivity/*drug therapy/immunology | 7 | 87.0 |
Glucocorticoids/therapeutic use | 10 | 14.0 |
RNA, Messenger/*genetics | 6 | 1.0 |
*Blood Cell Count | 3 | 30.0 |
*Electromagnetic Fields | 2 | 6.0 |
Hemoglobins/*analysis | 3 | 5.0 |
Immune System/*radiation effects | 3 | 75.0 |
Occupational Exposure | 3 | 3.0 |
Endosomes/virology | 2 | 100.0 |
Lectins/*physiology | 3 | 37.0 |
Interferon-alpha/therapeutic use | 9 | 23.0 |
Ribavirin/therapeutic use | 4 | 36.0 |
Acquired Immunodeficiency Syndrome/complications/drug therapy | 7 | 70.0 |
Liposomes | 23 | 8.0 |
Sarcoma, Kaposi/complications/*drug therapy | 8 | 88.0 |
Aging/*physiology | 11 | 4.0 |
Immune System/*physiology | 21 | 33.0 |
Immunity/physiology | 2 | 14.0 |
Lymphocyte Subsets/cytology | 9 | 52.0 |
Neutrophils/physiology | 10 | 9.0 |
Phagocytosis/physiology | 6 | 19.0 |
Annexin A5/analysis | 3 | 13.0 |
HIV Infections/*therapy | 26 | 83.0 |
Virus Replication/*genetics | 10 | 30.0 |
Microspheres | 19 | 9.0 |
AIDS Vaccines/administration & dosage/*therapeutic use | 2 | 100.0 |
Didanosine/administration & dosage/*therapeutic use | 13 | 100.0 |
Stavudine/administration & dosage/*therapeutic use | 5 | 100.0 |
Hospitals | 3 | 33.0 |
Anti-Inflammatory Agents/pharmacology | 2 | 3.0 |
Cyclosporine/*pharmacology | 15 | 14.0 |
Depression, Chemical | 8 | 4.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/biosynthesis | 6 | 15.0 |
Immunosuppressive Agents/*pharmacology | 31 | 15.0 |
Lymphocyte Activation/*drug effects/immunology | 3 | 13.0 |
Epstein-Barr Virus Nuclear Antigens/metabolism | 3 | 27.0 |
Herpesvirus 4, Human/*metabolism | 2 | 4.0 |
*Oxidation-Reduction | 2 | 9.0 |
Anti-Bacterial Agents | 2 | 18.0 |
Anti-Infective Agents/*pharmacology | 3 | 9.0 |
Microbial Sensitivity Tests | 44 | 18.0 |
Nigeria/epidemiology | 4 | 12.0 |
Community-Acquired Infections/epidemiology | 2 | 100.0 |
Cross Infection/epidemiology | 2 | 100.0 |
Kidney Failure, Chronic/therapy | 4 | 11.0 |
Lipopolysaccharides/immunology | 9 | 7.0 |
*Neutrophil Activation | 2 | 6.0 |
Antigens, CD57/analysis | 14 | 32.0 |
Biological Transport | 35 | 2.0 |
HIV Core Protein p24/analysis | 59 | 78.0 |
HIV-1/*growth & development | 40 | 62.0 |
Proviruses/physiology | 8 | 66.0 |
RNA Splicing | 11 | 2.0 |
*Transcription, Genetic | 18 | 0.0 |
Antigens, Differentiation, T-Lymphocyte/biosynthesis | 14 | 17.0 |
Lymphoid Tissue/*virology | 3 | 42.0 |
Phorbol Esters/*pharmacology | 8 | 20.0 |
Receptors, CXCR4/biosynthesis | 9 | 27.0 |
Transcription, Genetic/drug effects | 7 | 1.0 |
Virus Integration/drug effects | 3 | 42.0 |
Virus Latency/*drug effects | 2 | 100.0 |
Endopeptidases/metabolism | 6 | 4.0 |
HIV Infections/drug therapy/*metabolism | 3 | 60.0 |
Muscle, Skeletal/*metabolism | 2 | 1.0 |
Trypsin/metabolism | 4 | 2.0 |
Cell Division/physiology | 13 | 1.0 |
DNA-Binding Proteins/*metabolism | 6 | 0.0 |
Transforming Growth Factor beta/*metabolism | 2 | 0.0 |
CD8-Positive T-Lymphocytes/*virology | 9 | 90.0 |
HIV-1/immunology/*pathogenicity | 12 | 85.0 |
Antigens, Differentiation, T-Lymphocyte/blood | 8 | 34.0 |
Intraoperative Period | 2 | 3.0 |
Receptors, IgG/blood | 5 | 35.0 |
Asian Continental Ancestry Group | 4 | 1.0 |
*Promoter Regions (Genetics) | 15 | 0.0 |
*Substance Abuse, Intravenous | 17 | 89.0 |
Chromatography, High Pressure Liquid | 22 | 1.0 |
HIV-1/*enzymology | 2 | 11.0 |
Intracellular Fluid/metabolism | 7 | 6.0 |
*HIV-1/genetics | 46 | 82.0 |
Colitis/*immunology | 2 | 66.0 |
Gene Transfer Techniques | 19 | 3.0 |
Intestinal Mucosa/*immunology | 30 | 33.0 |
Tumor Necrosis Factor-alpha/genetics/*immunology | 2 | 16.0 |
Acquired Immunodeficiency Syndrome/*complications | 156 | 81.0 |
Stereotaxic Techniques | 3 | 10.0 |
Genetic Heterogeneity | 8 | 2.0 |
Genetic Markers | 13 | 0.0 |
*Genetics, Population | 8 | 2.0 |
Language | 2 | 8.0 |
Tandem Repeat Sequences/*genetics | 5 | 5.0 |
*Counseling | 3 | 50.0 |
New York City | 9 | 30.0 |
Gene Expression/drug effects | 17 | 2.0 |
*Gene Expression Profiling | 2 | 0.0 |
HIV Infections/immunology/*therapy/virology | 8 | 72.0 |
Immunotoxins/*therapeutic use | 7 | 15.0 |
Receptors, Interleukin-2/antagonists & inhibitors | 3 | 37.0 |
Viremia/therapy | 3 | 100.0 |
HIV Infections/blood/drug therapy/*immunology/virology | 4 | 100.0 |
Receptors, Antigen, T-Cell, alpha-beta/*blood | 3 | 100.0 |
*Treatment Refusal | 2 | 66.0 |
*Cognition | 3 | 6.0 |
HIV Infections/immunology/*psychology | 6 | 100.0 |
HIV Infections/blood/*drug therapy/immunology/virology | 6 | 100.0 |
Indinavir/therapeutic use | 25 | 89.0 |
Saquinavir/therapeutic use | 17 | 100.0 |
CD8-Positive T-Lymphocytes/cytology/*immunology | 18 | 66.0 |
HIV Infections/blood/*immunology/virology | 5 | 71.0 |
Receptors, Immunologic/*immunology | 11 | 9.0 |
Antigens, CD28 | 15 | 10.0 |
Membrane Glycoproteins | 8 | 18.0 |
Tonsil/cytology | 4 | 4.0 |
Apoptosis/drug effects | 27 | 4.0 |
B-Lymphocytes/*cytology | 2 | 3.0 |
RNA, Viral | 20 | 47.0 |
*Endocytosis/drug effects | 2 | 16.0 |
Protein Synthesis Inhibitors/pharmacology | 10 | 2.0 |
Sucrose/pharmacology | 2 | 6.0 |
HIV Infections/*complications/diagnosis/drug therapy | 6 | 100.0 |
Hemodynamic Processes | 5 | 2.0 |
Drug Utilization | 3 | 27.0 |
Substance-Related Disorders/complications | 14 | 58.0 |
*Women's Health | 8 | 27.0 |
Biotin | 3 | 4.0 |
HIV-1/immunology/*physiology | 36 | 67.0 |
Receptors, Virus/immunology | 9 | 69.0 |
DNA, Viral/analysis/genetics | 9 | 47.0 |
Genes, gag | 13 | 56.0 |
India/ethnology | 4 | 5.0 |
Asthma/drug therapy | 6 | 27.0 |
Eosinophils/*drug effects/immunology | 2 | 50.0 |
Lymphocytes/*drug effects/immunology | 12 | 50.0 |
Sputum/*cytology | 4 | 36.0 |
AIDS-Related Opportunistic Infections/diagnosis/*epidemiology | 12 | 100.0 |
Germany | 8 | 2.0 |
HIV Seropositivity/diagnosis/*epidemiology | 4 | 100.0 |
*Helicobacter pylori | 8 | 7.0 |
Antigens, CD95/biosynthesis | 8 | 27.0 |
T-Lymphocyte Subsets/immunology/*metabolism/pathology | 3 | 60.0 |
*Cytotoxicity, Immunologic | 67 | 13.0 |
Enzyme Activation/immunology | 8 | 6.0 |
T-Lymphocytes, Cytotoxic/enzymology/*immunology | 2 | 100.0 |
Epitopes, T-Lymphocyte/genetics/immunology | 5 | 62.0 |
Immunologic Memory/genetics | 3 | 42.0 |
Interphase/genetics/immunology | 3 | 33.0 |
Lymph Nodes/cytology/immunology | 7 | 29.0 |
Acquired Immunodeficiency Syndrome/*drug therapy | 45 | 71.0 |
Educational Status | 13 | 20.0 |
Gene Products, env/*genetics | 6 | 75.0 |
HIV Infections/complications/virology | 4 | 66.0 |
Mycobacterium tuberculosis | 6 | 37.0 |
Antigens, CD4/physiology | 61 | 75.0 |
Antigens, Differentiation, T-Lymphocyte/immunology/*metabolism | 5 | 38.0 |
Histocompatibility Antigens Class I/physiology | 5 | 22.0 |
T-Lymphocytes/metabolism/*virology | 6 | 31.0 |
*Virus Latency | 5 | 10.0 |
Cytopathogenic Effect, Viral | 78 | 52.0 |
HIV Envelope Protein gp120/*genetics/metabolism | 10 | 76.0 |
HIV-1/*genetics/*pathogenicity | 2 | 100.0 |
Recombination, Genetic | 25 | 2.0 |
Health Surveys | 9 | 13.0 |
Urban Health | 5 | 12.0 |
HIV Infections/*complications/*drug therapy | 15 | 100.0 |
Dogs | 39 | 3.0 |
Fluorescent Antibody Technique, Indirect | 30 | 3.0 |
Lymphatic System/*immunology | 2 | 100.0 |
Exercise/physiology | 5 | 7.0 |
Exercise Test | 8 | 3.0 |
Hydrocortisone/blood | 26 | 6.0 |
Lymphocyte Subsets/*drug effects | 17 | 85.0 |
Random Allocation | 23 | 5.0 |
Testosterone/blood | 12 | 2.0 |
Antiretroviral Therapy, Highly Active/economics | 4 | 100.0 |
Dideoxynucleosides/adverse effects/*therapeutic use | 3 | 100.0 |
Health Care Costs | 10 | 37.0 |
C-Reactive Protein/analysis | 13 | 2.0 |
Cell Nucleus/pathology | 2 | 2.0 |
Erythema/pathology | 2 | 100.0 |
*Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 5 | 41.0 |
L-Lactate Dehydrogenase/blood | 5 | 4.0 |
Antifungal Agents/adverse effects/*therapeutic use | 2 | 66.0 |
Candidiasis/*drug therapy | 2 | 50.0 |
*Peptides | 5 | 8.0 |
*Peptides, Cyclic | 2 | 28.0 |
Biopsy/methods | 8 | 16.0 |
*Lymphocytes | 6 | 37.0 |
*Macrophages | 4 | 33.0 |
Prostate/*pathology | 2 | 8.0 |
Prostatic Hyperplasia/*blood/*pathology | 2 | 100.0 |
Autopsy | 16 | 8.0 |
Cytogenetic Analysis | 4 | 3.0 |
Leukemia, Myeloid, Chronic/*immunology | 4 | 40.0 |
Receptors, Immunologic/*analysis | 6 | 11.0 |
Antigens, Neoplasm | 3 | 7.0 |
Cancer Vaccines/immunology | 2 | 10.0 |
Immunoassay/*methods | 2 | 2.0 |
Bronchoalveolar Lavage Fluid/*chemistry | 5 | 8.0 |
Antigens, CD8/*immunology | 38 | 74.0 |
Lasers/*therapeutic use | 2 | 15.0 |
Fluorouracil/administration & dosage | 4 | 3.0 |
Methotrexate/administration & dosage | 12 | 12.0 |
Interleukin-2/*immunology | 10 | 15.0 |
Lung Neoplasms/*drug therapy/immunology | 2 | 50.0 |
*Breast Feeding | 10 | 15.0 |
*Immunity | 12 | 24.0 |
*Infant Food | 2 | 5.0 |
*Adoptive Transfer | 5 | 41.0 |
Blood Component Removal | 4 | 8.0 |
CD4-Positive T-Lymphocytes/*transplantation | 4 | 100.0 |
Feasibility Studies | 17 | 7.0 |
HIV Infections/*immunology/therapy | 10 | 66.0 |
Transplantation, Autologous | 29 | 7.0 |
Hepatitis C/epidemiology | 2 | 40.0 |
Antibodies, Monoclonal/*therapeutic use | 66 | 20.0 |
Etoposide/*therapeutic use | 2 | 28.0 |
Lymphoma, AIDS-Related/*drug therapy/mortality | 3 | 100.0 |
Receptors, Antigen, T-Cell/chemistry | 3 | 75.0 |
Thymoma/*immunology/*pathology | 2 | 100.0 |
Alanine/chemistry | 3 | 4.0 |
Amino Acid Motifs | 17 | 1.0 |
*Antigens, Differentiation | 10 | 10.0 |
Cell Membrane/metabolism | 53 | 3.0 |
Cytoskeletal Proteins/*metabolism | 2 | 1.0 |
Glutathione Transferase/metabolism | 2 | 0.0 |
K562 Cells | 7 | 1.0 |
Luminescent Proteins/metabolism | 6 | 1.0 |
Membrane Proteins/*metabolism | 25 | 5.0 |
Microfilament Proteins/*metabolism | 2 | 3.0 |
Phosphoproteins/*metabolism | 8 | 1.0 |
Drug Resistance, Viral/*genetics | 16 | 88.0 |
HIV Protease Inhibitors/*pharmacology/therapeutic use | 5 | 100.0 |
HIV-1/*drug effects/genetics/physiology | 11 | 52.0 |
Antiviral Agents/*adverse effects | 6 | 75.0 |
Bilirubin/blood | 5 | 5.0 |
HIV Infections/*complications/*drug therapy/epidemiology | 2 | 100.0 |
HIV Protease Inhibitors/*adverse effects | 9 | 75.0 |
Hepatitis C/complications/epidemiology | 4 | 66.0 |
Ritonavir/adverse effects | 2 | 50.0 |
Body Composition/drug effects | 4 | 28.0 |
HIV Infections/blood/*drug therapy/pathology | 2 | 100.0 |
Hypercholesterolemia/chemically induced | 3 | 100.0 |
Hyperglycemia/chemically induced | 3 | 50.0 |
Triglycerides/blood | 19 | 1.0 |
Acquired Immunodeficiency Syndrome/*immunology/prevention & control | 4 | 100.0 |
Cloning, Organism | 2 | 11.0 |
HIV Infections/immunology | 58 | 67.0 |
Simian Acquired Immunodeficiency Syndrome/*immunology | 7 | 38.0 |
*Disease Progression | 7 | 36.0 |
Greece | 4 | 4.0 |
Hemophilia A/complications | 14 | 82.0 |
*Markov Chains | 6 | 66.0 |
Interleukin-2/genetics | 13 | 14.0 |
Interleukin-4/*genetics | 3 | 6.0 |
Transcription Factors/*physiology | 3 | 0.0 |
HIV Infections/complications/*therapy | 5 | 100.0 |
Dideoxynucleosides/therapeutic use | 7 | 87.0 |
Cyclophosphamide/pharmacology | 4 | 10.0 |
Cyclosporine/therapeutic use | 15 | 22.0 |
Infection Control | 3 | 42.0 |
Prednisone/therapeutic use | 18 | 17.0 |
*Transplantation Conditioning | 6 | 24.0 |
Carrier Proteins/analysis | 4 | 4.0 |
Gene Rearrangement, B-Lymphocyte, Heavy Chain | 4 | 6.0 |
Gene Rearrangement, T-Lymphocyte | 46 | 44.0 |
Lymph Nodes/chemistry/pathology | 5 | 22.0 |
Neoplasm Proteins/*analysis | 8 | 2.0 |
Neprilysin/*analysis | 3 | 25.0 |
Proto-Oncogene Proteins/analysis | 4 | 2.0 |
Transcription Factors/analysis | 2 | 2.0 |
Tumor Markers, Biological/*analysis | 15 | 1.0 |
Tumor Stem Cells/*metabolism | 2 | 13.0 |
Islets of Langerhans/immunology | 6 | 15.0 |
Peptide Fragments/therapeutic use | 2 | 22.0 |
DNA, Viral/genetics | 33 | 20.0 |
T-Lymphocyte Subsets/cytology/*immunology | 9 | 37.0 |
*Antibody Specificity | 3 | 4.0 |
B-Lymphocytes/*virology | 3 | 21.0 |
Vitreous Body/virology | 2 | 100.0 |
*HIV-1/immunology/physiology | 4 | 100.0 |
Receptors, Chemokine/genetics/metabolism | 4 | 17.0 |
Antitubercular Agents/*adverse effects | 2 | 50.0 |
Treatment Refusal | 6 | 46.0 |
Antigens, CD3/physiology | 18 | 24.0 |
CD40 Ligand/biosynthesis | 2 | 18.0 |
Cell Differentiation/drug effects/immunology | 9 | 12.0 |
Enzyme Activation/drug effects/immunology | 2 | 6.0 |
Lymphocyte Activation/drug effects/immunology | 16 | 26.0 |
Monocytes/cytology | 14 | 13.0 |
NF-kappa B/metabolism | 17 | 2.0 |
T-Lymphocytes/*immunology/metabolism | 39 | 25.0 |
Antigens, CD7/*metabolism | 2 | 20.0 |
HIV Infections/*diagnosis/immunology/virology | 2 | 100.0 |
Heroin | 3 | 75.0 |
Immunoglobulins/blood | 37 | 43.0 |
Medicine, Chinese Traditional | 3 | 23.0 |
Antineoplastic Agents/adverse effects/*therapeutic use | 6 | 18.0 |
Consumer Product Safety | 5 | 35.0 |
Salvage Therapy/*methods | 4 | 36.0 |
Blood Transfusion, Autologous | 6 | 25.0 |
Breast Neoplasms/immunology/pathology/*therapy | 2 | 66.0 |
*Lymphocyte Transfusion | 9 | 33.0 |
Education | 2 | 12.0 |
HIV Seropositivity/*drug therapy | 8 | 72.0 |
Aging/blood/*immunology | 2 | 50.0 |
Antigens, CD3 | 184 | 40.0 |
Carrier State | 9 | 33.0 |
Cytomegalovirus/immunology | 29 | 42.0 |
T-Lymphocyte Subsets/cytology | 8 | 53.0 |
Aging/*immunology | 42 | 35.0 |
Antigens, CD28/*biosynthesis | 2 | 11.0 |
Cell Aging | 3 | 3.0 |
Receptors, Interleukin-2/*biosynthesis | 14 | 35.0 |
Staining and Labeling | 41 | 6.0 |
Staphylococcus aureus | 10 | 15.0 |
Cerebrovascular Circulation/physiology | 2 | 9.0 |
Substance-Related Disorders/*complications | 5 | 38.0 |
Autoantibodies/*analysis | 8 | 3.0 |
T-Lymphocyte Subsets/*drug effects/immunology | 11 | 52.0 |
CD4 Lymphocyte Count/methods | 18 | 100.0 |
Immunophenotyping/methods | 12 | 24.0 |
*Biocompatible Materials | 2 | 5.0 |
Polymers | 4 | 3.0 |
Antiviral Agents/pharmacology/*therapeutic use | 8 | 88.0 |
HIV Infections/complications | 26 | 61.0 |
Organophosphorus Compounds/pharmacology/*therapeutic use | 2 | 100.0 |
*Phosphonic Acids | 29 | 65.0 |
Sarcoma, Kaposi/*drug therapy/virology | 4 | 100.0 |
HIV/isolation & purification | 26 | 81.0 |
DNA/isolation & purification | 5 | 3.0 |
DNA Fingerprinting/*methods | 2 | 3.0 |
Ukraine | 2 | 7.0 |
Hypersensitivity, Delayed/epidemiology/*immunology | 2 | 100.0 |
Colorado/epidemiology | 2 | 22.0 |
HIV Infections/complications/*epidemiology/mortality | 2 | 100.0 |
Health Services Accessibility | 9 | 60.0 |
Los Angeles/epidemiology | 5 | 35.0 |
Mental Disorders/complications | 3 | 60.0 |
Washington/epidemiology | 4 | 25.0 |
CD4-Positive T-Lymphocytes/*physiology | 58 | 70.0 |
CD8-Positive T-Lymphocytes/*physiology | 9 | 52.0 |
HIV Infections/*etiology | 10 | 83.0 |
Viral Proteins | 2 | 33.0 |
Ambulatory Care | 7 | 21.0 |
Arthritis, Rheumatoid/*genetics/*immunology | 2 | 9.0 |
HLA Antigens/*genetics | 8 | 0.0 |
HLA-DQ Antigens/genetics | 3 | 1.0 |
*Thymectomy | 5 | 62.0 |
CD8-Positive T-Lymphocytes/cytology/drug effects/*immunology | 4 | 50.0 |
Cytokines/biosynthesis/*pharmacology | 2 | 66.0 |
Blood Cells/pathology | 4 | 21.0 |
Gene Rearrangement, B-Lymphocyte | 4 | 7.0 |
Lymphocytes/pathology | 16 | 16.0 |
Spleen/pathology | 8 | 11.0 |
HIV Envelope Protein gp120/pharmacology | 12 | 54.0 |
Interleukin-16/*pharmacology | 4 | 100.0 |
3T3 Cells | 34 | 1.0 |
*Adjuvants, Immunologic | 6 | 19.0 |
Lymph Nodes/cytology | 14 | 34.0 |
Cervix Neoplasms/*immunology | 6 | 30.0 |
Dendritic Cells/*immunology | 36 | 14.0 |
Oncogene Proteins, Viral/genetics/*immunology | 6 | 35.0 |
1-Deoxynojirimycin/*pharmacology | 2 | 100.0 |
Antiviral Agents/*pharmacology | 43 | 28.0 |
Glycosylation/drug effects | 4 | 12.0 |
HIV/*drug effects/metabolism | 3 | 100.0 |
HIV Envelope Protein gp120/immunology/*metabolism | 16 | 80.0 |
Adjuvants, Immunologic/administration & dosage | 4 | 23.0 |
Administration, Intranasal | 7 | 8.0 |
CD4-Positive T-Lymphocytes/*immunology/transplantation | 3 | 60.0 |
CD8-Positive T-Lymphocytes/immunology/transplantation | 3 | 100.0 |
*Capsid Proteins | 4 | 3.0 |
*Escherichia coli Proteins | 4 | 1.0 |
Immunity, Mucosal/immunology | 4 | 44.0 |
Immunologic Deficiency Syndromes/genetics/immunology | 2 | 28.0 |
Mice, Nude | 31 | 1.0 |
Thymus Gland/immunology | 24 | 36.0 |
CD40 Ligand/*metabolism | 2 | 14.0 |
Deoxyribonuclease I/metabolism | 2 | 1.0 |
Enhancer Elements (Genetics) | 9 | 2.0 |
Adenoviridae/*genetics | 6 | 2.0 |
*Inflammation | 2 | 5.0 |
Neutrophils/metabolism | 7 | 5.0 |
Organ Size | 6 | 3.0 |
*Smoking | 4 | 4.0 |
CD8-Positive T-Lymphocytes/drug effects/*immunology | 9 | 69.0 |
*Transplantation Immunology | 9 | 20.0 |
HIV Infections/drug therapy/*physiopathology/psychology | 2 | 100.0 |
*Self Assessment (Psychology) | 3 | 60.0 |
*Severity of Illness Index | 7 | 13.0 |
*Outcome Assessment (Health Care) | 3 | 6.0 |
Research Design | 9 | 10.0 |
*Veterans | 5 | 45.0 |
Chemokines, CXC/*genetics | 4 | 12.0 |
Nucleosides/*therapeutic use | 4 | 57.0 |
AIDS-Related Opportunistic Infections/complications/*immunology | 3 | 75.0 |
Acquired Immunodeficiency Syndrome/*complications/drug therapy | 11 | 78.0 |
Interferon Type II/genetics/*immunology | 2 | 40.0 |
Mycobacterium avium/*immunology | 3 | 33.0 |
CD4-Positive T-Lymphocytes/*immunology/pathology/*virology | 2 | 66.0 |
CD8-Positive T-Lymphocytes/*immunology/pathology/*virology | 2 | 100.0 |
Major Histocompatibility Complex/immunology | 21 | 42.0 |
Acquired Immunodeficiency Syndrome/immunology | 63 | 68.0 |
CD4 Lymphocyte Count/*statistics & numerical data | 3 | 100.0 |
Randomized Controlled Trials/statistics & numerical data | 2 | 22.0 |
*Regression Analysis | 2 | 28.0 |
Gene Products, gag/*immunology | 15 | 62.0 |
HIV Antigens/*immunology | 33 | 62.0 |
Histocompatibility Antigens Class I/immunology | 32 | 31.0 |
Phycocyanin/metabolism | 2 | 50.0 |
Antigens, CD4/*analysis | 128 | 80.0 |
Antigens, Differentiation, T-Lymphocyte/*analysis | 88 | 42.0 |
HIV Infections/metabolism/*transmission | 2 | 100.0 |
Placenta/*metabolism | 2 | 1.0 |
Pregnancy Complications, Infectious/*metabolism | 2 | 100.0 |
Receptors, Cell Surface/immunology/*metabolism | 2 | 6.0 |
Antigens, CD95/*physiology | 7 | 8.0 |
CD4-Positive T-Lymphocytes/*immunology/virology | 20 | 80.0 |
Interleukin-1/*metabolism | 2 | 2.0 |
DNA/analysis | 32 | 3.0 |
*Gene Rearrangement, T-Lymphocyte | 9 | 19.0 |
*Genes, T-Cell Receptor | 4 | 66.0 |
Granulocyte Colony-Stimulating Factor/therapeutic use | 4 | 7.0 |
Neutrophils | 9 | 13.0 |
Pneumonia, Pneumocystis/prevention & control | 15 | 83.0 |
*Antigen-Antibody Reactions | 4 | 10.0 |
Immunomagnetic Separation | 17 | 16.0 |
Peptide Fragments/genetics/immunology | 9 | 26.0 |
Ionomycin/pharmacology | 31 | 13.0 |
Tyrosine/metabolism | 42 | 3.0 |
AIDS-Related Opportunistic Infections/*epidemiology | 30 | 96.0 |
Cytomegalovirus Infections/epidemiology | 7 | 77.0 |
Pneumonia, Bacterial/epidemiology | 2 | 100.0 |
Pneumonia, Pneumocystis/epidemiology | 8 | 100.0 |
HIV Infections/*drug therapy/*physiopathology/virology | 2 | 100.0 |
*Health Surveys | 2 | 40.0 |
Nevirapine/adverse effects/*therapeutic use | 9 | 100.0 |
Anti-Bacterial Agents/pharmacology/*therapeutic use | 2 | 25.0 |
*Antibiotic Prophylaxis | 7 | 58.0 |
Clarithromycin/pharmacology/*therapeutic use | 2 | 100.0 |
Mycobacterium avium Complex/drug effects | 3 | 100.0 |
Mycobacterium avium-intracellulare Infection/*prevention & control | 10 | 100.0 |
HIV Infections/*physiopathology/virology | 3 | 60.0 |
Drug Resistance, Multiple, Bacterial | 2 | 66.0 |
Mycobacterium tuberculosis/drug effects/isolation & purification | 2 | 100.0 |
HIV Infections/*complications/*drug therapy/immunology | 5 | 100.0 |
Herpesvirus 4, Human/isolation & purification/*physiology | 2 | 50.0 |
Viral Matrix Proteins/genetics/metabolism | 2 | 33.0 |
Immune System/*drug effects | 13 | 52.0 |
Candidiasis, Oral/epidemiology/prevention & control | 2 | 100.0 |
Cold | 3 | 2.0 |
Hemagglutination Inhibition Tests | 3 | 6.0 |
Influenza/prevention & control | 5 | 62.0 |
Influenza Vaccines/administration & dosage/*adverse effects/*immunology | 2 | 100.0 |
Virus Shedding | 14 | 58.0 |
Anti-Inflammatory Agents/therapeutic use | 15 | 18.0 |
Drug Hypersensitivity/*prevention & control | 2 | 100.0 |
Nevirapine/*adverse effects/therapeutic use | 4 | 100.0 |
Lipids/*blood | 7 | 1.0 |
Lipoproteins/blood | 3 | 0.0 |
Nevirapine/*therapeutic use | 10 | 90.0 |
Interleukin-2/*metabolism | 12 | 25.0 |
SIV/*immunology | 15 | 55.0 |
Vaccinia virus | 8 | 38.0 |
Viral Vaccines/*administration & dosage/immunology | 2 | 100.0 |
AIDS Vaccines | 6 | 50.0 |
Chemokines/immunology | 7 | 43.0 |
Dendritic Cells/immunology/*virology | 5 | 50.0 |
Gene Targeting | 4 | 1.0 |
HIV-1/*genetics/physiology | 10 | 38.0 |
Virulence/immunology | 2 | 18.0 |
Bacterial Infections/complications | 5 | 41.0 |
*Hematopoietic Stem Cell Transplantation/adverse effects | 3 | 8.0 |
Neutropenia/complications | 5 | 83.0 |
Opportunistic Infections/complications | 21 | 91.0 |
Antibodies, Bacterial/blood | 11 | 16.0 |
Infection/epidemiology | 5 | 45.0 |
Monocytes | 11 | 11.0 |
Streptococcus pneumoniae/immunology | 6 | 28.0 |
Tissue Donors | 11 | 4.0 |
Leukocytes, Mononuclear/pathology | 9 | 45.0 |
Senegal | 8 | 26.0 |
Gene Products, tat/immunology | 2 | 33.0 |
HIV Infections/*immunology/*therapy | 12 | 100.0 |
Isoantigens/administration & dosage | 2 | 40.0 |
Viral Envelope Proteins/immunology | 11 | 44.0 |
Viral Vaccines/therapeutic use | 2 | 100.0 |
Cytosine/*analogs & derivatives/therapeutic use | 2 | 100.0 |
Organophosphorus Compounds/therapeutic use | 6 | 100.0 |
HIV Infections/*drug therapy/genetics/immunology | 3 | 100.0 |
HIV-1/drug effects/*genetics | 14 | 77.0 |
Zalcitabine/*therapeutic use | 9 | 100.0 |
Terminology | 5 | 3.0 |
AIDS Vaccines/immunology | 9 | 64.0 |
*CD4-Positive T-Lymphocytes/immunology | 5 | 100.0 |
Didanosine/*adverse effects/therapeutic use | 3 | 100.0 |
Electromyography | 3 | 1.0 |
Reverse Transcriptase Inhibitors/*adverse effects/therapeutic use | 12 | 85.0 |
Stavudine/*adverse effects/therapeutic use | 3 | 100.0 |
HIV Infections/*drug therapy/transmission | 8 | 100.0 |
Pregnancy Complications, Infectious/*drug therapy/virology | 3 | 100.0 |
Immunocompromised Host | 46 | 56.0 |
Placebos | 28 | 11.0 |
AIDS Vaccines/immunology/pharmacology/*therapeutic use | 2 | 100.0 |
Freund's Adjuvant/therapeutic use | 2 | 66.0 |
HIV Protease Inhibitors/administration & dosage/*therapeutic use | 11 | 91.0 |
Ritonavir/administration & dosage/*therapeutic use | 4 | 66.0 |
Saquinavir/administration & dosage/*therapeutic use | 7 | 77.0 |
Stavudine/administration & dosage | 9 | 100.0 |
Zalcitabine/administration & dosage | 4 | 100.0 |
Europe/epidemiology | 23 | 26.0 |
HIV Infections/*drug therapy/*mortality | 5 | 100.0 |
HIV Seropositivity/epidemiology | 8 | 80.0 |
Sexual Behavior | 51 | 67.0 |
*Cell Line | 5 | 10.0 |
HIV Infections/immunology/pathology/*virology | 6 | 100.0 |
T-Lymphocytes/immunology/pathology/*virology | 2 | 100.0 |
Apoptosis/drug effects/*immunology | 7 | 18.0 |
Indoles/pharmacology | 2 | 0.0 |
Maleimides/pharmacology | 2 | 2.0 |
*DNA Helicases | 2 | 0.0 |
*DNA-Binding Proteins | 12 | 0.0 |
Genes, Recessive | 3 | 0.0 |
Proteins/genetics | 8 | 1.0 |
Severe Combined Immunodeficiency/genetics/immunology/pathology | 2 | 50.0 |
Transcription Factors/genetics | 3 | 0.0 |
*Transcription Factors, TFII | 2 | 1.0 |
*Flow Cytometry | 44 | 26.0 |
Thymoma/*immunology | 3 | 42.0 |
Thymus Neoplasms/*immunology | 3 | 42.0 |
Cell Communication/drug effects | 2 | 5.0 |
Contraceptive Agents, Female/*pharmacology | 2 | 33.0 |
Endothelial Cells/cytology/drug effects | 2 | 50.0 |
Endothelium, Vascular/cytology/*drug effects/metabolism | 2 | 2.0 |
Estradiol/pharmacology | 3 | 1.0 |
Leukocytes/cytology | 10 | 34.0 |
Medroxyprogesterone 17-Acetate/*pharmacology | 2 | 20.0 |
Nitric Oxide/metabolism | 6 | 3.0 |
Nitric-Oxide Synthase/genetics/metabolism | 2 | 9.0 |
Ovariectomy | 3 | 2.0 |
Progesterone/*pharmacology | 2 | 2.0 |
Signal Transduction/*drug effects | 11 | 3.0 |
Umbilical Veins/cytology | 5 | 1.0 |
Dendritic Cells/pathology | 5 | 21.0 |
In Situ Hybridization, Fluorescence | 20 | 0.0 |
Translocation, Genetic | 12 | 1.0 |
*Tumor Cells, Cultured | 6 | 8.0 |
CD8-Positive T-Lymphocytes/immunology/pathology | 16 | 76.0 |
Cell Division/genetics/immunology | 8 | 28.0 |
Immunotherapy, Adoptive/methods | 3 | 25.0 |
Injections, Intralesional | 8 | 17.0 |
Killer Cells, Natural/immunology/pathology | 10 | 66.0 |
Neoplasm Transplantation/immunology | 2 | 33.0 |
Vaccines, DNA/administration & dosage/genetics/immunology | 2 | 66.0 |
Cote d'Ivoire/epidemiology | 10 | 83.0 |
*Attitude to Health | 7 | 21.0 |
Homosexuality, Male/*psychology | 4 | 100.0 |
Perception | 3 | 21.0 |
Safe Sex | 2 | 100.0 |
Sexual Partners | 17 | 89.0 |
Africa South of the Sahara/epidemiology | 5 | 55.0 |
Tuberculosis/complications/*mortality | 2 | 100.0 |
Mycophenolic Acid/*analogs & derivatives/*therapeutic use | 2 | 50.0 |
Ireland | 3 | 5.0 |
HIV Seropositivity/immunology | 61 | 66.0 |
AIDS Vaccines/*administration & dosage | 5 | 62.0 |
HLA-A2 Antigen/*immunology | 3 | 13.0 |
Developing Countries | 16 | 22.0 |
Antitubercular Agents/*pharmacology | 2 | 18.0 |
Acquired Immunodeficiency Syndrome/*virology | 8 | 40.0 |
Genes, Viral/genetics | 2 | 8.0 |
Genetic Markers/genetics | 3 | 0.0 |
HIV/*genetics/pathogenicity | 4 | 80.0 |
Linkage Disequilibrium/genetics | 3 | 1.0 |
*Models, Genetic | 3 | 2.0 |
Mice, Inbred C3H | 24 | 3.0 |
Myristic Acid/metabolism | 2 | 8.0 |
Histocompatibility Antigens Class I/chemistry/genetics/*metabolism | 2 | 25.0 |
Peptide Fragments/chemistry/genetics/*metabolism | 2 | 15.0 |
HIV Infections/complications/*mortality | 6 | 100.0 |
HIV Infections/*etiology/physiopathology | 2 | 100.0 |
Hepacivirus/isolation & purification | 5 | 31.0 |
Immune System/physiopathology | 6 | 46.0 |
Interferons/therapeutic use | 7 | 24.0 |
Liver Cirrhosis/etiology | 3 | 42.0 |
*Alleles | 14 | 1.0 |
Portugal | 4 | 6.0 |
*Tandem Repeat Sequences | 5 | 4.0 |
Clinical Protocols | 11 | 17.0 |
HIV Infections/*drug therapy/*virology | 14 | 82.0 |
Cardiomyopathy, Dilated/etiology | 3 | 100.0 |
Myocarditis/etiology | 2 | 66.0 |
C-Reactive Protein/*metabolism | 2 | 0.0 |
Digestive System Surgical Procedures | 3 | 33.0 |
Interleukin-6/*metabolism | 3 | 2.0 |
*Laparoscopy | 4 | 22.0 |
CD4-Positive T-Lymphocytes/*physiology/virology | 2 | 66.0 |
Gene Expression Regulation, Viral | 30 | 11.0 |
JNK Mitogen-Activated Protein Kinases | 5 | 0.0 |
MAP Kinase Kinase 1 | 4 | 2.0 |
MAP Kinase Kinase 2 | 3 | 6.0 |
MAP Kinase Signaling System/*physiology | 2 | 2.0 |
Mitogen-Activated Protein Kinase Kinases/metabolism | 2 | 1.0 |
Protein-Serine-Threonine Kinases/metabolism | 12 | 1.0 |
Adrenergic alpha-Agonists/therapeutic use | 3 | 42.0 |
Arteries/physiopathology | 3 | 30.0 |
Blood Pressure/physiology | 3 | 1.0 |
Brain/physiopathology | 5 | 9.0 |
Cardiac Output, Low/*physiopathology | 3 | 25.0 |
Gene Therapy | 21 | 6.0 |
Hypertension/*physiopathology/therapy | 3 | 42.0 |
Receptors, Adrenergic, alpha/genetics/*physiology | 3 | 50.0 |
Polymerase Chain Reaction/methods | 52 | 4.0 |
Birth Weight | 8 | 5.0 |
HIV Infections/blood/*complications | 15 | 88.0 |
Malaria/complications | 3 | 50.0 |
Maternal Welfare | 2 | 40.0 |
Tanzania | 11 | 35.0 |
Mast Cells/immunology | 4 | 14.0 |
Sex Characteristics | 18 | 3.0 |
Skin Transplantation/immunology | 9 | 37.0 |
Transplantation Tolerance/*immunology | 3 | 37.0 |
Autoimmunity/*immunology | 8 | 17.0 |
Histocompatibility Antigens/*immunology | 7 | 29.0 |
Receptors, Antigen, T-Cell/chemistry/*immunology/metabolism | 2 | 100.0 |
Self Tolerance/immunology | 3 | 37.0 |
Hybridomas/immunology | 24 | 19.0 |
Receptors, Interleukin-2/*immunology | 11 | 26.0 |
Self Tolerance/*immunology | 3 | 60.0 |
HIV Infections/*drug therapy/immunology/physiopathology/virology | 4 | 100.0 |
HIV-1/genetics | 25 | 41.0 |
HIV Infections/*drug therapy/immunology/physiopathology/*virology | 2 | 100.0 |
Chromosomes, Human, Pair 2 | 3 | 1.0 |
Chromosomes, Human, Pair 8 | 3 | 2.0 |
Albendazole/therapeutic use | 5 | 100.0 |
Antiprotozoal Agents/therapeutic use | 9 | 90.0 |
Keratoconjunctivitis/diagnosis/drug therapy/*parasitology | 2 | 100.0 |
Immunity, Cellular/*drug effects | 18 | 43.0 |
Killer Cells, Natural/drug effects | 17 | 48.0 |
T-Lymphocytes, Helper-Inducer/drug effects | 5 | 45.0 |
Electrophoresis, Polyacrylamide Gel/methods | 2 | 1.0 |
Histamine Release | 3 | 5.0 |
Skin/immunology/pathology | 12 | 28.0 |
Bone Marrow Transplantation/immunology | 3 | 8.0 |
HLA Antigens/analysis | 22 | 8.0 |
Histocompatibility | 6 | 5.0 |
Immunotherapy, Adoptive/*methods | 9 | 23.0 |
Interleukin-7/pharmacology | 6 | 13.0 |
Antibodies | 18 | 4.0 |
Astrocytoma | 3 | 8.0 |
Cytomegalovirus/genetics | 5 | 5.0 |
Protein Folding | 14 | 3.0 |
RNA-Binding Proteins/*metabolism | 2 | 2.0 |
Viral Envelope Proteins/*metabolism | 18 | 41.0 |
beta 2-Microglobulin/metabolism | 25 | 32.0 |
Immunity, Mucosal | 22 | 32.0 |
Chemokines, CC/*physiology | 2 | 14.0 |
Dendritic Cells/virology | 5 | 50.0 |
HIV Envelope Protein gp120/physiology | 14 | 77.0 |
Receptors, HIV/*physiology | 24 | 64.0 |
Tropism/*physiology | 3 | 75.0 |
Virus Replication/*physiology | 14 | 27.0 |
Administration, Rectal | 2 | 22.0 |
Antibodies, Viral/biosynthesis | 12 | 31.0 |
HIV Antibodies/biosynthesis | 14 | 70.0 |
HIV-1/genetics/immunology | 12 | 92.0 |
Injections, Intramuscular | 12 | 7.0 |
SIV/genetics/immunology | 2 | 100.0 |
Acquired Immunodeficiency Syndrome/blood/*drug therapy | 6 | 85.0 |
Anti-HIV Agents/*pharmacology/therapeutic use | 17 | 68.0 |
Brazil | 19 | 8.0 |
Point Mutation | 23 | 1.0 |
Reverse Transcriptase Inhibitors/*pharmacology/therapeutic use | 5 | 55.0 |
Lung Diseases/*drug therapy | 2 | 50.0 |
Antibodies, Bacterial/*blood | 9 | 18.0 |
B-Lymphocyte Subsets/pathology | 2 | 40.0 |
Borrelia burgdorferi/*immunology | 2 | 50.0 |
Killer Cells, Natural/pathology | 18 | 60.0 |
Lyme Disease/drug therapy/*immunology | 2 | 66.0 |
T-Lymphocyte Subsets/pathology | 18 | 64.0 |
Antigens, CD4/*physiology | 107 | 93.0 |
Receptors, CXCR4/physiology | 24 | 52.0 |
Celiac Disease/*immunology | 6 | 31.0 |
Epithelium/immunology | 24 | 17.0 |
Intestinal Neoplasms/*immunology | 2 | 100.0 |
Lymphoma, T-Cell/*immunology | 5 | 71.0 |
Colitis, Ulcerative/immunology | 7 | 50.0 |
Colon/immunology | 5 | 23.0 |
Crohn Disease/*immunology | 8 | 21.0 |
Liver Function Tests | 12 | 6.0 |
Autoimmunity/immunology | 5 | 17.0 |
B-Lymphocytes/cytology/*immunology | 7 | 9.0 |
Immunity/*immunology | 4 | 40.0 |
*Immunotherapy, Adoptive | 17 | 27.0 |
Lymphocytes, Tumor-Infiltrating/*transplantation | 2 | 100.0 |
Insulin/*secretion | 2 | 2.0 |
Swine | 32 | 2.0 |
Transplantation, Heterologous/*immunology | 10 | 16.0 |
Body Mass Index | 29 | 2.0 |
Peptide Fragments/*immunology/metabolism | 2 | 16.0 |
HIV Protease Inhibitors/*adverse effects/therapeutic use | 5 | 62.0 |
European Continental Ancestry Group/genetics | 5 | 0.0 |
Polymorphism, Genetic/genetics | 6 | 0.0 |
Antigens, Surface/*physiology | 7 | 10.0 |
T-Lymphocytes/immunology/*virology | 8 | 50.0 |
Antibiotics, Antifungal/therapeutic use | 4 | 80.0 |
T-Lymphocytes/*classification | 25 | 65.0 |
Viremia/drug therapy/immunology/virology | 8 | 88.0 |
Cell Cycle/drug effects | 9 | 1.0 |
Outcome Assessment (Health Care) | 8 | 17.0 |
Gene Products, env/genetics/*metabolism | 9 | 75.0 |
Genes, nef | 22 | 81.0 |
Membrane Fusion/physiology | 5 | 27.0 |
Antibodies, Monoclonal/*chemistry/genetics | 2 | 50.0 |
Antigens, CD4/chemistry/*immunology | 10 | 100.0 |
Immunoglobulin Variable Region/chemistry/genetics | 2 | 33.0 |
Immunoglobulins, Heavy-Chain/chemistry/genetics | 2 | 33.0 |
Immunoglobulins, Light-Chain/chemistry/genetics | 2 | 33.0 |
Antigens, Differentiation, B-Lymphocyte/analysis | 33 | 18.0 |
Antigens, Differentiation, Myelomonocytic/analysis | 37 | 10.0 |
B-Lymphocytes/pathology | 21 | 24.0 |
Dyes/diagnostic use | 4 | 5.0 |
Gingiva/*enzymology | 2 | 50.0 |
Granulocyte Colony-Stimulating Factor/analysis | 3 | 42.0 |
Image Processing, Computer-Assisted | 12 | 3.0 |
Leukocytes, Mononuclear/*metabolism/pathology | 2 | 100.0 |
Macrophages/pathology | 24 | 20.0 |
Membrane Proteins/analysis | 11 | 9.0 |
Monocytes/pathology | 10 | 27.0 |
RNA-Binding Proteins/analysis | 8 | 40.0 |
Antigens, CD3/*analysis | 13 | 43.0 |
Antiretroviral Therapy, Highly Active/*psychology | 6 | 100.0 |
*Risk-Taking | 4 | 40.0 |
Sexual Behavior/*psychology | 3 | 100.0 |
Substance Abuse, Intravenous/*psychology | 2 | 100.0 |
CD4-Positive T-Lymphocytes/cytology/drug effects | 3 | 100.0 |
HIV Infections/*drug therapy/immunology/metabolism/virology | 3 | 100.0 |
HIV-1/*genetics/growth & development | 6 | 50.0 |
Receptors, Antigen, T-Cell/*genetics | 21 | 22.0 |
Antigens, CD4/analysis/genetics | 11 | 100.0 |
Gene Products, gag/genetics | 9 | 47.0 |
Gene Products, pol/genetics | 2 | 50.0 |
HIV Core Protein p24/genetics | 7 | 63.0 |
HT29 Cells | 2 | 1.0 |
HIV Infections/transmission/*virology | 5 | 45.0 |
Leukocytes, Mononuclear/physiology | 7 | 23.0 |
T-Lymphocyte Subsets | 83 | 63.0 |
Vagina/*virology | 5 | 83.0 |
Antigens, CD/biosynthesis/genetics | 3 | 8.0 |
Antigens, CD4/biosynthesis/genetics | 4 | 44.0 |
Antigens, Differentiation, T-Lymphocyte/biosynthesis/genetics | 2 | 20.0 |
Graft vs Host Disease/*immunology | 5 | 18.0 |
L-Selectin/biosynthesis | 6 | 31.0 |
Receptors, Interleukin-2/biosynthesis/genetics | 3 | 30.0 |
Blood Cell Count | 32 | 13.0 |
Integrin alphaXbeta2/*analysis | 2 | 33.0 |
Interleukin-12/secretion | 3 | 11.0 |
Receptors, Interleukin-3/*analysis | 2 | 50.0 |
CD8-Positive T-Lymphocytes/transplantation | 2 | 100.0 |
France/epidemiology | 23 | 17.0 |
Graft Survival | 15 | 3.0 |
*Blood Component Removal | 3 | 10.0 |
Cell Separation/*methods | 13 | 9.0 |
Fetal Blood/*cytology | 14 | 7.0 |
Granulocyte Colony-Stimulating Factor/*pharmacology | 7 | 5.0 |
Hematopoietic Stem Cell Mobilization | 3 | 3.0 |
Monocytes/*cytology | 3 | 3.0 |
Pinocytosis | 2 | 16.0 |
Synovial Fluid/metabolism | 2 | 6.0 |
Th1 Cells | 3 | 25.0 |
Antigens, CD1/metabolism | 3 | 7.0 |
Antigens, CD80/metabolism | 5 | 6.0 |
Mouth Mucosa/immunology/pathology | 3 | 30.0 |
Apoptosis/*physiology | 25 | 3.0 |
*Bacterial Proteins | 11 | 5.0 |
DNA Fragmentation | 14 | 4.0 |
Epithelial Cells/pathology | 2 | 2.0 |
Epithelium/pathology | 11 | 8.0 |
T-Lymphocytes/pathology | 28 | 26.0 |
*Cell Line, Transformed | 3 | 50.0 |
Leukocytes, Mononuclear/physiology/*virology | 2 | 100.0 |
HIV Infections/drug therapy/ethnology/*immunology | 2 | 100.0 |
New York City/epidemiology | 20 | 55.0 |
Biological Markers/*blood | 17 | 9.0 |
Zidovudine/*pharmacology/therapeutic use | 6 | 85.0 |
Antigens, CD45/*metabolism | 10 | 32.0 |
Bronchoalveolar Lavage Fluid/*cytology | 19 | 43.0 |
Antigens, CD4/*genetics/physiology | 2 | 100.0 |
Asthma/*immunology/pathology | 3 | 23.0 |
Bronchoalveolar Lavage Fluid/immunology | 11 | 31.0 |
Lung/pathology/physiopathology | 2 | 33.0 |
Pollen/immunology | 4 | 12.0 |
Herpesvirus 6, Human/*physiology | 3 | 30.0 |
Lymphoid Tissue/immunology/virology | 2 | 66.0 |
Receptors, CCR5/physiology | 15 | 48.0 |
CD4-Positive T-Lymphocytes/drug effects/*metabolism/physiology/*virology | 2 | 100.0 |
*Cell Death | 7 | 16.0 |
Cytochrome c Group/metabolism | 2 | 1.0 |
Intracellular Membranes/metabolism | 6 | 3.0 |
Permeability | 5 | 3.0 |
Protein Precursors/metabolism | 23 | 18.0 |
Receptors, Tumor Necrosis Factor/metabolism | 5 | 2.0 |
Viral Proteins/metabolism | 8 | 11.0 |
*Community Health Services | 4 | 66.0 |
HIV Infections/diagnosis/*therapy | 4 | 100.0 |
Medically Uninsured | 2 | 50.0 |
Patient Acceptance of Health Care/*statistics & numerical data | 3 | 100.0 |
Poverty Areas | 2 | 50.0 |
*Primary Health Care | 2 | 20.0 |
Interleukin-6/*blood | 8 | 2.0 |
Tumor Necrosis Factor-alpha/*analysis | 11 | 4.0 |
Antigens, CD95/immunology/metabolism | 2 | 15.0 |
Immunoglobulin Idiotypes/immunology | 10 | 43.0 |
Immunoglobulin Variable Region/genetics/*immunology | 3 | 42.0 |
Interferon Type II/immunology/metabolism | 6 | 42.0 |
Recombinant Proteins/immunology | 63 | 18.0 |
Hepatitis C/*complications | 6 | 33.0 |
*Chemical Industry | 3 | 17.0 |
CD4-Positive T-Lymphocytes/chemistry/*metabolism | 3 | 100.0 |
CD40 Ligand/analysis/*biosynthesis | 2 | 100.0 |
Immunoglobulin A/blood | 24 | 22.0 |
Immunoglobulin M/blood | 29 | 21.0 |
Annexin A5/metabolism | 11 | 12.0 |
Antibodies, Monoclonal/*pharmacology | 21 | 11.0 |
Flow Cytometry/*methods/statistics & numerical data | 3 | 42.0 |
Hepatitis C/*complications/*drug therapy | 4 | 100.0 |
Antigens, Differentiation, T-Lymphocyte/*immunology | 72 | 30.0 |
Antigens, Neoplasm/analysis | 30 | 9.0 |
HIV Infections/*immunology/*physiopathology/virology | 5 | 100.0 |
Saquinavir/*therapeutic use | 17 | 100.0 |
Triglycerides/*blood | 5 | 1.0 |
Herpesvirus 8, Human/*immunology | 5 | 71.0 |
*Homosexuality, Male | 33 | 97.0 |
HIV Infections/*complications/drug therapy/virology | 6 | 100.0 |
Papillomavirus, Human/genetics/isolation & purification | 3 | 42.0 |
Hepacivirus/genetics/isolation & purification | 2 | 33.0 |
Hepatitis C, Chronic/*complications/*drug therapy | 3 | 75.0 |
Antitubercular Agents/*therapeutic use | 11 | 57.0 |
Brazil/epidemiology | 11 | 13.0 |
Tuberculin Test | 24 | 46.0 |
Anti-HIV Agents/*administration & dosage/therapeutic use | 5 | 83.0 |
Receptors, Antigen, T-Cell, alpha-beta/*metabolism | 5 | 38.0 |
*HIV-1/isolation & purification/physiology | 3 | 100.0 |
Killer Cells, Natural/cytology/*immunology | 5 | 17.0 |
Interleukin-2/administration & dosage | 5 | 26.0 |
Peptides/*immunology | 10 | 14.0 |
Dendritic Cells/*physiology | 8 | 10.0 |
Interferon-alpha/*biosynthesis | 7 | 41.0 |
Stem Cells/*physiology | 2 | 3.0 |
CD8-Positive T-Lymphocytes/*immunology/physiology | 2 | 66.0 |
Antigens, CD95/*analysis | 8 | 38.0 |
Membrane Glycoproteins/*analysis | 9 | 6.0 |
Hepacivirus/genetics | 6 | 25.0 |
Antibody-Dependent Cell Cytotoxicity/drug effects | 3 | 17.0 |
Dexamethasone/*pharmacology | 8 | 3.0 |
Macrophages/*drug effects/immunology | 2 | 22.0 |
Up-Regulation/drug effects | 10 | 2.0 |
Follicle Stimulating Hormone/blood | 6 | 1.0 |
Progesterone/blood | 3 | 1.0 |
Heterozygote | 23 | 0.0 |
Receptors, Calcitriol/*genetics | 2 | 0.0 |
Antigens, Neoplasm/*immunology | 17 | 10.0 |
Dendritic Cells/classification/*immunology | 2 | 28.0 |
Immunotherapy, Adoptive | 17 | 23.0 |
T-Lymphocyte Subsets/classification | 7 | 58.0 |
Mycobacterium bovis/*immunology | 4 | 20.0 |
HIV Infections/drug therapy/*epidemiology/virology | 2 | 100.0 |
Nucleosides/*pharmacology/therapeutic use | 2 | 100.0 |
Cytomegalovirus/isolation & purification | 8 | 50.0 |
Herpesvirus 6, Human/isolation & purification | 3 | 100.0 |
Adenoviridae Infections/*immunology | 2 | 40.0 |
HLA-DR Antigens/immunology | 54 | 25.0 |
Immunosuppression | 39 | 22.0 |
Monocytes/metabolism/virology | 5 | 83.0 |
Viremia/virology | 22 | 81.0 |
Beclomethasone/*administration & dosage | 2 | 66.0 |
Monitoring, Physiologic | 7 | 8.0 |
Peak Expiratory Flow Rate | 4 | 33.0 |
Antigens, CD2/biosynthesis | 3 | 30.0 |
Antigens, CD56/biosynthesis | 3 | 33.0 |
*Chromosome Aberrations | 11 | 1.0 |
*Chromosome Deletion | 4 | 0.0 |
*Chromosomes, Human, Pair 3 | 2 | 0.0 |
*Chromosomes, Human, Pair 6 | 3 | 1.0 |
Gene Duplication | 2 | 1.0 |
Herpesvirus 4, Human/genetics | 9 | 13.0 |
Guidelines | 5 | 19.0 |
Nervous System Diseases/chemically induced | 2 | 20.0 |
*HIV-1/immunology | 28 | 84.0 |
Vaccines, Subunit | 2 | 66.0 |
Baculoviridae/genetics | 5 | 3.0 |
Chimeric Proteins/genetics/*immunology | 2 | 50.0 |
Epitopes/chemistry | 5 | 6.0 |
HIV-1/*genetics/*immunology | 4 | 50.0 |
Antigens, Bacterial/*immunology | 18 | 15.0 |
Epitopes, T-Lymphocyte | 4 | 40.0 |
HLA-DQ Antigens/physiology | 2 | 66.0 |
Tuberculosis/drug therapy/*immunology | 4 | 100.0 |
Methotrexate/*adverse effects | 2 | 22.0 |
Pulmonary Alveoli/*immunology | 2 | 18.0 |
*SIV | 7 | 63.0 |
Antigens, CD57/metabolism | 2 | 20.0 |
Immune System/*physiopathology | 7 | 46.0 |
Intracellular Membranes/*metabolism | 3 | 4.0 |
Monocytes/*metabolism | 19 | 5.0 |
Indinavir/pharmacology | 3 | 30.0 |
Zidovudine/pharmacology | 27 | 49.0 |
Flaviviridae Infections/*complications/virology | 2 | 100.0 |
*GB virus C | 4 | 100.0 |
Antigens, CD34/immunology | 3 | 5.0 |
Antigens, CD4/genetics | 36 | 70.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology | 24 | 6.0 |
HIV Infections/metabolism/*virology | 4 | 66.0 |
Luciferases/genetics/metabolism | 3 | 1.0 |
Placenta | 2 | 4.0 |
Recombinant Fusion Proteins/genetics/metabolism | 18 | 1.0 |
AIDS-Related Opportunistic Infections/drug therapy/*etiology | 3 | 100.0 |
Antibiotic Prophylaxis | 3 | 42.0 |
Trimethoprim-Sulfamethoxazole Combination/therapeutic use | 25 | 71.0 |
Chemokines, CC/immunology | 3 | 20.0 |
Dog Diseases/*immunology | 2 | 50.0 |
Pollen/*immunology | 5 | 29.0 |
Reverse Transcriptase Polymerase Chain Reaction/methods | 6 | 1.0 |
Templates, Genetic | 3 | 1.0 |
Antibodies/immunology/pharmacology | 2 | 6.0 |
Antigen-Presenting Cells/cytology/immunology | 2 | 25.0 |
CD8-Positive T-Lymphocytes/*cytology/*immunology | 3 | 42.0 |
Cell Culture Techniques/*methods | 3 | 3.0 |
*Clinical Trials | 6 | 28.0 |
Epitopes/chemistry/immunology | 11 | 26.0 |
Interleukin-15/pharmacology | 3 | 13.0 |
Neoplasms/blood/*immunology | 2 | 33.0 |
Peptide Fragments/chemistry/immunology | 4 | 7.0 |
Antigens, CD/immunology/metabolism | 5 | 9.0 |
Antigens, CD3/immunology/metabolism | 2 | 11.0 |
Antigens, CD4/immunology/metabolism | 20 | 83.0 |
Antigens, CD8/immunology/metabolism | 3 | 75.0 |
Blood Specimen Collection | 4 | 8.0 |
Cytokines/*blood | 29 | 9.0 |
Th2 Cells/*immunology | 34 | 26.0 |
Adjuvants, Immunologic/pharmacology | 10 | 11.0 |
Interferon-beta/*pharmacology | 2 | 3.0 |
Monocytes/*drug effects/immunology | 6 | 15.0 |
Up-Regulation/drug effects/genetics/immunology | 2 | 22.0 |
HIV Infections/blood/*epidemiology/etiology/*prevention & control | 2 | 100.0 |
Academic Medical Centers | 6 | 50.0 |
Leukapheresis | 10 | 9.0 |
Nebraska | 2 | 28.0 |
Interleukin-4/*biosynthesis | 18 | 34.0 |
HIV Infections/complications/drug therapy | 6 | 60.0 |
Lymphoma, AIDS-Related/*epidemiology | 3 | 100.0 |
Paris/epidemiology | 6 | 54.0 |
Cytomegalovirus Infections/etiology | 3 | 33.0 |
HIV-1/drug effects/genetics/*isolation & purification | 2 | 100.0 |
Prurigo/etiology | 2 | 100.0 |
Viremia/etiology | 3 | 75.0 |
*Withholding Treatment | 3 | 100.0 |
T-Lymphocytes, Helper-Inducer/immunology/metabolism | 5 | 41.0 |
Gene Products, nef/chemistry/genetics/*physiology | 3 | 75.0 |
HIV-1/*genetics/pathogenicity/*physiology | 2 | 100.0 |
CD4-Positive T-Lymphocytes/*drug effects/physiology | 3 | 100.0 |
Membrane Glycoproteins/*pharmacology | 3 | 3.0 |
Tumor Necrosis Factor-alpha/*pharmacology | 13 | 1.0 |
*Cell Fusion | 19 | 52.0 |
HIV Envelope Protein gp120/*immunology/metabolism | 10 | 83.0 |
Antigen-Presenting Cells/metabolism | 5 | 27.0 |
Antigens, CD4/analysis/physiology | 4 | 100.0 |
Receptors, CCR5/analysis/physiology | 4 | 100.0 |
Receptors, Chemokine/physiology | 6 | 23.0 |
Electrostatics | 3 | 2.0 |
HIV Envelope Protein gp120/chemistry/*physiology | 4 | 66.0 |
HIV-2/*physiology | 12 | 54.0 |
Receptors, CCR5/chemistry/*physiology | 4 | 100.0 |
Chemokines, CC/*biosynthesis | 2 | 10.0 |
HIV Envelope Protein gp120/*pharmacology | 23 | 54.0 |
Macrophages/*metabolism | 8 | 3.0 |
Lymphoma, AIDS-Related/blood/*drug therapy | 2 | 100.0 |
HIV Infections/*blood/immunology/virology | 2 | 100.0 |
*Influenza Vaccines | 2 | 22.0 |
HTLV-I Infections/*complications | 4 | 100.0 |
*Human T-lymphotropic virus 1 | 6 | 30.0 |
HIV Infections/*blood/immunology | 21 | 80.0 |
Substance P/*blood | 2 | 16.0 |
Zidovudine/administration & dosage/adverse effects/*therapeutic use | 14 | 87.0 |
Pregnancy Complications, Infectious/drug therapy | 4 | 100.0 |
HIV-1/genetics/pathogenicity/*physiology | 6 | 54.0 |
HLA-DQ Antigens/*genetics/immunology | 2 | 7.0 |
Peptide Fragments/immunology/metabolism | 7 | 15.0 |
Transgenes/*immunology | 6 | 60.0 |
HIV Envelope Protein gp120/*chemistry/genetics/*immunology | 2 | 66.0 |
HIV-1/classification/genetics/*immunology | 2 | 50.0 |
Immunoglobulin Isotypes/immunology | 9 | 31.0 |
Recombinant Proteins/chemistry/immunology | 4 | 14.0 |
CD4-Positive T-Lymphocytes/*immunology/metabolism/*virology | 2 | 40.0 |
HIV Infections/immunology/therapy/virology | 3 | 75.0 |
Indinavir/*adverse effects | 4 | 100.0 |
Bronchoalveolar Lavage Fluid/cytology/*immunology | 4 | 36.0 |
T-Lymphocyte Subsets/*pathology | 29 | 90.0 |
Kidney Tubules/immunology | 2 | 33.0 |
Drug Design | 24 | 7.0 |
HIV-2/drug effects | 3 | 60.0 |
Inhibitory Concentration 50 | 5 | 1.0 |
AIDS-Related Opportunistic Infections/blood/*diagnosis | 2 | 66.0 |
Pneumocystis/isolation & purification | 5 | 71.0 |
Anxiety/etiology | 2 | 33.0 |
Depression/etiology | 2 | 33.0 |
*War | 2 | 6.0 |
Carcinoma, Hepatocellular/*immunology | 2 | 9.0 |
Transforming Growth Factor beta/blood | 2 | 7.0 |
AIDS-Related Opportunistic Infections/*epidemiology/parasitology | 2 | 100.0 |
Esophagoscopy | 6 | 18.0 |
Esophagus/pathology | 2 | 12.0 |
Administration, Topical | 16 | 14.0 |
Aminoquinolines/*therapeutic use | 2 | 16.0 |
RNA, Neoplasm/genetics/metabolism | 2 | 1.0 |
DNA Mutational Analysis | 29 | 0.0 |
Antigenic Variation | 6 | 20.0 |
Antigens, Fungal | 2 | 28.0 |
Cytomegalovirus Infections/complications/immunology | 6 | 85.0 |
Pneumonia, Pneumocystis/immunology | 4 | 100.0 |
Personality Inventory | 6 | 16.0 |
Psychoneuroimmunology | 8 | 53.0 |
Sick Role | 4 | 40.0 |
Antigens, Neoplasm/immunology | 15 | 11.0 |
Photopheresis | 3 | 50.0 |
Skin Neoplasms/immunology/pathology/*therapy | 3 | 75.0 |
Human T-lymphotropic virus 1/*genetics | 6 | 11.0 |
Leukemia-Lymphoma, T-Cell, Acute, HTLV-I-Associated/immunology/*pathology | 3 | 60.0 |
CD40 Ligand/*pharmacology | 2 | 28.0 |
Cell Movement/drug effects | 6 | 1.0 |
Membrane Glycoproteins/*biosynthesis | 6 | 6.0 |
Oligodeoxyribonucleotides/*pharmacology | 4 | 12.0 |
Receptors, Cell Surface/*biosynthesis | 3 | 5.0 |
Receptors, Chemokine/biosynthesis | 3 | 6.0 |
Gambia | 6 | 16.0 |
Immunodominant Epitopes | 3 | 21.0 |
Malaria, Falciparum/*immunology | 3 | 20.0 |
Arthritis, Rheumatoid/*immunology/pathology | 7 | 21.0 |
Synovial Membrane/pathology | 5 | 23.0 |
Allergens/*immunology | 13 | 16.0 |
Antigens, CD4/genetics/*immunology | 22 | 100.0 |
Asthma/etiology/*immunology | 2 | 25.0 |
Bronchoalveolar Lavage Fluid/chemistry/cytology/immunology | 2 | 66.0 |
Methacholine Chloride/pharmacology | 3 | 23.0 |
Tumor Necrosis Factor-alpha/genetics/immunology | 2 | 25.0 |
Anti-HIV Agents/adverse effects/pharmacology/*therapeutic use | 4 | 80.0 |
Antigens, CD27/analysis | 6 | 33.0 |
HIV-1/classification/*pathogenicity | 3 | 50.0 |
T-Lymphocyte Subsets/*virology | 6 | 75.0 |
Gene Products, nef/*physiology | 21 | 80.0 |
Brain/*virology | 4 | 33.0 |
Gene Products, env/chemistry | 3 | 100.0 |
Cell Lineage | 22 | 5.0 |
Fetal Blood/cytology | 19 | 9.0 |
Hematopoiesis | 16 | 6.0 |
Hematopoietic Stem Cells/cytology | 7 | 7.0 |
Lymphocytes/*cytology | 7 | 22.0 |
Lymphoid Tissue/*cytology | 3 | 33.0 |
Proteins/*metabolism | 7 | 0.0 |
Receptors, Cell Surface/*metabolism | 9 | 1.0 |
Stromal Cells/cytology | 2 | 4.0 |
T-Lymphocytes/cytology | 14 | 15.0 |
Acquired Immunodeficiency Syndrome/prevention & control | 10 | 83.0 |
Epidemiologic Methods | 6 | 11.0 |
HIV Infections/diagnosis/*drug therapy | 7 | 100.0 |
14-3-3 Proteins | 2 | 1.0 |
Blotting, Western/methods | 3 | 1.0 |
Protein Isoforms | 2 | 0.0 |
AIDS-Related Opportunistic Infections/*complications/immunology | 4 | 100.0 |
Tuberculosis/*complications/immunology | 2 | 100.0 |
Killer Cells, Natural/immunology/*pathology | 3 | 23.0 |
Lymphoma/immunology/*pathology | 3 | 60.0 |
Postpartum Period | 3 | 3.0 |
Pregnancy Complications, Infectious/*drug therapy | 12 | 100.0 |
Prenatal Care | 5 | 21.0 |
Zidovudine/administration & dosage/*therapeutic use | 25 | 89.0 |
AIDS-Related Opportunistic Infections/diagnosis/prevention & control | 2 | 100.0 |
AIDS-Related Opportunistic Infections/drug therapy/immunology | 3 | 100.0 |
*Giant Cells | 4 | 80.0 |
HIV-1/classification/*physiology | 2 | 100.0 |
CD8-Positive T-Lymphocytes/drug effects | 17 | 85.0 |
Immunologic Memory/*drug effects | 4 | 57.0 |
T-Lymphocytes, Suppressor-Effector/*drug effects/immunology | 3 | 60.0 |
AIDS-Related Opportunistic Infections/*etiology | 6 | 100.0 |
Adenine/*analogs & derivatives/therapeutic use | 3 | 100.0 |
HIV Protease Inhibitors/adverse effects/therapeutic use | 11 | 100.0 |
Hydroxyurea/therapeutic use | 5 | 41.0 |
Insulin Resistance | 2 | 1.0 |
Nevirapine/therapeutic use | 4 | 80.0 |
Interleukin-2/*administration & dosage | 11 | 42.0 |
Gene Rearrangement, T-Lymphocyte/*genetics | 2 | 25.0 |
Leukocytes, Mononuclear/immunology/*metabolism | 2 | 13.0 |
Receptors, Antigen, T-Cell/*blood | 3 | 75.0 |
Thymus Gland/*physiology | 4 | 33.0 |
Gene Rearrangement, T-Lymphocyte/genetics | 9 | 50.0 |
Binding Sites/genetics/immunology | 6 | 13.0 |
Gene Products, nef/*genetics/metabolism | 2 | 100.0 |
Histocompatibility Antigens Class I/*biosynthesis/genetics | 2 | 18.0 |
Mutagenesis, Site-Directed/genetics | 2 | 4.0 |
Peptide Fragments/*genetics/metabolism | 4 | 30.0 |
Signal Transduction/genetics/immunology | 6 | 7.0 |
Diet | 7 | 1.0 |
Evolution | 15 | 4.0 |
*Health | 3 | 30.0 |
Graft Rejection/immunology | 7 | 10.0 |
Enzyme Inhibitors/pharmacology | 24 | 0.0 |
Phospholipase C/metabolism | 10 | 3.0 |
Interleukin-16/pharmacology | 3 | 100.0 |
Tumor Necrosis Factor-alpha/*antagonists & inhibitors/pharmacology | 2 | 7.0 |
Copper/blood | 3 | 13.0 |
HIV Infections/*blood/physiopathology | 6 | 100.0 |
Acquired Immunodeficiency Syndrome/drug therapy/*immunology/*virology | 2 | 100.0 |
Antigens, CD20/immunology | 2 | 14.0 |
Antigens, CD8/immunology | 44 | 57.0 |
Immunoglobulin G/analysis | 41 | 10.0 |
Receptors, IgG/immunology | 4 | 10.0 |
Saliva/chemistry | 2 | 4.0 |
Colon/*pathology | 2 | 12.0 |
Intestinal Mucosa/*immunology/pathology | 13 | 50.0 |
Cysteine/*blood | 2 | 28.0 |
Electrochemistry | 3 | 3.0 |
Glutathione/*blood | 3 | 18.0 |
HIV Infections/*blood | 33 | 71.0 |
Corticotropin/blood | 7 | 4.0 |
*Space Flight | 4 | 12.0 |
Recombinant Proteins/administration & dosage | 12 | 13.0 |
Electrophoresis | 3 | 1.0 |
Israel | 5 | 3.0 |
Autoimmune Diseases/immunology | 13 | 15.0 |
Blood/immunology | 4 | 30.0 |
Complementarity Determining Regions/genetics | 7 | 33.0 |
Membrane Glycoproteins/biosynthesis/genetics | 4 | 8.0 |
Polymyositis/*immunology | 2 | 66.0 |
Receptors, Antigen, T-Cell, alpha-beta/biosynthesis/*genetics | 3 | 75.0 |
Antigens, CD2/analysis | 14 | 35.0 |
Rats, Wistar | 15 | 1.0 |
Receptors, Antigen, T-Cell, alpha-beta/biosynthesis/genetics | 3 | 27.0 |
Stem Cells/classification/immunology | 2 | 100.0 |
False Negative Reactions | 11 | 7.0 |
*Herpesvirus 1, Human | 3 | 30.0 |
*Herpesvirus 2, Human | 2 | 66.0 |
Granulocytes/immunology | 8 | 14.0 |
HLA-A2 Antigen/analysis | 3 | 21.0 |
HLA-B Antigens/analysis | 2 | 1.0 |
Immune System/drug effects | 8 | 44.0 |
Interleukin-6/analysis | 4 | 5.0 |
Receptors, Chemokine/analysis | 4 | 13.0 |
HIV/genetics/*isolation & purification | 10 | 83.0 |
Evidence-Based Medicine | 4 | 12.0 |
HIV Infections/*complications/therapy | 4 | 80.0 |
Pneumococcal Vaccines/*administration & dosage | 3 | 100.0 |
Receptors, Cell Surface/metabolism/*physiology | 2 | 10.0 |
Receptors, HIV/physiology | 7 | 43.0 |
Autoimmune Diseases/*immunology/physiopathology | 3 | 60.0 |
AIDS-Related Opportunistic Infections/*drug therapy/mortality | 6 | 100.0 |
Cytomegalovirus Retinitis/*drug therapy | 4 | 100.0 |
Recurrence/prevention & control | 4 | 10.0 |
HIV Infections/*complications/*physiopathology | 2 | 100.0 |
Carcinoma, Renal Cell/*immunology | 3 | 16.0 |
Epitopes/*immunology | 33 | 16.0 |
HLA-D Antigens/*immunology | 13 | 22.0 |
*Sleep | 2 | 8.0 |
Women's Health | 3 | 8.0 |
Receptors, HIV/*biosynthesis | 4 | 80.0 |
CD4-Positive T-Lymphocytes/*immunology/*virology | 15 | 100.0 |
HIV/immunology/*physiology | 15 | 78.0 |
Immunologic Memory/*physiology | 5 | 55.0 |
Muromonab-CD3/immunology | 5 | 50.0 |
Plant Extracts/*therapeutic use | 3 | 25.0 |
T-Lymphocytes/drug effects | 14 | 23.0 |
HIV Seropositivity/*diagnosis | 6 | 100.0 |
Cell Transformation, Neoplastic | 8 | 1.0 |
Lymph Nodes/metabolism/pathology | 2 | 8.0 |
Lymphatic Metastasis | 16 | 1.0 |
Neoplasm Proteins/immunology/*metabolism | 2 | 13.0 |
Dextran Sulfate/pharmacology | 9 | 50.0 |
*Photochemotherapy | 4 | 9.0 |
Lung/*metabolism | 2 | 2.0 |
AIDS-Related Opportunistic Infections/*immunology/microbiology | 5 | 83.0 |
Antigens, Fungal/*immunology | 4 | 25.0 |
Bronchoalveolar Lavage Fluid/microbiology | 8 | 47.0 |
Clinical Trials, Phase III | 7 | 16.0 |
HIV Envelope Protein gp41/pharmacology/*therapeutic use | 2 | 100.0 |
Peptide Fragments/pharmacology/*therapeutic use | 2 | 40.0 |
Lymphocyte Subsets/*physiology | 7 | 63.0 |
Sampling Studies | 15 | 8.0 |
CD4-Positive T-Lymphocytes/immunology/pathology/virology | 3 | 100.0 |
DNA, Viral/genetics/metabolism | 3 | 10.0 |
T-Lymphocyte Subsets/immunology/pathology/virology | 2 | 66.0 |
Antigens, CD1/analysis | 11 | 14.0 |
Antigens, CD20/analysis | 8 | 18.0 |
Fetus | 18 | 3.0 |
Frozen Sections | 14 | 17.0 |
Paraffin Embedding | 8 | 3.0 |
Receptors, Antigen, B-Cell/analysis | 4 | 22.0 |
Receptors, Interleukin-3/analysis | 3 | 27.0 |
Cerebrospinal Fluid/cytology | 7 | 29.0 |
Antibodies, Protozoan/blood | 7 | 36.0 |
Malaysia/epidemiology | 4 | 23.0 |
Toxoplasma/immunology | 8 | 66.0 |
Blood Proteins/analysis | 2 | 1.0 |
Bronchoalveolar Lavage Fluid/*cytology/immunology | 2 | 22.0 |
Eosinophil Granule Proteins | 5 | 2.0 |
Macrophages, Alveolar/*immunology | 10 | 24.0 |
Radioimmunoassay | 26 | 1.0 |
*Ribonucleases | 5 | 2.0 |
Electromagnetic Fields/*adverse effects | 5 | 41.0 |
Antigens, CD3/analysis/genetics | 4 | 80.0 |
Antigens, CD30/analysis | 9 | 25.0 |
Herpesvirus 4, Human | 23 | 16.0 |
Lymphocytes/*chemistry | 2 | 11.0 |
Membrane Glycoproteins/*analysis/genetics | 2 | 16.0 |
Hepatitis B virus/*drug effects | 3 | 100.0 |
Saliva/*virology | 4 | 50.0 |
Viral Envelope Proteins/*genetics | 8 | 26.0 |
Virus Cultivation | 12 | 27.0 |
*Virus Shedding | 6 | 75.0 |
*Peritoneal Dialysis, Continuous Ambulatory | 8 | 7.0 |
Genes, MHC Class I/immunology | 2 | 22.0 |
Genes, MHC Class II/immunology | 4 | 26.0 |
Langerhans Cells/immunology | 12 | 35.0 |
Adrenal Glands/physiopathology | 2 | 25.0 |
Cosyntropin/diagnostic use | 3 | 75.0 |
Dehydroepiandrosterone Sulfate/blood | 4 | 4.0 |
Energy Intake/physiology | 2 | 7.0 |
Ovary/physiopathology | 2 | 12.0 |
Hepacivirus/physiology | 3 | 50.0 |
Liver/*virology | 2 | 40.0 |
RNA, Viral/analysis/blood | 9 | 100.0 |
Adenine/adverse effects/*analogs & derivatives/*therapeutic use | 2 | 40.0 |
Cytomegalovirus Infections/diagnosis | 3 | 37.0 |
HIV Infections/*drug therapy/immunology/mortality/virology | 6 | 100.0 |
Oxazines/therapeutic use | 6 | 100.0 |
Tumor Necrosis Factor-alpha/*biosynthesis | 15 | 3.0 |
HIV-1/genetics/*immunology/physiology | 7 | 63.0 |
RNA, Messenger/*blood | 3 | 8.0 |
Receptors, CCR5/genetics/metabolism | 11 | 42.0 |
*Virus Replication/drug effects | 5 | 35.0 |
AIDS-Related Opportunistic Infections/immunology/prevention & control | 2 | 100.0 |
*Virus Assembly | 5 | 20.0 |
Candida albicans/isolation & purification | 4 | 57.0 |
Staphylococcus aureus/isolation & purification | 5 | 45.0 |
Streptococcus/isolation & purification | 2 | 33.0 |
*Apoptosis/immunology | 3 | 75.0 |
HIV Infections/metabolism | 4 | 28.0 |
AIDS Dementia Complex/mortality | 3 | 100.0 |
AIDS-Related Opportunistic Infections/mortality | 9 | 100.0 |
HIV Wasting Syndrome/mortality | 3 | 100.0 |
Glucocorticoids/pharmacology | 3 | 2.0 |
Nuclear Proteins/*metabolism | 2 | 0.0 |
Promoter Regions (Genetics)/*genetics | 4 | 0.0 |
Antigens, Viral/*immunology | 24 | 26.0 |
Autoimmune Diseases/etiology/*immunology | 2 | 40.0 |
Diabetes Mellitus, Type 1/etiology/*immunology | 2 | 66.0 |
Enterovirus B, Human/*immunology/pathogenicity | 2 | 66.0 |
*Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 8 | 29.0 |
Receptors, Antigen, T-Cell, alpha-beta/*genetics | 25 | 37.0 |
Superantigens/immunology | 6 | 12.0 |
Apoptosis/drug effects/*physiology | 4 | 1.0 |
HIV-1 Reverse Transcriptase/metabolism | 7 | 77.0 |
Mitochondria/metabolism | 4 | 1.0 |
Proteins/metabolism | 9 | 0.0 |
Stimulation, Chemical | 10 | 2.0 |
Transforming Growth Factor beta/*pharmacology | 5 | 1.0 |
Multienzyme Complexes/metabolism | 3 | 1.0 |
Vaccines, DNA/immunology | 2 | 33.0 |
Xenograft Model Antitumor Assays | 2 | 0.0 |
CD4-Positive T-Lymphocytes/classification/*immunology | 3 | 50.0 |
Colony-Forming Units Assay | 33 | 5.0 |
*Genes, T-Cell Receptor beta | 3 | 27.0 |
Hematopoietic Stem Cells/chemistry/cytology | 2 | 40.0 |
Immunoglobulin Variable Region/*genetics | 7 | 6.0 |
Antigens, CD4/*chemistry/metabolism | 13 | 92.0 |
Chromatography | 2 | 1.0 |
Dimerization | 22 | 1.0 |
Models, Statistical | 20 | 10.0 |
Ultracentrifugation | 4 | 2.0 |
Viral Fusion Proteins/*chemistry | 2 | 100.0 |
Bronchoalveolar Lavage Fluid/cytology/immunology | 6 | 16.0 |
Lymphocyte Subsets/drug effects/immunology | 14 | 73.0 |
Neutrophils/drug effects/*immunology | 2 | 6.0 |
Particle Size | 5 | 1.0 |
Alu Elements/*genetics | 3 | 9.0 |
Microsatellite Repeats/*genetics | 4 | 1.0 |
Tandem Repeat Sequences/genetics | 3 | 6.0 |
*Weightlessness | 2 | 10.0 |
Antibody Formation/physiology | 2 | 14.0 |
Antigens, CD4/analysis/immunology/metabolism | 2 | 100.0 |
Antigens, Surface | 16 | 29.0 |
Lymph Nodes/cytology/immunology/metabolism | 2 | 40.0 |
Bronchial Provocation Tests | 14 | 18.0 |
CD8-Positive T-Lymphocytes/*immunology/metabolism | 9 | 37.0 |
Antigens, CD4/*chemistry/genetics/immunology | 4 | 100.0 |
HIV Envelope Protein gp120/chemistry/immunology | 2 | 66.0 |
HIV Infections/genetics/*virology | 2 | 66.0 |
HIV-1/*genetics/pathogenicity | 5 | 38.0 |
Protein-Tyrosine Kinase/*genetics | 5 | 2.0 |
Proto-Oncogene Proteins/*genetics | 3 | 0.0 |
Virulence/genetics | 7 | 10.0 |
Virus Replication/genetics | 8 | 16.0 |
Macrophages/metabolism/*virology | 11 | 50.0 |
Proteoglycans/*physiology | 2 | 16.0 |
HIV Seropositivity/*drug therapy/*immunology | 3 | 100.0 |
Hypersensitivity, Delayed/etiology | 2 | 50.0 |
HIV Infections/*transmission/virology | 6 | 75.0 |
HIV Long Terminal Repeat/*genetics | 7 | 9.0 |
Africa, Western/ethnology | 2 | 33.0 |
HIV Seropositivity/*drug therapy/immunology/virology | 3 | 100.0 |
Antigens, CD13/analysis | 2 | 8.0 |
Antigens, Differentiation, Myelomonocytic/*analysis | 9 | 8.0 |
Antigens, Neoplasm/*analysis | 22 | 5.0 |
Drug Resistance, Multiple | 7 | 4.0 |
Macrophage-1 Antigen/analysis | 5 | 11.0 |
Hematologic Neoplasms/therapy | 6 | 26.0 |
Hematopoietic Stem Cell Transplantation/*methods | 6 | 6.0 |
Lymphocyte Depletion/*methods | 6 | 27.0 |
T-Lymphocyte Subsets/immunology/*transplantation | 2 | 100.0 |
Leukemia Virus, Murine/immunology | 2 | 100.0 |
Acquired Immunodeficiency Syndrome/diagnosis/drug therapy/epidemiology | 2 | 100.0 |
HIV Infections/diagnosis/*drug therapy/*epidemiology | 2 | 100.0 |
Endothelium, Vascular/immunology | 6 | 14.0 |
HIV-1/*metabolism/*pathogenicity | 4 | 100.0 |
Leukocyte Elastase/metabolism | 2 | 9.0 |
Antigens, CD8/genetics/metabolism | 6 | 60.0 |
Dendritic Cells/physiology | 3 | 10.0 |
Lymphocyte Specific Protein Tyrosine Kinase p56(lck)/metabolism | 21 | 38.0 |
Astrocytes/*virology | 2 | 28.0 |
Cell Transformation, Viral | 35 | 11.0 |
Genes, Viral | 29 | 12.0 |
Viral Proteins/genetics/metabolism | 2 | 5.0 |
Hepatitis C, Chronic/*immunology | 4 | 28.0 |
Antigen Presentation/drug effects | 5 | 16.0 |
Bone Marrow Transplantation/adverse effects | 3 | 20.0 |
*PUVA Therapy | 9 | 60.0 |
T-Lymphocytes, Cytotoxic/drug effects | 2 | 28.0 |
Lymphocyte Subsets/pathology | 15 | 60.0 |
Tumor Stem Cells/pathology | 6 | 18.0 |
*Cesarean Section | 2 | 22.0 |
*Physician's Practice Patterns | 3 | 16.0 |
Pregnancy Complications, Infectious/*virology | 7 | 53.0 |
RNA, Viral/isolation & purification | 3 | 23.0 |
Receptors, CXCR4/genetics/metabolism | 8 | 32.0 |
Cytomegalovirus Infections/*immunology | 5 | 22.0 |
Gene Products, env/*immunology | 17 | 68.0 |
HIV Infections/*immunology/mortality/physiopathology | 2 | 100.0 |
Phytohemagglutinins | 36 | 39.0 |
Tetanus Toxoid/immunology | 28 | 35.0 |
Smoking | 15 | 3.0 |
Organophosphorus Compounds/*administration & dosage/adverse effects | 2 | 100.0 |
Acquired Immunodeficiency Syndrome/drug therapy | 28 | 90.0 |
Antiviral Agents/*administration & dosage | 5 | 45.0 |
Leukoencephalopathy, Progressive Multifocal/*drug therapy/mortality | 2 | 100.0 |
Acquired Immunodeficiency Syndrome/*drug therapy/mortality | 10 | 100.0 |
Anti-HIV Agents/administration & dosage | 10 | 100.0 |
AIDS Dementia Complex/immunology/*virology | 2 | 100.0 |
Fetus/cytology | 5 | 7.0 |
Luciferases/genetics | 5 | 1.0 |
Receptors, CXCR4/genetics/*immunology | 2 | 66.0 |
Serotyping | 9 | 4.0 |
Antibodies/pharmacology | 18 | 5.0 |
Antigens, CD4/genetics/immunology/*metabolism | 7 | 100.0 |
Cytokines/administration & dosage | 2 | 40.0 |
*Drug Delivery Systems | 2 | 6.0 |
Influenza Vaccines/administration & dosage | 2 | 22.0 |
Vaccines/*administration & dosage | 2 | 40.0 |
Antigens, Differentiation, B-Lymphocyte/*analysis | 4 | 6.0 |
Cell Membrane Permeability | 5 | 3.0 |
Fluorescent Dyes/chemistry | 2 | 8.0 |
Formaldehyde/chemistry | 2 | 33.0 |
Polymers/chemistry | 2 | 8.0 |
AIDS-Related Opportunistic Infections/epidemiology | 26 | 96.0 |
Acquired Immunodeficiency Syndrome/drug therapy/epidemiology | 3 | 100.0 |
HIV Infections/*drug therapy/immunology/mortality | 18 | 100.0 |
Anti-Bacterial Agents/*pharmacology | 5 | 3.0 |
Antigens, Differentiation, T-Lymphocyte/*pharmacology | 2 | 40.0 |
Antigens, Surface/*blood | 3 | 20.0 |
Cardiac Surgical Procedures | 2 | 10.0 |
Cardiopulmonary Bypass | 2 | 4.0 |
Discriminant Analysis | 6 | 7.0 |
Granulocytes/*metabolism | 4 | 10.0 |
Heart Defects, Congenital/surgery | 2 | 20.0 |
Preoperative Care/methods | 2 | 7.0 |
Ki-67 Antigen/metabolism | 7 | 3.0 |
Immunoglobulins, Fab/immunology | 13 | 12.0 |
Viremia/drug therapy/virology | 7 | 87.0 |
Papillomavirus, Human/isolation & purification | 3 | 12.0 |
*Vaginal Smears | 5 | 11.0 |
Luminescent Proteins/genetics/metabolism | 4 | 2.0 |
Asthma/*drug therapy/immunology | 5 | 50.0 |
*Peritoneal Dialysis, Continuous Ambulatory/adverse effects | 5 | 33.0 |
Uremia/immunology/therapy | 2 | 40.0 |
*Acute-Phase Reaction | 2 | 9.0 |
Prednisolone/administration & dosage | 7 | 10.0 |
Cytological Techniques | 3 | 7.0 |
Hepacivirus/*isolation & purification | 5 | 71.0 |
DNA Primers/genetics | 30 | 2.0 |
Herpesvirus 2, Saimiriine | 4 | 80.0 |
Retroviridae Proteins, Oncogenic/metabolism | 2 | 5.0 |
T-Lymphocytes, Helper-Inducer/*immunology/metabolism | 3 | 25.0 |
History, 20th Century | 5 | 3.0 |
Portraits | 3 | 10.0 |
Anti-HIV Agents/*metabolism/pharmacology | 3 | 42.0 |
Peptide Fragments/*metabolism | 14 | 10.0 |
Reverse Transcriptase Inhibitors/pharmacology | 6 | 40.0 |
CD4-Positive T-Lymphocytes/*drug effects/immunology/*metabolism | 3 | 100.0 |
Liver/immunology/pathology | 4 | 23.0 |
Prednisolone/therapeutic use | 12 | 13.0 |
Didanosine/*administration & dosage/adverse effects | 6 | 100.0 |
*HIV-1/drug effects | 7 | 58.0 |
Immunologic Memory/drug effects | 6 | 54.0 |
Stavudine/*administration & dosage/adverse effects | 4 | 100.0 |
Mycobacterium avium-intracellulare Infection/*diagnosis | 2 | 100.0 |
*Tissue Donors | 3 | 2.0 |
Antifungal Agents/*administration & dosage | 4 | 44.0 |
Cytokines/blood/*metabolism | 2 | 22.0 |
Menstrual Cycle/*immunology | 4 | 40.0 |
HIV Infections/complications/drug therapy/*immunology | 4 | 100.0 |
Drug Resistance, Microbial/genetics | 28 | 30.0 |
HIV-1 Reverse Transcriptase/*genetics | 7 | 63.0 |
Malawi | 6 | 37.0 |
*Drug Therapy, Combination | 3 | 50.0 |
*HIV | 23 | 82.0 |
CD4-Positive T-Lymphocytes/*metabolism/virology | 7 | 63.0 |
Antigens, CD/immunology/*physiology | 5 | 15.0 |
Bronchoalveolar Lavage Fluid/chemistry | 5 | 7.0 |
Integrin alpha4 | 4 | 10.0 |
Lung/cytology | 4 | 6.0 |
Signal Transduction/*physiology | 17 | 1.0 |
Alkaline Phosphatase/analysis | 4 | 7.0 |
Phosphoproteins/analysis | 4 | 11.0 |
Sialoglycoproteins/analysis | 4 | 10.0 |
HIV Infections/prevention & control/*transmission | 4 | 66.0 |
Singapore | 3 | 6.0 |
Acquired Immunodeficiency Syndrome/*complications/immunology | 13 | 72.0 |
Skin/immunology/microbiology/pathology | 2 | 100.0 |
HIV Infections/*drug therapy/*physiopathology | 2 | 66.0 |
*Immunization, Passive | 21 | 38.0 |
Immunoglobulins/therapeutic use | 3 | 60.0 |
Killer Cells, Lymphokine-Activated/drug effects/immunology | 4 | 57.0 |
HIV Infections/genetics/*immunology/virology | 4 | 80.0 |
HIV-1/pathogenicity | 12 | 60.0 |
Growth Hormone/*therapeutic use | 3 | 15.0 |
RNA, Messenger/analysis/genetics | 7 | 1.0 |
Radiation Chimera | 8 | 16.0 |
Transgenes/genetics | 2 | 2.0 |
Macrophages | 11 | 14.0 |
APACHE | 5 | 9.0 |
Antigens, CD/*classification | 2 | 66.0 |
HIV Infections/blood/immunology | 3 | 37.0 |
HIV-1/*genetics/immunology | 13 | 54.0 |
Polymerase Chain Reaction/*methods | 19 | 3.0 |
HIV Infections/epidemiology/immunology/*physiopathology | 3 | 100.0 |
HIV-1/*immunology/pathogenicity | 4 | 36.0 |
HIV-2/*immunology/pathogenicity | 2 | 100.0 |
Antigens, CD4/drug effects/metabolism | 6 | 75.0 |
Mucous Membrane/metabolism/virology | 2 | 100.0 |
Receptors, CCR5/drug effects/metabolism | 2 | 50.0 |
Receptors, CXCR4/drug effects/*metabolism | 2 | 40.0 |
Receptors, HIV/drug effects/*metabolism | 3 | 75.0 |
*Immunophenotyping | 41 | 22.0 |
Antigens, CD4 | 59 | 72.0 |
Cell Wall/metabolism | 2 | 14.0 |
Glycolipids/metabolism | 2 | 10.0 |
HIV-1/*drug effects/genetics/isolation & purification | 9 | 100.0 |
Maximum Tolerated Dose | 3 | 8.0 |
Zidovudine/*administration & dosage | 20 | 95.0 |
Anti-HIV Agents/administration & dosage/adverse effects/*therapeutic use | 10 | 100.0 |
Diarrhea/chemically induced | 4 | 16.0 |
Nausea/chemically induced | 5 | 17.0 |
Zidovudine/*administration & dosage/adverse effects/therapeutic use | 4 | 100.0 |
Epithelial Cells/immunology/pathology | 2 | 50.0 |
Immunity, Cellular/immunology | 32 | 53.0 |
Salivary Glands/immunology/pathology | 2 | 66.0 |
Sjogren's Syndrome/immunology/*pathology | 2 | 50.0 |
Lipids/metabolism | 5 | 1.0 |
Spectrometry, Fluorescence | 8 | 1.0 |
Thymus Gland/cytology | 27 | 27.0 |
Antibodies, Viral/*blood | 16 | 34.0 |
Chickenpox/*immunology | 4 | 66.0 |
Sarcoma, Kaposi/*complications | 3 | 100.0 |
Cholesterol/*metabolism | 2 | 0.0 |
HIV Infections/*metabolism | 25 | 52.0 |
*Milk Proteins | 5 | 1.0 |
Protein-Tyrosine Kinase/*metabolism | 64 | 7.0 |
Receptor-CD3 Complex, Antigen, T-Cell/immunology | 9 | 37.0 |
Trans-Activators/*metabolism | 4 | 0.0 |
Antigens, CD8/*immunology/metabolism | 2 | 100.0 |
*Antigens, Surface | 6 | 8.0 |
*Blood Proteins | 4 | 5.0 |
Clodronic Acid/pharmacology | 3 | 50.0 |
Glial Fibrillary Acidic Protein/metabolism | 2 | 0.0 |
Lymphocytes/cytology/drug effects/immunology | 3 | 50.0 |
Macrophage Activation/*immunology | 2 | 6.0 |
Phagocytosis/*immunology | 5 | 8.0 |
CD4-Positive T-Lymphocytes/radiation effects | 2 | 100.0 |
CD8-Positive T-Lymphocytes/radiation effects | 2 | 100.0 |
Dose-Response Relationship, Radiation | 11 | 3.0 |
Environmental Exposure/*adverse effects | 3 | 10.0 |
Herpesvirus 4, Human/*isolation & purification | 10 | 26.0 |
HIV-1/genetics/immunology/*metabolism | 3 | 33.0 |
Viral Envelope Proteins/genetics/immunology/*metabolism | 2 | 28.0 |
Transcription Factors/physiology | 2 | 0.0 |
Antigens, CD4/genetics/metabolism | 17 | 80.0 |
Gene Products, nef/genetics/*physiology | 7 | 87.0 |
Serial Passage | 6 | 37.0 |
Age of Onset | 16 | 1.0 |
Alcohol Drinking | 5 | 3.0 |
Liver/drug effects/pathology | 2 | 10.0 |
Antigens, Fungal/analysis | 3 | 60.0 |
Pneumocystis/*isolation & purification | 3 | 75.0 |
CA-15-3 Antigen/analysis | 2 | 3.0 |
Emulsions | 3 | 4.0 |
Interferon Type II/genetics | 10 | 13.0 |
Interleukin-10/genetics | 5 | 11.0 |
Interleukin-4/genetics | 7 | 17.0 |
Kidney Transplantation/*immunology/pathology | 5 | 29.0 |
Lymphocytes/drug effects/*immunology | 11 | 26.0 |
Antibodies/*pharmacology | 5 | 15.0 |
Complement/*pharmacology | 2 | 15.0 |
Embryo | 2 | 0.0 |
Epitopes/immunology | 77 | 15.0 |
Microglia/*immunology | 2 | 20.0 |
Trisaccharides/*immunology | 2 | 66.0 |
Interleukin-1/blood | 6 | 3.0 |
Monocytes/*drug effects/*immunology | 2 | 15.0 |
Antigens, CD1/immunology | 2 | 18.0 |
Ionomycin/*pharmacology | 4 | 28.0 |
HIV Infections/therapy | 4 | 26.0 |
T-Lymphocytes, Helper-Inducer/*physiology | 7 | 41.0 |
Hematopoiesis/drug effects | 5 | 6.0 |
Leukemia, T-Cell/immunology | 2 | 28.0 |
Receptors, Antigen, T-Cell/chemistry/*metabolism | 5 | 38.0 |
*T-Lymphocyte Subsets | 59 | 78.0 |
CD4-Positive T-Lymphocytes/*pathology/virology | 3 | 100.0 |
Viral Envelope Proteins/*chemistry/genetics/*metabolism | 2 | 66.0 |
Antigens, CD4/*chemistry | 18 | 100.0 |
Crystallography | 3 | 9.0 |
Models, Chemical | 6 | 1.0 |
Hydrocortisone/pharmacology | 2 | 2.0 |
Interleukin-1/*pharmacology | 7 | 1.0 |
Colorectal Neoplasms/*immunology/pathology | 2 | 11.0 |
Intercellular Adhesion Molecule-1/metabolism | 18 | 9.0 |
*Parenteral Nutrition, Total | 5 | 8.0 |
Brefeldin A/pharmacology | 3 | 3.0 |
Lymphocytes/*cytology/*immunology | 2 | 66.0 |
Th1 Cells/*cytology | 2 | 66.0 |
Th2 Cells/*cytology | 2 | 66.0 |
Thyroiditis, Autoimmune/*immunology | 8 | 10.0 |
Acquired Immunodeficiency Syndrome/diagnosis | 15 | 75.0 |
Glycoproteins/*chemistry/metabolism | 2 | 25.0 |
Monocytes/microbiology | 8 | 50.0 |
Primary Health Care | 2 | 14.0 |
Antiviral Agents/pharmacology | 12 | 18.0 |
Catalysis | 8 | 1.0 |
Hydrogen-Ion Concentration | 34 | 2.0 |
Hydrolysis | 9 | 1.0 |
Peptides/chemistry | 8 | 2.0 |
Respiratory Hypersensitivity/*immunology | 2 | 40.0 |
Spores, Fungal/immunology | 2 | 33.0 |
*Anti-HIV Agents | 2 | 100.0 |
Pennsylvania/epidemiology | 2 | 14.0 |
AIDS Vaccines/administration & dosage/*immunology | 4 | 57.0 |
Antigens, Viral/biosynthesis | 3 | 25.0 |
Vaccines, DNA/administration & dosage/*immunology | 2 | 28.0 |
Vaccinia virus/genetics/immunology | 2 | 22.0 |
Gene Products, env/metabolism | 32 | 62.0 |
HIV-1/*chemistry | 16 | 55.0 |
Linear Models | 50 | 10.0 |
*Chlamydia trachomatis | 6 | 75.0 |
Genitalia, Female/*immunology | 3 | 42.0 |
Acquired Immunodeficiency Syndrome/drug therapy/*virology | 2 | 66.0 |
HIV Infections/complications/*drug therapy/immunology/mortality | 2 | 100.0 |
Substance Abuse, Intravenous/*complications/mortality | 2 | 100.0 |
Antigens, CD40/*immunology | 3 | 7.0 |
Cell Differentiation/*immunology | 3 | 11.0 |
Endocytosis/immunology | 3 | 13.0 |
Monocytes/cytology/*immunology | 4 | 11.0 |
Antigens, CD20/*analysis | 2 | 28.0 |
Leukemia, T-Cell/*pathology | 6 | 60.0 |
Lymphoma, T-Cell/*pathology | 5 | 35.0 |
Hepatitis B/blood/*immunology | 2 | 66.0 |
HIV Infections/drug therapy/*immunology/pathology | 2 | 66.0 |
Receptors, Chemokine/*immunology | 9 | 32.0 |
Virus Replication/*immunology | 16 | 51.0 |
Pneumonia, Pneumocystis/drug therapy | 3 | 50.0 |
HIV Core Protein p24/*blood | 21 | 91.0 |
Thyroid Gland/immunology/physiopathology | 2 | 66.0 |
Thyroid Hormones/blood | 5 | 5.0 |
Thyrotropin/blood | 6 | 1.0 |
Zinc/*blood | 5 | 20.0 |
Bile Ducts, Intrahepatic/pathology | 2 | 40.0 |
Cholangiopancreatography, Endoscopic Retrograde | 5 | 33.0 |
Nevirapine/*administration & dosage | 3 | 100.0 |
p38 Mitogen-Activated Protein Kinases | 8 | 1.0 |
England/epidemiology | 6 | 11.0 |
Population Surveillance/*methods | 3 | 21.0 |
Wales/epidemiology | 3 | 50.0 |
HIV Infections/*immunology/metabolism | 4 | 33.0 |
Sequence Deletion/immunology | 2 | 13.0 |
Cytokines/biosynthesis/secretion | 3 | 33.0 |
Interferon Type II/biosynthesis/secretion | 4 | 40.0 |
Antigens, CD4/*biosynthesis/blood | 2 | 66.0 |
Antigens, CD45/biosynthesis | 17 | 32.0 |
Antigens, Differentiation/physiology | 3 | 5.0 |
HLA-DR Antigens/biosynthesis | 13 | 13.0 |
T-Lymphocyte Subsets/*immunology/metabolism | 17 | 37.0 |
Antigens, CD2/blood | 3 | 60.0 |
Antigens, CD8/blood | 22 | 56.0 |
Interleukin-2/blood | 18 | 25.0 |
Alanine Transaminase/metabolism | 2 | 10.0 |
Cholesterol/blood | 16 | 1.0 |
*Insulin Resistance | 6 | 3.0 |
Antigens, CD34/*blood | 3 | 4.0 |
Transplantation, Autologous/methods | 2 | 20.0 |
Gene Products, nef/*chemistry/*metabolism | 2 | 100.0 |
HIV-1/*chemistry/metabolism | 2 | 50.0 |
*Protein Structure, Tertiary | 5 | 4.0 |
Receptors, HIV/chemistry/metabolism | 4 | 100.0 |
HIV Infections/*drug therapy/*immunology/physiopathology/virology | 2 | 100.0 |
HIV-1/immunology/*isolation & purification | 7 | 87.0 |
Antigens, CD95/physiology | 4 | 5.0 |
HIV Envelope Protein gp120/*physiology | 23 | 74.0 |
HIV Infections/pathology/*virology | 2 | 33.0 |
Membrane Potentials/physiology | 2 | 2.0 |
Mitochondria/physiology | 4 | 6.0 |
Antigens, CD14 | 19 | 6.0 |
Cytomegalovirus/*physiology | 5 | 18.0 |
Macaca mulatta/*immunology | 4 | 28.0 |
*Parvovirus B19, Human | 2 | 66.0 |
AIDS-Related Opportunistic Infections/*drug therapy | 23 | 88.0 |
Sarcoma, Kaposi/*epidemiology | 4 | 80.0 |
Tuberculosis, Pulmonary/epidemiology | 3 | 100.0 |
*Prisoners | 11 | 61.0 |
*Prisons | 4 | 100.0 |
Lipoproteins/*blood | 3 | 0.0 |
Lipoproteins, HDL Cholesterol/blood | 8 | 1.0 |
Vasodilation/drug effects | 2 | 3.0 |
Biological Factors/immunology | 3 | 60.0 |
Culture Media, Conditioned | 9 | 2.0 |
Up-Regulation/*immunology | 7 | 12.0 |
Personality/*physiology | 2 | 50.0 |
Up-Regulation/physiology | 3 | 2.0 |
HIV Infections/*psychology | 10 | 62.0 |
Interpersonal Relations | 3 | 13.0 |
Social Support | 13 | 31.0 |
Guinea-Bissau/epidemiology | 11 | 100.0 |
HIV Infections/complications/immunology/*mortality | 6 | 100.0 |
Antigens, CD28/biosynthesis | 6 | 20.0 |
Antigens, Differentiation/biosynthesis | 10 | 19.0 |
Lymphocyte Subsets/*metabolism | 4 | 44.0 |
NAD+ Nucleosidase/biosynthesis | 2 | 28.0 |
Dendritic Cells/drug effects/*immunology | 4 | 15.0 |
Interferon Type I/*biosynthesis | 3 | 27.0 |
Interferon-alpha/biosynthesis | 4 | 16.0 |
HIV Seropositivity/*virology | 4 | 66.0 |
Herpesvirus 8, Human/*isolation & purification | 5 | 31.0 |
Acquired Immunodeficiency Syndrome/physiopathology | 7 | 100.0 |
Continental Population Groups | 16 | 9.0 |
Asthma/*immunology/prevention & control | 2 | 66.0 |
Cytokines/*biosynthesis/genetics | 9 | 12.0 |
E-Selectin/biosynthesis | 2 | 11.0 |
Forced Expiratory Volume | 12 | 13.0 |
Histamine Release/drug effects | 2 | 8.0 |
Prednisone/*pharmacology | 2 | 25.0 |
Lymphopenia/*etiology | 8 | 72.0 |
CD4-Positive T-Lymphocytes/chemistry | 10 | 55.0 |
Macrophages/chemistry | 3 | 12.0 |
Monocytes/chemistry | 4 | 16.0 |
Feedback | 5 | 2.0 |
Half-Life | 24 | 4.0 |
Glucose Tolerance Test | 4 | 0.0 |
Lymphopenia/*etiology/immunology | 4 | 100.0 |
Antigens, CD27/*metabolism | 2 | 14.0 |
Biotinylation | 4 | 2.0 |
CD4-Positive T-Lymphocytes/*immunology/*metabolism | 6 | 46.0 |
Hematopoietic Stem Cells/immunology/metabolism | 2 | 28.0 |
Protein Transport/genetics/immunology | 2 | 28.0 |
*Receptors, Tumor Necrosis Factor | 4 | 10.0 |
Up-Regulation/genetics/immunology | 4 | 7.0 |
Killer Cells, Natural/cytology/immunology | 6 | 35.0 |
Macrophages/cytology/immunology | 5 | 26.0 |
*Genes, MHC Class I | 3 | 1.0 |
SIV/genetics | 4 | 66.0 |
T-Lymphocytes/*immunology/*virology | 5 | 50.0 |
Anxiety/psychology | 2 | 16.0 |
*Embryo Transfer | 2 | 8.0 |
Neuropsychological Tests | 35 | 13.0 |
T-Lymphocytes/physiology | 27 | 22.0 |
Chromatography, Affinity | 12 | 1.0 |
*Enzyme-Linked Immunosorbent Assay | 4 | 5.0 |
Epitopes/metabolism | 7 | 12.0 |
Plasmids | 38 | 2.0 |
Heart Transplantation/*adverse effects | 2 | 14.0 |
Mice, Knockout/genetics | 2 | 5.0 |
Monocytes/physiology | 7 | 6.0 |
Tissue Distribution | 19 | 0.0 |
Transplantation, Homologous/adverse effects | 4 | 22.0 |
Cercopithecus aethiops | 31 | 2.0 |
Macrophages/cytology/virology | 2 | 40.0 |
Receptors, CXCR4/genetics/*metabolism | 13 | 27.0 |
Tropism | 4 | 30.0 |
Erythrocyte Count | 7 | 7.0 |
HIV Seropositivity/drug therapy/*immunology | 5 | 100.0 |
Glomerulonephritis, IGA/*immunology | 5 | 27.0 |
Purpura, Schoenlein-Henoch/*immunology | 2 | 50.0 |
E-Selectin/analysis | 5 | 25.0 |
Lymphocyte Function-Associated Antigen-1/analysis | 14 | 34.0 |
Vascular Cell Adhesion Molecule-1/analysis | 9 | 23.0 |
Allergens/pharmacology | 2 | 33.0 |
CD4-Positive T-Lymphocytes/*enzymology | 4 | 80.0 |
Leukocytes, Mononuclear/cytology/drug effects | 4 | 26.0 |
Pyridines/pharmacology | 3 | 1.0 |
Rolipram/pharmacology | 2 | 10.0 |
Theophylline/pharmacology | 2 | 5.0 |
Interferon-gamma, Recombinant/adverse effects/*therapeutic use | 2 | 66.0 |
T-Lymphocyte Subsets/immunology/*metabolism | 12 | 34.0 |
HIV Antibodies/blood/*immunology | 8 | 100.0 |
HIV-1/genetics/*immunology/isolation & purification | 3 | 60.0 |
Macrophage Inflammatory Protein-1/blood | 3 | 33.0 |
RANTES/blood | 2 | 18.0 |
AIDS-Related Opportunistic Infections/blood/immunology/*virology | 2 | 100.0 |
Aspartate Aminotransferases/blood | 6 | 4.0 |
T-Lymphocytes/*immunology/*metabolism | 7 | 21.0 |
Aneuploidy | 4 | 2.0 |
*Renal Dialysis | 25 | 5.0 |
Antigens, CD/blood/immunology | 3 | 33.0 |
Kidney Failure, Chronic/*surgery | 2 | 40.0 |
Kidney Transplantation/*immunology | 31 | 15.0 |
Multiple Sclerosis, Relapsing-Remitting/*immunology | 2 | 100.0 |
Oligoclonal Bands | 3 | 42.0 |
Biological Availability | 8 | 2.0 |
Nutritional Status/drug effects | 2 | 40.0 |
Antigens, CD19/biosynthesis | 3 | 25.0 |
Hepatitis B/complications | 4 | 16.0 |
Liver/physiopathology | 3 | 11.0 |
Morbidity | 13 | 22.0 |
Cell Membrane/immunology/metabolism | 12 | 11.0 |
Interphase/*immunology | 3 | 33.0 |
Intracellular Fluid/immunology/metabolism | 3 | 10.0 |
Cell Death/genetics/immunology | 3 | 33.0 |
Inflammation/immunology | 13 | 11.0 |
*Protein-Serine-Threonine Kinases | 3 | 0.0 |
RNA, Viral/blood/cerebrospinal fluid | 4 | 100.0 |
HIV/drug effects/genetics | 7 | 100.0 |
HIV/drug effects | 13 | 65.0 |
*Herpesvirus 8, Human/immunology/isolation & purification | 2 | 100.0 |
Sexually Transmitted Diseases | 3 | 100.0 |
HIV Infections/immunology/*transmission/virology | 3 | 100.0 |
*Pregnancy Complications, Infectious/immunology/virology | 2 | 100.0 |
Health Planning Guidelines | 2 | 100.0 |
World Health Organization | 15 | 19.0 |
HIV Infections/blood/drug therapy/immunology/*virology | 2 | 100.0 |
Africa South of the Sahara | 5 | 33.0 |
Ethnic Groups/genetics | 4 | 2.0 |
Genetics, Population | 4 | 1.0 |
Antibodies, Viral/*biosynthesis | 7 | 31.0 |
Measles Vaccine/adverse effects/*immunology | 2 | 100.0 |
Measles virus/*immunology | 3 | 25.0 |
CD4-Positive T-Lymphocytes/*cytology/metabolism | 3 | 100.0 |
CD8-Positive T-Lymphocytes/*cytology/metabolism | 3 | 100.0 |
Scleroderma, Systemic/*immunology | 9 | 34.0 |
Receptors, CCR5/analysis/genetics | 2 | 50.0 |
Receptors, CXCR4/analysis/genetics | 3 | 100.0 |
HIV-1/*metabolism/ultrastructure | 2 | 66.0 |
Microscopy, Immunoelectron | 19 | 3.0 |
Disulfides | 6 | 6.0 |
HIV Envelope Protein gp120/*chemistry/metabolism | 12 | 100.0 |
HIV Envelope Protein gp120/genetics | 9 | 26.0 |
Leukocytes, Mononuclear/*immunology/virology | 3 | 75.0 |
Peptide Fragments/genetics | 7 | 10.0 |
Chemokines, CC/pharmacology | 4 | 12.0 |
Chemokines, CXC/pharmacology | 16 | 22.0 |
Immunoglobulins/biosynthesis | 24 | 22.0 |
*Lymphocyte Cooperation | 4 | 14.0 |
T-Lymphocyte Subsets/classification/immunology | 2 | 40.0 |
T-Lymphocytes, Helper-Inducer/drug effects/*immunology | 8 | 57.0 |
Tonsil/immunology | 10 | 15.0 |
CD40 Ligand/metabolism | 2 | 8.0 |
Food | 3 | 2.0 |
Immunoglobulin E/*biosynthesis | 8 | 16.0 |
Evolution, Molecular | 13 | 1.0 |
HIV-1/classification/*genetics/physiology | 2 | 100.0 |
*Immunologic Techniques | 2 | 6.0 |
Anti-HIV Agents/*chemical synthesis/chemistry/pharmacology | 2 | 18.0 |
HIV Infections/*drug therapy/immunology/metabolism | 2 | 100.0 |
Indinavir/*adverse effects/therapeutic use | 2 | 100.0 |
Insulin/metabolism | 3 | 2.0 |
HIV Infections/*complications/drug therapy/immunology/virology | 4 | 80.0 |
Eosinophilia/diagnosis/*immunology | 2 | 100.0 |
Eosinophils/*immunology | 11 | 18.0 |
Integrins/*metabolism | 4 | 2.0 |
Asthma/immunology | 3 | 8.0 |
*Chemotaxis, Leukocyte/drug effects | 2 | 14.0 |
Interleukin-16/physiology | 3 | 100.0 |
Ascitic Fluid/*immunology | 3 | 27.0 |
Interleukin-2/analysis/biosynthesis | 3 | 50.0 |
Lymphocytes/*immunology/physiology | 2 | 100.0 |
Ovarian Neoplasms/*immunology | 4 | 12.0 |
Interferon-beta/*therapeutic use | 6 | 26.0 |
Multiple Sclerosis/*drug therapy | 4 | 40.0 |
Tissue Fixation | 5 | 5.0 |
HIV Infections/epidemiology/*immunology | 12 | 85.0 |
India/epidemiology | 7 | 7.0 |
Indinavir/administration & dosage/*therapeutic use | 4 | 100.0 |
HIV Infections/*drug therapy/mortality/virology | 3 | 100.0 |
Killer Cells, Natural/*metabolism | 7 | 12.0 |
Receptors, Immunologic/*metabolism | 8 | 4.0 |
T-Lymphocytes, Cytotoxic/metabolism | 4 | 18.0 |
Electroporation | 5 | 8.0 |
HIV-1/*genetics/immunology/pathogenicity | 2 | 100.0 |
Macrophages/*immunology/virology | 2 | 28.0 |
*Phagocytosis | 4 | 3.0 |
Bacteremia/complications | 2 | 66.0 |
Genes, T-Cell Receptor beta/genetics | 2 | 40.0 |
Lupus Erythematosus, Systemic/*immunology | 16 | 10.0 |
Interferon Type II/genetics/metabolism | 3 | 30.0 |
Interleukin-2/genetics/metabolism | 6 | 40.0 |
RNA, Messenger/genetics/metabolism | 22 | 0.0 |
Th1 Cells/drug effects/*immunology | 2 | 25.0 |
Th2 Cells/drug effects/*immunology | 2 | 25.0 |
Interleukin-12/metabolism | 3 | 5.0 |
Th1 Cells/*drug effects/*immunology | 2 | 100.0 |
Th2 Cells/drug effects/immunology | 2 | 33.0 |
Antibodies, Viral/*immunology | 13 | 30.0 |
Antigen-Antibody Reactions | 35 | 10.0 |
Th2 Cells | 3 | 20.0 |
Chromosome Banding | 9 | 1.0 |
Chromosomes, Human, Pair 13 | 2 | 1.0 |
Chromosomes, Human, Pair 14 | 4 | 2.0 |
*Killer Cells, Natural/immunology/pathology | 2 | 100.0 |
Filgrastim/*pharmacology | 2 | 25.0 |
Hematopoietic Stem Cells/*cytology/immunology | 8 | 9.0 |
Neurodegenerative Diseases/etiology | 2 | 28.0 |
Retroviridae Infections/*immunology | 2 | 40.0 |
*Infant, Premature | 2 | 3.0 |
Zidovudine/pharmacology/*therapeutic use | 8 | 88.0 |
Breast Feeding | 11 | 18.0 |
HIV Infections/genetics/*transmission | 2 | 100.0 |
*HIV-1/pathogenicity | 5 | 41.0 |
Kenya | 11 | 25.0 |
CD8-Positive T-Lymphocytes/virology | 2 | 100.0 |
Cytomegalovirus Infections/immunology/*prevention & control | 2 | 66.0 |
Cell Membrane/metabolism/virology | 7 | 63.0 |
Dyes/pharmacology | 2 | 2.0 |
Fluoresceins/pharmacology | 2 | 22.0 |
Fluorescent Dyes/pharmacology | 2 | 10.0 |
HIV Envelope Protein gp41/*chemistry/*metabolism | 3 | 100.0 |
Vaccinia virus/genetics | 21 | 30.0 |
DNA Fingerprinting/methods | 2 | 3.0 |
Ethnic Groups/*genetics | 4 | 2.0 |
*Gene Frequency | 6 | 1.0 |
India | 21 | 6.0 |
HIV Infections/*mortality | 5 | 100.0 |
Switzerland/epidemiology | 11 | 52.0 |
HIV Envelope Protein gp120 | 50 | 92.0 |
HLA Antigens/*immunology | 12 | 4.0 |
HLA-C Antigens/*immunology | 2 | 14.0 |
Histocompatibility Antigens Class I/*immunology | 12 | 10.0 |
Receptors, Fc/immunology | 9 | 20.0 |
Hepatitis C, Chronic/complications/*drug therapy | 4 | 57.0 |
Interferon Alfa-2a/adverse effects/*therapeutic use | 3 | 50.0 |
Anti-Retroviral Agents/therapeutic use | 11 | 84.0 |
Carcinoma, Squamous Cell/immunology | 3 | 10.0 |
Acquired Immunodeficiency Syndrome/complications | 25 | 53.0 |
Breast Neoplasms/immunology/*pathology | 3 | 16.0 |
Lymph Nodes/*pathology | 10 | 10.0 |
HIV-1/*genetics/isolation & purification | 12 | 80.0 |
Sequence Homology, Nucleic Acid | 28 | 1.0 |
*Magnetic Resonance Imaging | 10 | 6.0 |
Organophosphorus Compounds/*therapeutic use | 5 | 71.0 |
Antiretroviral Therapy, Highly Active/adverse effects | 13 | 72.0 |
Cyclophosphamide/therapeutic use | 11 | 11.0 |
Doxorubicin/therapeutic use | 5 | 9.0 |
Etoposide/therapeutic use | 3 | 16.0 |
Lipoproteins, LDL Cholesterol/blood | 8 | 1.0 |
Feces/parasitology | 14 | 32.0 |
Influenza Vaccines/*adverse effects | 2 | 66.0 |
Orthomyxoviridae/immunology | 5 | 26.0 |
Cancer Vaccines/*immunology | 9 | 16.0 |
*Histocompatibility Antigens Class II | 3 | 4.0 |
Antigens, CD7/blood | 2 | 40.0 |
Lymphoproliferative Disorders/blood | 2 | 100.0 |
Tumor Markers, Biological/*blood | 3 | 0.0 |
HIV Protease Inhibitors/pharmacology/*therapeutic use | 8 | 80.0 |
Nigeria | 3 | 4.0 |
Weight Gain/drug effects | 5 | 23.0 |
*B-Lymphocyte Subsets | 3 | 37.0 |
Cell Membrane/physiology | 11 | 7.0 |
Virion/*physiology | 7 | 53.0 |
CD4-Positive T-Lymphocytes/cytology/immunology/metabolism | 5 | 55.0 |
Lymphocyte Activation/genetics/*immunology | 5 | 27.0 |
Phosphoproteins/metabolism | 18 | 2.0 |
Signal Transduction/genetics/*immunology | 8 | 9.0 |
Autoantibodies/blood | 15 | 8.0 |
Acquired Immunodeficiency Syndrome/*epidemiology | 13 | 81.0 |
California/epidemiology | 7 | 17.0 |
Income | 5 | 50.0 |
*Self Disclosure | 2 | 50.0 |
Antineoplastic Agents/*administration & dosage | 8 | 13.0 |
Interferon Type II/*administration & dosage | 4 | 28.0 |
von Willebrand Factor/analysis | 6 | 1.0 |
Adenoviridae/genetics | 9 | 1.0 |
Hematopoietic Stem Cells/immunology/*metabolism | 3 | 16.0 |
Hematopoietic Stem Cells/*physiology | 7 | 6.0 |
Lymphocytes/physiology | 10 | 11.0 |
HIV Infections/*drug therapy/genetics | 6 | 85.0 |
Antigen-Presenting Cells | 5 | 25.0 |
DNA/*metabolism | 3 | 0.0 |
Hemagglutinins/biosynthesis | 2 | 28.0 |
Lymphocyte Subsets/cytology/immunology | 3 | 33.0 |
Antigens, CD4/genetics/*metabolism | 46 | 97.0 |
Cell Adhesion/physiology | 6 | 2.0 |
Recombinant Proteins/genetics/metabolism | 9 | 1.0 |
*Antigens, Bacterial | 3 | 5.0 |
Carrier Proteins/genetics/*physiology | 2 | 2.0 |
Membrane Proteins/physiology | 4 | 4.0 |
Antigens, CD4/analysis/immunology | 11 | 91.0 |
Intracellular Fluid | 3 | 13.0 |
Actuarial Analysis | 9 | 12.0 |
Antineoplastic Combined Chemotherapy Protocols/administration & dosage | 3 | 9.0 |
Antiviral Agents/administration & dosage | 4 | 57.0 |
HLA-DR3 Antigen/*immunology | 2 | 50.0 |
Tetanus Toxoid/*immunology | 4 | 25.0 |
Antiretroviral Therapy, Highly Active/*trends | 2 | 100.0 |
District of Columbia/epidemiology | 5 | 55.0 |
Hospital Mortality | 3 | 9.0 |
Length of Stay/statistics & numerical data | 5 | 14.0 |
Lung/*radiography | 3 | 42.0 |
Adenoidectomy | 2 | 40.0 |
Cytoplasm/*metabolism | 4 | 3.0 |
AIDS-Related Opportunistic Infections/*microbiology | 10 | 55.0 |
Leukocytes, Mononuclear/*immunology | 41 | 24.0 |
Radiography, Thoracic | 9 | 24.0 |
Sputum/microbiology | 14 | 58.0 |
Tuberculosis, Pulmonary/complications/*immunology | 6 | 85.0 |
Chemokines, CC/*metabolism | 4 | 7.0 |
RANTES/biosynthesis | 5 | 29.0 |
RNA, Messenger | 9 | 2.0 |
Interleukin-12/*biosynthesis/immunology | 2 | 66.0 |
Toxoplasmosis/complications/immunology | 2 | 100.0 |
Africa, Western/epidemiology | 3 | 50.0 |
*Infant Mortality | 2 | 28.0 |
Zidovudine/*adverse effects/therapeutic use | 6 | 54.0 |
Delivery, Obstetric | 4 | 11.0 |
Disease Management | 3 | 21.0 |
HIV Infections/drug therapy/epidemiology/*transmission | 2 | 100.0 |
Data Interpretation, Statistical | 22 | 9.0 |
Bone Density | 4 | 3.0 |
Waiting Lists | 3 | 14.0 |
HIV Infections/epidemiology/*immunology/*virology | 3 | 100.0 |
*HIV-1/classification | 2 | 100.0 |
*Proviruses | 2 | 33.0 |
Interferon Type II/biosynthesis/blood | 7 | 41.0 |
Interleukin-2/biosynthesis/blood | 3 | 42.0 |
Lymph Nodes/cytology/*immunology | 3 | 42.0 |
Receptors, Interleukin-2/biosynthesis/immunology | 2 | 50.0 |
Th1 Cells/immunology/metabolism | 11 | 28.0 |
Th2 Cells/immunology/metabolism | 13 | 32.0 |
Interleukins/blood | 5 | 12.0 |
*Thoracic Surgical Procedures | 2 | 40.0 |
*Vascular Surgical Procedures | 2 | 22.0 |
Histocompatibility Antigens Class II/*analysis | 8 | 7.0 |
Herpesvirus 3, Human/immunology | 4 | 57.0 |
Simplexvirus/immunology | 8 | 36.0 |
*Mycobacterium xenopi | 3 | 100.0 |
Patient Acceptance of Health Care | 5 | 21.0 |
Danazol/therapeutic use | 2 | 20.0 |
Energy Intake | 12 | 6.0 |
HIV/drug effects/physiology | 9 | 75.0 |
CD4 Lymphocyte Count/*drug effects | 16 | 100.0 |
HIV/*isolation & purification | 17 | 68.0 |
Acquired Immunodeficiency Syndrome/*diagnosis/immunology/virology | 2 | 100.0 |
Lamivudine | 9 | 75.0 |
Nevirapine | 7 | 77.0 |
Zidovudine/administration & dosage/therapeutic use | 16 | 100.0 |
*AIDS Vaccines | 5 | 41.0 |
Acquired Immunodeficiency Syndrome/immunology/*prevention & control | 2 | 100.0 |
Boston | 4 | 28.0 |
Clinical Trials/*methods | 5 | 55.0 |
Zidovudine/administration & dosage | 25 | 100.0 |
Indinavir | 4 | 80.0 |
*Patient Selection | 5 | 20.0 |
*Randomized Controlled Trials | 4 | 21.0 |
HIV Infections/blood/*therapy | 5 | 100.0 |
*Plants, Medicinal | 6 | 8.0 |
Adjuvants, Immunologic/pharmacology/*therapeutic use | 3 | 50.0 |
HIV/physiology | 23 | 63.0 |
CD4 Lymphocyte Count/drug effects | 52 | 96.0 |
Acquired Immunodeficiency Syndrome/epidemiology | 9 | 81.0 |
Acquired Immunodeficiency Syndrome/diagnosis/*mortality | 2 | 100.0 |
*Face | 3 | 27.0 |
Hong Kong/epidemiology | 2 | 7.0 |
Lipodystrophy/*chemically induced/epidemiology | 2 | 100.0 |
Acquired Immunodeficiency Syndrome/diagnosis/*drug therapy | 3 | 100.0 |
Clinical Protocols/standards | 3 | 50.0 |
Clinical Trials/*standards | 2 | 40.0 |
HIV Infections/diagnosis/drug therapy | 2 | 100.0 |
Antifungal Agents/*therapeutic use | 8 | 66.0 |
Itraconazole/therapeutic use | 6 | 85.0 |
AIDS-Related Opportunistic Infections/*complications/diagnosis | 3 | 100.0 |
Fever of Unknown Origin/*etiology | 3 | 60.0 |
Bias (Epidemiology) | 13 | 24.0 |
*Data Interpretation, Statistical | 5 | 38.0 |
Immunoglobulins, Intravenous/*therapeutic use | 14 | 46.0 |
Patient Dropouts/*statistics & numerical data | 4 | 80.0 |
Acquired Immunodeficiency Syndrome/drug therapy/immunology | 4 | 100.0 |
AIDS-Related Opportunistic Infections/diagnosis/*drug therapy/immunology | 2 | 100.0 |
Cytomegalovirus Retinitis/diagnosis/*drug therapy/immunology | 2 | 100.0 |
Acyclovir/*therapeutic use | 5 | 50.0 |
Cytodiagnosis | 4 | 15.0 |
Bacterial Vaccines/*immunology | 10 | 43.0 |
*Vaccination/adverse effects | 3 | 100.0 |
Acquired Immunodeficiency Syndrome/*immunology/transmission | 2 | 66.0 |
*Polymerase Chain Reaction | 10 | 4.0 |
Antibody Specificity/immunology | 7 | 10.0 |
HIV Antibodies/*blood | 27 | 69.0 |
Immunoglobulin G/*blood | 8 | 12.0 |
Maternal-Fetal Exchange/immunology | 4 | 25.0 |
Corticotropin/*blood | 3 | 4.0 |
HIV Infections/*immunology/prevention & control | 2 | 66.0 |
Staphylococcus aureus/*immunology | 4 | 4.0 |
Superantigens/*immunology | 18 | 22.0 |
HIV Infections/*immunology/*transmission/virology | 2 | 66.0 |
Pregnancy Complications, Infectious/*immunology/virology | 3 | 100.0 |
Joint Prosthesis/*adverse effects | 2 | 28.0 |
Pulmonary Fibrosis/*immunology | 2 | 22.0 |
*Disease Outbreaks | 6 | 10.0 |
*Influenza A Virus, Human | 2 | 66.0 |
Influenza Vaccines/immunology | 3 | 50.0 |
Disease Reservoirs | 2 | 14.0 |
Immune System | 3 | 25.0 |
*Immunotherapy/methods | 2 | 28.0 |
*Genes, MHC Class II | 10 | 3.0 |
HLA-DR Antigens/*genetics | 8 | 1.0 |
RNA, Messenger/*biosynthesis | 7 | 3.0 |
CD4-Positive T-Lymphocytes/drug effects/virology | 5 | 71.0 |
Cytopathogenic Effect, Viral/*drug effects | 3 | 42.0 |
Glycosphingolipids/isolation & purification/*pharmacology | 2 | 100.0 |
Lymphocyte Function-Associated Antigen-1/biosynthesis | 5 | 23.0 |
Membrane Fusion/drug effects | 12 | 36.0 |
Signal Transduction/drug effects | 16 | 2.0 |
Autoantibodies/*immunology | 16 | 6.0 |
HLA-A2 Antigen/metabolism | 3 | 18.0 |
Adaptation, Psychological | 10 | 21.0 |
Mental Health | 2 | 9.0 |
*Antigenic Variation | 4 | 40.0 |
Chemokines/metabolism | 7 | 9.0 |
HIV Envelope Protein gp120/genetics/*metabolism | 22 | 59.0 |
Immunoglobulin G/metabolism | 13 | 7.0 |
Diagnostic Errors | 3 | 4.0 |
Paternity | 2 | 2.0 |
SIV/*pathogenicity | 7 | 43.0 |
Virion | 11 | 44.0 |
5' Untranslated Regions | 2 | 1.0 |
Polymorphism, Restriction Fragment Length | 12 | 0.0 |
Neoplasms/*drug therapy/mortality | 2 | 100.0 |
HIV Envelope Protein gp120/chemistry/*immunology | 10 | 71.0 |
HIV Seropositivity/blood/*immunology | 10 | 66.0 |
*Protein Conformation | 19 | 8.0 |
Antigens | 4 | 4.0 |
Immunoglobulin G/biosynthesis | 34 | 21.0 |
Polysaccharides, Bacterial/immunology | 3 | 23.0 |
Reference Standards | 18 | 8.0 |
Injections, Intradermal | 4 | 9.0 |
Skin/cytology | 6 | 3.0 |
Toxoplasma/*immunology | 7 | 31.0 |
Endoplasmic Reticulum/*metabolism | 15 | 10.0 |
T-Lymphocytes/*physiology | 61 | 21.0 |
Acquired Immunodeficiency Syndrome/complications/drug therapy/mortality | 2 | 100.0 |
Aqueous Humor/immunology | 2 | 66.0 |
Granuloma/immunology | 5 | 41.0 |
Mycobacterium avium-intracellulare Infection/immunology | 2 | 50.0 |
Oropharynx | 2 | 66.0 |
Down-Regulation/*immunology | 17 | 32.0 |
Histocompatibility Antigens Class I/*biosynthesis | 6 | 15.0 |
Histocompatibility Antigens Class II/*biosynthesis | 5 | 19.0 |
*Papillomavirus, Human | 9 | 27.0 |
Papovaviridae Infections/*complications | 6 | 50.0 |
Tumor Virus Infections/*complications | 10 | 38.0 |
Demography | 22 | 19.0 |
Cross Infection/*epidemiology | 3 | 60.0 |
HIV Infections/*microbiology | 21 | 77.0 |
*Mycobacterium bovis | 2 | 22.0 |
Hypersensitivity/immunology | 3 | 7.0 |
Vaccination/*adverse effects | 2 | 40.0 |
Virus Diseases/immunology | 2 | 10.0 |
*Immunity, Natural | 6 | 10.0 |
Killer Cells, Natural/physiology | 8 | 47.0 |
Phagocytosis | 24 | 6.0 |
Stomatitis, Aphthous/*immunology | 3 | 50.0 |
*Molecular Mimicry | 6 | 16.0 |
Consensus Sequence | 10 | 1.0 |
Genes, Synthetic | 2 | 3.0 |
Golgi Apparatus/virology | 2 | 66.0 |
HIV Envelope Protein gp41/genetics/metabolism | 4 | 100.0 |
Immunoglobulin G/genetics/metabolism | 2 | 25.0 |
Protein Biosynthesis/drug effects | 2 | 3.0 |
HIV Envelope Protein gp41/genetics/*metabolism | 6 | 60.0 |
HIV-1/metabolism/*physiology | 8 | 47.0 |
Quail | 3 | 7.0 |
Neutrophils/*immunology | 8 | 4.0 |
*AIDS-Related Opportunistic Infections | 8 | 88.0 |
Cytomegalovirus Infections/complications | 7 | 43.0 |
Syphilis/complications | 3 | 60.0 |
Tuberculosis/complications | 4 | 100.0 |
Antigens, Protozoan/immunology | 8 | 25.0 |
HIV-1/metabolism/*pathogenicity | 7 | 38.0 |
Macrophage Inflammatory Protein-1/pharmacology | 9 | 20.0 |
RANTES/pharmacology | 8 | 15.0 |
Receptors, CCR5/*genetics/metabolism | 4 | 25.0 |
HIV Infections/*drug therapy/genetics/*immunology | 2 | 66.0 |
Antigens, Differentiation, T-Lymphocyte/*metabolism | 30 | 25.0 |
Interleukins/metabolism | 4 | 12.0 |
Antibodies, Bacterial/*biosynthesis | 5 | 29.0 |
Cell Adhesion Molecules/metabolism | 18 | 7.0 |
Antigens, CD | 22 | 16.0 |
Antigens, CD2 | 59 | 12.0 |
Antigens, Differentiation, Myelomonocytic | 2 | 7.0 |
Killer Cells, Natural/*immunology/pathology | 4 | 33.0 |
Vincristine/therapeutic use | 5 | 13.0 |
Antigens, CD4/chemistry/*metabolism | 25 | 92.0 |
Biosensing Techniques | 5 | 8.0 |
Drosophila | 2 | 0.0 |
HIV Envelope Protein gp120/chemistry/genetics/*metabolism | 5 | 62.0 |
Protein Binding/genetics | 4 | 1.0 |
Adsorption | 8 | 5.0 |
HIV Infections/*etiology/*immunology | 2 | 100.0 |
Plants, Medicinal | 2 | 4.0 |
Proviruses/drug effects/genetics | 3 | 75.0 |
Receptor Aggregation/drug effects | 2 | 28.0 |
AIDS Dementia Complex/epidemiology | 3 | 100.0 |
Zalcitabine/*administration & dosage/adverse effects | 6 | 100.0 |
Killer Cells, Natural/radiation effects | 3 | 100.0 |
T-Lymphocytes/drug effects/metabolism | 3 | 8.0 |
Lymphoma/complications | 2 | 25.0 |
Chemokines/*metabolism | 4 | 7.0 |
Codon | 8 | 1.0 |
Zalcitabine/*administration & dosage | 4 | 80.0 |
Acquired Immunodeficiency Syndrome/*drug therapy/virology | 10 | 90.0 |
HIV Core Protein p24/blood | 84 | 91.0 |
Physician's Practice Patterns | 3 | 7.0 |
Australia | 10 | 5.0 |
Marital Status | 3 | 27.0 |
*European Continental Ancestry Group | 8 | 9.0 |
Adrenal Cortex Hormones/*administration & dosage/adverse effects | 2 | 18.0 |
Pregnancy Complications/drug therapy | 2 | 14.0 |
Antigen Presentation/genetics/immunology | 2 | 50.0 |
Vaccination/methods | 3 | 25.0 |
T-Lymphocyte Subsets/drug effects/*immunology | 12 | 44.0 |
Antidepressive Agents, Tricyclic/*therapeutic use | 2 | 28.0 |
Diarrhea/*drug therapy/etiology | 2 | 28.0 |
Irritable Bowel Syndrome/complications/*drug therapy | 2 | 66.0 |
HIV Infections/complications/immunology/transmission/*virology | 2 | 100.0 |
*HIV-1/isolation & purification | 19 | 82.0 |
*Polymorphism, Single Nucleotide | 3 | 0.0 |
Adaptation, Physiological/*physiology | 2 | 9.0 |
Medical History Taking | 3 | 7.0 |
Cerebrospinal Fluid/*virology | 2 | 66.0 |
HIV Envelope Protein gp120/chemistry/genetics | 4 | 33.0 |
HIV Infections/drug therapy/virology | 4 | 57.0 |
Peptide Fragments/chemistry/genetics | 4 | 14.0 |
*Sequence Analysis, DNA | 2 | 2.0 |
Cyclin B/metabolism | 2 | 2.0 |
*DNA Damage | 2 | 0.0 |
Protein Kinases/*physiology | 2 | 3.0 |
Membrane Fusion/*physiology | 10 | 38.0 |
Protein Transport | 4 | 0.0 |
Antigens, CD7/*analysis | 3 | 12.0 |
Antigens, Viral/immunology | 33 | 29.0 |
Cell Proliferation | 4 | 2.0 |
Acquired Immunodeficiency Syndrome/*immunology/therapy | 4 | 66.0 |
Ambulatory Care Facilities | 11 | 47.0 |
HIV Infections/drug therapy/*immunology/*virology | 6 | 75.0 |
HIV-2/*isolation & purification | 3 | 75.0 |
RNA, Viral/*cerebrospinal fluid | 4 | 80.0 |
HLA-A Antigens/immunology | 4 | 5.0 |
Lamivudine/administration & dosage | 13 | 100.0 |
*Sickness Impact Profile | 2 | 22.0 |
Celiac Disease/diet therapy/*immunology | 2 | 50.0 |
Gluten/administration & dosage | 2 | 25.0 |
Immunoglobulin A/*immunology | 5 | 18.0 |
Antibodies, Antinuclear/immunology | 3 | 18.0 |
Enzyme-Linked Immunosorbent Assay/veterinary | 2 | 14.0 |
Immunophenotyping/veterinary | 3 | 60.0 |
Pedigree | 17 | 0.0 |
HIV Infections/drug therapy/*epidemiology/immunology | 2 | 100.0 |
HTLV-I Infections/complications/*epidemiology | 2 | 100.0 |
Cytokines/analysis/biosynthesis | 2 | 22.0 |
Epitopes, T-Lymphocyte/analysis | 2 | 33.0 |
Immunodominant Epitopes/chemistry/*immunology | 2 | 33.0 |
Viral Proteins/chemistry/*immunology | 2 | 66.0 |
Viremia/*drug therapy | 5 | 71.0 |
Lamivudine/administration & dosage/adverse effects/*therapeutic use | 2 | 100.0 |
Zidovudine/*administration & dosage/adverse effects/pharmacokinetics | 4 | 100.0 |
AIDS Dementia Complex/*etiology | 2 | 40.0 |
*Blood-Brain Barrier | 3 | 12.0 |
CD8-Positive T-Lymphocytes/physiology | 15 | 62.0 |
Ritonavir/*administration & dosage | 5 | 71.0 |
Sickness Impact Profile | 2 | 25.0 |
Hydroxyurea/*administration & dosage | 2 | 66.0 |
HIV Seropositivity/*drug therapy/mortality | 3 | 100.0 |
*Codon | 2 | 4.0 |
Saquinavir/*administration & dosage/adverse effects/pharmacokinetics | 2 | 100.0 |
Antibodies, Bacterial/*analysis | 2 | 8.0 |
B-Lymphocytes/physiology | 15 | 25.0 |
*Heart Transplantation | 11 | 14.0 |
Polysaccharides, Bacterial/*immunology | 2 | 8.0 |
Streptococcus pneumoniae/*immunology | 9 | 27.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/*pharmacology | 6 | 3.0 |
Hepatitis B Antibodies/blood | 7 | 38.0 |
Hepatitis B Vaccines/*immunology | 4 | 30.0 |
Fatigue/chemically induced | 2 | 28.0 |
Interferon-alpha/administration & dosage/*therapeutic use | 2 | 25.0 |
Didanosine/adverse effects/*therapeutic use | 16 | 100.0 |
Bronchoalveolar Lavage Fluid/*immunology | 19 | 59.0 |
Antigens, Viral/*blood | 8 | 61.0 |
Viremia/drug therapy/immunology | 6 | 100.0 |
HIV-1/genetics/isolation & purification | 13 | 68.0 |
T-Lymphocytes/drug effects/immunology/virology | 2 | 66.0 |
HIV Infections/*psychology/*therapy | 4 | 100.0 |
Vitamin E/blood | 6 | 13.0 |
Acquired Immunodeficiency Syndrome/immunology/virology | 6 | 75.0 |
RNA, Viral/analysis/genetics | 6 | 66.0 |
Ethnic Groups | 19 | 7.0 |
Monocyte Chemoattractant Protein-1/metabolism | 3 | 4.0 |
Monocytes/drug effects/metabolism | 5 | 5.0 |
RANTES/metabolism | 10 | 16.0 |
*Disease Transmission, Horizontal | 4 | 57.0 |
HIV Infections/epidemiology/*transmission | 3 | 75.0 |
Semen/*virology | 15 | 100.0 |
HIV Infections/complications/*drug therapy/metabolism | 2 | 100.0 |
Hepatitis B virus/genetics | 2 | 15.0 |
Japan/epidemiology | 10 | 3.0 |
Dendritic Cells/immunology/*pathology | 2 | 13.0 |
Cancer Vaccines/*administration & dosage | 2 | 25.0 |
*Genes, p53 | 2 | 0.0 |
HIV-2/physiology | 4 | 100.0 |
RNA, Viral/*genetics | 3 | 6.0 |
Transfection/methods | 4 | 3.0 |
Macrophage Inflammatory Protein-1/biosynthesis/genetics | 3 | 75.0 |
RANTES/biosynthesis/genetics | 2 | 33.0 |
Transcription, Genetic/immunology | 8 | 10.0 |
Drug Carriers | 14 | 11.0 |
HIV Protease Inhibitors/chemistry/*therapeutic use | 2 | 100.0 |
Substance Abuse, Intravenous/complications/*psychology | 2 | 100.0 |
Mouth Mucosa/immunology | 2 | 33.0 |
Papillomavirus/*immunology | 3 | 50.0 |
Papovaviridae Infections/immunology/*veterinary | 2 | 100.0 |
Tumor Virus Infections/immunology/*veterinary | 2 | 100.0 |
HIV Envelope Protein gp120/*genetics | 15 | 60.0 |
Protein Kinase C/*metabolism | 7 | 2.0 |
Two-Hybrid System Techniques | 4 | 0.0 |
Acquired Immunodeficiency Syndrome/transmission | 5 | 83.0 |
Interleukin-10/*pharmacology | 8 | 8.0 |
Pregnancy Complications, Infectious | 11 | 64.0 |
Recombinant Proteins | 50 | 6.0 |
Lectins/*metabolism | 3 | 5.0 |
*Pregnancy Complications, Infectious | 20 | 71.0 |
T-Lymphocytes/*metabolism/virology | 3 | 37.0 |
ATP-Binding Cassette Transporters/genetics | 2 | 3.0 |
*Peptide Library | 3 | 5.0 |
Cervix Uteri/*pathology | 3 | 25.0 |
HIV Infections/*immunology/pathology/virology | 4 | 100.0 |
Lymphocytes/immunology/pathology | 9 | 36.0 |
HLA-C Antigens/genetics/immunology | 3 | 21.0 |
Antigens, Differentiation, Myelomonocytic/metabolism | 8 | 5.0 |
Calcium-Binding Proteins/metabolism | 4 | 5.0 |
Calgranulin A | 4 | 10.0 |
Calgranulin B | 3 | 7.0 |
Interleukin-16/metabolism | 2 | 66.0 |
Major Histocompatibility Complex/physiology | 2 | 12.0 |
Immunoglobulins, Intravenous/therapeutic use | 15 | 40.0 |
Antigens, CD/genetics | 12 | 8.0 |
Leukocytes/immunology | 11 | 8.0 |
Drug Hypersensitivity/*immunology | 2 | 28.0 |
Serine Endopeptidases/biosynthesis | 2 | 25.0 |
Bronchoalveolar Lavage Fluid/chemistry/immunology | 2 | 28.0 |
Epithelial Cells/cytology/*immunology | 2 | 66.0 |
Fetal Tissue Transplantation | 4 | 18.0 |
Gene Expression Regulation, Neoplastic | 7 | 0.0 |
Lung Neoplasms | 2 | 1.0 |
Lung Transplantation/*immunology | 2 | 22.0 |
Didanosine/administration & dosage | 10 | 100.0 |
Dideoxynucleosides/administration & dosage | 4 | 100.0 |
Nelfinavir/administration & dosage | 3 | 100.0 |
Ritonavir/administration & dosage | 5 | 83.0 |
Saquinavir/administration & dosage | 6 | 100.0 |
Alzheimer Disease/*immunology | 3 | 21.0 |
Blood Loss, Surgical | 2 | 7.0 |
Fever/etiology | 5 | 21.0 |
Hemoglobinometry | 3 | 9.0 |
Insurance, Health | 3 | 60.0 |
*Postoperative Complications | 4 | 6.0 |
Granulocyte Colony-Stimulating Factor/administration & dosage | 2 | 7.0 |
Indinavir/administration & dosage | 6 | 100.0 |
*Complementary Therapies | 4 | 80.0 |
*Health Status | 7 | 17.0 |
Nutrition | 2 | 5.0 |
Phytotherapy | 3 | 11.0 |
Vitamins/administration & dosage | 6 | 54.0 |
*Cancer Vaccines | 7 | 26.0 |
Dendritic Cells/metabolism | 5 | 11.0 |
Immunoglobulins/metabolism | 9 | 8.0 |
Epithelium/metabolism | 5 | 1.0 |
Recombinant Proteins/*metabolism | 2 | 6.0 |
Chemokines, CC/*analysis | 2 | 33.0 |
Leukocytes | 4 | 7.0 |
Cytomegalovirus Infections/immunology | 12 | 46.0 |
Epstein-Barr Virus Infections/immunology | 3 | 37.0 |
Lymphoma, B-Cell/*pathology | 2 | 8.0 |
T-Lymphocytes/immunology/*pathology | 23 | 60.0 |
Antigens, Dermatophagoides | 3 | 5.0 |
Immunoglobulin E/immunology | 7 | 11.0 |
Interferon Type II/biosynthesis/*immunology | 2 | 33.0 |
Mites/immunology | 5 | 13.0 |
Th2 Cells/*immunology/metabolism | 4 | 14.0 |
Interleukins/biosynthesis | 10 | 22.0 |
Viral Core Proteins/immunology | 11 | 47.0 |
Complement | 5 | 11.0 |
Neurons/metabolism | 3 | 0.0 |
Down-Regulation/genetics/immunology | 2 | 7.0 |
Fibroblasts/metabolism | 7 | 0.0 |
*Lymphocyte Activation/drug effects/genetics | 2 | 50.0 |
Promoter Regions (Genetics)/immunology | 6 | 8.0 |
Receptors, Antigen, T-Cell/*physiology | 42 | 26.0 |
Caspases/*physiology | 2 | 9.0 |
Lymphocyte Specific Protein Tyrosine Kinase p56(lck)/physiology | 3 | 21.0 |
Membrane Glycoproteins/pharmacology | 4 | 7.0 |
Signal Transduction/*immunology | 30 | 7.0 |
T-Lymphocytes/*cytology/enzymology/*immunology | 2 | 100.0 |
T-Lymphocyte Subsets/cytology/*immunology/*metabolism | 3 | 37.0 |
Antigens, CD5/metabolism | 2 | 10.0 |
Histocompatibility Antigens Class I/immunology/metabolism | 3 | 75.0 |
Histocompatibility Antigens Class II/immunology/metabolism | 5 | 50.0 |
Liver/cytology/embryology | 2 | 8.0 |
Membrane Proteins/genetics/*metabolism | 6 | 2.0 |
Promoter Regions (Genetics)/genetics | 11 | 1.0 |
Transcription Factor AP-1/metabolism | 6 | 2.0 |
1-Phosphatidylinositol 3-Kinase/antagonists & inhibitors/*metabolism | 2 | 3.0 |
Cell Membrane/*metabolism | 14 | 4.0 |
Chromones/pharmacology | 3 | 1.0 |
GTP Phosphohydrolases/metabolism | 2 | 1.0 |
Gene Products, nef/chemistry/*metabolism | 3 | 75.0 |
Golgi Apparatus/chemistry/metabolism | 2 | 33.0 |
Morpholines/pharmacology | 3 | 1.0 |
B-Lymphocytes/classification/pathology | 2 | 100.0 |
Connective Tissue/pathology | 2 | 11.0 |
Cyclosporine/*adverse effects | 3 | 18.0 |
Gingiva/pathology | 3 | 37.0 |
Immunosuppressive Agents/*adverse effects | 6 | 15.0 |
Lymphocyte Subsets/*classification/pathology | 3 | 100.0 |
Infant Welfare | 2 | 20.0 |
Pneumonia, Pneumocystis/*etiology | 4 | 80.0 |
Pregnancy Complications, Infectious/*microbiology | 2 | 40.0 |
Binomial Distribution | 2 | 25.0 |
HIV Infections/complications/epidemiology/*immunology | 3 | 100.0 |
Herpesvirus 1, Human/*immunology | 3 | 23.0 |
Herpesvirus 2, Human/*immunology | 4 | 40.0 |
*Gene Silencing | 3 | 1.0 |
Homeodomain Proteins/*metabolism | 2 | 1.0 |
Repressor Proteins/*metabolism | 2 | 1.0 |
DNA, Viral/biosynthesis | 16 | 30.0 |
Tumor Necrosis Factor-alpha/biosynthesis/immunology | 2 | 14.0 |
Antigens, CD45/*immunology | 10 | 30.0 |
Interferon Type II/analysis/*biosynthesis | 2 | 66.0 |
Acquired Immunodeficiency Syndrome/drug therapy/*immunology | 9 | 64.0 |
Viral Envelope Proteins/*immunology | 13 | 34.0 |
Skin/metabolism/pathology | 2 | 4.0 |
Adaptor Protein Complex alpha Subunits | 9 | 20.0 |
Endocytosis/physiology | 5 | 6.0 |
Endosomes/metabolism | 6 | 5.0 |
HIV Infections/*complications/diagnosis/mortality | 2 | 100.0 |
Hepatitis B e Antigens/analysis | 2 | 13.0 |
Helicobacter pylori/*immunology/pathogenicity | 2 | 50.0 |
*Urban Population | 2 | 14.0 |
Ethiopia | 10 | 38.0 |
*Prostitution | 8 | 47.0 |
Bone Marrow/*immunology/pathology | 2 | 11.0 |
Breast Neoplasms/*immunology/pathology | 4 | 16.0 |
Keratin/analysis | 8 | 3.0 |
Macrophages/immunology/pathology | 11 | 33.0 |
Monocytes/immunology/pathology | 4 | 26.0 |
*Bacterial Toxins | 16 | 11.0 |
Rosette Formation | 31 | 10.0 |
Dilatation, Pathologic | 2 | 20.0 |
HIV Infections/*pathology | 15 | 57.0 |
*Neuropsychological Tests | 8 | 25.0 |
Acquired Immunodeficiency Syndrome/blood/*drug therapy/immunology | 7 | 100.0 |
Anti-Inflammatory Agents/adverse effects/*therapeutic use | 2 | 66.0 |
Prednisone/adverse effects/*therapeutic use | 2 | 40.0 |
RNA/blood | 3 | 50.0 |
Homosexuality, Male/statistics & numerical data | 4 | 100.0 |
Neoplasm Proteins/analysis | 9 | 2.0 |
*HIV-1/*immunology | 2 | 100.0 |
Celiac Disease/*complications/immunology | 3 | 75.0 |
Infection/etiology/immunology | 2 | 40.0 |
Genes, MHC Class II | 14 | 5.0 |
Dehydroepiandrosterone/*blood | 3 | 16.0 |
HIV Infections/*immunology/*metabolism | 4 | 80.0 |
Neuroimmunomodulation | 3 | 15.0 |
Antibodies, Monoclonal/blood | 4 | 30.0 |
Mucocutaneous Lymph Node Syndrome/*immunology | 3 | 25.0 |
Antilymphocyte Serum/*analysis | 2 | 22.0 |
Cats | 24 | 7.0 |
HIV Seropositivity/*immunology/psychology | 5 | 100.0 |
*Massage | 3 | 42.0 |
Psychometrics | 10 | 15.0 |
Adaptor Protein Complex gamma Subunits | 2 | 25.0 |
Recombinant Fusion Proteins | 6 | 1.0 |
Antigens, CD4/*chemistry/*metabolism | 6 | 100.0 |
Nuclear Magnetic Resonance, Biomolecular | 4 | 2.0 |
Antigens, CD4/analysis/*metabolism | 2 | 100.0 |
DNA, Recombinant/genetics | 5 | 8.0 |
Macaca mulatta/virology | 3 | 100.0 |
Golgi Apparatus/metabolism | 13 | 7.0 |
HIV-1/*metabolism/physiology | 7 | 53.0 |
Microscopy, Electron, Scanning | 10 | 3.0 |
Adaptation, Biological | 4 | 30.0 |
Microglia/metabolism/*virology | 3 | 60.0 |
Antibodies, Viral/blood/immunology | 2 | 100.0 |
Measles virus/immunology | 3 | 25.0 |
HIV Envelope Protein gp120/*chemistry | 11 | 68.0 |
Antigen-Presenting Cells/immunology/virology | 2 | 50.0 |
HIV/genetics/*physiology | 3 | 75.0 |
Cytokines/analysis/*biosynthesis | 2 | 14.0 |
Allergens | 2 | 11.0 |
Asthma/*drug therapy/immunology/physiopathology | 5 | 83.0 |
Fingers | 2 | 11.0 |
Papillomavirus, Human/classification/*isolation & purification | 3 | 37.0 |
Complement Activation | 8 | 2.0 |
Inflammation Mediators/*metabolism | 2 | 3.0 |
CD4-Positive T-Lymphocytes/metabolism/virology | 10 | 76.0 |
Giant Cells/*virology | 8 | 80.0 |
HIV/immunology/*pathogenicity | 4 | 100.0 |
HIV-1/immunology/pathogenicity | 2 | 100.0 |
Viral Envelope Proteins/metabolism | 15 | 29.0 |
Antigens, Surface/*metabolism | 11 | 18.0 |
Bone Marrow/drug effects | 9 | 12.0 |
Granulocyte Colony-Stimulating Factor/*administration & dosage | 4 | 14.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/*administration & dosage | 6 | 35.0 |
Ovarian Neoplasms/immunology/therapy | 2 | 50.0 |
Receptors, IgG/metabolism | 4 | 5.0 |
Signal Transduction/physiology | 9 | 0.0 |
Antigens, CD95/*blood | 7 | 41.0 |
Genes, erbB-2 | 2 | 2.0 |
Granulocytes/cytology | 4 | 8.0 |
*Ovariectomy | 2 | 4.0 |
Antigen-Presenting Cells/*immunology/metabolism | 3 | 37.0 |
B-Lymphocytes/*immunology/metabolism | 4 | 8.0 |
Cysteine/genetics/metabolism | 2 | 11.0 |
Growth Inhibitors/pharmacology | 4 | 2.0 |
Peptides/immunology/metabolism | 5 | 25.0 |
Acquired Immunodeficiency Syndrome/*blood/complications | 4 | 40.0 |
Glutathione/blood | 3 | 6.0 |
HIV Infections/blood/complications | 2 | 100.0 |
Oxidative Stress | 7 | 2.0 |
gamma-Glutamyltransferase/blood | 2 | 4.0 |
Dideoxynucleosides/administration & dosage/*therapeutic use | 2 | 100.0 |
Lamivudine/administration & dosage/*therapeutic use | 6 | 100.0 |
Antigens, CD3/*metabolism | 10 | 20.0 |
T-Lymphocytes/drug effects/immunology | 26 | 29.0 |
1-Phosphatidylinositol 3-Kinase/metabolism | 5 | 0.0 |
Antigens, CD29/*metabolism | 2 | 5.0 |
Cell Compartmentation | 20 | 5.0 |
Health Care Costs/*statistics & numerical data | 2 | 100.0 |
Life Expectancy | 6 | 13.0 |
Quality-Adjusted Life Years | 4 | 66.0 |
Value of Life | 2 | 50.0 |
Substance-Related Disorders | 7 | 33.0 |
Avipoxvirus/*genetics | 2 | 66.0 |
Rhode Island/epidemiology | 3 | 100.0 |
Brain Mapping | 5 | 3.0 |
Image Processing, Computer-Assisted/methods | 2 | 10.0 |
Magnetic Resonance Imaging/methods | 4 | 5.0 |
Oxygen/blood | 3 | 2.0 |
Viral Load/methods | 7 | 63.0 |
Lymphocyte Subsets/*cytology | 11 | 47.0 |
Interleukin-2/secretion | 18 | 25.0 |
Lymphoid Tissue/cytology/immunology | 2 | 20.0 |
Lymphokines/secretion | 9 | 23.0 |
Antigens, CD7/analysis | 2 | 10.0 |
Leukemia, Lymphocytic, Chronic/immunology | 2 | 20.0 |
Lymphoma, B-Cell/*immunology | 2 | 5.0 |
SIV/*isolation & purification | 3 | 100.0 |
Simian Acquired Immunodeficiency Syndrome/immunology/*virology | 4 | 66.0 |
Acquired Immunodeficiency Syndrome/immunology/*virology | 9 | 69.0 |
Antigens, CD8/metabolism | 35 | 66.0 |
*Membrane Proteins | 14 | 1.0 |
Hypercalcemia/etiology | 2 | 33.0 |
Lymphopenia/etiology | 5 | 71.0 |
Peptidyl-Dipeptidase A/blood | 2 | 2.0 |
beta 2-Microglobulin/blood | 7 | 29.0 |
Blood-Brain Barrier/immunology | 3 | 37.0 |
Encephalitis/immunology | 2 | 25.0 |
Granulocytes/immunology/*metabolism | 2 | 33.0 |
Macrophages/immunology/metabolism | 3 | 6.0 |
Microglia/immunology/*metabolism | 2 | 100.0 |
Antigens, CD/*physiology | 26 | 8.0 |
Receptors, Interferon/*physiology | 2 | 33.0 |
Arthritis/immunology | 3 | 42.0 |
Inflammation/*immunology | 4 | 7.0 |
Liver/immunology | 6 | 12.0 |
Liver Cirrhosis/immunology | 2 | 14.0 |
Lymphocyte Subsets/classification/immunology | 2 | 100.0 |
Receptors, Cytokine/*metabolism | 9 | 10.0 |
Receptors, Lymphocyte Homing/metabolism | 2 | 5.0 |
T-Lymphocytes, Cytotoxic/*classification/immunology | 3 | 42.0 |
Color | 4 | 15.0 |
Interleukin-4/analysis/metabolism | 2 | 66.0 |
Ionophores/pharmacology | 6 | 4.0 |
Phytohemagglutinins/*pharmacology | 6 | 16.0 |
CD4 Immunoadhesins/*pharmacology | 3 | 75.0 |
HIV Envelope Protein gp41/*pharmacology | 5 | 62.0 |
Peptide Fragments/*pharmacology | 8 | 4.0 |
HIV Infections/blood/immunology/*virology | 7 | 87.0 |
Influenza Vaccines/*administration & dosage | 4 | 44.0 |
CD4-Positive T-Lymphocytes/chemistry/immunology | 5 | 50.0 |
CD8-Positive T-Lymphocytes/chemistry/*immunology | 2 | 33.0 |
Human T-lymphotropic virus 1/*immunology | 5 | 25.0 |
Tumor Necrosis Factor-alpha/*immunology | 8 | 6.0 |
HIV Infections/*blood/*drug therapy | 5 | 100.0 |
Factor XIII/genetics | 2 | 25.0 |
Gene Amplification | 7 | 0.0 |
Nucleic Acid Amplification Techniques | 3 | 7.0 |
Reagent Kits, Diagnostic | 15 | 10.0 |
Placenta/*virology | 2 | 50.0 |
Pregnancy Complications, Infectious/immunology/*virology | 3 | 60.0 |
Antigens, CD34/*analysis | 5 | 1.0 |
DNA-Binding Proteins/genetics/*metabolism | 2 | 0.0 |
Fluoresceins/metabolism | 2 | 9.0 |
Granulocytes/metabolism | 3 | 7.0 |
Hematopoietic Stem Cells/*metabolism | 3 | 2.0 |
*Saccharomyces cerevisiae Proteins | 4 | 0.0 |
Bacterial Proteins/*metabolism | 2 | 4.0 |
Heat-Shock Proteins/*metabolism | 2 | 3.0 |
T-Lymphocyte Subsets/*metabolism | 13 | 43.0 |
Intestinal Mucosa/metabolism/*pathology | 2 | 18.0 |
Anus/pathology | 2 | 66.0 |
HIV Seropositivity/complications | 26 | 81.0 |
Erythropoietin/*therapeutic use | 2 | 2.0 |
HIV Infections/complications/*drug therapy/immunology | 10 | 100.0 |
Recombinant Proteins/therapeutic use | 32 | 9.0 |
Cell Differentiation/*physiology | 5 | 2.0 |
Cell Division/*physiology | 3 | 1.0 |
Cell Movement/*physiology | 2 | 0.0 |
Interleukin-16/*metabolism | 2 | 100.0 |
Microglia/cytology/*metabolism | 2 | 20.0 |
Neurons/cytology/*metabolism | 2 | 2.0 |
Gene Rearrangement, delta-Chain T-Cell Antigen Receptor | 2 | 25.0 |
Leukemia, T-Cell/*genetics/metabolism/pathology | 2 | 100.0 |
Receptors, Antigen, T-Cell, gamma-delta/genetics/*metabolism | 3 | 60.0 |
Acquired Immunodeficiency Syndrome/*blood/physiopathology | 2 | 66.0 |
*Chemotaxis | 2 | 6.0 |
*Life Expectancy | 2 | 33.0 |
T-Lymphocytes/*chemistry/*immunology | 2 | 100.0 |
Testicular Neoplasms/*immunology/pathology | 2 | 50.0 |
Antigens, Viral/genetics/immunology | 2 | 33.0 |
Immunotherapy, Active | 2 | 15.0 |
Linkage (Genetics) | 15 | 0.0 |
Lung Neoplasms/therapy | 2 | 25.0 |
Membrane Proteins/genetics/*immunology | 5 | 38.0 |
Cryptococcus neoformans/*immunology | 9 | 45.0 |
Interleukin-12/blood | 3 | 13.0 |
Interleukin-18/blood | 2 | 28.0 |
Linkage (Genetics)/genetics | 2 | 0.0 |
Antigens, Neoplasm/metabolism | 2 | 2.0 |
DNA Nucleotidylexotransferase | 2 | 40.0 |
DNA, Neoplasm/analysis | 26 | 3.0 |
Blood Platelets/metabolism | 2 | 1.0 |
Leukocytes, Mononuclear/*metabolism | 11 | 7.0 |
Phosphatidylinositol Diacylglycerol-Lyase | 6 | 6.0 |
Lymphocyte Subsets/*cytology/immunology | 5 | 71.0 |
Acyclovir/therapeutic use | 9 | 81.0 |
Biometry/*methods | 6 | 85.0 |
*Meta-Analysis | 2 | 22.0 |
Palliative Care | 3 | 7.0 |
Gene Products, vpr/genetics/metabolism | 2 | 66.0 |
Measles Vaccine/administration & dosage/*immunology | 2 | 100.0 |
Immunodeficiency Virus, Feline | 2 | 66.0 |
Receptors, CXCR4/immunology/*metabolism | 2 | 33.0 |
AIDS-Related Opportunistic Infections/*complications/drug therapy | 3 | 100.0 |
Fluorescein Angiography | 7 | 6.0 |
Vitreous Body/*pathology | 2 | 15.0 |
Antitubercular Agents/*administration & dosage/adverse effects/economics | 2 | 100.0 |
Tuberculosis, Multidrug-Resistant/prevention & control | 2 | 100.0 |
AIDS-Related Opportunistic Infections/diagnosis/*drug therapy | 6 | 100.0 |
Cytomegalovirus Retinitis/diagnosis/*drug therapy | 4 | 100.0 |
Canada/epidemiology | 3 | 7.0 |
Complementary Therapies | 4 | 80.0 |
Databases, Factual | 11 | 3.0 |
HIV Infections/immunology/physiopathology | 2 | 66.0 |
Zambia | 5 | 35.0 |
HIV Infections/*drug therapy/immunology/psychology/virology | 2 | 100.0 |
HIV Infections/genetics/immunology/*virology | 3 | 60.0 |
HIV Protease Inhibitors/*pharmacology | 9 | 32.0 |
Leukocytes, Mononuclear/immunology/*virology | 6 | 66.0 |
Lymph Nodes/immunology/*virology | 2 | 100.0 |
Receptors, CCR5/biosynthesis/*metabolism | 3 | 100.0 |
Receptors, CXCR4/biosynthesis/*metabolism | 2 | 50.0 |
Immunomagnetic Separation/*methods | 2 | 11.0 |
Capsid/genetics | 2 | 8.0 |
Gene Products, env/genetics | 8 | 53.0 |
HIV Infections/blood/transmission/*virology | 3 | 100.0 |
*Antibodies, Monoclonal | 20 | 8.0 |
*Antigens, CD4 | 24 | 96.0 |
Gene Expression Profiling | 5 | 0.0 |
Acquired Immunodeficiency Syndrome/microbiology/*pathology | 5 | 83.0 |
DNA, Bacterial/analysis | 3 | 5.0 |
Myocardium/pathology | 8 | 8.0 |
Helicobacter Infections/*immunology | 3 | 21.0 |
Leukocytes, Mononuclear/*immunology/metabolism | 3 | 23.0 |
T-Lymphocyte Subsets/metabolism | 8 | 34.0 |
Aging/*metabolism | 4 | 1.0 |
Embryonic and Fetal Development/physiology | 3 | 3.0 |
G(M3) Ganglioside/metabolism | 2 | 100.0 |
Leukocytes, Mononuclear/metabolism/*virology | 2 | 50.0 |
Gene Products, tat/physiology | 3 | 17.0 |
Radiographic Image Enhancement | 3 | 23.0 |
Antibody Formation/immunology | 12 | 26.0 |
Antigens, CD/analysis/genetics | 6 | 20.0 |
Antigens, CD2/analysis/genetics | 2 | 66.0 |
Antigens, CD7/analysis/genetics | 2 | 100.0 |
Antigens, CD8/analysis/genetics | 4 | 100.0 |
Antigens, Differentiation, T-Lymphocyte/analysis/genetics | 4 | 80.0 |
Immunoglobulin Isotypes/analysis | 4 | 26.0 |
Molecular Weight | 68 | 2.0 |
Anti-HIV Agents | 2 | 100.0 |
Chemokines/*physiology | 5 | 16.0 |
HIV Infections/genetics | 2 | 20.0 |
Twins, Monozygotic | 5 | 6.0 |
*Papillomavirus, Human/genetics | 6 | 60.0 |
Papovaviridae Infections/complications | 5 | 38.0 |
Tumor Virus Infections/complications | 7 | 33.0 |
Fundus Oculi | 8 | 8.0 |
Lymphopenia/complications | 4 | 80.0 |
Retinal Detachment/etiology/surgery | 2 | 66.0 |
Vitrectomy | 6 | 14.0 |
Antibodies/analysis | 5 | 3.0 |
Mucous Membrane/immunology | 7 | 26.0 |
Electrophysiology | 5 | 1.0 |
Interferon-alpha/analysis | 4 | 40.0 |
Interleukin-1/analysis | 8 | 9.0 |
HIV Infections/drug therapy/immunology/*physiopathology | 6 | 100.0 |
Lipodystrophy/chemically induced | 3 | 75.0 |
Ritonavir/adverse effects/pharmacokinetics/*therapeutic use | 3 | 100.0 |
Hong Kong | 4 | 8.0 |
*Maternal-Fetal Exchange | 3 | 8.0 |
X Chromosome/genetics | 2 | 1.0 |
Glutathione Peroxidase/blood | 3 | 8.0 |
Superoxide Dismutase/blood | 2 | 4.0 |
Phytohemagglutinins/*therapeutic use | 2 | 66.0 |
Pokeweed Mitogens/*therapeutic use | 2 | 100.0 |
Interleukin-2/*adverse effects/therapeutic use | 3 | 37.0 |
Antigens, CD8/genetics/immunology | 4 | 66.0 |
Histocompatibility Antigens Class II/genetics/immunology | 5 | 25.0 |
Immunotherapy/methods | 10 | 12.0 |
Recombinant Fusion Proteins/genetics/immunology | 4 | 8.0 |
AIDS-Related Opportunistic Infections/drug therapy/*prevention & control | 4 | 100.0 |
Pneumonia, Pneumocystis/drug therapy/*prevention & control | 3 | 100.0 |
Immunoglobulins/*blood | 13 | 39.0 |
Interleukin-4/blood/immunology | 2 | 66.0 |
Glycoproteins/immunology | 10 | 11.0 |
Receptors, Antigen, T-Cell/genetics/*immunology | 5 | 31.0 |
Hydroxyurea/administration & dosage | 2 | 66.0 |
Echocardiography | 9 | 4.0 |
Immunity, Cellular/*immunology | 11 | 39.0 |
Intercellular Adhesion Molecule-1/biosynthesis | 8 | 9.0 |
Pemphigus/*immunology/pathology | 2 | 50.0 |
DNA/*blood | 2 | 6.0 |
*Genetic Markers | 5 | 1.0 |
Poland | 5 | 3.0 |
Complement 3/analysis | 6 | 1.0 |
Complement 4/analysis | 2 | 0.0 |
HLA-DR Antigens/blood | 19 | 34.0 |
Receptors, Antigen, T-Cell, alpha-beta/blood | 2 | 50.0 |
Receptors, Antigen, T-Cell, gamma-delta/blood | 2 | 100.0 |
Antigens, CD19/blood | 5 | 38.0 |
Binding Sites/genetics | 13 | 1.0 |
Endocytosis/*physiology | 4 | 3.0 |
HIV-1/*genetics/*physiology | 2 | 40.0 |
Abdomen | 3 | 3.0 |
HIV Infections/complications/immunology/*virology | 3 | 100.0 |
Lymphocyte Subsets/immunology/metabolism | 3 | 27.0 |
Mice, Inbred MRL lpr | 2 | 7.0 |
Genetic Markers/immunology | 3 | 15.0 |
Immunoglobulin E/biosynthesis | 6 | 15.0 |
HLA-B Antigens/genetics | 5 | 2.0 |
Major Histocompatibility Complex/*genetics | 6 | 3.0 |
Microsatellite Repeats | 6 | 0.0 |
Administration, Intravesical | 5 | 19.0 |
B-Lymphocytes/drug effects/immunology | 7 | 24.0 |
*Immunity, Mucosal | 6 | 35.0 |
Breast Neoplasms/*immunology | 7 | 12.0 |
Receptor, erbB-2/*immunology | 2 | 11.0 |
Carrier Proteins/*pharmacology | 3 | 6.0 |
HIV Envelope Protein gp120/drug effects/*metabolism | 4 | 80.0 |
AIDS-Related Opportunistic Infections/blood/*immunology/virology | 2 | 100.0 |
Cytokines | 6 | 5.0 |
Leukocytes, Mononuclear | 15 | 31.0 |
Cell Aggregation | 9 | 8.0 |
HIV/*physiology/ultrastructure | 2 | 100.0 |
Sulfhydryl Reagents/pharmacology | 2 | 4.0 |
Viral Envelope Proteins/immunology/*physiology | 3 | 75.0 |
Lamivudine/pharmacology/therapeutic use | 2 | 50.0 |
Proto-Oncogene Proteins c-bcl-2/biosynthesis | 4 | 2.0 |
Zidovudine/pharmacology/therapeutic use | 7 | 70.0 |
Interleukin-2/pharmacology/*therapeutic use | 2 | 28.0 |
Indinavir/administration & dosage/therapeutic use | 6 | 100.0 |
Lamivudine/administration & dosage/therapeutic use | 9 | 100.0 |
Granulocytes/radiation effects | 2 | 100.0 |
Radiotherapy/*adverse effects | 3 | 20.0 |
Antigens, CD4/analysis/*physiology | 6 | 100.0 |
Histocompatibility Antigens Class II/physiology | 9 | 45.0 |
CD40 Ligand/*physiology | 2 | 33.0 |
Isoantigens/immunology | 9 | 10.0 |
Catalytic Domain | 3 | 1.0 |
Proton-Translocating ATPases/*metabolism | 2 | 40.0 |
*Vacuolar Proton-Translocating ATPases | 2 | 15.0 |
Viral Regulatory Proteins/genetics/*metabolism | 2 | 100.0 |
AIDS-Related Opportunistic Infections/*blood | 2 | 100.0 |
HIV Infections/*blood/complications | 8 | 80.0 |
Catheters, Indwelling/*adverse effects | 2 | 25.0 |
Recombinant Proteins/immunology/*pharmacology | 2 | 50.0 |
HIV-1/genetics/*isolation & purification/physiology | 4 | 100.0 |
RNA, Viral/*analysis/blood | 8 | 88.0 |
*HIV Infections/drug therapy/immunology/virology | 3 | 100.0 |
HIV Infections/*complications/immunology/physiopathology | 4 | 100.0 |
CD4-Positive T-Lymphocytes/cytology/*drug effects/immunology | 3 | 100.0 |
Leukocytes, Mononuclear/cytology/*drug effects | 2 | 50.0 |
AIDS-Related Opportunistic Infections/*epidemiology/mortality | 3 | 100.0 |
HIV-1/drug effects/genetics/physiology | 4 | 100.0 |
HIV Infections/blood/*epidemiology/etiology | 2 | 100.0 |
Injections, Spinal | 2 | 5.0 |
Killer Cells, Natural/*drug effects/immunology | 6 | 22.0 |
Gene Expression Regulation, Viral/physiology | 4 | 16.0 |
Transcription, Genetic/physiology | 3 | 1.0 |
Adjuvants, Immunologic/pharmacology/therapeutic use | 2 | 25.0 |
Antigens, Differentiation/chemistry | 2 | 40.0 |
DNA-Binding Proteins/genetics/physiology | 3 | 3.0 |
Killer Cells, Natural/immunology/metabolism | 5 | 16.0 |
*Diet | 6 | 2.0 |
*Immune System | 4 | 50.0 |
Cysteine Endopeptidases/*metabolism | 2 | 0.0 |
Multienzyme Complexes/*metabolism | 2 | 1.0 |
Active Transport, Cell Nucleus | 2 | 0.0 |
Gene Expression Regulation, Viral/drug effects | 3 | 14.0 |
Protein Kinase C/physiology | 6 | 3.0 |
Lymphoma, T-Cell, Cutaneous/*drug therapy/pathology | 2 | 40.0 |
Mycosis Fungoides/drug therapy/pathology | 2 | 66.0 |
Antigen Presentation/physiology | 3 | 25.0 |
Antigens, Differentiation/pharmacology | 7 | 33.0 |
Epitopes/physiology | 2 | 25.0 |
Pneumonia/immunology | 2 | 50.0 |
Cell Communication/*physiology | 2 | 3.0 |
Extracellular Matrix/physiology | 3 | 3.0 |
Integrins/physiology | 2 | 2.0 |
CD4-Positive T-Lymphocytes/physiology/*radiation effects | 2 | 100.0 |
CD8-Positive T-Lymphocytes/physiology/*radiation effects | 2 | 100.0 |
CD4-Positive T-Lymphocytes/*radiation effects | 2 | 100.0 |
CD8-Positive T-Lymphocytes/*radiation effects | 2 | 100.0 |
Cells, Cultured/drug effects | 6 | 6.0 |
Drug Screening Assays, Antitumor | 2 | 0.0 |
Viremia/drug therapy | 13 | 100.0 |
Interferon Type II/physiology | 12 | 14.0 |
Intestinal Mucosa/metabolism | 2 | 1.0 |
T-Lymphocytes, Helper-Inducer/physiology | 12 | 70.0 |
HIV-1/genetics/physiology | 6 | 46.0 |
*Health Status Indicators | 4 | 44.0 |
*Cause of Death | 3 | 15.0 |
HIV/*drug effects/genetics | 2 | 50.0 |
Hepacivirus/genetics/*isolation & purification | 4 | 57.0 |
Hepatitis C/*complications/virology | 8 | 80.0 |
Viremia/*virology | 7 | 43.0 |
Histocompatibility Antigens Class I/*physiology | 4 | 19.0 |
CD4-Positive T-Lymphocytes/*classification | 4 | 100.0 |
Antigens, CD45/genetics | 3 | 42.0 |
Glycoproteins/genetics | 2 | 2.0 |
Interphase | 8 | 5.0 |
Lymph Nodes/*metabolism | 2 | 11.0 |
Skin Neoplasms | 2 | 16.0 |
CD4 Lymphocyte Count/economics/methods | 2 | 100.0 |
Costs and Cost Analysis | 11 | 16.0 |
HIV Infections/*diagnosis/immunology | 10 | 100.0 |
Proto-Oncogene Proteins c-bcl-2/*blood | 3 | 75.0 |
Hepacivirus/*drug effects/physiology | 2 | 100.0 |
Aging/*blood | 3 | 4.0 |
Interferon Type II/*blood | 7 | 22.0 |
Antigens, CD4/*genetics/metabolism | 8 | 88.0 |
T-Lymphocytes, Helper-Inducer | 17 | 53.0 |
Viral Envelope Proteins/genetics/immunology | 3 | 37.0 |
Antigens, Differentiation/*analysis | 31 | 16.0 |
L-Selectin/analysis | 3 | 15.0 |
NAD+ Nucleosidase/*analysis | 5 | 20.0 |
Lymphocyte Activation/drug effects/*immunology | 12 | 28.0 |
*Lymphocyte Culture Test, Mixed | 15 | 26.0 |
HLA-A2 Antigen/*metabolism | 2 | 25.0 |
HIV-1/*immunology/pathogenicity/physiology | 2 | 100.0 |
Integrins/*biosynthesis | 2 | 11.0 |
L-Selectin/*biosynthesis | 2 | 33.0 |
Cations | 3 | 3.0 |
Guanosine Triphosphate/metabolism | 2 | 0.0 |
T-Lymphocytes/*drug effects | 18 | 26.0 |
Granulocytes/pathology | 3 | 9.0 |
Mast Cells/pathology | 7 | 20.0 |
Single-Blind Method | 13 | 5.0 |
AIDS Dementia Complex/*epidemiology | 3 | 100.0 |
Lymphoma, AIDS-Related/epidemiology | 2 | 100.0 |
Meningitis, Cryptococcal/epidemiology | 3 | 100.0 |
Toxoplasmosis, Cerebral/epidemiology | 4 | 100.0 |
Gene Products, nef/*metabolism/pharmacology | 3 | 100.0 |
Dendritic Cells/*immunology/*virology | 5 | 50.0 |
T-Lymphocytes, Cytotoxic/immunology/physiology | 2 | 100.0 |
HIV Envelope Protein gp120/chemistry/metabolism | 8 | 88.0 |
Acquired Immunodeficiency Syndrome/virology | 10 | 52.0 |
Gene Products, nef/chemistry/genetics/*metabolism | 5 | 71.0 |
Genes, nef/*genetics | 7 | 100.0 |
CD4-Positive T-Lymphocytes/*immunology/metabolism/pathology | 3 | 75.0 |
CD8-Positive T-Lymphocytes/*immunology/metabolism/pathology | 2 | 66.0 |
CD4-Positive T-Lymphocytes/immunology/metabolism/pathology | 2 | 40.0 |
Cell Movement/genetics/immunology | 3 | 27.0 |
Complement 3/metabolism | 3 | 1.0 |
T-Lymphocytes/*immunology/metabolism/pathology | 4 | 100.0 |
Azathioprine/pharmacology | 3 | 30.0 |
Prednisone/pharmacology | 2 | 18.0 |
CD4-Positive T-Lymphocytes/physiology/virology | 2 | 66.0 |
CD8-Positive T-Lymphocytes/physiology/virology | 2 | 100.0 |
Caspases/physiology | 2 | 3.0 |
*Genes, env | 17 | 54.0 |
Candidiasis/*immunology | 2 | 25.0 |
Herpesvirus 4, Human/immunology | 14 | 18.0 |
Amino Acids | 2 | 6.0 |
HIV Envelope Protein gp120/chemistry/*genetics/immunology | 2 | 100.0 |
Gene Products, nef/genetics/immunology/*physiology | 3 | 100.0 |
*src Homology Domains | 2 | 1.0 |
Culture Media/pharmacology | 3 | 3.0 |
Staphylococcus aureus/metabolism | 2 | 11.0 |
Antigens, CD/*immunology/physiology | 2 | 40.0 |
Endothelium, Vascular/cytology/*immunology | 4 | 12.0 |
Hypersensitivity/*immunology | 4 | 8.0 |
Immunoglobulin E/*analysis | 7 | 36.0 |
Delavirdine/therapeutic use | 2 | 100.0 |
Antigens, CD8/*physiology | 6 | 66.0 |
Receptors, Virus/*physiology | 16 | 41.0 |
Stavudine/*therapeutic use | 9 | 100.0 |
Creatinine/urine | 3 | 2.0 |
Energy Metabolism | 5 | 2.0 |
Antiviral Agents/adverse effects/*therapeutic use | 15 | 62.0 |
Protease Inhibitors/adverse effects/*therapeutic use | 2 | 100.0 |
Epithelial Cells/*virology | 3 | 42.0 |
HIV-1/*growth & development/immunology | 5 | 100.0 |
Proviruses/*isolation & purification | 7 | 77.0 |
Antigens, CD14/biosynthesis | 4 | 6.0 |
Cell Differentiation/drug effects | 44 | 4.0 |
*Polyploidy | 2 | 7.0 |
Antigens, CD19 | 19 | 11.0 |
Bacterial Outer Membrane Proteins/*immunology | 2 | 8.0 |
Chemokines/*biosynthesis | 2 | 6.0 |
Chemokines, CXC/biosynthesis | 4 | 16.0 |
Macrophage Inflammatory Protein-1/biosynthesis | 5 | 25.0 |
Drugs, Chinese Herbal/adverse effects/*therapeutic use | 3 | 100.0 |
Infant, Premature | 7 | 6.0 |
Anti-Bacterial Agents/*therapeutic use | 6 | 12.0 |
Clarithromycin/*therapeutic use | 2 | 33.0 |
Cryptosporidium parvum | 2 | 100.0 |
Mycobacterium avium Complex | 5 | 83.0 |
Mycobacterium avium-intracellulare Infection/prevention & control | 3 | 100.0 |
Rifabutin/*therapeutic use | 4 | 100.0 |
HIV Infections/drug therapy/immunology/*virology | 11 | 91.0 |
Substance Abuse, Intravenous/*complications/immunology | 3 | 100.0 |
HIV Envelope Protein gp41/*immunology | 12 | 57.0 |
HIV Infections/*therapy/virology | 2 | 100.0 |
HIV-1/pathogenicity/physiology | 3 | 37.0 |
Interleukin-2/analysis | 12 | 28.0 |
Antigens, CD4/genetics/immunology | 9 | 75.0 |
Isoantibodies/blood | 3 | 12.0 |
Substance Abuse, Intravenous/epidemiology | 10 | 76.0 |
Human T-lymphotropic virus 1/*metabolism | 2 | 10.0 |
Protein-Tyrosine Kinase/genetics | 4 | 3.0 |
Proto-Oncogene Proteins/genetics | 6 | 1.0 |
Adjuvants, Immunologic/*administration & dosage | 6 | 19.0 |
Phagocytosis/drug effects | 4 | 4.0 |
Antigens, CD27/biosynthesis | 2 | 33.0 |
Intestinal Mucosa/cytology/immunology/metabolism | 2 | 25.0 |
Organ Specificity/immunology | 4 | 13.0 |
Cell Communication/*immunology | 7 | 17.0 |
HIV Infections/*complications/transmission | 3 | 100.0 |
Alkaline Phosphatase/blood | 4 | 2.0 |
Hepatitis C, Chronic/*complications | 4 | 44.0 |
Liver Diseases/complications | 3 | 42.0 |
Sarcoma, Kaposi/*etiology | 5 | 83.0 |
HIV Infections/*complications/physiopathology | 7 | 77.0 |
Culture Media | 18 | 2.0 |
Cyclosporine/pharmacology | 22 | 10.0 |
*Drug Design | 5 | 5.0 |
Graft Rejection/prevention & control | 14 | 34.0 |
Peptides, Cyclic/chemical synthesis/chemistry/*pharmacology | 3 | 50.0 |
Acute-Phase Proteins/analysis | 2 | 5.0 |
Antibodies, Monoclonal/immunology/therapeutic use | 3 | 15.0 |
Proteins/*analysis | 3 | 2.0 |
HIV-2/*immunology | 17 | 85.0 |
Receptors, HIV/*immunology | 6 | 54.0 |
Lymphocyte Activation/*physiology | 10 | 12.0 |
Th1 Cells/*physiology | 4 | 23.0 |
Th2 Cells/*physiology | 2 | 16.0 |
Biological Markers/*analysis | 11 | 9.0 |
Blood Preservation | 3 | 4.0 |
Drug Stability | 5 | 2.0 |
Antineoplastic Agents/adverse effects | 3 | 10.0 |
Hematopoietic Stem Cell Transplantation/*adverse effects | 4 | 10.0 |
Antigens, CD/genetics/metabolism | 4 | 7.0 |
Gene Expression/genetics | 3 | 1.0 |
RNA, Viral/genetics | 9 | 10.0 |
Lymphocyte Subsets/*classification | 2 | 66.0 |
Antigens, CD95/*immunology | 16 | 44.0 |
Proto-Oncogene Proteins/*metabolism | 18 | 1.0 |
Transcription Factors/*metabolism | 4 | 0.0 |
Antigens, CD4/*biosynthesis | 40 | 88.0 |
Enzyme Inhibitors/*pharmacology | 4 | 0.0 |
T-Lymphocytes/cytology/drug effects/*immunology | 4 | 14.0 |
Antigens, CD/*drug effects | 3 | 42.0 |
Killer Cells, Natural/*drug effects | 4 | 13.0 |
Neoadjuvant Therapy | 3 | 8.0 |
Th2 Cells/cytology | 2 | 25.0 |
Thymus Gland/*cytology | 21 | 39.0 |
Vesicular stomatitis-Indiana virus/physiology | 3 | 30.0 |
Chile/epidemiology | 4 | 22.0 |
Hospitalization/statistics & numerical data | 4 | 26.0 |
HIV Infections/*drug therapy/psychology | 4 | 100.0 |
Hepatomegaly | 2 | 22.0 |
DNA/biosynthesis | 12 | 2.0 |
SIV/immunology | 6 | 75.0 |
Africa/epidemiology | 9 | 37.0 |
Gene Frequency/genetics | 3 | 0.0 |
Genetic Predisposition to Disease/*genetics | 3 | 0.0 |
Haplotypes/genetics | 2 | 0.0 |
North America/epidemiology | 3 | 21.0 |
Polymorphism, Genetic/*genetics | 3 | 0.0 |
HIV-1/drug effects/*immunology | 9 | 75.0 |
Virion/chemistry/immunology | 2 | 100.0 |
Anti-HIV Agents/*pharmacology/*therapeutic use | 2 | 100.0 |
CD8-Positive T-Lymphocytes/cytology/drug effects/immunology | 4 | 66.0 |
Immunologic Memory/drug effects/immunology | 2 | 100.0 |
T-Lymphocyte Subsets/cytology/*drug effects/immunology | 2 | 66.0 |
Dideoxynucleosides/pharmacology/*therapeutic use | 3 | 100.0 |
HIV Infections/*drug therapy/*immunology/pathology | 5 | 100.0 |
Subcellular Fractions/metabolism | 3 | 0.0 |
Cloning, Molecular/*methods | 4 | 6.0 |
Gene Library | 10 | 0.0 |
Leishmaniasis, Cutaneous/immunology | 2 | 50.0 |
Recombinant Fusion Proteins/biosynthesis/immunology | 2 | 18.0 |
Adjuvants, Immunologic/*physiology | 2 | 6.0 |
Bone Marrow Cells/cytology/*immunology | 2 | 15.0 |
Interleukin-2/biosynthesis/genetics | 12 | 30.0 |
Interleukin-4/biosynthesis/genetics | 2 | 11.0 |
Mice, Nude/*genetics/*immunology | 2 | 100.0 |
Transplantation Chimera/immunology | 2 | 40.0 |
Mice, Inbred A | 8 | 14.0 |
Binding, Competitive/immunology | 13 | 14.0 |
Cell Lineage/immunology | 6 | 20.0 |
Cell Migration Inhibition | 9 | 8.0 |
Intestinal Mucosa/immunology/metabolism | 2 | 33.0 |
T-Lymphocyte Subsets/cytology/immunology/*metabolism | 2 | 40.0 |
Th1 Cells/cytology/immunology/*metabolism | 2 | 50.0 |
Th2 Cells/cytology/immunology/*metabolism | 2 | 66.0 |
Fluorescence | 7 | 2.0 |
Interferon-alpha/*administration & dosage | 3 | 33.0 |
HLA-DP Antigens/immunology | 5 | 31.0 |
HLA-DQ Antigens/immunology | 7 | 17.0 |
T-Lymphocytes, Helper-Inducer/cytology/*immunology | 3 | 33.0 |
Vaccines, Synthetic/*immunology | 9 | 33.0 |
Mitogens/immunology/pharmacology | 2 | 40.0 |
Transforming Growth Factor beta/*biosynthesis | 2 | 8.0 |
Antigens, CD80/analysis | 2 | 4.0 |
Cytokines/*genetics | 10 | 7.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/genetics | 4 | 14.0 |
Leukemia, B-Cell, Chronic/*immunology | 4 | 8.0 |
Tumor Necrosis Factor-alpha/genetics | 6 | 2.0 |
Interleukin-8/*metabolism | 3 | 5.0 |
Pemphigoid, Bullous/*immunology | 3 | 16.0 |
Antibodies, Monoclonal/immunology/pharmacology | 10 | 10.0 |
Antigen-Presenting Cells/immunology/metabolism | 3 | 14.0 |
Crosses, Genetic | 11 | 1.0 |
Interleukin-2/*biosynthesis/pharmacology | 3 | 15.0 |
Mitogens/*pharmacology | 7 | 6.0 |
*Nuclear Warfare | 5 | 38.0 |
Antibodies, Anti-Idiotypic/blood | 5 | 35.0 |
HLA-DR Antigens/*immunology | 17 | 13.0 |
Vitiligo/blood/*immunology | 2 | 100.0 |
Antigens, Surface/genetics | 5 | 10.0 |
*Carrier Proteins | 3 | 0.0 |
Collagen/immunology | 7 | 25.0 |
Hypersensitivity, Immediate/immunology | 3 | 13.0 |
Th1 Cells/*immunology/metabolism | 7 | 33.0 |
Antigens, CD/physiology | 19 | 9.0 |
Antigens, CD28/physiology | 11 | 13.0 |
Heart Transplantation/*immunology | 13 | 19.0 |
Histocompatibility Antigens Class I/genetics/immunology | 4 | 26.0 |
Homeodomain Proteins/genetics | 2 | 0.0 |
CD4-Positive T-Lymphocytes/cytology/*immunology/*metabolism | 2 | 66.0 |
HLA-DR Antigens/genetics/metabolism | 3 | 27.0 |
Hematopoietic Stem Cells/cytology/immunology | 6 | 18.0 |
HIV-1/genetics/immunology/physiology | 2 | 66.0 |
T-Lymphocytes, Cytotoxic/cytology/*immunology | 5 | 29.0 |
Circadian Rhythm | 5 | 1.0 |
HIV Infections/*diagnosis/drug therapy/virology | 2 | 100.0 |
African Continental Ancestry Group/*genetics | 4 | 1.0 |
*Sex Characteristics | 4 | 2.0 |
Peptide Fragments/metabolism | 15 | 4.0 |
Recombinant Proteins/chemistry/metabolism | 13 | 2.0 |
Antibody-Dependent Cell Cytotoxicity/*immunology | 4 | 26.0 |
Nasal Mucosa/cytology/*immunology | 2 | 100.0 |
T-Lymphocyte Subsets/*chemistry | 5 | 83.0 |
Cytomegalovirus Infections | 2 | 40.0 |
Forecasting | 27 | 8.0 |
Puerto Rico | 4 | 44.0 |
Antigens, Differentiation, T-Lymphocyte | 120 | 44.0 |
*Brain Chemistry | 5 | 2.0 |
HIV Infections/metabolism/pathology | 2 | 66.0 |
Cyclic AMP/metabolism | 4 | 0.0 |
Gene Products, tat/*metabolism | 3 | 3.0 |
HIV-1/drug effects/*immunology/physiology | 2 | 50.0 |
Cell Death/drug effects | 4 | 2.0 |
Receptors, Antigen, T-Cell, alpha-beta/*physiology | 3 | 27.0 |
Antigens/pharmacology | 2 | 11.0 |
Receptors, Interleukin-2/analysis/genetics | 2 | 100.0 |
Antigens, CD4/drug effects/*immunology | 3 | 75.0 |
Monocytes/drug effects/immunology | 5 | 13.0 |
Denmark/epidemiology | 9 | 15.0 |
Receptors, Cell Surface/*blood | 3 | 16.0 |
HIV Infections/blood/drug therapy/*mortality | 3 | 100.0 |
Immunosuppressive Agents/administration & dosage | 3 | 11.0 |
Cryptococcus neoformans | 4 | 80.0 |
Vidarabine/adverse effects/analogs & derivatives | 2 | 100.0 |
Diarrhea/drug therapy/*parasitology | 2 | 100.0 |
Trimethoprim/therapeutic use | 2 | 50.0 |
CA-15-3 Antigen/*immunology | 2 | 3.0 |
Peptide Fragments/genetics/metabolism | 7 | 6.0 |
Receptors, Antigen, T-Cell/genetics/*metabolism | 5 | 27.0 |
Receptors, Antigen, T-Cell, alpha-beta/genetics/metabolism | 3 | 33.0 |
Adenoviridae/genetics/immunology | 2 | 33.0 |
Blood Preservation/*methods | 2 | 8.0 |
Receptors, CXCR4/*antagonists & inhibitors | 3 | 11.0 |
Antiretroviral Therapy, Highly Active/*economics | 3 | 75.0 |
HIV Infections/blood/complications/*drug therapy | 3 | 75.0 |
Tuberculosis/complications/*drug therapy | 2 | 100.0 |
Antiretroviral Therapy, Highly Active/adverse effects/methods | 2 | 66.0 |
HIV Infections/*drug therapy/immunology/transmission | 2 | 100.0 |
*HIV-1/drug effects/immunology | 2 | 100.0 |
Virus Replication/genetics/*immunology | 2 | 50.0 |
ADP-ribosyl Cyclase/analysis | 3 | 14.0 |
Influenza/*immunology | 3 | 33.0 |
T-Lymphocytes/*immunology/physiology | 9 | 24.0 |
Anti-HIV Agents/chemistry/*pharmacology | 5 | 25.0 |
Clinical Trials, Phase I | 6 | 10.0 |
Antigens, CD4/drug effects/*metabolism | 7 | 100.0 |
China | 3 | 0.0 |
*Antibody Affinity | 3 | 16.0 |
Leukemia, Lymphocytic/*pathology | 2 | 10.0 |
Lymphoma/*pathology | 5 | 22.0 |
HIV Infections/complications/*drug therapy/*immunology | 2 | 100.0 |
Texas | 3 | 8.0 |
Iodide Peroxidase/immunology | 3 | 5.0 |
Receptors, Thyrotropin/immunology | 2 | 11.0 |
Thyroxine/blood | 6 | 2.0 |
Inflammatory Bowel Diseases/*immunology | 7 | 30.0 |
Lymphocytes/*drug effects | 5 | 12.0 |
Receptors, IgG/analysis | 13 | 20.0 |
HLA-DR4 Antigen/*immunology | 5 | 83.0 |
*Blood Preservation | 3 | 5.0 |
*Cryopreservation | 5 | 7.0 |
Interferon-alpha/adverse effects/*therapeutic use | 3 | 33.0 |
Antigens, CD4/*chemistry/genetics/metabolism | 4 | 100.0 |
HIV Envelope Protein gp120/*chemistry/genetics/metabolism | 2 | 66.0 |
AIDS-Related Complex/diagnosis | 2 | 40.0 |
CD4-Positive T-Lymphocytes/cytology/virology | 4 | 66.0 |
HIV/genetics/*growth & development | 5 | 100.0 |
HLA-DR Antigens | 10 | 2.0 |
Sulfonamides/therapeutic use | 2 | 33.0 |
Drug Resistance, Microbial/*genetics | 3 | 15.0 |
Hepatitis C/complications/*immunology | 3 | 60.0 |
HIV Seropositivity/complications/immunology | 4 | 100.0 |
Anti-HIV Agents/metabolism/*pharmacology | 7 | 50.0 |
Antigens, CD8/biosynthesis/genetics | 2 | 100.0 |
Cytokines/*biosynthesis/*genetics | 2 | 28.0 |
HLA-DR Antigens/biosynthesis/genetics | 2 | 33.0 |
Receptors, Antigen, T-Cell/biosynthesis/genetics | 2 | 50.0 |
Transcription, Genetic/*immunology | 4 | 12.0 |
Antigens, CD4/metabolism/*physiology | 4 | 100.0 |
Stromal Cells/immunology | 3 | 12.0 |
T-Lymphocytes/enzymology/immunology/metabolism | 2 | 66.0 |
src Homology Domains/immunology | 5 | 18.0 |
HIV Infections/prevention & control/transmission | 2 | 66.0 |
Macaca fascicularis | 23 | 8.0 |
Simian Acquired Immunodeficiency Syndrome/*prevention & | 2 | 100.0 |
Acquired Immunodeficiency Syndrome/*immunology/pathology | 10 | 66.0 |
Lymph Nodes/pathology/virology | 5 | 62.0 |
Acquired Immunodeficiency Syndrome/immunology/*physiopathology | 9 | 100.0 |
Colloids | 3 | 12.0 |
Postoperative Complications/*diagnosis | 2 | 18.0 |
Fatigue/etiology | 4 | 36.0 |
HIV Seropositivity/diagnosis/*physiopathology | 2 | 100.0 |
*Affect | 2 | 25.0 |
HIV-1/chemistry/*immunology | 4 | 66.0 |
Peptides/chemistry/*immunology | 3 | 23.0 |
Life Change Events | 6 | 35.0 |
Lymphoma, T-Cell/genetics/immunology/*pathology | 2 | 40.0 |
Receptors, Antigen, T-Cell, gamma-delta/analysis | 20 | 54.0 |
Testicular Neoplasms/*pathology | 3 | 21.0 |
AIDS-Related Opportunistic Infections/*complications | 18 | 94.0 |
Aspergillus/isolation & purification | 2 | 66.0 |
Massachusetts/epidemiology | 2 | 18.0 |
Sex Hormone-Binding Globulin/metabolism | 3 | 1.0 |
*Weight Loss | 7 | 14.0 |
AIDS-Related Opportunistic Infections/immunology/*microbiology | 3 | 100.0 |
DNA, Viral/chemistry | 3 | 23.0 |
Mouth/microbiology | 2 | 15.0 |
Cisplatin/administration & dosage/*therapeutic use | 2 | 25.0 |
Lymphocyte Activation/drug effects/radiation effects | 2 | 40.0 |
Lymphocyte Subsets/*drug effects/*radiation effects | 2 | 100.0 |
Cytotoxicity, Immunologic/drug effects | 22 | 18.0 |
Granulocyte Colony-Stimulating Factor/pharmacology | 3 | 1.0 |
Immunoglobulin G/therapeutic use | 4 | 10.0 |
Capsid/*immunology | 4 | 30.0 |
Capsid Proteins | 4 | 22.0 |
Viral Proteins/*immunology | 5 | 14.0 |
HIV Envelope Protein gp120/*chemistry/*immunology | 4 | 100.0 |
Polysaccharides/*physiology | 3 | 60.0 |
Antigens, CD4/*analysis/physiology | 5 | 100.0 |
San Francisco/epidemiology | 15 | 71.0 |
Skin/immunology/*pathology | 7 | 43.0 |
Antigens, Bacterial/pharmacology | 2 | 25.0 |
HIV Infections/blood/complications/*immunology | 2 | 66.0 |
Receptors, Chemokine/blood | 2 | 50.0 |
Receptors, Immunologic/*blood | 2 | 28.0 |
*Receptors, Prostaglandin | 2 | 33.0 |
Mycobacterium tuberculosis/physiology | 2 | 66.0 |
Herpesvirus 4, Human/*immunology | 8 | 11.0 |
Infectious Mononucleosis/*immunology/pathology | 2 | 100.0 |
T-Lymphocyte Subsets/immunology/metabolism/pathology | 3 | 42.0 |
Leukemia, Monocytic, Acute/*pathology | 2 | 15.0 |
Lymphoma, Large-Cell/*pathology | 2 | 33.0 |
HIV Seropositivity/immunology/virology | 3 | 60.0 |
HIV Infections/complications/drug therapy/*virology | 2 | 100.0 |
Leukoplakia, Hairy/complications/epidemiology | 3 | 100.0 |
Blood/virology | 2 | 66.0 |
Tonsil/virology | 2 | 66.0 |
Chemotaxis, Leukocyte/drug effects | 5 | 6.0 |
Lymphoma, T-Cell/pathology | 3 | 20.0 |
Neoplasm Proteins/biosynthesis/genetics | 2 | 1.0 |
RNA, Messenger/biosynthesis/genetics | 7 | 1.0 |
Receptors, CCR5/*biosynthesis/genetics | 2 | 13.0 |
Receptors, CXCR4/*biosynthesis/genetics | 2 | 18.0 |
T-Lymphocytes/*drug effects/metabolism | 5 | 14.0 |
HIV Infections/*genetics/*immunology | 4 | 50.0 |
Interleukin-10/*analysis | 2 | 33.0 |
Interleukin-8/*analysis | 2 | 14.0 |
Adenosine Triphosphate/metabolism | 4 | 0.0 |
Calnexin | 4 | 13.0 |
Disulfides/metabolism | 3 | 8.0 |
Dithiothreitol/pharmacology | 5 | 5.0 |
Endoplasmic Reticulum/metabolism | 11 | 4.0 |
Protein Processing, Post-Translational/*drug effects | 2 | 3.0 |
Virion/pathogenicity | 2 | 40.0 |
Splenectomy | 6 | 9.0 |
Transforming Growth Factor beta/analysis | 4 | 9.0 |
Bone Marrow Transplantation/*adverse effects | 3 | 6.0 |
Neutropenia/*complications | 2 | 50.0 |
Monocytes/cytology/drug effects/immunology | 2 | 20.0 |
Monokines/*biosynthesis | 2 | 28.0 |
Tacrolimus/*pharmacology | 3 | 8.0 |
Receptors, CXCR4/genetics | 7 | 36.0 |
Immunosuppression/methods | 5 | 15.0 |
Whole-Body Irradiation | 9 | 11.0 |
Calcium/physiology | 12 | 5.0 |
Interferon Type II/*pharmacology | 12 | 2.0 |
Interleukin-6/*pharmacology | 2 | 0.0 |
RANTES/analysis | 5 | 38.0 |
*Antimicrobial Cationic Peptides | 6 | 30.0 |
Carrier Proteins/pharmacology | 2 | 3.0 |
Interleukin-6/pharmacology | 5 | 1.0 |
Lymphocytes/drug effects/*physiology | 2 | 14.0 |
Monocytes/*physiology | 9 | 5.0 |
*Cryptosporidium parvum/isolation & purification | 2 | 100.0 |
HIV Infections/*physiopathology/*psychology | 3 | 100.0 |
*Lymphocyte Activation/physiology | 2 | 100.0 |
Mitogen-Activated Protein Kinases/*physiology | 2 | 2.0 |
Transforming Growth Factor beta/*physiology | 4 | 3.0 |
B-Lymphocytes/immunology/*metabolism | 5 | 8.0 |
Hemochromatosis/*immunology/metabolism | 2 | 100.0 |
T-Lymphocytes/immunology/*metabolism | 20 | 21.0 |
Muscle, Skeletal/metabolism | 2 | 1.0 |
Polymyositis/*etiology | 2 | 66.0 |
*Adaptation, Physiological | 2 | 3.0 |
Antigens, Viral/analysis | 13 | 16.0 |
Macrophages, Alveolar/*virology | 2 | 100.0 |
Immune Tolerance/drug effects | 10 | 38.0 |
Purpura, Thrombocytopenic, Idiopathic/*immunology | 2 | 50.0 |
Th1 Cells/secretion | 2 | 50.0 |
Th2 Cells/secretion | 2 | 50.0 |
Lymphocytes | 17 | 10.0 |
Antigens, CD11b/analysis | 2 | 25.0 |
Antigens, CD11c/analysis | 4 | 40.0 |
Killer Cells, Natural/chemistry/*pathology | 3 | 50.0 |
Receptors, Interleukin/analysis | 2 | 18.0 |
Tumor Stem Cells/chemistry/*pathology | 2 | 40.0 |
Polyethylene Glycols/pharmacology | 2 | 4.0 |
Sulfates/pharmacology | 2 | 50.0 |
X-Ray Diffraction | 6 | 7.0 |
Antibodies, Monoclonal/therapeutic use | 20 | 10.0 |
Antineoplastic Agents, Phytogenic/*pharmacology/therapeutic use | 2 | 33.0 |
Cytotoxicity, Immunologic/*drug effects | 7 | 9.0 |
Killer Cells, Lymphokine-Activated | 3 | 37.0 |
Neoplasms/drug therapy/immunology | 2 | 28.0 |
*Biological Markers | 13 | 12.0 |
Killer Cells, Natural/metabolism | 12 | 23.0 |
Vinblastine/administration & dosage | 3 | 7.0 |
Health Personnel | 2 | 11.0 |
Occupational Diseases/prevention & control | 2 | 66.0 |
HIV-1/*classification/genetics | 4 | 100.0 |
Tuberculosis, Pulmonary/*complications | 3 | 50.0 |
Doxorubicin/administration & dosage/therapeutic use | 2 | 66.0 |
Hysterectomy | 3 | 3.0 |
Graft vs Host Disease/immunology/*prevention & control | 3 | 42.0 |
Graft vs Leukemia Effect/*immunology | 3 | 42.0 |
Bone Marrow Transplantation/adverse effects/*immunology/pathology | 2 | 66.0 |
Cytomegalovirus Infections/*immunology/pathology | 2 | 66.0 |
Epithelial Cells/cytology | 3 | 4.0 |
Macrophages/cytology | 9 | 13.0 |
Neutrophils/cytology | 2 | 4.0 |
Vagina/*cytology | 2 | 100.0 |
Immunoglobulins/*therapeutic use | 2 | 40.0 |
Synovial Fluid/*immunology | 12 | 21.0 |
Anemia/chemically induced | 7 | 63.0 |
Asthma/*metabolism | 2 | 9.0 |
Bacterial Outer Membrane Proteins/immunology | 6 | 31.0 |
Biopolymers | 2 | 1.0 |
*Lipoproteins | 2 | 5.0 |
*Chemokines | 2 | 20.0 |
Chemotaxis | 9 | 5.0 |
Lymphokines/*analysis | 3 | 1.0 |
Vascular Endothelial Growth Factor A | 2 | 0.0 |
Vascular Endothelial Growth Factors | 2 | 0.0 |
Macrophages, Alveolar/pathology | 3 | 42.0 |
Psoriasis/*drug therapy | 5 | 33.0 |
Immune System/physiology | 4 | 17.0 |
Intercellular Adhesion Molecule-1/*blood | 5 | 8.0 |
Saliva/secretion | 3 | 33.0 |
Secretory Rate | 3 | 9.0 |
Xerostomia/*etiology | 2 | 100.0 |
T-Lymphocytes/immunology/pathology | 19 | 32.0 |
Candidiasis/immunology | 2 | 50.0 |
HIV Infections/*immunology/physiopathology | 4 | 40.0 |
Abortion, Habitual/*immunology/therapy | 2 | 100.0 |
Lymphocytes/metabolism/pathology | 2 | 11.0 |
Membrane Proteins/*biosynthesis | 3 | 5.0 |
Recombinant Fusion Proteins/physiology | 2 | 0.0 |
*HIV/genetics | 4 | 80.0 |
Bacterial Vaccines/*therapeutic use | 2 | 40.0 |
Pneumococcal Infections/*prevention & control | 2 | 40.0 |
Pneumonia, Pneumococcal/prevention & control | 3 | 100.0 |
Antigens, CD80/genetics/immunology | 2 | 16.0 |
Cytotoxicity, Immunologic/immunology | 14 | 20.0 |
*Intercellular Signaling Peptides and Proteins | 3 | 0.0 |
*Energy Intake | 3 | 8.0 |
*Antineoplastic Combined Chemotherapy Protocols | 3 | 21.0 |
HIV Infections | 5 | 62.0 |
Scalp/pathology | 2 | 50.0 |
Cytomegalovirus/immunology/isolation & purification | 2 | 66.0 |
Mycobacterium avium Complex/isolation & purification | 2 | 40.0 |
Simplexvirus/immunology/isolation & purification | 2 | 100.0 |
Antibody Formation/*immunology | 2 | 15.0 |
Melanoma/immunology | 2 | 5.0 |
*Endocytosis | 19 | 11.0 |
*Health Knowledge, Attitudes, Practice | 3 | 10.0 |
Interviews/methods | 2 | 100.0 |
Intestinal Mucosa/*immunology/virology | 2 | 100.0 |
Receptors, HIV/metabolism/*physiology | 2 | 100.0 |
HIV Core Protein p24 | 51 | 67.0 |
Macrophages/drug effects/*virology | 4 | 100.0 |
Monocytes/drug effects/*virology | 2 | 66.0 |
HIV/drug effects/*physiology | 3 | 42.0 |
HIV Core Protein p24/analysis/blood | 4 | 100.0 |
Lymphocytes/metabolism/*virology | 2 | 66.0 |
Receptors, HIV/biosynthesis | 3 | 50.0 |
Virus Replication/physiology | 8 | 34.0 |
Biometry/methods | 3 | 75.0 |
Antigens, CD20/*blood | 2 | 50.0 |
Extracellular Space | 2 | 8.0 |
HIV-1/immunology/*metabolism | 4 | 40.0 |
Didanosine/adverse effects/therapeutic use | 2 | 66.0 |
Thymidine/analogs & derivatives | 2 | 100.0 |
Hepatitis, Viral, Human/*virology | 3 | 75.0 |
Adenoviridae | 4 | 4.0 |
Neoplasms, Experimental/*immunology | 2 | 16.0 |
Brain Neoplasms/immunology/*therapy | 2 | 66.0 |
Interferon-beta/administration & dosage/*genetics/therapeutic use | 2 | 100.0 |
Colon/pathology | 5 | 11.0 |
Severe Combined Immunodeficiency/*complications | 2 | 66.0 |
Vitamin A/blood | 6 | 26.0 |
Antigens, CD29/blood | 2 | 66.0 |
Antigens, Differentiation/blood | 5 | 45.0 |
Receptors, Interleukin-2/blood | 11 | 15.0 |
Lymphocytes/*virology | 9 | 75.0 |
Proviruses/genetics/physiology | 7 | 70.0 |
*Virus Integration | 5 | 7.0 |
Cell Movement/*immunology | 11 | 15.0 |
Stromal Cells/immunology/metabolism | 3 | 20.0 |
Gene Expression Regulation/*immunology | 11 | 10.0 |
Genetic Vectors/immunology | 2 | 20.0 |
Membrane Proteins/biosynthesis | 4 | 6.0 |
Protein Processing, Post-Translational/immunology | 2 | 16.0 |
Injections, Intraventricular | 2 | 1.0 |
Lymphopenia/*immunology | 5 | 100.0 |
Receptors, Antigen, T-Cell/biosynthesis | 4 | 28.0 |
Tumor Cells, Cultured/transplantation | 2 | 6.0 |
Weight Loss/immunology | 3 | 100.0 |
Hypertrophy | 6 | 5.0 |
Drug Evaluation | 41 | 16.0 |
Lymphocyte Count/methods | 4 | 100.0 |
Hypersensitivity, Delayed/immunology | 18 | 29.0 |
Hematopoiesis/*drug effects | 5 | 5.0 |
Leukocyte Count/drug effects | 56 | 47.0 |
Neutropenia/*drug therapy/etiology | 2 | 66.0 |
Platelet Count/drug effects | 2 | 5.0 |
AIDS-Associated Nephropathy/*drug therapy | 2 | 100.0 |
Adrenal Cortex Hormones/*therapeutic use | 2 | 8.0 |
Renal Dialysis | 7 | 2.0 |
Antigens, CD40/metabolism | 8 | 12.0 |
Antigens, CD11/immunology | 2 | 18.0 |
Chromosome Disorders | 8 | 2.0 |
HLA-D Antigens/immunology | 14 | 35.0 |
Interferon Type II/*biosynthesis/blood | 3 | 27.0 |
Tuberculosis, Pulmonary/drug therapy/*immunology | 3 | 50.0 |
HIV Seropositivity/*pathology | 7 | 77.0 |
Gingivitis/complications | 2 | 100.0 |
HIV Core Protein p24/pharmacology | 2 | 100.0 |
HIV Seropositivity/drug therapy | 5 | 100.0 |
Cities | 2 | 25.0 |
HIV Infections/ethnology/immunology/*virology | 2 | 100.0 |
Substance Abuse, Intravenous/immunology/virology | 2 | 100.0 |
*Life Change Events | 3 | 16.0 |
Vagina/microbiology | 2 | 22.0 |
Glutamine/*therapeutic use | 2 | 100.0 |
Antineoplastic Agents/*adverse effects/*therapeutic use | 2 | 100.0 |
Leukemia, Lymphocytic, Chronic/*drug therapy | 3 | 37.0 |
Alcohol Drinking/adverse effects | 2 | 4.0 |
HIV Infections/*complications/diagnosis/immunology | 2 | 100.0 |
Prostitution | 9 | 50.0 |
Endoscopy, Digestive System | 4 | 44.0 |
Wound Healing | 2 | 1.0 |
*Hip Prosthesis | 4 | 12.0 |
*Prosthesis Failure | 3 | 14.0 |
Leukemia, Myelocytic, Acute/therapy | 2 | 15.0 |
Leukemia, Myeloid, Chronic/therapy | 2 | 14.0 |
HIV Infections/*drug therapy/enzymology/immunology | 3 | 100.0 |
Monocytes/drug effects/physiology | 2 | 11.0 |
Stavudine/adverse effects/pharmacology/*therapeutic use | 2 | 100.0 |
Zidovudine/adverse effects/pharmacology/*therapeutic use | 2 | 100.0 |
Acquired Immunodeficiency Syndrome/diagnosis/immunology/*mortality | 2 | 100.0 |
*Papillomavirus, Human/genetics/isolation & purification | 3 | 50.0 |
HIV Infections/immunology/*mortality/virology | 3 | 100.0 |
Intestinal Mucosa/*pathology | 4 | 17.0 |
Antibodies, Antineutrophil Cytoplasmic/*immunology | 2 | 7.0 |
Acetylcysteine/*therapeutic use | 2 | 28.0 |
Antioxidants/therapeutic use | 2 | 14.0 |
Carnitine/*therapeutic use | 2 | 33.0 |
Acquired Immunodeficiency Syndrome/blood/immunology/*physiopathology | 3 | 100.0 |
HIV Infections/blood/immunology/*physiopathology | 9 | 100.0 |
HIV Infections/complications/*epidemiology/transmission | 4 | 100.0 |
Phagocytes/immunology | 5 | 20.0 |
Lymphocyte Count/drug effects | 27 | 75.0 |
CD4-Positive T-Lymphocytes/drug effects/immunology/metabolism | 4 | 80.0 |
CD8-Positive T-Lymphocytes/drug effects/immunology/metabolism | 2 | 66.0 |
Base Sequence/genetics | 3 | 0.0 |
HIV Infections/complications/*transmission | 4 | 100.0 |
Ritonavir/administration & dosage/therapeutic use | 3 | 100.0 |
Cervix Uteri/*immunology | 5 | 50.0 |
Herpes Genitalis/*immunology | 4 | 100.0 |
Herpesvirus 2, Human | 2 | 66.0 |
Epitopes, B-Lymphocyte/*immunology | 2 | 16.0 |
Stomach Neoplasms/immunology | 2 | 16.0 |
HIV Infections/epidemiology | 6 | 66.0 |
Abortion, Spontaneous/*immunology | 2 | 13.0 |
B-Lymphocyte Subsets/*immunology | 15 | 19.0 |
Parity | 2 | 1.0 |
Integrins/immunology | 3 | 14.0 |
B-Lymphocytes/metabolism/*physiology | 2 | 28.0 |
Chemotactic Factors/*physiology | 2 | 12.0 |
Interleukin-16/biosynthesis/*physiology | 2 | 100.0 |
CD4-Positive T-Lymphocytes/immunology/virology | 22 | 78.0 |
Molecular Conformation | 3 | 1.0 |
Electroencephalography | 2 | 0.0 |
Video Recording | 4 | 15.0 |
*Chromosomes, Human, Pair 14 | 8 | 4.0 |
Immunoglobulins, Heavy-Chain/*genetics | 4 | 2.0 |
*In Situ Hybridization, Fluorescence | 3 | 1.0 |
*Translocation, Genetic | 13 | 1.0 |
Antigens, CD/*biosynthesis/immunology | 2 | 8.0 |
Brain/metabolism | 3 | 0.0 |
Brain Chemistry | 3 | 1.0 |
Choline/analysis | 2 | 40.0 |
Creatine/analysis | 2 | 20.0 |
Inositol/analysis | 2 | 50.0 |
Anti-Retroviral Agents/*pharmacology | 2 | 100.0 |
Disease Transmission, Horizontal | 7 | 58.0 |
HIV Infections/blood/drug therapy/*transmission | 2 | 100.0 |
Acquired Immunodeficiency Syndrome/diagnosis/*immunology | 3 | 75.0 |
Asia | 4 | 5.0 |
Evaluation Studies | 52 | 7.0 |
Indicators and Reagents | 14 | 4.0 |
Laboratories, Hospital/standards | 2 | 33.0 |
Hepatitis, Toxic/etiology | 3 | 33.0 |
Lipids/blood | 10 | 1.0 |
Pancreatitis/chemically induced | 9 | 81.0 |
Bacterial Proteins/*immunology | 2 | 6.0 |
Protein-Tyrosine Kinase/*genetics/metabolism | 2 | 4.0 |
T-Lymphocytes/enzymology/*metabolism | 2 | 20.0 |
Antibodies, Anti-Idiotypic/*immunology | 15 | 33.0 |
Antigens, CD80/*immunology | 4 | 8.0 |
Immunization, Passive/*methods | 4 | 44.0 |
Serine Endopeptidases/immunology | 2 | 9.0 |
Insects | 3 | 1.0 |
Enzyme-Linked Immunosorbent Assay/*methods | 9 | 6.0 |
HIV Seropositivity/*diagnosis/immunology | 3 | 75.0 |
Mitogens | 15 | 22.0 |
Tetradecanoylphorbol Acetate | 5 | 7.0 |
CD4-Positive T-Lymphocytes/drug effects/metabolism | 6 | 46.0 |
Interleukin-13/biosynthesis | 3 | 16.0 |
Interleukin-4/biosynthesis/pharmacology | 4 | 57.0 |
Transforming Growth Factor beta/biosynthesis | 2 | 4.0 |
Pokeweed Mitogens/pharmacology | 23 | 28.0 |
T-Lymphocyte Subsets/*drug effects | 12 | 63.0 |
Tyrosine | 4 | 3.0 |
Immunocompromised Host/*physiology | 2 | 66.0 |
Lymphoma, B-Cell/immunology/pathology | 3 | 30.0 |
Lymphoma, Non-Hodgkin/*immunology/pathology | 3 | 27.0 |
T-Lymphocyte Subsets/chemistry/immunology | 3 | 75.0 |
T-Lymphocytes, Cytotoxic/chemistry/*immunology | 2 | 28.0 |
*Body Mass Index | 4 | 4.0 |
B-Lymphocytes/immunology/metabolism | 4 | 7.0 |
Heart Failure, Congestive/immunology/*surgery | 2 | 100.0 |
*Heart-Assist Devices | 2 | 8.0 |
Materials Testing | 2 | 2.0 |
Acidosis, Lactic/*chemically induced | 2 | 100.0 |
Anti-HIV Agents/adverse effects | 2 | 50.0 |
Didanosine/*adverse effects | 2 | 66.0 |
Reverse Transcriptase Inhibitors/*adverse effects | 7 | 70.0 |
Stavudine/*adverse effects | 3 | 75.0 |
Injections | 6 | 5.0 |
Spleen | 5 | 20.0 |
Antigens, CD34/*metabolism | 3 | 2.0 |
Hematopoietic Stem Cells/cytology/*metabolism | 2 | 8.0 |
Vero Cells | 13 | 5.0 |
Receptors, CCR5/immunology/metabolism | 4 | 36.0 |
RNA, Viral/metabolism | 14 | 16.0 |
HIV-1/immunology/*pathogenicity/physiology | 3 | 100.0 |
Receptors, Virus/*metabolism | 39 | 40.0 |
Antigens, CD44/biosynthesis | 3 | 9.0 |
Epithelial Cells | 17 | 3.0 |
Hypoxanthine Phosphoribosyltransferase/genetics | 3 | 3.0 |
*Leukopoiesis | 2 | 22.0 |
Nuclear Proteins/genetics | 2 | 0.0 |
*Transcription Factors | 7 | 0.0 |
Antigens, CD8/*biosynthesis | 9 | 47.0 |
CD4-Positive T-Lymphocytes/cytology/*metabolism | 4 | 80.0 |
Antigens, Viral/diagnostic use | 2 | 100.0 |
Immunity, Cellular/physiology | 7 | 58.0 |
Interleukin-4/*blood | 4 | 28.0 |
Genes, Structural, Viral | 3 | 20.0 |
Vaccines, Synthetic/*therapeutic use | 3 | 75.0 |
Viral Vaccines/*therapeutic use | 2 | 40.0 |
Affect | 3 | 25.0 |
Cognition | 6 | 11.0 |
HIV Infections/complications/immunology/*psychology | 2 | 100.0 |
Stress, Psychological/etiology | 2 | 66.0 |
Laboratories/*standards | 4 | 17.0 |
*Quality Assurance, Health Care | 6 | 27.0 |
Milk, Human/virology | 4 | 80.0 |
Pregnancy Complications, Infectious/epidemiology/*virology | 2 | 66.0 |
Saliva/virology | 2 | 66.0 |
Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 130 | 57.0 |
Dextrans | 2 | 4.0 |
Nasal Mucosa/pathology | 2 | 33.0 |
Gene Expression Regulation, Neoplastic/physiology | 2 | 1.0 |
Interleukin-12/*genetics | 2 | 9.0 |
Nitric-Oxide Synthase/metabolism | 2 | 1.0 |
Antigens, CD80/*metabolism | 8 | 14.0 |
HIV Infections/*drug therapy/immunology/*psychology | 2 | 100.0 |
HIV Infections/*complications/diagnosis | 7 | 87.0 |
Skin Tests/methods | 2 | 20.0 |
CD4 Immunoadhesins | 5 | 100.0 |
Cesarean Section | 8 | 12.0 |
Delivery, Obstetric/*methods | 2 | 50.0 |
HIV Antibodies | 22 | 36.0 |
Mycobacterium avium-intracellulare Infection/*complications | 2 | 100.0 |
Acquired Immunodeficiency Syndrome/etiology | 11 | 84.0 |
Viremia/*complications | 4 | 80.0 |
Hodgkin Disease/pathology | 2 | 20.0 |
*Adoptive Transfer/adverse effects | 2 | 66.0 |
Antigens, CD4/*genetics/*immunology | 3 | 100.0 |
Antigens, CD20/metabolism | 3 | 14.0 |
Antigens, CD56/metabolism | 3 | 11.0 |
Infant, Newborn/*immunology | 5 | 20.0 |
Th2 Cells/*pathology | 2 | 100.0 |
*Integrin alpha Chains | 6 | 21.0 |
AIDS-Related Opportunistic Infections/complications | 19 | 100.0 |
Color Perception/*physiology | 2 | 15.0 |
Cytomegalovirus Retinitis/complications/*diagnosis | 2 | 100.0 |
Myocardium/immunology | 3 | 27.0 |
T-Lymphocytes, Helper-Inducer/immunology/pathology | 2 | 66.0 |
CD4-Positive T-Lymphocytes/immunology/physiology | 4 | 80.0 |
Immunoglobulin G/biosynthesis/blood | 2 | 20.0 |
Multiple Sclerosis/drug therapy/*immunology | 4 | 57.0 |
Spinal Puncture | 2 | 16.0 |
Transforming Growth Factor beta/cerebrospinal fluid | 2 | 100.0 |
Chlamydia trachomatis/*immunology | 2 | 16.0 |
HIV Infections/blood/*complications/*drug therapy | 4 | 100.0 |
Kuwait/epidemiology | 2 | 25.0 |
Antigens, CD3/analysis/immunology | 5 | 41.0 |
Antigens, CD8/analysis/immunology | 6 | 66.0 |
Brain/immunology/pathology | 3 | 30.0 |
Monocyte Chemoattractant Protein-1/genetics | 2 | 10.0 |
Receptors, Interleukin-2/analysis/immunology | 4 | 66.0 |
*Cell Communication | 15 | 18.0 |
Cell Death | 23 | 6.0 |
Iodine Radioisotopes | 8 | 2.0 |
Sputum/cytology | 3 | 33.0 |
Tumor Necrosis Factor-alpha/*metabolism | 15 | 2.0 |
Toxoplasmosis/prevention & control | 2 | 100.0 |
T-Lymphocytes/cytology/*microbiology | 3 | 60.0 |
HIV Infections/*mortality/*physiopathology | 2 | 100.0 |
HIV Infections/*immunology/mortality/*virology | 4 | 100.0 |
Acquired Immunodeficiency Syndrome/blood/immunology/virology | 2 | 100.0 |
HIV Infections/blood/*immunology/*virology | 7 | 87.0 |
HIV-1/genetics/*growth & development | 8 | 72.0 |
Sarcoma, Kaposi/complications/*drug therapy/pathology | 2 | 100.0 |
Alcohol Drinking/*adverse effects | 3 | 7.0 |
Membrane Glycoproteins/genetics/*immunology | 3 | 5.0 |
Anti-HIV Agents/chemistry/metabolism/*pharmacology | 2 | 50.0 |
Cell Membrane/drug effects/metabolism | 3 | 3.0 |
Genetic Vectors/genetics | 6 | 2.0 |
Protein Processing, Post-Translational/drug effects | 5 | 4.0 |
HIV Envelope Protein gp160/metabolism | 7 | 87.0 |
HIV-1/*immunology/*isolation & purification | 2 | 100.0 |
Immunodominant Epitopes/immunology | 4 | 20.0 |
Acquired Immunodeficiency Syndrome/*mortality/transmission | 2 | 100.0 |
HIV Infections/*drug therapy/*immunology/mortality | 3 | 100.0 |
HIV Infections/blood/*drug therapy/*virology | 4 | 80.0 |
*Viremia | 2 | 100.0 |
Asparagine/metabolism | 2 | 15.0 |
Receptors, CCR5/metabolism/*physiology | 2 | 50.0 |
Trans-Activators/*genetics | 2 | 0.0 |
Cytokines/genetics/*immunology | 3 | 60.0 |
Epstein-Barr Virus Infections/*immunology | 2 | 25.0 |
HIV Infections/*complications/etiology/immunology | 2 | 100.0 |
Cytokines/*physiology | 10 | 5.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/physiology | 3 | 10.0 |
Interleukin-10/physiology | 2 | 8.0 |
Interleukin-2/physiology | 13 | 15.0 |
Interleukin-4/physiology | 4 | 10.0 |
Interleukin-6/physiology | 2 | 3.0 |
Lymphoma, T-Cell, Cutaneous/*pathology | 4 | 100.0 |
T-Lymphocytes, Cytotoxic/*cytology | 3 | 42.0 |
T-Lymphocytopenia, Idiopathic CD4-Positive/*complications/immunology | 2 | 100.0 |
*Leukocytes, Mononuclear | 2 | 25.0 |
RNA, Viral/drug effects/metabolism | 2 | 66.0 |
Perinatal Care | 4 | 44.0 |
HIV Envelope Protein gp120/drug effects/physiology | 2 | 100.0 |
RANTES/*pharmacology | 3 | 17.0 |
Antigens, CD98 | 2 | 18.0 |
Protein-Tyrosine-Phosphatase/physiology | 2 | 8.0 |
Receptors, Cell Surface/physiology | 3 | 2.0 |
Interleukin-12/*pharmacology | 12 | 24.0 |
Interleukin-12/*physiology | 4 | 21.0 |
HIV Infections/*immunology/*psychology | 3 | 100.0 |
Apoptosis/genetics | 7 | 3.0 |
Consanguinity | 3 | 0.0 |
Immunologic Deficiency Syndromes/*genetics/immunology | 2 | 13.0 |
Lung/immunology/pathology | 5 | 21.0 |
Herpesvirus 3, Human/isolation & purification | 4 | 100.0 |
Adjuvants, Immunologic/physiology | 3 | 6.0 |
Arthritis, Rheumatoid/*immunology/metabolism/pathology | 2 | 28.0 |
Histocompatibility Antigens Class I/metabolism | 14 | 21.0 |
Killer Cells, Natural/immunology/*metabolism | 4 | 13.0 |
Phosphotyrosine/metabolism | 7 | 1.0 |
Kidney Calculi/chemically induced | 2 | 100.0 |
AIDS-Related Opportunistic Infections/*physiopathology | 4 | 100.0 |
Alkaline Phosphatase | 4 | 26.0 |
Mycobacterium avium-intracellulare Infection/*physiopathology | 2 | 100.0 |
Cameroon/epidemiology | 5 | 41.0 |
Acquired Immunodeficiency Syndrome/drug therapy/immunology/mortality | 3 | 100.0 |
Likelihood Functions | 18 | 10.0 |
Zalcitabine/therapeutic use | 15 | 100.0 |
Lymphoma, T-Cell/*drug therapy | 2 | 66.0 |
Mycobacterium/*immunology | 7 | 38.0 |
Lymphoma, T-Cell/genetics/metabolism/*pathology | 3 | 100.0 |
Down-Regulation/*physiology | 3 | 9.0 |
HIV Envelope Protein gp120/metabolism/*physiology | 4 | 100.0 |
Phosphoproteins/physiology | 2 | 3.0 |
CD8-Positive T-Lymphocytes/*immunology/*virology | 2 | 66.0 |
Leukemia, Experimental/prevention & control | 2 | 100.0 |
Colony Count, Microbial | 10 | 12.0 |
Monocytes/*microbiology | 16 | 59.0 |
Adaptation, Physiological | 5 | 5.0 |
HIV Envelope Protein gp41/physiology | 4 | 57.0 |
T-Lymphocytes/immunology/virology | 9 | 50.0 |
Disease Transmission | 3 | 23.0 |
Travel | 2 | 16.0 |
Neurons/*metabolism | 2 | 0.0 |
Receptors, Dopamine D2/*metabolism | 2 | 20.0 |
Aorta/pathology | 2 | 5.0 |
Cadaver | 6 | 2.0 |
Coronary Vessels/pathology | 2 | 4.0 |
Heart Diseases/complications | 2 | 25.0 |
Anti-HIV Agents/adverse effects/pharmacokinetics/*therapeutic use | 4 | 100.0 |
Immunoglobulin A/biosynthesis | 3 | 11.0 |
Viral Vaccines/*immunology | 9 | 36.0 |
RNA, Viral/biosynthesis | 5 | 10.0 |
Spectrum Analysis, Mass | 5 | 0.0 |
Deoxycytidine/*analogs & derivatives/*therapeutic use | 2 | 40.0 |
Epithelium/immunology/pathology | 7 | 25.0 |
Rubella Vaccine/administration & dosage/*immunology | 3 | 100.0 |
Anti-Retroviral Agents/administration & dosage/*therapeutic use | 3 | 100.0 |
HIV Infections/*drug therapy/prevention & control/transmission | 2 | 100.0 |
Labor, Obstetric | 3 | 6.0 |
Pregnancy Trimester, Third | 11 | 5.0 |
*Genotype | 5 | 2.0 |
*Nutritional Requirements | 2 | 22.0 |
Antigens, CD45/blood | 12 | 50.0 |
CD8-Positive T-Lymphocytes/chemistry | 5 | 62.0 |
Lymphocyte Subsets/chemistry/immunology | 2 | 100.0 |
Antibodies, Monoclonal/immunology/*therapeutic use | 11 | 33.0 |
Lymphocytes, Tumor-Infiltrating | 2 | 12.0 |
Melanoma/immunology/pathology/*therapy | 2 | 33.0 |
Burkina Faso | 3 | 33.0 |
Peripheral Nervous System Diseases/complications | 2 | 66.0 |
Emergency Service, Hospital | 2 | 16.0 |
*HIV Seroprevalence | 9 | 100.0 |
Autoimmune Diseases/*immunology | 18 | 11.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/immunology | 3 | 10.0 |
Prostate-Specific Antigen/*immunology | 2 | 18.0 |
Scintillation Counting | 2 | 15.0 |
Antigens, CD5/analysis | 4 | 8.0 |
Receptors, Antigen, T-Cell, gamma-delta/analysis/genetics | 2 | 50.0 |
Antigens, CD/*analysis/immunology | 8 | 26.0 |
Controlled Clinical Trials | 6 | 26.0 |
Nucleic Acid Heteroduplexes | 3 | 6.0 |
Dermatitis, Contact/*immunology | 5 | 41.0 |
Proviruses/genetics/*isolation & purification | 5 | 100.0 |
Cytomegalovirus Retinitis/*complications | 2 | 66.0 |
Intestines/*cytology | 2 | 12.0 |
Spleen/*cytology | 2 | 18.0 |
Antigens, Differentiation/analysis | 54 | 17.0 |
NAD+ Nucleosidase/analysis | 3 | 6.0 |
Medical Staff, Hospital | 2 | 66.0 |
Occupational Exposure/adverse effects | 2 | 9.0 |
Phosphoproteins/*blood | 4 | 36.0 |
Viral Matrix Proteins/*blood | 4 | 80.0 |
Sarcoma, Kaposi/*drug therapy | 5 | 83.0 |
Hypersensitivity, Delayed | 23 | 36.0 |
Oropharynx/microbiology | 5 | 55.0 |
Interleukins/pharmacology | 7 | 10.0 |
T-Lymphocytes/drug effects/physiology | 2 | 13.0 |
Antigens, Differentiation, T-Lymphocyte/*blood | 7 | 46.0 |
Heart Transplantation/*immunology/*pathology | 2 | 66.0 |
Cerebrospinal Fluid/cytology/immunology | 2 | 20.0 |
Myelin Sheath/immunology | 3 | 17.0 |
HIV-1/enzymology | 3 | 75.0 |
Colorectal Neoplasms/immunology/*therapy | 4 | 66.0 |
Genes, ras | 2 | 0.0 |
Antilymphocyte Serum/*therapeutic use | 8 | 27.0 |
Azathioprine/therapeutic use | 9 | 22.0 |
Immunosuppressive Agents/pharmacology/*therapeutic use | 2 | 33.0 |
Lymphocyte Count/*drug effects | 6 | 85.0 |
HIV Seroprevalence | 14 | 77.0 |
Sjogren's Syndrome/metabolism/*pathology | 3 | 60.0 |
Patient Satisfaction | 2 | 5.0 |
Antigens, Differentiation/*immunology | 19 | 14.0 |
HIV Infections/blood/*mortality | 3 | 100.0 |
AIDS-Related Opportunistic Infections/*drug therapy/microbiology | 6 | 66.0 |
Amphotericin B/*therapeutic use | 2 | 100.0 |
Candida/*drug effects/isolation & purification | 2 | 66.0 |
Candidiasis, Oral/*drug therapy/microbiology | 2 | 50.0 |
Fluconazole/pharmacology/*therapeutic use | 2 | 66.0 |
Cerebrospinal Fluid/virology | 3 | 60.0 |
Busulfan/therapeutic use | 2 | 16.0 |
Isoantibodies/*immunology | 4 | 10.0 |
Antigens, CD4/chemistry/metabolism | 5 | 100.0 |
Cell Membrane/chemistry | 4 | 3.0 |
Magnetics | 7 | 8.0 |
*Gastrostomy | 2 | 100.0 |
T-Lymphocytes/cytology/*immunology/metabolism | 3 | 14.0 |
*Alternative Splicing | 3 | 0.0 |
Antigens, CD80 | 4 | 12.0 |
Hematopoietic Stem Cells/immunology | 15 | 18.0 |
Lymphoid Tissue/immunology | 8 | 22.0 |
Graft Enhancement, Immunologic | 2 | 22.0 |
T-Lymphocytes, Cytotoxic/*immunology/secretion | 2 | 50.0 |
Virus Activation/drug effects | 4 | 44.0 |
Apoptosis/*genetics | 3 | 1.0 |
Cisplatin/administration & dosage | 6 | 2.0 |
Membrane Proteins/*genetics | 2 | 0.0 |
Antioxidants/*metabolism | 2 | 2.0 |
Complement/analysis | 7 | 5.0 |
HIV Envelope Protein gp120/immunology/*pharmacology | 5 | 100.0 |
Antigens, CD/genetics/*immunology | 2 | 5.0 |
Antigens, CD40/genetics/*immunology | 2 | 66.0 |
Antibody-Dependent Cell Cytotoxicity | 18 | 21.0 |
CD40 Ligand | 23 | 13.0 |
*Cell Transplantation | 2 | 7.0 |
Liver/*cytology/immunology | 3 | 75.0 |
Lymphocyte Cooperation | 21 | 27.0 |
Transplantation, Heterotopic | 2 | 12.0 |
Transplantation, Homologous/*immunology/pathology | 2 | 50.0 |
Hepacivirus/genetics/immunology | 3 | 50.0 |
Ejaculation | 2 | 14.0 |
*Energy Metabolism | 3 | 3.0 |
Insulin-Like Growth Factor I/*metabolism | 2 | 1.0 |
Muromonab-CD3/*therapeutic use | 2 | 25.0 |
Receptors, Complement 3b/immunology | 2 | 9.0 |
Ascitic Fluid/pathology | 2 | 50.0 |
HIV Protease Inhibitors/administration & dosage/therapeutic use | 8 | 100.0 |
Dactinomycin/analogs & derivatives | 3 | 75.0 |
Dyes | 7 | 6.0 |
Flow Cytometry/*methods/standards | 3 | 42.0 |
Lymphocyte Subsets/chemistry/*cytology | 2 | 100.0 |
Propidium | 2 | 8.0 |
HIV Infections/blood/*drug therapy/*immunology | 5 | 100.0 |
*Cholecystectomy | 3 | 30.0 |
*Cholecystectomy, Laparoscopic | 3 | 25.0 |
Hepatitis B, Chronic/*immunology | 3 | 37.0 |
Liver Cirrhosis/*immunology | 3 | 27.0 |
Postoperative Complications/*immunology | 5 | 31.0 |
*Immunoenzyme Techniques | 11 | 8.0 |
*Infant, Low Birth Weight | 2 | 9.0 |
*Pregnancy Outcome | 6 | 10.0 |
Hematologic Tests/*standards | 3 | 100.0 |
T-Lymphocytes/immunology/*microbiology | 14 | 87.0 |
Zidovudine/*administration & dosage/therapeutic use | 3 | 100.0 |
Antibiotics, Antitubercular/*therapeutic use | 2 | 50.0 |
Antigens, CD4/immunology/*metabolism/physiology | 2 | 100.0 |
Antigens, CD95/biosynthesis/*physiology | 2 | 25.0 |
Immunologic Memory/immunology | 8 | 20.0 |
Proto-Oncogene Proteins/*physiology | 5 | 2.0 |
T-Lymphocyte Subsets/cytology/immunology | 9 | 50.0 |
*Conserved Sequence | 6 | 4.0 |
HLA-A2 Antigen/*biosynthesis | 2 | 66.0 |
Receptors, CCR5/genetics/immunology/*metabolism | 2 | 40.0 |
DNA-Binding Proteins/*genetics/*metabolism | 2 | 1.0 |
Tacrolimus/pharmacology | 4 | 8.0 |
HIV/genetics/*immunology | 4 | 50.0 |
HIV Antigens/*analysis | 12 | 80.0 |
Laboratories/standards | 4 | 22.0 |
Acquired Immunodeficiency Syndrome/*diagnosis/*immunology | 2 | 100.0 |
Flow Cytometry/instrumentation/*methods/standards | 2 | 66.0 |
AIDS-Related Opportunistic Infections/immunology/mortality | 2 | 100.0 |
HIV Infections/*immunology/mortality | 6 | 85.0 |
HIV Infections/blood/*complications/immunology | 7 | 87.0 |
Virus Replication/drug effects/immunology | 4 | 57.0 |
Autoantibodies/immunology | 16 | 14.0 |
Neck | 2 | 3.0 |
Cervix Uteri/virology | 5 | 83.0 |
Herpesvirus 8, Human/genetics/immunology/*isolation & purification | 2 | 100.0 |
Kenya/epidemiology | 11 | 52.0 |
Sperm Count | 2 | 3.0 |
China/ethnology | 4 | 2.0 |
AIDS-Related Opportunistic Infections | 17 | 89.0 |
Candidiasis, Oral | 2 | 100.0 |
Epitopes/genetics | 8 | 9.0 |
HIV-1/drug effects/*genetics/isolation & purification | 3 | 100.0 |
RNA, Viral/blood/isolation & purification | 7 | 100.0 |
Gene Products, gag/immunology | 20 | 68.0 |
HIV-1 Reverse Transcriptase/genetics/metabolism | 2 | 100.0 |
HIV/*growth & development | 9 | 75.0 |
Leprostatic Agents/*therapeutic use | 2 | 100.0 |
HIV Infections/*complications/drug therapy/mortality | 2 | 100.0 |
Lymphoma, AIDS-Related/mortality | 4 | 100.0 |
Prostate-Specific Antigen/analysis | 2 | 4.0 |
Antigens, CD28/genetics/metabolism | 2 | 66.0 |
Protein-Tyrosine-Phosphatase/*metabolism | 5 | 3.0 |
Thymus Gland/immunology/metabolism | 4 | 40.0 |
Anus Diseases/*complications | 2 | 100.0 |
Anus Neoplasms/*virology | 2 | 100.0 |
Condylomata Acuminata/*complications | 2 | 100.0 |
Neoplasm Invasiveness | 15 | 1.0 |
Acetylcarnitine/*therapeutic use | 2 | 100.0 |
HIV-1 Reverse Transcriptase/*antagonists & inhibitors | 5 | 71.0 |
Nerve Regeneration/drug effects | 2 | 33.0 |
Nootropic Agents/*therapeutic use | 2 | 50.0 |
Peripheral Nervous System Diseases/chemically induced/*drug therapy | 2 | 100.0 |
HIV Infections/*drug therapy/genetics/mortality | 2 | 100.0 |
Interleukin-1/*genetics | 2 | 2.0 |
Viremia/*genetics | 2 | 100.0 |
Antibodies/blood | 6 | 10.0 |
Arthritis, Rheumatoid/genetics/immunology/*metabolism | 2 | 50.0 |
Citrulline/immunology/*metabolism | 2 | 100.0 |
Fibrinogen/immunology/*metabolism | 2 | 66.0 |
HLA-DR4 Antigen/immunology | 4 | 100.0 |
HIV Infections/etiology/*immunology | 6 | 75.0 |
Membrane Glycoproteins/*blood | 6 | 11.0 |
Lactones/pharmacology | 3 | 7.0 |
Lymphocyte Specific Protein Tyrosine Kinase p56(lck)/genetics/*metabolism | 4 | 57.0 |
Quinones/pharmacology | 14 | 10.0 |
src-Family Kinases/metabolism | 11 | 5.0 |
CD4-Positive T-Lymphocytes/immunology/parasitology | 2 | 100.0 |
Interferon-gamma, Recombinant/pharmacology | 6 | 3.0 |
Tritium | 6 | 2.0 |
Antigens, Surface/*analysis | 49 | 25.0 |
Observer Variation | 12 | 10.0 |
Bronchi/immunology/*pathology | 2 | 66.0 |
Eosinophils/*pathology | 2 | 14.0 |
HIV Envelope Protein gp41/chemistry/*genetics/metabolism | 2 | 100.0 |
Interleukin-1/metabolism/pharmacology | 2 | 14.0 |
Tumor Necrosis Factor-alpha/metabolism/pharmacology | 3 | 8.0 |
Graft Survival/*immunology | 6 | 10.0 |
Interferon Type II/cerebrospinal fluid | 2 | 40.0 |
Interleukin-6/cerebrospinal fluid | 4 | 36.0 |
AIDS-Related Opportunistic Infections/*drug therapy/immunology/virology | 3 | 75.0 |
*Virus Activation | 7 | 22.0 |
HIV Seropositivity/*complications/epidemiology | 3 | 100.0 |
AIDS-Related Opportunistic Infections/*chemically induced | 2 | 100.0 |
Anti-HIV Agents/*administration & dosage/*adverse effects | 2 | 100.0 |
HIV Protease Inhibitors/administration & dosage/adverse effects | 2 | 100.0 |
Lamivudine/administration & dosage/adverse effects | 5 | 100.0 |
Ritonavir/administration & dosage/adverse effects | 4 | 100.0 |
Stavudine/administration & dosage/adverse effects | 3 | 100.0 |
Anti-HIV Agents/pharmacology | 10 | 22.0 |
*Herpesvirus 8, Human/genetics/isolation & purification | 2 | 100.0 |
Nuclear Proteins/*immunology | 2 | 9.0 |
Gene Products, env/physiology | 4 | 50.0 |
Lymphocytes/immunology/*virology | 3 | 75.0 |
Acquired Immunodeficiency Syndrome/metabolism | 3 | 23.0 |
HIV Envelope Protein gp120/metabolism/pharmacology | 3 | 100.0 |
Dideoxynucleosides/administration & dosage/adverse effects | 2 | 100.0 |
HIV-1/*drug effects/immunology | 7 | 63.0 |
Nelfinavir/administration & dosage/adverse effects | 3 | 100.0 |
Zidovudine/administration & dosage/adverse effects | 5 | 100.0 |
Metronidazole/therapeutic use | 4 | 80.0 |
HIV Infections/epidemiology/*prevention & control/*transmission | 2 | 100.0 |
Antigens, CD4/pharmacology | 5 | 71.0 |
Epithelial Cells/virology | 2 | 12.0 |
Malawi/epidemiology | 2 | 66.0 |
Gambia/epidemiology | 4 | 28.0 |
HIV-2/genetics/*isolation & purification | 3 | 100.0 |
Cervix Uteri/*virology | 5 | 50.0 |
Proviruses/genetics/isolation & purification | 7 | 58.0 |
Receptors, Cytokine/*genetics | 8 | 14.0 |
Weight Gain | 13 | 20.0 |
Graft vs Host Disease/*prevention & control | 4 | 14.0 |
*Stem Cell Transplantation | 4 | 6.0 |
*T-Lymphocyte Subsets/immunology | 13 | 92.0 |
Arthritis, Rheumatoid/blood/*immunology | 5 | 19.0 |
Synovial Membrane/immunology | 6 | 20.0 |
Borrelia burgdorferi Group/immunology | 2 | 66.0 |
Lyme Disease/*immunology | 2 | 33.0 |
*Gene Amplification | 4 | 1.0 |
*Genes, myc | 4 | 1.0 |
HLA-A1 Antigen/immunology | 2 | 50.0 |
HIV Antibodies/*biosynthesis/immunology | 3 | 100.0 |
Immunoglobulin M/biosynthesis | 11 | 12.0 |
HIV Infections/*genetics/immunology | 4 | 25.0 |
Anti-Bacterial Agents/administration & dosage/*therapeutic use | 2 | 40.0 |
Dendritic Cells/*classification | 4 | 100.0 |
Interleukin-12/analysis | 4 | 36.0 |
Spleen/cytology | 25 | 14.0 |
AIDS-Related Opportunistic Infections/etiology/pathology | 2 | 66.0 |
HIV Infections/*complications/epidemiology/virology | 2 | 100.0 |
CD4-Positive T-Lymphocytes/*drug effects/metabolism/pathology | 2 | 66.0 |
CD8-Positive T-Lymphocytes/*drug effects/metabolism/pathology | 2 | 66.0 |
Protein Binding/drug effects/immunology | 3 | 18.0 |
IgA Deficiency/*immunology | 2 | 66.0 |
IgG Deficiency/*immunology | 2 | 100.0 |
Infection/etiology | 4 | 18.0 |
Fibronectins/metabolism | 5 | 2.0 |
Mitosis/drug effects | 2 | 1.0 |
Etoposide/administration & dosage | 11 | 9.0 |
Lymphoma, Non-Hodgkin/*drug therapy | 2 | 14.0 |
Monocytes/cytology/drug effects | 2 | 5.0 |
Antigens, CD45/analysis/immunology | 4 | 66.0 |
Antigens, CD7/analysis/immunology | 2 | 100.0 |
Antigens, Differentiation, T-Lymphocyte/analysis/immunology | 6 | 46.0 |
Membrane Glycoproteins/analysis/immunology | 2 | 20.0 |
CD8-Positive T-Lymphocytes/chemistry/immunology | 3 | 50.0 |
Acquired Immunodeficiency Syndrome/*diagnosis | 12 | 63.0 |
Heat | 15 | 2.0 |
Protein Denaturation | 9 | 3.0 |
Cytarabine/*therapeutic use | 4 | 26.0 |
Patient Admission/*statistics & numerical data | 2 | 66.0 |
Acquired Immunodeficiency Syndrome/*blood/drug therapy | 5 | 100.0 |
Diabetes Mellitus/chemically induced | 3 | 100.0 |
HIV Infections/blood/drug therapy | 2 | 66.0 |
Antigens, Differentiation, T-Lymphocyte/*biosynthesis | 7 | 18.0 |
HIV Infections/*complications/*diagnosis | 3 | 100.0 |
RNA, Viral/drug effects | 8 | 88.0 |
Actins/*metabolism | 4 | 1.0 |
T-Lymphocytes/drug effects/*immunology/*metabolism | 3 | 30.0 |
Chimera/immunology | 4 | 33.0 |
GTP-Binding Proteins/*metabolism | 5 | 1.0 |
Electrophoresis, Agar Gel | 4 | 0.0 |
Antigens, CD56/blood | 4 | 66.0 |
Bone Marrow Transplantation/*immunology | 19 | 15.0 |
Antigens, CD4/*biosynthesis/drug effects | 3 | 100.0 |
Cell Line/virology | 2 | 28.0 |
HIV-1/immunology/physiology | 5 | 50.0 |
Herpesviridae Infections/*complications/immunology | 3 | 75.0 |
Acquired Immunodeficiency Syndrome/*complications/mortality | 8 | 80.0 |
Bisexuality | 16 | 80.0 |
Lymphocyte Subsets/metabolism | 3 | 15.0 |
Receptors, Antigen, T-Cell, gamma-delta/*biosynthesis/genetics | 2 | 100.0 |
Fibroblast Growth Factor 2/pharmacology | 2 | 0.0 |
Lymphokines/pharmacology | 6 | 3.0 |
Umbilical Cord/cytology | 2 | 10.0 |
Antigens, CD13/metabolism | 2 | 22.0 |
Lymphoma, Non-Hodgkin/*immunology/therapy | 2 | 100.0 |
Chromosomes, Human, Pair 3 | 2 | 1.0 |
Lymphocyte Subsets/*drug effects/metabolism | 3 | 100.0 |
Haplorhini | 9 | 3.0 |
Vagina/*microbiology | 2 | 50.0 |
Hepatitis B virus/immunology | 2 | 11.0 |
Cytokines/*pharmacology | 12 | 3.0 |
Interleukin-1/pharmacology | 14 | 2.0 |
Organ Specificity/genetics/immunology | 4 | 11.0 |
Interleukin-15/*physiology | 2 | 28.0 |
Interleukin-2/*physiology | 10 | 13.0 |
Receptors, HIV/analysis | 3 | 75.0 |
Antibodies, Antinuclear/analysis | 5 | 6.0 |
Rheumatoid Factor/analysis | 4 | 6.0 |
Sjogren's Syndrome/blood/*immunology | 2 | 22.0 |
*Bacterial Vaccines | 3 | 60.0 |
Lung/immunology | 8 | 24.0 |
Vaccines, DNA | 2 | 50.0 |
Cholesterol/*blood | 4 | 1.0 |
Hydroxyurea/adverse effects/*therapeutic use | 3 | 100.0 |
Deoxyribonucleotides/metabolism | 2 | 28.0 |
Hydroxyurea/*pharmacology | 3 | 21.0 |
T-Lymphocytes/drug effects/virology | 3 | 50.0 |
Nucleosides/metabolism | 2 | 22.0 |
P-Glycoprotein | 6 | 13.0 |
Stavudine/*administration & dosage | 3 | 75.0 |
Antigens, CD4/*drug effects/immunology | 3 | 100.0 |
Exotoxins/pharmacology | 2 | 20.0 |
Interleukin-1/biosynthesis | 16 | 8.0 |
Interleukin-6/biosynthesis | 12 | 5.0 |
T-Lymphocytes/drug effects/*metabolism | 6 | 12.0 |
Carcinoma, Squamous Cell/immunology/pathology/*therapy | 2 | 66.0 |
Acquired Immunodeficiency Syndrome/immunology/*therapy/virology | 3 | 50.0 |
HIV Envelope Protein gp160/immunology | 6 | 60.0 |
CD4-Positive T-Lymphocytes/cytology/immunology/*virology | 3 | 100.0 |
Cell Adhesion Molecules/physiology | 10 | 10.0 |
Lectins/physiology | 2 | 50.0 |
Cytokines/genetics/*metabolism | 2 | 5.0 |
Gene Expression Regulation/genetics | 7 | 3.0 |
Orbit | 2 | 33.0 |
HIV Infections/*complications/pathology | 6 | 66.0 |
Leukoencephalopathy, Progressive Multifocal/*etiology/pathology | 2 | 100.0 |
Staining and Labeling/methods | 6 | 5.0 |
Caspases/*metabolism | 5 | 2.0 |
Cameroon | 2 | 9.0 |
*Developing Countries | 11 | 36.0 |
Nevirapine/administration & dosage/adverse effects | 2 | 100.0 |
Neoplasms/therapy | 4 | 8.0 |
Sarcoma, Kaposi/etiology | 4 | 66.0 |
Skin Diseases/*etiology/pathology | 2 | 66.0 |
Dust/*immunology | 2 | 50.0 |
Hypersensitivity/*diagnosis | 2 | 33.0 |
Mites/*immunology | 4 | 8.0 |
*Patch Tests | 5 | 41.0 |
Receptors, IgE/analysis | 7 | 23.0 |
Lung Neoplasms/*immunology/pathology | 2 | 15.0 |
Counseling | 9 | 40.0 |
Chlamydia Infections/complications | 2 | 40.0 |
Gonorrhea/complications | 3 | 75.0 |
Stavudine/administration & dosage/*adverse effects/therapeutic use | 2 | 100.0 |
Thymus Gland/*pathology | 4 | 36.0 |
Anemia, Hemolytic/*etiology | 2 | 11.0 |
Lymphoma, T-Cell/*complications/pathology | 2 | 66.0 |
Thrombocytopenia/*etiology | 2 | 12.0 |
Antigens, Viral/blood | 3 | 50.0 |
Viremia/*diagnosis | 3 | 100.0 |
HIV-1/*growth & development/metabolism | 2 | 100.0 |
*Apolipoproteins | 7 | 21.0 |
*Glycoproteins | 10 | 1.0 |
*Membrane Transport Proteins | 10 | 1.0 |
Antibodies/*immunology | 9 | 7.0 |
Interferon Type II | 2 | 11.0 |
Interleukin-4/*immunology | 2 | 11.0 |
Antigens, CD28/*analysis | 5 | 26.0 |
Antigens, CD8/*analysis | 41 | 60.0 |
Leukocytes, Mononuclear/drug effects/metabolism | 5 | 9.0 |
Florida | 2 | 16.0 |
*Substance-Related Disorders | 2 | 33.0 |
Lymphoid Tissue/virology | 3 | 60.0 |
Amino Acids/immunology | 2 | 50.0 |
HIV Envelope Protein gp120/genetics/*immunology | 11 | 57.0 |
Antibiotics, Antitubercular/therapeutic use | 3 | 75.0 |
Antibiotics, Combined/therapeutic use | 8 | 44.0 |
Clarithromycin/therapeutic use | 3 | 25.0 |
Ethambutol/therapeutic use | 3 | 75.0 |
*Mycobacterium avium | 2 | 100.0 |
Rifabutin/therapeutic use | 3 | 75.0 |
Killer Cells/immunology | 8 | 28.0 |
Chimera/genetics | 2 | 5.0 |
Gene Expression Regulation, Viral/genetics | 2 | 13.0 |
Genes, env/*genetics | 2 | 33.0 |
*Recombination, Genetic | 5 | 1.0 |
Vaccines, Inactivated/immunology | 4 | 44.0 |
Viral Proteins/immunology | 6 | 20.0 |
Enzyme Activation/physiology | 4 | 2.0 |
Anticoagulants | 2 | 10.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/immunology/pharmacology | 2 | 25.0 |
Heparin | 2 | 2.0 |
Macrophage Colony-Stimulating Factor/immunology/pharmacology | 2 | 50.0 |
Gastric Mucosa/immunology/pathology | 2 | 22.0 |
Immune Tolerance/*physiology | 4 | 28.0 |
Peptide Fragments/*immunology | 14 | 13.0 |
Spleen/immunology/pathology | 5 | 29.0 |
Thymus Gland/*immunology/pathology | 6 | 66.0 |
Great Britain/epidemiology | 9 | 8.0 |
HLA-DQ Antigens/genetics/immunology | 2 | 10.0 |
Lymphocytes/drug effects/immunology | 6 | 18.0 |
Peptide Fragments/*immunology/pharmacology | 3 | 33.0 |
Transglutaminases/*metabolism | 2 | 6.0 |
Collagenases/pharmacology | 2 | 33.0 |
Deoxyribonucleases/pharmacology | 3 | 37.0 |
Edetic Acid/pharmacology | 7 | 3.0 |
Integrins/metabolism | 4 | 2.0 |
L-Selectin/metabolism | 6 | 18.0 |
Tonsil/*cytology/immunology | 3 | 37.0 |
Hemophilia A/*complications/immunology | 5 | 71.0 |
Receptors, Antigen, T-Cell, alpha-beta/genetics/immunology | 7 | 50.0 |
Interferon Type II/*metabolism | 8 | 12.0 |
Interleukin-5/metabolism | 2 | 11.0 |
Exercise | 4 | 3.0 |
Fever | 4 | 23.0 |
HIV Infections/immunology/*microbiology | 4 | 80.0 |
Cattle/*immunology | 5 | 29.0 |
Receptors, Lymphocyte Homing/analysis | 3 | 9.0 |
CD8-Positive T-Lymphocytes/*immunology/virology | 10 | 55.0 |
Diabetes Complications | 2 | 1.0 |
Diabetes Mellitus/*immunology | 2 | 22.0 |
*Macrophage Activation | 2 | 3.0 |
*T-Lymphocytes | 25 | 53.0 |
HIV Infections/*complications/epidemiology/immunology | 8 | 88.0 |
Chemokines/pharmacology | 7 | 21.0 |
Lipopolysaccharides/*pharmacology | 6 | 1.0 |
Macrophages/*immunology/*virology | 4 | 100.0 |
Monocytes/immunology/virology | 4 | 50.0 |
Protein Binding/immunology | 14 | 7.0 |
Skin/immunology/metabolism | 2 | 18.0 |
Embryonic and Fetal Development/*immunology | 2 | 25.0 |
Animals, Genetically Modified | 7 | 2.0 |
HIV Long Terminal Repeat/drug effects | 3 | 33.0 |
Antigens, CD95/blood | 4 | 33.0 |
Lymphocytes/*cytology/virology | 2 | 100.0 |
Retroviridae/drug effects | 5 | 83.0 |
Streptococcus pyogenes/*immunology | 2 | 10.0 |
CpG Islands/*immunology | 2 | 12.0 |
Interferon Type I/immunology | 2 | 33.0 |
Interleukin-12/immunology | 3 | 13.0 |
Oxidative Stress/*physiology | 4 | 4.0 |
*Surgical Procedures, Minimally Invasive | 2 | 50.0 |
Acquired Immunodeficiency Syndrome/*transmission | 6 | 60.0 |
Antigens, CD95/*genetics | 4 | 14.0 |
Mutation/*genetics | 4 | 0.0 |
Antigens, CD55/immunology | 2 | 15.0 |
Antibody-Producing Cells/immunology | 5 | 20.0 |
Protein Kinases/metabolism | 6 | 1.0 |
Proto-Oncogene Proteins c-raf/metabolism | 2 | 2.0 |
T-Lymphocytes/enzymology/*immunology | 8 | 36.0 |
Antigens, CD3/*biosynthesis | 3 | 50.0 |
Breast Neoplasms/immunology | 4 | 11.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/immunology/*pharmacology | 2 | 40.0 |
AIDS-Related Opportunistic Infections/*epidemiology/prevention & control | 3 | 100.0 |
Endoscopy, Gastrointestinal | 4 | 20.0 |
Gastric Mucosa/pathology | 4 | 10.0 |
Intestinal Mucosa/pathology | 5 | 9.0 |
CD4-CD8 Ratio/drug effects | 16 | 88.0 |
HIV Infections/*complications/*immunology | 9 | 90.0 |
Lymphocytes/*immunology/pathology | 8 | 40.0 |
HIV-1/genetics/metabolism/*physiology | 2 | 28.0 |
Leukocytes, Mononuclear/cytology/virology | 5 | 41.0 |
Muscle, Skeletal | 2 | 10.0 |
China/epidemiology | 3 | 1.0 |
RNA-Directed DNA Polymerase/genetics | 8 | 80.0 |
HIV Infections/*drug therapy/immunology/psychology | 2 | 100.0 |
Zalcitabine/administration & dosage/*therapeutic use | 3 | 75.0 |
Basement Membrane/pathology | 2 | 5.0 |
Sclerosis | 3 | 5.0 |
Lung/*immunology/pathology | 3 | 50.0 |
Lung/pathology/radiography | 2 | 25.0 |
Gene Products, gag/metabolism | 5 | 38.0 |
Immunodeficiency Virus, Feline/immunology | 2 | 100.0 |
Interferon Type II/*biosynthesis/genetics | 6 | 28.0 |
Interleukin-10/*biosynthesis/genetics | 3 | 27.0 |
Nucleic Acid Synthesis Inhibitors/therapeutic use | 2 | 50.0 |
AIDS Dementia Complex/*diagnosis/physiopathology | 2 | 100.0 |
Inflammatory Bowel Diseases/*immunology/pathology | 3 | 37.0 |
T-Lymphocytes, Cytotoxic/*immunology/pathology | 4 | 33.0 |
Pentostatin/*pharmacology | 2 | 100.0 |
Interleukin-10/*blood | 2 | 6.0 |
Calcitriol/pharmacology | 6 | 5.0 |
T-Lymphocytes/cytology/drug effects/*physiology | 2 | 40.0 |
Immunoglobulin Isotypes/blood | 3 | 15.0 |
AIDS-Related Opportunistic Infections/*pathology | 8 | 42.0 |
Papovaviridae Infections/complications/*epidemiology | 2 | 40.0 |
Tumor Virus Infections/complications/*epidemiology | 2 | 50.0 |
Biocompatible Materials | 2 | 3.0 |
Complement 4/metabolism | 2 | 2.0 |
Integrin alphaXbeta2 | 3 | 8.0 |
Kidney | 9 | 2.0 |
Recombinant Fusion Proteins/biosynthesis | 10 | 2.0 |
*Transfection | 10 | 4.0 |
Bacterial Infections/immunology | 2 | 8.0 |
Lymphocytes, Tumor-Infiltrating/*metabolism | 2 | 22.0 |
Cytotoxicity, Immunologic/*immunology | 11 | 22.0 |
HLA Antigens/immunology | 32 | 17.0 |
HIV Infections/*complications/*epidemiology | 4 | 100.0 |
Respiratory Tract Infections/complications/epidemiology | 2 | 100.0 |
Immunoglobulin G/*metabolism | 5 | 8.0 |
Cell Fusion/drug effects | 12 | 60.0 |
Chemotaxis/drug effects | 4 | 4.0 |
Collagen | 3 | 1.0 |
Cytopathogenic Effect, Viral/drug effects | 4 | 17.0 |
MAP Kinase Signaling System/drug effects | 2 | 2.0 |
Receptor Cross-Talk | 2 | 5.0 |
Gene Products, env/*physiology | 4 | 80.0 |
Collagen/metabolism | 3 | 1.0 |
Liver/metabolism/pathology | 2 | 4.0 |
Th1 Cells/*metabolism | 5 | 18.0 |
Vagina/*immunology | 4 | 57.0 |
*Disease Transmission, Vertical/statistics & numerical data | 2 | 100.0 |
CD4-Positive T-Lymphocytes/*cytology/virology | 2 | 100.0 |
Bacterial Toxins/immunology | 3 | 37.0 |
Kidney Failure, Chronic/immunology/therapy | 3 | 30.0 |
Oligonucleotide Probes | 18 | 2.0 |
Antigens, CD34/*immunology | 4 | 5.0 |
Lymphoma, Non-Hodgkin/immunology/*therapy | 2 | 22.0 |
Multiple Myeloma/immunology/*therapy | 3 | 27.0 |
Langerhans Cells/immunology/metabolism | 2 | 33.0 |
Antigens, CD30/metabolism | 2 | 10.0 |
T-Lymphocyte Subsets/*immunology/pathology | 14 | 66.0 |
Peritoneal Dialysis, Continuous Ambulatory/*adverse effects | 5 | 12.0 |
Peritonitis/etiology/*immunology | 4 | 57.0 |
Ethiopia/epidemiology | 3 | 50.0 |
Hepatitis C/complications/immunology/*virology | 2 | 100.0 |
Immunologic Tests | 4 | 12.0 |
Acquired Immunodeficiency Syndrome/complications/*diagnosis/drug therapy | 2 | 100.0 |
Cytodiagnosis/methods | 2 | 16.0 |
Cytomegalovirus/*isolation & purification | 7 | 53.0 |
Molecular Chaperones/metabolism | 2 | 4.0 |
HIV Infections/drug therapy/*psychology | 2 | 100.0 |
T-Lymphocytes, Cytotoxic | 4 | 18.0 |
CD8-Positive T-Lymphocytes/metabolism/virology | 5 | 100.0 |
Receptors, CXCR4/antagonists & inhibitors/*metabolism | 2 | 33.0 |
Oligopeptides/*chemistry | 2 | 13.0 |
Peptide Fragments/chemistry | 9 | 4.0 |
T-Lymphocytes/drug effects/*immunology/metabolism | 6 | 26.0 |
Thymidine/pharmacokinetics | 2 | 12.0 |
Allergens/*administration & dosage | 2 | 22.0 |
Skin/blood supply/immunology/pathology | 2 | 66.0 |
Cell Adhesion Molecules/*analysis | 13 | 10.0 |
Germinal Center/immunology | 2 | 16.0 |
Lymph Nodes/*immunology | 11 | 29.0 |
Stomach Neoplasms/*immunology | 3 | 16.0 |
Amino Acid Substitution/genetics | 3 | 1.0 |
Arthritis, Reactive/*immunology | 3 | 50.0 |
Chaperonin 60/*immunology | 2 | 25.0 |
Clone Cells/immunology/metabolism | 3 | 27.0 |
Yersinia enterocolitica/*immunology | 2 | 20.0 |
Human T-lymphotropic virus 1/isolation & purification | 6 | 75.0 |
Peripheral Nervous System Diseases/diagnosis/*etiology | 3 | 100.0 |
Egg Proteins/immunology | 2 | 25.0 |
H-2 Antigens/*immunology | 6 | 40.0 |
Lung/cytology/*immunology | 3 | 23.0 |
Receptors, Tumor Necrosis Factor/*metabolism | 4 | 1.0 |
Receptors, Cholinergic/immunology | 2 | 11.0 |
Hepatitis, Chronic/immunology | 3 | 23.0 |
Lymphocytes/*chemistry/physiology | 2 | 66.0 |
Superantigens/*immunology/metabolism | 2 | 50.0 |
Acquired Immunodeficiency Syndrome/*pathology | 4 | 21.0 |
Body Weight/drug effects | 9 | 4.0 |
Lichen Sclerosus et Atrophicus/*immunology | 2 | 50.0 |
Vulvar Diseases/*immunology | 2 | 66.0 |
Immunity, Cellular/genetics | 2 | 18.0 |
Immunologic Memory/*genetics | 2 | 50.0 |
Cell Differentiation/physiology | 8 | 1.0 |
Dendritic Cells/cytology/*immunology | 5 | 8.0 |
Hospitals, Urban | 3 | 37.0 |
Hospitals, Veterans | 3 | 27.0 |
HIV Infections/complications/*drug therapy/virology | 2 | 100.0 |
Nuclear Proteins/immunology | 3 | 10.0 |
Affect/*drug effects | 4 | 44.0 |
Androgens/blood | 2 | 2.0 |
HIV Seropositivity/blood/*complications | 3 | 75.0 |
Cryptosporidiosis/*drug therapy | 3 | 100.0 |
Rifamycins/*therapeutic use | 2 | 66.0 |
HIV-1/growth & development/*pathogenicity | 5 | 100.0 |
Cell Cycle/radiation effects | 2 | 7.0 |
Phosphoproteins/blood/*immunology | 2 | 100.0 |
Viral Matrix Proteins/blood/*immunology | 2 | 100.0 |
*Complementarity Determining Regions | 3 | 37.0 |
Immunoglobulin Variable Region/immunology | 9 | 31.0 |
Tonsil/*immunology | 5 | 29.0 |
Mitosis | 7 | 1.0 |
*Enteral Nutrition | 7 | 29.0 |
*Postoperative Care | 2 | 12.0 |
Intelligence Tests | 2 | 3.0 |
*Neurologic Examination | 2 | 28.0 |
HIV Envelope Protein gp120/genetics/*physiology | 5 | 83.0 |
Peptide Fragments/genetics/*physiology | 5 | 50.0 |
Proline | 2 | 3.0 |
Receptors, HIV/genetics/*metabolism | 12 | 60.0 |
HLA-B Antigens/genetics/immunology | 2 | 8.0 |
Melanoma/*immunology | 11 | 13.0 |
Skin Neoplasms/*immunology | 9 | 24.0 |
Lymphocyte Activation/physiology | 10 | 14.0 |
DNA/genetics | 18 | 0.0 |
HLA-A2 Antigen/immunology | 7 | 18.0 |
Liver Cirrhosis, Biliary/*immunology | 5 | 14.0 |
Gene Products, env/genetics/*physiology | 2 | 100.0 |
Clinical Trials, Phase II | 6 | 11.0 |
Cytosine/analogs & derivatives/therapeutic use | 4 | 100.0 |
Paclitaxel/administration & dosage | 2 | 7.0 |
Cervix Neoplasms/*immunology/*virology | 2 | 100.0 |
Papillomavirus, Human/*immunology | 4 | 33.0 |
Papovaviridae Infections/*immunology | 2 | 66.0 |
Lymphoma, T-Cell/immunology/*pathology | 3 | 50.0 |
Immunologic Techniques | 21 | 6.0 |
Autonomic Nervous System/*physiopathology | 2 | 10.0 |
Heart Rate | 2 | 0.0 |
Sequence Analysis, RNA | 5 | 13.0 |
Urethritis/*virology | 2 | 100.0 |
Cervical Intraepithelial Neoplasia/immunology/*virology | 2 | 100.0 |
Cervix Neoplasms/immunology/*virology | 2 | 100.0 |
HIV-2/genetics | 3 | 75.0 |
Papovaviridae Infections/*complications/immunology | 3 | 100.0 |
AIDS Serodiagnosis | 10 | 71.0 |
HIV-2 | 5 | 83.0 |
Tumor Virus Infections/*complications/immunology | 4 | 80.0 |
Africa/ethnology | 6 | 13.0 |
Chickens | 7 | 0.0 |
Receptors, Lymphocyte Homing/*immunology | 3 | 15.0 |
Antigens, Surface/*biosynthesis | 9 | 37.0 |
Lymphocyte Subsets/drug effects | 14 | 73.0 |
beta 2-Microglobulin/genetics | 2 | 9.0 |
B-Lymphocytes/immunology/*virology | 4 | 36.0 |
Gene Products, gag/blood | 9 | 75.0 |
Endopeptidases/genetics | 4 | 40.0 |
Biological Response Modifiers/therapeutic use | 3 | 18.0 |
Leukemic Infiltration | 3 | 23.0 |
*Splenectomy | 19 | 57.0 |
Immunologic Deficiency Syndromes/etiology | 2 | 33.0 |
Receptors, Antigen, T-Cell, alpha-beta/metabolism | 10 | 34.0 |
Skin Transplantation/*immunology | 2 | 20.0 |
Acquired Immunodeficiency Syndrome/immunology/mortality | 4 | 100.0 |
Gene Products, nef/genetics | 2 | 40.0 |
Histocompatibility Antigens Class I/biosynthesis | 7 | 14.0 |
HIV Seropositivity/*immunology/*virology | 4 | 80.0 |
*Menstrual Cycle | 2 | 3.0 |
beta 2-Microglobulin/*analysis | 17 | 22.0 |
Antigens, Neoplasm/genetics/*immunology | 2 | 16.0 |
Neoplasm Proteins/genetics | 2 | 0.0 |
Antigens, CD/analysis/*biosynthesis | 4 | 15.0 |
Antigens, CD28/*immunology | 19 | 13.0 |
CD4-Positive T-Lymphocytes/drug effects/*immunology/metabolism | 4 | 44.0 |
ras Proteins/metabolism | 3 | 1.0 |
Receptors, CCR5/metabolism/physiology | 2 | 66.0 |
Recombinant Proteins/biosynthesis | 11 | 2.0 |
Antimetabolites, Antineoplastic/*therapeutic use | 4 | 10.0 |
Gene Expression Regulation/*drug effects | 3 | 0.0 |
Gene Expression Regulation, Neoplastic/immunology | 4 | 14.0 |
Chlamydia trachomatis/isolation & purification | 4 | 57.0 |
Neisseria gonorrhoeae/isolation & purification | 4 | 100.0 |
Glycosaminoglycans/*metabolism | 3 | 13.0 |
AIDS Dementia Complex/diagnosis/*immunology | 2 | 66.0 |
Cytokines/immunology/metabolism | 4 | 18.0 |
Salivary Glands/pathology | 2 | 33.0 |
Antigens, CD56/*metabolism | 3 | 21.0 |
Mycobacterium avium-intracellulare Infection/*immunology | 3 | 33.0 |
HIV Infections/drug therapy/*immunology/*therapy | 3 | 100.0 |
Interleukin-2/*administration & dosage/adverse effects | 3 | 25.0 |
Lymph Nodes/immunology/virology | 2 | 100.0 |
HIV-1/drug effects/*isolation & purification/physiology | 2 | 100.0 |
Leukocytes, Mononuclear/*cytology | 4 | 19.0 |
*Gene Expression Regulation, Viral | 24 | 8.0 |
HIV-1/*drug effects/genetics/metabolism | 3 | 50.0 |
Peptides/chemical synthesis | 2 | 7.0 |
HIV/immunology/pathogenicity | 2 | 66.0 |
HIV Antigens | 16 | 51.0 |
Vitreous Body | 2 | 14.0 |
Leukocytes, Mononuclear/cytology | 8 | 16.0 |
Bayes Theorem | 5 | 9.0 |
Vaccinia virus/immunology | 5 | 71.0 |
Viral Envelope Proteins/*genetics/immunology | 2 | 33.0 |
Macaca mulatta/immunology | 2 | 40.0 |
Macaca nemestrina/immunology | 2 | 100.0 |
Muscarinic Agonists/pharmacology | 2 | 5.0 |
Oligopeptides/pharmacology | 3 | 1.0 |
Leukemia/*blood/pathology | 2 | 100.0 |
Lymphoma/*blood/pathology | 2 | 66.0 |
T-Lymphocytes/*cytology/metabolism | 4 | 18.0 |
Blood Physiology | 2 | 2.0 |
Lung/*pathology | 5 | 16.0 |
HIV Envelope Protein gp41/*physiology | 5 | 100.0 |
Antibodies, Monoclonal/chemistry/immunology | 3 | 27.0 |
HIV Envelope Protein gp120/immunology/*physiology | 6 | 85.0 |
Chromatography, Thin Layer | 3 | 1.0 |
T-Lymphocytes/*enzymology/immunology | 4 | 17.0 |
Receptors, Tumor Necrosis Factor/blood | 5 | 6.0 |
Thymidine Kinase/blood | 2 | 40.0 |
beta 2-Microglobulin/analysis | 57 | 44.0 |
Caspase 1/metabolism | 2 | 10.0 |
Antigens, CD1 | 17 | 17.0 |
Dermatitis, Allergic Contact/*immunology | 2 | 22.0 |
T-Lymphocytes/*immunology/radiation effects | 2 | 18.0 |
Ultraviolet Rays | 4 | 0.0 |
Acquired Immunodeficiency Syndrome/diagnosis/immunology | 6 | 100.0 |
HIV Seropositivity/diagnosis/*immunology | 3 | 60.0 |
Heparin/metabolism | 3 | 2.0 |
Virion/physiology | 8 | 34.0 |
Immunoglobulin G/immunology/metabolism | 5 | 31.0 |
Lymphokines/*physiology | 4 | 3.0 |
Pertussis Toxin | 2 | 1.0 |
Glycoproteins/*metabolism | 5 | 2.0 |
HIV-1 Reverse Transcriptase/analysis | 2 | 66.0 |
HIV-1/*drug effects/immunology/physiology | 5 | 83.0 |
Serum Albumin/*pharmacology | 2 | 18.0 |
HIV/drug effects/immunology/*physiology | 2 | 100.0 |
DNA, Neoplasm/*analysis | 5 | 2.0 |
Fluorescent Dyes/analysis | 3 | 30.0 |
Propidium/analysis | 2 | 100.0 |
Tyrosine/*metabolism | 11 | 3.0 |
Arthroscopy | 2 | 18.0 |
Biological Markers/metabolism | 2 | 12.0 |
Genes, p53 | 2 | 0.0 |
Viral Load/statistics & numerical data | 3 | 100.0 |
Arthritis, Rheumatoid/*complications | 2 | 13.0 |
*Cross-Linking Reagents | 3 | 20.0 |
*Fixatives | 2 | 20.0 |
Heating | 4 | 18.0 |
Tissue Fixation/*methods | 4 | 26.0 |
Reactive Oxygen Species | 4 | 3.0 |
Acquired Immunodeficiency Syndrome/drug therapy/*ethnology | 2 | 100.0 |
Africa South of the Sahara/ethnology | 3 | 75.0 |
Ambulatory Care Facilities/*statistics & numerical data | 2 | 100.0 |
Referral and Consultation | 2 | 11.0 |
HLA-DQ Antigens/*genetics | 6 | 1.0 |
Hepatitis C, Chronic/complications | 2 | 33.0 |
Hepatocytes/*immunology | 2 | 50.0 |
Integrins/*physiology | 5 | 5.0 |
Lymphocyte Subsets/immunology/*pathology | 11 | 84.0 |
Membrane Proteins/biosynthesis/*physiology | 3 | 50.0 |
Vascular Cell Adhesion Molecule-1/metabolism | 6 | 7.0 |
Tetanus Toxoid/administration & dosage/immunology | 2 | 66.0 |
Virus Latency/immunology | 2 | 66.0 |
Lysosomes/enzymology | 2 | 3.0 |
HIV-2/pathogenicity | 2 | 100.0 |
NIH 3T3 Cells | 5 | 1.0 |
SIV/pathogenicity | 4 | 100.0 |
*Dental Care for Chronically Ill | 4 | 100.0 |
*Dental Implantation, Endosseous | 2 | 100.0 |
Aminophylline/adverse effects/therapeutic use | 2 | 100.0 |
Bronchodilator Agents/*therapeutic use | 3 | 33.0 |
Bronchospirometry | 2 | 100.0 |
Calcitonin/adverse effects/*therapeutic use | 2 | 100.0 |
HIV Infections/immunology/*pathology | 10 | 90.0 |
Epstein-Barr Virus Infections/complications/immunology/*pathology | 2 | 100.0 |
Lymphoma/complications/immunology/*pathology | 2 | 50.0 |
Lymphoproliferative Disorders/complications/immunology/*pathology | 2 | 100.0 |
B-Lymphocytes/immunology/*pathology | 5 | 19.0 |
Mutation/*physiology | 3 | 2.0 |
Osteoarthritis/genetics/immunology/*pathology | 2 | 100.0 |
Synovitis/genetics/immunology/*pathology | 2 | 100.0 |
Administration, Intravaginal | 2 | 10.0 |
Antimetabolites, Antineoplastic/administration & dosage/*therapeutic use | 3 | 75.0 |
Cervical Intraepithelial Neoplasia/complications/*drug therapy/immunology | 2 | 100.0 |
Cervix Dysplasia/complications/*drug therapy/immunology | 2 | 100.0 |
Cervix Neoplasms/complications/*drug therapy/immunology | 2 | 100.0 |
Fluorouracil/administration & dosage/*therapeutic use | 2 | 33.0 |
Neoplasm Recurrence, Local/prevention & control | 4 | 33.0 |
Denmark | 12 | 7.0 |
HIV Infections/*drug therapy/etiology/immunology | 3 | 100.0 |
HIV Protease Inhibitors/pharmacokinetics/*therapeutic use | 4 | 100.0 |
Saquinavir/pharmacokinetics/*therapeutic use | 3 | 100.0 |
Diarrhea/complications | 7 | 70.0 |
HIV Wasting Syndrome/*complications | 2 | 100.0 |
Inflammation/*complications | 2 | 16.0 |
Nutrition Disorders/*complications | 3 | 42.0 |
Calcineurin/metabolism | 3 | 12.0 |
Calmodulin/metabolism | 3 | 6.0 |
Luciferases/metabolism | 7 | 1.0 |
Vanadium Compounds/*antagonists & inhibitors | 2 | 100.0 |
Calcium Channel Agonists/pharmacology | 2 | 9.0 |
Dimethyl Sulfoxide/pharmacology | 4 | 4.0 |
HL-60 Cells/drug effects/metabolism | 2 | 22.0 |
Thapsigargin/pharmacology | 3 | 2.0 |
src Homology Domains/genetics/*physiology | 2 | 15.0 |
Corneal Transplantation/*immunology | 3 | 25.0 |
HLA-DP Antigens/analysis | 6 | 42.0 |
Lymphatic System/cytology/*immunology | 2 | 100.0 |
Succinimides | 2 | 11.0 |
T-Lymphocytes, Cytotoxic/cytology/immunology | 5 | 45.0 |
Tissue Distribution/immunology | 2 | 66.0 |
Thymoma/diagnosis/*immunology/therapy | 2 | 100.0 |
Thymus Neoplasms/diagnosis/*immunology/therapy | 2 | 100.0 |
Colombia/epidemiology | 3 | 27.0 |
Mycobacterium Infections/complications/*epidemiology | 2 | 100.0 |
Tuberculosis, Pulmonary/*epidemiology/microbiology | 3 | 100.0 |
Acquired Immunodeficiency Syndrome/blood/*drug therapy/enzymology | 2 | 100.0 |
Arachidonate 5-Lipoxygenase/*blood | 2 | 100.0 |
Epidermis/*cytology | 3 | 10.0 |
Psoriasis/blood/*pathology | 2 | 100.0 |
T-Lymphocytes/drug effects/immunology/*metabolism | 7 | 30.0 |
T-Lymphocytes, Cytotoxic/*metabolism | 4 | 19.0 |
Th1 Cells/cytology/*metabolism | 2 | 100.0 |
HIV Seropositivity/*complications/pathology | 3 | 100.0 |
Herpesviridae/genetics | 2 | 50.0 |
Herpesviridae Infections/*complications/virology | 2 | 100.0 |
Keratoconjunctivitis Sicca/pathology/*virology | 2 | 100.0 |
Atrophy/pathology/radiography | 2 | 100.0 |
Bipolar Disorder/diagnosis/*etiology/*prevention & control | 2 | 100.0 |
Brain/pathology/radiography | 4 | 36.0 |
HIV Seropositivity/*drug therapy/*psychology | 2 | 100.0 |
Acquired Immunodeficiency Syndrome/drug therapy/*pathology | 2 | 66.0 |
HIV Infections/*complications/*drug therapy/virology | 2 | 100.0 |
Hemophilia A/*complications/virology | 3 | 100.0 |
Hemophilia A/*complications/epidemiology | 2 | 100.0 |
Helix-Loop-Helix Motifs | 2 | 0.0 |
*Repressor Proteins | 3 | 0.0 |
Transcription Factors/genetics/*physiology | 2 | 1.0 |
Transcription Factors/*genetics | 2 | 0.0 |
Ventricular Function, Left | 3 | 9.0 |
Genetic Vectors/*genetics | 9 | 12.0 |
Hela Cells/virology | 2 | 20.0 |
Membrane Fusion/genetics | 2 | 50.0 |
Geography | 2 | 3.0 |
HIV Infections/drug therapy/*mortality | 5 | 100.0 |
Mass Screening/standards | 2 | 100.0 |
*Medical Audit | 2 | 22.0 |
Macrophage Inflammatory Protein-1/metabolism | 16 | 28.0 |
Receptors, Cytokine/genetics/metabolism | 3 | 25.0 |
Arthritis, Rheumatoid/genetics/*immunology | 3 | 8.0 |
Autoantibodies/analysis | 17 | 9.0 |
Diabetes Mellitus, Type 1/genetics/*immunology | 7 | 15.0 |
Gene Rearrangement, beta-Chain T-Cell Antigen Receptor/*genetics | 5 | 55.0 |
Protein p53/analysis | 4 | 1.0 |
Proto-Oncogene Proteins c-bcl-2/analysis | 3 | 1.0 |
DNA Replication/drug effects | 10 | 5.0 |
DNA, Viral/drug effects | 3 | 60.0 |
Epitopes/chemistry/metabolism | 2 | 20.0 |
Cell Lineage/genetics/immunology | 4 | 30.0 |
Immunoglobulin G/genetics | 2 | 5.0 |
Oligopeptides/metabolism | 3 | 5.0 |
Recombinant Fusion Proteins/chemistry/genetics/metabolism | 2 | 1.0 |
HIV-1/*genetics/metabolism | 3 | 11.0 |
*Protein Engineering | 2 | 9.0 |
Apoptosis/*drug effects/*immunology | 2 | 25.0 |
CD4-Positive T-Lymphocytes/cytology/*drug effects/*immunology | 2 | 100.0 |
Etoposide/pharmacology | 2 | 1.0 |
Nucleic Acid Synthesis Inhibitors/pharmacology | 3 | 2.0 |
Anemia/etiology | 4 | 12.0 |
HIV Infections/*blood/*complications | 3 | 50.0 |
Leukopenia/etiology | 3 | 37.0 |
Thrombocytopenia/etiology | 4 | 14.0 |
Arthritis, Rheumatoid/immunology/*pathology | 4 | 40.0 |
Synovial Membrane/immunology/*pathology | 2 | 40.0 |
Carcinoma, Squamous Cell/*immunology/pathology | 4 | 28.0 |
Head and Neck Neoplasms/*immunology/pathology | 2 | 40.0 |
Plastics | 4 | 12.0 |
Acquired Immunodeficiency Syndrome/epidemiology/*transmission | 3 | 75.0 |
HIV-1/growth & development | 9 | 64.0 |
Retroviridae Infections/transmission | 2 | 100.0 |
Leukocytes, Mononuclear/*drug effects | 2 | 11.0 |
Intercellular Adhesion Molecule-1/immunology/*physiology | 2 | 66.0 |
T-Lymphocytes, Cytotoxic/physiology | 12 | 66.0 |
T-Lymphocytes, Suppressor-Effector/drug effects/*immunology | 3 | 75.0 |
Antineoplastic Agents/*adverse effects | 6 | 11.0 |
Opportunistic Infections/immunology/prevention & control | 2 | 100.0 |
HIV-1/genetics/*pathogenicity/*physiology | 2 | 33.0 |
Dendritic Cells/*virology | 6 | 42.0 |
Genes, gag/genetics | 3 | 50.0 |
HIV Infections/*immunology/physiopathology/virology | 4 | 80.0 |
AIDS Vaccines/*administration & dosage/*immunology | 2 | 100.0 |
Peptides/chemical synthesis/*immunology | 5 | 33.0 |
Viral Envelope Proteins/chemistry | 2 | 66.0 |
Cytokines/therapeutic use | 4 | 28.0 |
Receptors, IgE/immunology | 2 | 14.0 |
T-Lymphocytes/*immunology/virology | 9 | 50.0 |
Leprosy, Lepromatous/*immunology | 2 | 22.0 |
Leprosy, Tuberculoid/*immunology | 3 | 50.0 |
Histocompatibility Antigens Class II/*immunology/metabolism | 2 | 50.0 |
Receptor-CD3 Complex, Antigen, T-Cell/immunology/*metabolism | 2 | 66.0 |
Calcium | 2 | 7.0 |
RNA, Messenger/immunology | 3 | 42.0 |
Receptors, Chemokine/genetics/*immunology | 3 | 30.0 |
Receptors, Lymphocyte Homing/immunology | 5 | 35.0 |
Blood | 3 | 1.0 |
Granulocyte-Macrophage Colony-Stimulating Factor | 6 | 7.0 |
Interleukin-4 | 9 | 10.0 |
CD4-Positive T-Lymphocytes/metabolism/*pathology | 3 | 100.0 |
HIV Infections/drug therapy/immunology/*metabolism | 3 | 75.0 |
T-Lymphocytes/*drug effects/immunology/metabolism | 5 | 35.0 |
Lymphokines/*biosynthesis | 9 | 3.0 |
Skin/chemistry/pathology | 2 | 8.0 |
Interferon Type II/biosynthesis/genetics | 5 | 13.0 |
Lymphocyte Transfusion | 6 | 21.0 |
Recombinant Proteins/administration & dosage/therapeutic use | 5 | 13.0 |
Methods | 4 | 1.0 |
Lymphoma, AIDS-Related/*pathology | 3 | 100.0 |
*Drug Resistance, Microbial | 4 | 36.0 |
Gastrointestinal Diseases/chemically induced | 2 | 18.0 |
HIV/*drug effects/genetics/physiology | 3 | 60.0 |
Peripheral Nervous System Diseases/chemically induced | 11 | 64.0 |
NAD+ Nucleosidase/immunology | 2 | 25.0 |
Acquired Immunodeficiency Syndrome/psychology | 2 | 100.0 |
HIV Infections/physiopathology/*psychology | 2 | 100.0 |
T-Lymphocytes, Helper-Inducer/*pathology | 6 | 85.0 |
T-Lymphocytes, Suppressor-Effector/*pathology | 5 | 83.0 |
Antigens, CD/classification/immunology | 2 | 100.0 |
Lymphoid Tissue/cytology | 2 | 9.0 |
Swine, Miniature | 6 | 16.0 |
T-Lymphocyte Subsets/*classification/immunology | 4 | 80.0 |
AIDS-Related Opportunistic Infections/*parasitology | 3 | 75.0 |
Diarrhea/*parasitology | 5 | 100.0 |
*Microsporida | 4 | 100.0 |
Microsporidiosis/*parasitology | 3 | 75.0 |
Disease Notification/statistics & numerical data | 2 | 100.0 |
Bacterial Vaccines/*immunology/therapeutic use | 2 | 100.0 |
*Immunization | 9 | 20.0 |
*Immunotherapy, Active | 9 | 36.0 |
Peptide Fragments/chemical synthesis/*immunology | 2 | 25.0 |
*Pertussis Toxin | 4 | 13.0 |
Virulence Factors, Bordetella/*immunology | 2 | 100.0 |
Cerebrospinal Fluid/*cytology | 4 | 57.0 |
*Immunohistochemistry | 6 | 7.0 |
Inflammation/metabolism/pathology | 2 | 8.0 |
Sequence Analysis | 11 | 2.0 |
Forced Expiratory Volume/physiology | 3 | 8.0 |
Bronchoalveolar Lavage Fluid/chemistry/cytology | 2 | 5.0 |
Phagocytosis/immunology | 5 | 7.0 |
*Radiation Tolerance | 3 | 5.0 |
L-Selectin/immunology | 2 | 25.0 |
Receptors, Cytokine/*immunology | 3 | 33.0 |
Recombinant Fusion Proteins/immunology | 10 | 9.0 |
AIDS Serodiagnosis/*methods | 5 | 100.0 |
HIV-1/immunology/isolation & purification | 2 | 100.0 |
HIV-2/immunology/isolation & purification | 2 | 100.0 |
Intestinal Mucosa/immunology/pathology | 4 | 21.0 |
HIV Infections/genetics/*immunology | 7 | 58.0 |
Lymphoma, T-Cell/genetics/*pathology | 4 | 57.0 |
Trisomy | 6 | 5.0 |
Herpesviridae Infections/*immunology/virology | 2 | 100.0 |
Antibodies, Fungal/*blood | 2 | 40.0 |
Immunoglobulin Isotypes/*blood | 2 | 25.0 |
Dengue/immunology | 2 | 100.0 |
Virion/immunology | 8 | 47.0 |
Leukocytes, Mononuclear/immunology/virology | 4 | 36.0 |
Tacrolimus/*therapeutic use | 3 | 23.0 |
Th2 Cells/*metabolism | 3 | 12.0 |
Mortality/trends | 3 | 60.0 |
HIV-1/genetics/*growth & development/immunology | 7 | 100.0 |
Viremia/immunology | 15 | 75.0 |
Complement/*immunology | 7 | 4.0 |
Arthritis, Rheumatoid/*drug therapy/immunology | 3 | 15.0 |
*Kidney Neoplasms | 2 | 28.0 |
Glucose/metabolism | 4 | 1.0 |
HIV/genetics/isolation & purification | 7 | 77.0 |
Leucine/*metabolism | 3 | 15.0 |
Liver/metabolism | 3 | 0.0 |
AIDS Dementia Complex/diagnosis | 2 | 100.0 |
Adipose Tissue/pathology | 5 | 16.0 |
Zidovudine/*adverse effects | 4 | 57.0 |
Freund's Adjuvant/administration & dosage | 2 | 100.0 |
HIV-1/genetics/immunology/*isolation & purification | 5 | 100.0 |
*Military Personnel | 10 | 34.0 |
Luminescent Proteins | 2 | 3.0 |
Seminal Vesicles/*chemistry | 2 | 100.0 |
T-Lymphocytes/cytology/immunology/*metabolism | 3 | 23.0 |
Thymus Gland/cytology/immunology/*metabolism | 2 | 40.0 |
*Homeodomain Proteins | 12 | 4.0 |
Transformation, Genetic | 4 | 2.0 |
Cell Adhesion/*immunology | 7 | 35.0 |
Antibiotics, Antineoplastic/adverse effects/*therapeutic use | 3 | 37.0 |
Pentostatin/adverse effects/*therapeutic use | 3 | 100.0 |
HIV Envelope Protein gp120/*metabolism/pharmacology | 3 | 100.0 |
T-Lymphocytes/enzymology | 4 | 10.0 |
Transfection/*methods | 3 | 5.0 |
beta-Galactosidase/genetics | 4 | 3.0 |
Blood Platelets/immunology | 4 | 5.0 |
Epitopes/*genetics | 2 | 6.0 |
Swine, Miniature/*genetics/*immunology | 2 | 50.0 |
Adjuvants, Immunologic/adverse effects/*therapeutic use | 4 | 50.0 |
Lentinan/adverse effects/*therapeutic use | 2 | 100.0 |
AIDS-Related Opportunistic Infections/complications/*drug therapy | 4 | 100.0 |
Receptors, Interleukin-2/*analysis | 21 | 30.0 |
T-Lymphocyte Subsets/*physiology | 9 | 31.0 |
Acquired Immunodeficiency Syndrome/*complications/diagnosis | 3 | 60.0 |
HIV Seropositivity/pathology | 6 | 75.0 |
Plasma Cells/pathology | 9 | 23.0 |
Tryptophan Oxygenase/metabolism | 3 | 60.0 |
Acquired Immunodeficiency Syndrome/complications/immunology | 9 | 100.0 |
Brain/*immunology | 9 | 37.0 |
Substance Abuse, Intravenous/*immunology | 4 | 100.0 |
*Activities of Daily Living | 6 | 46.0 |
HIV Infections/diagnosis/drug therapy/*epidemiology | 2 | 100.0 |
Histocytochemistry | 16 | 2.0 |
Blood Transfusion/*adverse effects | 19 | 30.0 |
*Mannose-Binding Lectins | 3 | 6.0 |
Receptors, Fc/genetics/*immunology | 2 | 50.0 |
HIV Protease/metabolism | 3 | 30.0 |
Nitric Oxide/*physiology | 2 | 2.0 |
HLA-B Antigens/immunology | 4 | 6.0 |
Hematologic Neoplasms/mortality/*therapy | 2 | 66.0 |
Pregnancy Trimester, Second | 5 | 2.0 |
Infection/*epidemiology | 2 | 100.0 |
Interview, Psychological | 2 | 28.0 |
Antigens, CD44/*analysis | 3 | 2.0 |
Arthritis, Rheumatoid/drug therapy/*immunology/pathology | 2 | 50.0 |
Lymphoma, AIDS-Related/mortality/*therapy | 2 | 100.0 |
Lymphopenia/*diagnosis | 2 | 100.0 |
Herpesviridae Infections/complications | 4 | 57.0 |
Bronchitis/immunology/pathology/*physiopathology | 2 | 100.0 |
Inositol/metabolism | 2 | 8.0 |
Primates/*genetics | 2 | 4.0 |
Antigens, CD/biosynthesis/immunology | 3 | 10.0 |
Stromal Cells/cytology/immunology | 3 | 50.0 |
Antigens, CD44/analysis | 3 | 4.0 |
*Receptors, Chemokine | 13 | 13.0 |
Inositol 1,4,5-Trisphosphate/metabolism | 4 | 7.0 |
Gene Products, gag/genetics/*metabolism | 3 | 30.0 |
Receptors, CXCR4/*immunology | 6 | 37.0 |
Immunoglobulin E/analysis | 9 | 16.0 |
Antibodies, Antineutrophil Cytoplasmic | 2 | 4.0 |
Antigen-Antibody Complex | 14 | 7.0 |
Acquired Immunodeficiency Syndrome/complications/*drug therapy | 5 | 71.0 |
Lymphoproliferative Disorders/*etiology | 2 | 100.0 |
T-Lymphocytes, Cytotoxic/immunology/pathology | 5 | 71.0 |
Interferon Inducers/*therapeutic use | 4 | 57.0 |
Keratinocytes/pathology | 3 | 12.0 |
CD4-Positive T-Lymphocytes/cytology/*virology | 7 | 77.0 |
HIV Infections/*immunology/*mortality | 4 | 100.0 |
Survivors | 31 | 37.0 |
Interleukin-10/blood | 7 | 8.0 |
Acquired Immunodeficiency Syndrome/*physiopathology | 8 | 57.0 |
Mass Screening/methods | 2 | 4.0 |
Sulfonamides/administration & dosage | 2 | 50.0 |
Polyethylene Glycols/*pharmacology | 3 | 11.0 |
CD8-Positive T-Lymphocytes/immunology/*physiology | 2 | 50.0 |
T-Lymphocyte Subsets/immunology/*physiology | 9 | 69.0 |
CD4-Positive T-Lymphocytes/immunology/*metabolism/virology | 2 | 50.0 |
Cell Movement/drug effects/*immunology | 2 | 14.0 |
Gamma Rays | 5 | 2.0 |
Lymphocyte Activation/*genetics | 6 | 24.0 |
T-Lymphocytes/cytology/*physiology | 4 | 25.0 |
Antigens, CD4/*metabolism/physiology | 4 | 100.0 |
Antigens, CD8/genetics | 8 | 53.0 |
Chimeric Proteins/biosynthesis/metabolism | 2 | 10.0 |
Gene Products, nef/genetics/*immunology | 2 | 40.0 |
Macaca | 23 | 26.0 |
Tyrosine/genetics/*metabolism | 2 | 8.0 |
T-Lymphocytes/physiology/virology | 2 | 50.0 |
AIDS-Related Opportunistic Infections/epidemiology/*etiology | 2 | 100.0 |
Catheterization, Central Venous/*adverse effects | 2 | 20.0 |
Leukocytes, Mononuclear/drug effects | 4 | 10.0 |
Lymphoma, T-Cell, Cutaneous/drug therapy/*pathology | 2 | 100.0 |
PUVA Therapy/methods | 2 | 100.0 |
Skin Neoplasms/drug therapy/*pathology | 2 | 33.0 |
Skin/*drug effects/pathology | 3 | 50.0 |
Vascular Cell Adhesion Molecule-1/biosynthesis | 2 | 5.0 |
Cell Line/immunology | 4 | 50.0 |
Nickel/*immunology | 3 | 42.0 |
Biological Response Modifiers/*pharmacology | 2 | 10.0 |
Uveitis/*immunology | 5 | 35.0 |
Plaque Assay | 6 | 8.0 |
Nitric-Oxide Synthase/*metabolism | 2 | 2.0 |
Peptide Fragments/genetics/*metabolism | 2 | 7.0 |
Hepacivirus/*metabolism | 2 | 14.0 |
Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase | 5 | 16.0 |
*Protein Sorting Signals | 2 | 7.0 |
E-Selectin/*blood | 2 | 7.0 |
Pre-Eclampsia/*blood | 2 | 4.0 |
*Prenatal Diagnosis | 2 | 0.0 |
*Biopsy, Needle | 2 | 5.0 |
Cytomegalovirus/isolation & purification/physiology | 2 | 100.0 |
RNA, Viral/blood/*cerebrospinal fluid | 2 | 66.0 |
HIV Protease Inhibitors/blood/*therapeutic use | 3 | 75.0 |
Recombinant Proteins/immunology/therapeutic use | 2 | 20.0 |
Tuberculin/*immunology | 5 | 29.0 |
Pentamidine/therapeutic use | 11 | 91.0 |
Pyrimethamine/therapeutic use | 5 | 38.0 |
Sulfadiazine/therapeutic use | 5 | 83.0 |
B-Lymphocyte Subsets/immunology | 12 | 32.0 |
*Adaptor Proteins, Signal Transducing | 5 | 0.0 |
*Adaptor Proteins, Vesicular Transport | 2 | 0.0 |
Monocytes/drug effects/*immunology | 5 | 7.0 |
Antigen-Presenting Cells/immunology/pathology | 2 | 50.0 |
Dendritic Cells/*immunology/*pathology | 3 | 60.0 |
Isoantigens | 5 | 18.0 |
Antigens, CD18/*metabolism | 2 | 10.0 |
Candidiasis, Oral/epidemiology | 4 | 100.0 |
Mycobacterium avium-intracellulare Infection/epidemiology | 3 | 100.0 |
Outpatient Clinics, Hospital/statistics & numerical data | 3 | 75.0 |
Receptors, HIV/*analysis | 4 | 80.0 |
Spermatozoa/virology | 2 | 100.0 |
Chemokines/physiology | 6 | 23.0 |
Inflammation Mediators/immunology | 3 | 33.0 |
Proto-Oncogene Proteins c-bcl-2/*genetics | 2 | 2.0 |
Interferon Inducers/*pharmacology | 4 | 22.0 |
Interleukin-4/*pharmacology | 11 | 4.0 |
Immune System/*drug effects/physiology | 2 | 100.0 |
Immunoglobulins/blood/drug effects | 2 | 100.0 |
Acquired Immunodeficiency Syndrome/*diagnosis/immunology | 5 | 55.0 |
California | 4 | 8.0 |
*Heterosexuality | 5 | 71.0 |
Amino Acids/genetics | 2 | 6.0 |
Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor | 2 | 25.0 |
Gene Rearrangement, beta-Chain T-Cell Antigen Receptor/genetics | 2 | 28.0 |
Receptors, Antigen, T-Cell, alpha-beta/genetics/*metabolism | 3 | 37.0 |
HIV Protease Inhibitors/adverse effects/pharmacokinetics/*therapeutic use | 6 | 100.0 |
*HIV-1/drug effects/isolation & purification | 3 | 75.0 |
Nelfinavir/adverse effects/pharmacokinetics/*therapeutic use | 2 | 100.0 |
Antibiotics, Antifungal/*therapeutic use | 3 | 60.0 |
Candida albicans/drug effects/isolation & purification | 3 | 100.0 |
Fluconazole/*therapeutic use | 8 | 88.0 |
Interferon-alpha/metabolism | 2 | 9.0 |
Interferon-beta/metabolism | 2 | 10.0 |
AIDS-Related Opportunistic Infections/mortality/*prevention & control | 3 | 75.0 |
Blood/microbiology | 2 | 33.0 |
Fasting | 3 | 0.0 |
Insulin/*blood | 2 | 1.0 |
HIV/genetics/physiology | 2 | 66.0 |
HIV Infections/*drug therapy/*metabolism/virology | 3 | 100.0 |
Peptide Fragments/*genetics | 7 | 16.0 |
Cervical Intraepithelial Neoplasia/*epidemiology/virology | 2 | 100.0 |
Cervix Neoplasms/*epidemiology/virology | 2 | 100.0 |
Rwanda/epidemiology | 3 | 75.0 |
Receptors, CCR5/genetics/physiology | 3 | 42.0 |
Receptors, CXCR4/genetics/physiology | 3 | 50.0 |
HIV Infections/*complications/immunology/mortality | 5 | 100.0 |
Gene Products, nef/immunology | 3 | 60.0 |
Gene Products, pol/immunology | 4 | 40.0 |
Membrane Glycoproteins/*immunology | 14 | 7.0 |
Adenoids/*pathology | 2 | 100.0 |
HIV Infections/immunology/*metabolism | 5 | 71.0 |
Antigens, CD57/immunology | 3 | 37.0 |
Antibodies, Monoclonal/administration & dosage/*immunology | 2 | 33.0 |
Macaca fascicularis/*immunology | 4 | 50.0 |
Pan troglodytes/*immunology | 2 | 33.0 |
Primates | 6 | 8.0 |
Acquired Immunodeficiency Syndrome/blood/immunology | 6 | 66.0 |
Acquired Immunodeficiency Syndrome/immunology/metabolism | 2 | 66.0 |
Membrane Glycoproteins/antagonists & inhibitors/*biosynthesis | 2 | 66.0 |
Staphylococcus aureus/immunology | 10 | 9.0 |
Binding Sites/immunology | 3 | 5.0 |
Patch Tests | 3 | 9.0 |
T-Lymphocyte Subsets/drug effects/*immunology/metabolism | 5 | 71.0 |
Up-Regulation/drug effects/immunology | 5 | 13.0 |
B-Lymphocyte Subsets/immunology/pathology | 3 | 75.0 |
Immunoglobulin M/analysis | 17 | 7.0 |
Neural Conduction | 5 | 5.0 |
Antigens, CD28/blood | 4 | 50.0 |
Membrane Glycoproteins/blood | 3 | 10.0 |
Multiple Sclerosis/diagnosis/*immunology | 4 | 66.0 |
Gene Products, env/chemistry/*genetics/metabolism | 3 | 75.0 |
Candida/*isolation & purification | 2 | 100.0 |
HIV Infections/microbiology | 5 | 50.0 |
Amino Acid Substitution/genetics/immunology | 2 | 10.0 |
Oligopeptides/physiology | 2 | 18.0 |
Recombinant Proteins/genetics/pharmacology | 3 | 10.0 |
HIV-1/isolation & purification/*metabolism/physiology | 2 | 33.0 |
SIV/isolation & purification/*metabolism/physiology | 2 | 100.0 |
Mink | 3 | 4.0 |
Protein Hybridization | 4 | 6.0 |
Acquired Immunodeficiency Syndrome/genetics/*immunology | 2 | 100.0 |
Leukocytes/virology | 3 | 60.0 |
HIV-2/genetics/isolation & purification/*pathogenicity | 2 | 100.0 |
Lymphocytes/virology | 6 | 30.0 |
Acquired Immunodeficiency Syndrome/*drug therapy/immunology/mortality | 10 | 100.0 |
Antigens, CD3/*genetics | 4 | 40.0 |
Polymerase Chain Reaction/veterinary | 2 | 5.0 |
Acquired Immunodeficiency Syndrome/*complications/physiopathology | 2 | 66.0 |
Haemophilus influenzae/*immunology | 7 | 30.0 |
HIV Seropositivity/epidemiology/*immunology | 4 | 100.0 |
Cephalosporins/therapeutic use | 2 | 33.0 |
Penicillins/therapeutic use | 3 | 23.0 |
T-Lymphocytes/metabolism/*pathology | 4 | 28.0 |
B-Lymphocytes/immunology/pathology | 16 | 36.0 |
Cytogenetics | 4 | 4.0 |
*Gene Rearrangement, delta-Chain T-Cell Antigen Receptor | 2 | 33.0 |
Lymphoma/*genetics/*immunology/pathology | 2 | 100.0 |
Interleukin-2/*genetics | 6 | 9.0 |
Melanoma/immunology/*therapy | 2 | 20.0 |
Skin Neoplasms/immunology/therapy | 2 | 66.0 |
Autoimmune Diseases/immunology/*metabolism | 2 | 40.0 |
Antigens, CD30/*analysis | 6 | 30.0 |
Sezary Syndrome/*diagnosis/pathology | 2 | 100.0 |
Rats, Inbred F344 | 6 | 1.0 |
Receptors, Transferrin/*metabolism | 2 | 8.0 |
Lymphocytes, Tumor-Infiltrating/*chemistry | 2 | 100.0 |
T-Lymphocytes/chemistry/immunology | 3 | 21.0 |
Prednisolone/pharmacology | 3 | 15.0 |
Coated Pits, Cell-Membrane/*metabolism | 5 | 35.0 |
Fluorescent Dyes/pharmacokinetics | 2 | 22.0 |
*Lung Transplantation | 3 | 11.0 |
T-Lymphocyte Subsets/drug effects/metabolism | 2 | 40.0 |
HIV Seropositivity/*epidemiology | 10 | 76.0 |
Abdomen/*surgery | 3 | 27.0 |
Enteral Nutrition/*methods | 2 | 33.0 |
Postoperative Care | 4 | 5.0 |
Leukemia-Lymphoma, T-Cell, Acute, HTLV-I-Associated/*immunology | 5 | 62.0 |
Taiwan | 4 | 2.0 |
Adenine/*analogs & derivatives/*therapeutic use | 2 | 100.0 |
HIV-1/drug effects/genetics | 5 | 71.0 |
Carcinoma, Renal Cell/*immunology/pathology | 6 | 60.0 |
Immunoglobulins/*immunology | 5 | 17.0 |
Kidney Neoplasms/*immunology/pathology | 5 | 41.0 |
Membrane Proteins/*immunology | 7 | 11.0 |
Cell Adhesion Molecules | 7 | 13.0 |
Endothelium, Vascular/pathology | 7 | 6.0 |
DNA/immunology | 5 | 10.0 |
Transplantation Conditioning/*methods | 3 | 17.0 |
Iron/blood | 2 | 2.0 |
Proteins/analysis | 7 | 4.0 |
Immunoglobulin G/blood/cerebrospinal fluid | 3 | 60.0 |
Calcimycin/*pharmacology | 4 | 13.0 |
Interferon-alpha/*pharmacology | 5 | 3.0 |
*Aged | 2 | 4.0 |
HIV Infections/diagnosis/*drug therapy/mortality | 5 | 100.0 |
Arizona/epidemiology | 2 | 16.0 |
Retina/pathology | 4 | 11.0 |
Autoimmune Diseases/pathology | 4 | 66.0 |
Folliculitis/drug therapy/immunology/*pathology | 2 | 100.0 |
Leukoplakia, Hairy/*epidemiology | 2 | 100.0 |
Mouth/pathology | 2 | 50.0 |
Cytokines/genetics | 11 | 10.0 |
Electrophoresis, Gel, Two-Dimensional | 11 | 3.0 |
Lymphocyte Subsets/immunology/*physiology | 3 | 100.0 |
Leukemia, B-Cell, Chronic/*genetics/immunology/pathology | 2 | 28.0 |
Acquired Immunodeficiency Syndrome/*therapy | 9 | 60.0 |
Acyclovir/administration & dosage/*therapeutic use | 3 | 60.0 |
HIV Seropositivity/complications/*epidemiology | 2 | 66.0 |
Depression/complications | 4 | 66.0 |
Pneumonia, Pneumocystis/complications | 11 | 84.0 |
Acquired Immunodeficiency Syndrome/*metabolism | 8 | 57.0 |
Intestinal Absorption | 4 | 2.0 |
Lymphocytes/*metabolism/physiology | 3 | 100.0 |
Epitopes, B-Lymphocyte/immunology | 2 | 12.0 |
HIV Envelope Protein gp160/*immunology | 4 | 66.0 |
Brain/*metabolism | 6 | 1.0 |
T-Lymphocytes/*drug effects/immunology/physiology | 2 | 66.0 |
Antigens, Surface/*immunology | 31 | 19.0 |
Recombinant Proteins/administration & dosage/immunology | 5 | 83.0 |
T-Lymphocytes/cytology/*immunology/*metabolism | 3 | 25.0 |
Acquired Immunodeficiency Syndrome/complications/*drug therapy/immunology | 5 | 83.0 |
Sarcoma, Kaposi/complications/*drug therapy/immunology | 2 | 100.0 |
Herpesvirus 6, Human/*immunology | 3 | 50.0 |
Immunoglobulin G/*analysis | 2 | 2.0 |
Ceramides/biosynthesis | 2 | 18.0 |
Lymphocytes/cytology | 13 | 15.0 |
Serum Albumin/analysis | 11 | 6.0 |
Restriction Mapping | 28 | 1.0 |
Telomere/*genetics | 2 | 5.0 |
Antigens, CD4/chemistry/metabolism/*pharmacology | 2 | 100.0 |
Binding Sites, Antibody/genetics | 2 | 15.0 |
HIV Envelope Protein gp120/genetics/immunology/*metabolism | 6 | 100.0 |
HIV Seropositivity/complications/immunology/physiopathology | 2 | 100.0 |
Mathematical Computing | 4 | 17.0 |
Antibodies, Antinuclear/blood | 4 | 8.0 |
Antigens, Differentiation/analysis/immunology | 2 | 22.0 |
Cytokines/*biosynthesis/immunology | 2 | 15.0 |
HLA-DR Antigens/analysis/immunology | 6 | 31.0 |
NAD+ Nucleosidase/analysis/immunology | 2 | 100.0 |
Tritium/diagnostic use | 2 | 1.0 |
Antigen-Antibody Complex/*immunology | 5 | 6.0 |
*Reagent Kits, Diagnostic | 4 | 7.0 |
Antibodies, Viral/blood/*immunology | 2 | 33.0 |
Hematology | 2 | 40.0 |
Lymphocyte Subsets/*drug effects/immunology | 8 | 88.0 |
Galactosylceramides/*metabolism | 5 | 62.0 |
*Drug Resistance, Multiple | 3 | 2.0 |
*HIV Seropositivity/immunology | 3 | 100.0 |
*Substance Abuse, Intravenous/immunology | 2 | 100.0 |
Culture Media, Serum-Free | 11 | 2.0 |
Hybridomas/*physiology | 2 | 100.0 |
Leukemia, Lymphocytic, Acute/*pathology | 2 | 10.0 |
Antigens, CD7/*biosynthesis | 2 | 40.0 |
HIV Antibodies/metabolism | 5 | 71.0 |
HIV Envelope Protein gp160/genetics/*metabolism | 6 | 100.0 |
Bone Marrow Cells/cytology | 2 | 2.0 |
Cysteine/physiology | 2 | 22.0 |
*Mutagenesis, Site-Directed | 7 | 7.0 |
Immunoglobulin M/immunology | 9 | 6.0 |
Viral Envelope Proteins/physiology | 5 | 50.0 |
Hematologic Neoplasms/*therapy | 4 | 14.0 |
Tumor Stem Cells/*pathology | 2 | 7.0 |
Gene Products, nef/metabolism | 5 | 41.0 |
Gene Products, vpu/metabolism | 2 | 66.0 |
Lysosomes/metabolism | 6 | 4.0 |
Semen/virology | 7 | 87.0 |
Acquired Immunodeficiency Syndrome/*drug therapy/*immunology | 7 | 87.0 |
Mycobacterium tuberculosis/isolation & purification | 7 | 31.0 |
Proviruses/*genetics | 9 | 47.0 |
Cytomegalovirus Retinitis/complications | 2 | 100.0 |
DNA, Viral/*metabolism | 2 | 6.0 |
*Gene Transfer Techniques | 14 | 3.0 |
Acquired Immunodeficiency Syndrome/mortality | 4 | 80.0 |
HIV Seronegativity/*physiology | 4 | 100.0 |
Cytotoxicity Tests, Immunologic/methods | 5 | 19.0 |
Infertility, Male | 2 | 22.0 |
Lymphocyte Subsets/chemistry/*immunology | 3 | 75.0 |
Microinjections | 2 | 0.0 |
Oncogene Proteins, Viral/*immunology | 2 | 20.0 |
T-Lymphocytes, Cytotoxic/*chemistry | 2 | 100.0 |
Dermatitis, Atopic/*drug therapy | 2 | 66.0 |
Transfer Factor/*therapeutic use | 3 | 8.0 |
*Gold | 2 | 28.0 |
*Mining | 3 | 50.0 |
Mycobacterium Infections, Atypical/*diagnosis/mortality | 2 | 100.0 |
Mycobacterium avium-intracellulare Infection/diagnosis/mortality | 2 | 100.0 |
Occupational Diseases/*diagnosis/mortality | 2 | 100.0 |
AIDS-Related Opportunistic Infections/*diagnosis/mortality | 2 | 100.0 |
Clone Cells/cytology/immunology | 2 | 33.0 |
Ambulatory Care/statistics & numerical data | 2 | 66.0 |
SIV/physiology | 7 | 58.0 |
Adenoviridae/*genetics/immunology | 2 | 18.0 |
Antibodies, Monoclonal/*administration & dosage/therapeutic use | 2 | 33.0 |
Gene Therapy/methods | 3 | 3.0 |
Cell Aggregation/immunology | 3 | 15.0 |
Receptors, CCR5/immunology/*metabolism | 2 | 50.0 |
Lymphocyte Specific Protein Tyrosine Kinase p56(lck)/*physiology | 5 | 50.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/metabolism | 5 | 1.0 |
HIV Infections/immunology/pathology | 4 | 66.0 |
HIV-1/*immunology/*pathogenicity | 5 | 55.0 |
Tropical Climate | 2 | 18.0 |
Carrier Proteins/biosynthesis | 2 | 3.0 |
Hematopoietic Stem Cells/*immunology/*virology | 2 | 66.0 |
*Myelin Proteins | 2 | 15.0 |
Serine/*physiology | 2 | 50.0 |
Proto-Oncogene Proteins/*biosynthesis | 3 | 1.0 |
Proto-Oncogene Proteins c-bcl-2/*biosynthesis | 2 | 1.0 |
HIV-1/*pathogenicity/*physiology | 2 | 50.0 |
Antigens, CD8/physiology | 8 | 61.0 |
HIV/*pathogenicity/*physiology | 2 | 100.0 |
Feces/microbiology/parasitology | 4 | 100.0 |
Acquired Immunodeficiency Syndrome/blood/*complications | 6 | 75.0 |
Blood Chemical Analysis | 3 | 6.0 |
Personality Tests | 2 | 10.0 |
Stress, Psychological/*immunology/*psychology | 2 | 100.0 |
Mycobacterium tuberculosis/drug effects/*isolation & purification | 2 | 50.0 |
GTP-Binding Proteins/metabolism | 5 | 1.0 |
Sweden | 8 | 3.0 |
Chemiluminescent Measurements | 6 | 3.0 |
Respiratory Burst | 6 | 9.0 |
Antibodies, Monoclonal/biosynthesis/*immunology | 5 | 21.0 |
DNA/*immunology | 3 | 7.0 |
HTLV-I Infections/complications | 3 | 75.0 |
Vietnam | 3 | 15.0 |
*Reference Values | 2 | 33.0 |
HIV Infections/*complications/immunology/transmission | 5 | 83.0 |
Cytarabine/therapeutic use | 2 | 5.0 |
Leukemia, Myeloid/drug therapy/metabolism/*pathology | 2 | 100.0 |
Methotrexate/therapeutic use | 2 | 3.0 |
HIV Infections/drug therapy/mortality | 2 | 100.0 |
*Longitudinal Studies | 4 | 100.0 |
*Patient Dropouts | 4 | 80.0 |
Macrophage Inflammatory Protein-1/genetics | 3 | 23.0 |
RANTES/genetics | 2 | 13.0 |
SIV/isolation & purification/*physiology | 2 | 66.0 |
Sepharose | 5 | 8.0 |
Nasal Mucosa/*pathology | 3 | 60.0 |
Lymphocyte Subsets/*pathology | 8 | 80.0 |
Immunoglobulins/*metabolism | 4 | 7.0 |
Papillomavirus, Human/classification/genetics/*isolation & purification | 3 | 37.0 |
Cell Cycle Proteins/analysis | 2 | 7.0 |
Electrophoresis, Capillary | 2 | 4.0 |
HIV-1/genetics/metabolism/*pathogenicity | 3 | 27.0 |
Synovial Membrane/*immunology | 5 | 14.0 |
Antigens, Surface/analysis/genetics | 2 | 33.0 |
Antigens, CD45/*analysis | 18 | 40.0 |
Bone Marrow/immunology | 12 | 9.0 |
RANTES/analogs & derivatives | 2 | 66.0 |
HIV Seropositivity/complications/*immunology | 10 | 90.0 |
Kidney Neoplasms | 2 | 11.0 |
*Tuberculin Test | 8 | 28.0 |
HIV-1/growth & development/*isolation & purification | 4 | 100.0 |
Genome, Viral | 19 | 14.0 |
Viral Proteins/analysis | 2 | 8.0 |
Culture Techniques/methods | 4 | 7.0 |
Hematopoietic Stem Cells/*cytology | 6 | 2.0 |
H-2 Antigens/immunology | 3 | 14.0 |
Mammary Tumor Virus, Mouse/*immunology | 2 | 50.0 |
HIV-1 Reverse Transcriptase/*immunology | 2 | 100.0 |
Antigens, Differentiation, T-Lymphocyte/genetics | 5 | 15.0 |
Receptors, Interleukin-2/genetics | 5 | 13.0 |
HIV-1/genetics/isolation & purification/*pathogenicity | 3 | 75.0 |
Receptors, HIV/genetics/*physiology | 2 | 25.0 |
Antigens, CD8/*genetics | 5 | 62.0 |
Gene Expression Regulation, Developmental | 3 | 0.0 |
HIV Envelope Protein gp120/genetics/*pharmacology | 2 | 100.0 |
Antigens, CD45/physiology | 7 | 46.0 |
Cytoskeleton/immunology/physiology | 2 | 100.0 |
Immunoglobulin Variable Region/metabolism | 2 | 40.0 |
Receptor-CD3 Complex, Antigen, T-Cell/physiology | 6 | 22.0 |
HIV-1/drug effects/physiology | 7 | 43.0 |
*Bisexuality | 8 | 100.0 |
Microsomes/immunology | 2 | 8.0 |
Mitochondria/immunology | 2 | 15.0 |
Muscle, Smooth/immunology | 2 | 20.0 |
Rheumatoid Factor/blood | 4 | 10.0 |
Thyroid Gland/immunology | 3 | 7.0 |
Biological Response Modifiers/*therapeutic use | 3 | 13.0 |
Skin Neoplasms/*therapy | 3 | 50.0 |
Antigens, Differentiation, Myelomonocytic/immunology | 3 | 6.0 |
Keratinocytes/immunology | 6 | 24.0 |
Interleukins/analysis | 4 | 12.0 |
Leukocytes/*physiology | 3 | 5.0 |
Mast Cells/*physiology | 2 | 12.0 |
Acquired Immunodeficiency Syndrome/*complications/drug therapy/immunology | 2 | 100.0 |
Herpesvirus 8, Human/isolation & purification | 2 | 40.0 |
Viremia/complications/drug therapy | 2 | 100.0 |
Body Fluids/*immunology | 3 | 75.0 |
*Clonal Anergy | 6 | 20.0 |
Antirheumatic Agents/*therapeutic use | 6 | 10.0 |
Methotrexate/*therapeutic use | 6 | 24.0 |
*Evolution | 4 | 2.0 |
HIV Long Terminal Repeat/genetics | 6 | 13.0 |
HIV-1/*classification/*genetics/isolation & purification | 2 | 33.0 |
Bronchiectasis/*complications/diagnosis | 2 | 100.0 |
Adenocarcinoma/immunology | 3 | 6.0 |
Biopsy, Needle/methods | 2 | 18.0 |
HIV/pathogenicity | 7 | 70.0 |
Antigens, CD8/*blood | 11 | 35.0 |
Receptors, Interleukin-2/*blood | 14 | 26.0 |
Least-Squares Analysis | 5 | 14.0 |
Acquired Immunodeficiency Syndrome/*prevention & control | 13 | 86.0 |
Antigen-Antibody Complex/metabolism | 3 | 5.0 |
Lymphopenia/*therapy | 2 | 100.0 |
Polyethylene Glycols | 11 | 12.0 |
Antigens, CD27/*analysis | 3 | 30.0 |
T-Lymphocytes/*chemistry/physiology | 2 | 66.0 |
Panniculitis/*pathology | 2 | 50.0 |
Formaldehyde | 5 | 5.0 |
Antibodies, Monoclonal/*immunology/pharmacology | 4 | 28.0 |
Antigens, CD4/*analysis/immunology | 8 | 88.0 |
CD8-Positive T-Lymphocytes/chemistry/cytology/immunology | 2 | 100.0 |
*Microspheres | 2 | 15.0 |
Arthritis, Rheumatoid/immunology | 7 | 7.0 |
*Tropism | 2 | 66.0 |
Wegener's Granulomatosis/*immunology | 2 | 18.0 |
Clathrin/metabolism | 3 | 6.0 |
Fibroblasts | 4 | 0.0 |
Nerve Tissue Proteins/*metabolism | 2 | 0.0 |
SIV/*metabolism | 15 | 62.0 |
CD8-Positive T-Lymphocytes/*drug effects/*immunology | 2 | 100.0 |
Dinoprostone/*pharmacology | 3 | 5.0 |
Leukocytes, Mononuclear/immunology/*pathology | 2 | 33.0 |
Synovial Fluid/*cytology/immunology | 2 | 25.0 |
T-Lymphocytes/chemistry/*immunology | 2 | 14.0 |
Antigen-Presenting Cells/physiology | 13 | 23.0 |
HLA Antigens/physiology | 2 | 20.0 |
Synovial Fluid/cytology | 6 | 24.0 |
Neoplasm Recurrence, Local/pathology | 3 | 5.0 |
HIV Infections/*complications/*immunology/virology | 5 | 100.0 |
Intercellular Adhesion Molecule-1/blood | 4 | 4.0 |
Isoniazid/therapeutic use | 7 | 87.0 |
Pyrazinamide/therapeutic use | 2 | 100.0 |
Rifampin/therapeutic use | 3 | 42.0 |
Tuberculosis/diagnosis/drug therapy/*etiology | 2 | 100.0 |
Glucocorticoids | 6 | 20.0 |
DNA Probes, HPV | 7 | 36.0 |
NF-kappa B/physiology | 2 | 2.0 |
Drug Hypersensitivity/*etiology | 3 | 37.0 |
Trimethoprim-Sulfamethoxazole Combination/*adverse effects | 3 | 50.0 |
Clindamycin/therapeutic use | 4 | 50.0 |
Clonal Anergy/immunology | 4 | 28.0 |
Interleukin-15/*pharmacology | 3 | 18.0 |
RNA, Messenger/*analysis | 13 | 3.0 |
Receptors, Tumor Necrosis Factor/*blood | 3 | 6.0 |
T-Lymphocyte Subsets/virology | 4 | 80.0 |
Amoxicillin/therapeutic use | 2 | 15.0 |
*Herpesvirus 4, Human | 4 | 11.0 |
Antigens, CD4/isolation & purification | 6 | 100.0 |
B-Lymphocytes/chemistry/pathology | 2 | 25.0 |
T-Lymphocytes/chemistry/pathology | 2 | 25.0 |
X Chromosome | 3 | 0.0 |
Macrophages/drug effects/*microbiology | 3 | 50.0 |
Neoplasms/*drug therapy/immunology | 4 | 40.0 |
Chloramphenicol O-Acetyltransferase/genetics | 6 | 2.0 |
Antibodies, Monoclonal/*immunology/therapeutic use | 3 | 27.0 |
Protein Binding/physiology | 5 | 1.0 |
Candidiasis, Oral/immunology/*prevention & control | 2 | 100.0 |
HIV Infections/*drug therapy/enzymology | 3 | 75.0 |
Selenium/*deficiency | 2 | 100.0 |
HIV Infections/*metabolism/physiopathology | 2 | 100.0 |
Kidney Neoplasms/*drug therapy/immunology | 2 | 28.0 |
Colonic Neoplasms/immunology | 2 | 9.0 |
Candida/*drug effects | 2 | 66.0 |
Candidiasis, Oral/*drug therapy | 2 | 40.0 |
HIV Seropositivity/*microbiology | 10 | 66.0 |
Antibody Formation/*drug effects/immunology | 2 | 100.0 |
Immunization/methods | 3 | 23.0 |
Indoles/*pharmacology | 3 | 3.0 |
HLA-B7 Antigen/*immunology | 2 | 50.0 |
Lymphokines | 2 | 18.0 |
Antigens, CD/*analysis/genetics | 6 | 25.0 |
Cladribine/therapeutic use | 2 | 33.0 |
Herpesviridae Infections/*complications | 4 | 57.0 |
Proviruses/metabolism | 2 | 66.0 |
Dendritic Cells/immunology/*metabolism | 3 | 17.0 |
Macrophages/immunology/*metabolism | 2 | 6.0 |
Mitomycin/administration & dosage | 3 | 7.0 |
Radiotherapy Dosage | 3 | 2.0 |
Lymphopenia/*complications/immunology | 3 | 100.0 |
Stomach/pathology | 2 | 9.0 |
Pneumonia, Bacterial/*complications | 2 | 66.0 |
Streptococcus pneumoniae/isolation & purification | 2 | 22.0 |
Primary Prevention | 3 | 25.0 |
Accidents, Traffic | 2 | 16.0 |
DNA-Binding Proteins/*genetics | 4 | 0.0 |
Surgical Procedures, Elective | 3 | 13.0 |
*Transplantation Chimera | 3 | 15.0 |
Hemophilia A/*immunology | 6 | 33.0 |
Hepatitis, Viral, Human/complications | 2 | 33.0 |
DNA, Recombinant/*genetics | 2 | 16.0 |
*Home Care Services | 2 | 66.0 |
Monitoring, Immunologic | 14 | 58.0 |
Recombinant Proteins/pharmacokinetics/therapeutic use | 3 | 30.0 |
Glycolipids/*metabolism | 3 | 10.0 |
Spermatozoa/metabolism/*virology | 2 | 66.0 |
Galactosylceramides/metabolism | 5 | 35.0 |
HIV-2/*metabolism | 8 | 57.0 |
Fertility | 2 | 7.0 |
Indinavir/administration & dosage/adverse effects | 2 | 100.0 |
Saquinavir/administration & dosage/adverse effects | 2 | 100.0 |
Leukemia, Lymphocytic, Acute/immunology | 2 | 18.0 |
Leukemia, Myelocytic, Acute/immunology | 2 | 15.0 |
Gene Dosage | 4 | 1.0 |
*Cell Transformation, Viral | 20 | 11.0 |
Lymphocyte Function-Associated Antigen-1/*physiology | 9 | 21.0 |
Lysosomes/*metabolism | 3 | 3.0 |
*RNA, Viral | 2 | 15.0 |
Antigens, CD/chemistry | 3 | 20.0 |
Carbohydrate Conformation | 6 | 4.0 |
Receptors, Immunologic/chemistry | 2 | 25.0 |
*Receptors, Lipoprotein | 3 | 2.0 |
Depression | 3 | 27.0 |
*Stress, Psychological | 3 | 20.0 |
Interferon-alpha/pharmacology | 3 | 3.0 |
Proto-Oncogene Proteins c-jun/metabolism | 2 | 1.0 |
Proto-Oncogene Proteins/biosynthesis/*physiology | 3 | 18.0 |
HIV-1/*immunology/*physiology | 2 | 33.0 |
Viremia/immunology/virology | 3 | 75.0 |
Antibodies, Bacterial/biosynthesis | 2 | 13.0 |
Haemophilus Vaccines/*administration & dosage | 2 | 100.0 |
*Eosinophilia | 2 | 66.0 |
Killer Cells/*immunology | 8 | 23.0 |
Antigens, CD4/*genetics/immunology | 13 | 100.0 |
*Genetic Predisposition to Disease | 3 | 0.0 |
Antifungal Agents/administration & dosage/*therapeutic use | 5 | 100.0 |
Cerebrospinal Fluid/microbiology | 3 | 42.0 |
Interferon-gamma, Recombinant/administration & dosage/*therapeutic use | 2 | 66.0 |
Immunoglobulin A/immunology | 5 | 13.0 |
Neurons, Afferent/physiology | 4 | 13.0 |
Pain Measurement | 2 | 2.0 |
Immunoassay | 8 | 3.0 |
*Rosette Formation | 3 | 6.0 |
Killer Cells, Lymphokine-Activated/*immunology | 8 | 11.0 |
Immunoglobulin Variable Region/*immunology | 2 | 10.0 |
Antigen-Presenting Cells/*immunology/virology | 2 | 40.0 |
Dendritic Cells/*immunology/virology | 3 | 33.0 |
T-Lymphocytes, Cytotoxic/*immunology/virology | 2 | 22.0 |
Receptors, Interleukin/genetics | 4 | 13.0 |
HIV Infections/*genetics | 6 | 22.0 |
Fiber Optics | 2 | 15.0 |
B-Lymphocytes/*physiology | 6 | 4.0 |
Lymphocyte Specific Protein Tyrosine Kinase p56(lck)/analysis | 3 | 50.0 |
Cycloheximide/pharmacology | 12 | 1.0 |
Cranial Irradiation | 2 | 25.0 |
Cytoplasm/immunology/metabolism | 3 | 25.0 |
Alanine | 3 | 3.0 |
Immunoglobulins, Fab/chemistry | 3 | 37.0 |
Vaccines, Attenuated/immunology | 3 | 25.0 |
*Mice, Mutant Strains | 2 | 25.0 |
Antigens, CD4/chemistry/*genetics | 3 | 100.0 |
Coatomer Protein | 2 | 9.0 |
Down-Regulation/physiology | 4 | 4.0 |
HIV Infections/*drug therapy/*epidemiology | 3 | 100.0 |
Hospitalization/*statistics & numerical data | 4 | 50.0 |
Body Height | 3 | 1.0 |
Nitrogen Isotopes | 2 | 5.0 |
HIV Infections/physiopathology/*virology | 3 | 60.0 |
Receptors, CCR5/chemistry/genetics/*metabolism | 2 | 16.0 |
HIV-1/*immunology/metabolism/physiology | 3 | 100.0 |
Theilovirus/*immunology | 2 | 66.0 |
Viral Envelope Proteins/genetics | 5 | 21.0 |
Skin/*cytology/immunology | 3 | 37.0 |
Gene Products, tat/*immunology | 2 | 28.0 |
Interferon-alpha/blood | 4 | 40.0 |
HIV Seropositivity/*immunology/virology | 3 | 100.0 |
Multiple Myeloma/*immunology | 8 | 21.0 |
*Adaptation, Psychological | 3 | 10.0 |
HIV Seropositivity/*psychology | 3 | 75.0 |
*Sick Role | 7 | 50.0 |
Antigen-Antibody Complex/*blood | 6 | 11.0 |
Lymphopenia/immunology | 4 | 57.0 |
Adrenergic beta-Agonists/therapeutic use | 2 | 40.0 |
Bronchi/*immunology | 2 | 20.0 |
Bronchoconstrictor Agents/diagnostic use | 2 | 28.0 |
Forced Expiratory Volume/drug effects | 3 | 14.0 |
Methacholine Chloride/diagnostic use | 4 | 22.0 |
Mitogens/immunology | 12 | 46.0 |
B-Lymphocytes/immunology/physiology | 3 | 33.0 |
CD8-Positive T-Lymphocytes/immunology/physiology | 3 | 75.0 |
Tonsillitis/immunology | 2 | 66.0 |
Candida/drug effects/isolation & purification | 4 | 100.0 |
Fluconazole/pharmacology | 2 | 14.0 |
Oropharynx/*microbiology | 4 | 80.0 |
Spleen/*immunology | 3 | 13.0 |
Sexually Transmitted Diseases/*complications/epidemiology | 2 | 100.0 |
Georgia/epidemiology | 2 | 28.0 |
Hospitals, Public | 2 | 100.0 |
Antigens, CD2/*metabolism | 2 | 6.0 |
BCG Vaccine/*therapeutic use | 4 | 23.0 |
Health Care Surveys | 2 | 16.0 |
Hospitals/*utilization | 2 | 100.0 |
*Survivors | 4 | 28.0 |
Astrocytes/metabolism/*virology | 2 | 50.0 |
Ultraviolet Therapy/*methods | 2 | 100.0 |
T-Lymphocyte Subsets/immunology/metabolism | 11 | 23.0 |
CD8-Positive T-Lymphocytes/*immunology/*metabolism | 2 | 50.0 |
Fetal Blood/metabolism | 2 | 3.0 |
Demyelinating Diseases/*immunology | 3 | 20.0 |
HTLV-I Antibodies/blood | 2 | 66.0 |
Human T-lymphotropic virus 1/*isolation & purification | 3 | 42.0 |
Fetal Blood | 9 | 6.0 |
*Pseudomonas aeruginosa | 2 | 40.0 |
Macrophages/*metabolism/virology | 2 | 28.0 |
AIDS-Related Opportunistic Infections/*diagnosis | 10 | 62.0 |
Duodenum/pathology | 2 | 22.0 |
*Endoscopy, Gastrointestinal | 3 | 42.0 |
Ileum/pathology | 2 | 66.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/secretion | 2 | 12.0 |
Immunoradiometric Assay | 2 | 1.0 |
Interleukin-1/secretion | 3 | 7.0 |
Interleukin-6/secretion | 6 | 10.0 |
Sarcoma, Kaposi/*immunology/*virology | 2 | 100.0 |
Antigens, CD4/*isolation & purification | 2 | 100.0 |
Detergents/*pharmacology | 2 | 12.0 |
Leukemia, T-Cell, Acute/pathology | 2 | 5.0 |
Protein Kinases/analysis | 2 | 14.0 |
Acquired Immunodeficiency Syndrome/etiology/immunology | 2 | 100.0 |
Killer Cells, Lymphokine-Activated/immunology | 14 | 21.0 |
*Graft Survival | 5 | 3.0 |
Muromonab-CD3/therapeutic use | 3 | 23.0 |
Lymphocytes/cytology/*virology | 2 | 66.0 |
Protein-Tyrosine Kinase/antagonists & inhibitors/metabolism | 2 | 3.0 |
*Signal Transduction/drug effects | 2 | 2.0 |
Interferon Alfa-2b/adverse effects/*therapeutic use | 5 | 83.0 |
*Autoimmunity | 13 | 20.0 |
Epithelial Cells/immunology/metabolism | 2 | 28.0 |
Cervix Neoplasms/*complications/immunology/pathology | 2 | 100.0 |
HIV Infections/*complications/immunology/pathology | 6 | 100.0 |
Churg-Strauss Syndrome/*immunology | 3 | 75.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/analysis | 3 | 12.0 |
Antigens, Differentiation/biosynthesis/genetics | 2 | 22.0 |
B-Lymphocytes/*immunology/virology | 3 | 37.0 |
CD8-Positive T-Lymphocytes/immunology/virology | 3 | 60.0 |
Zidovudine/adverse effects/pharmacokinetics/*therapeutic use | 5 | 100.0 |
Growth Substances/*blood | 3 | 11.0 |
Platelet-Derived Growth Factor/analysis | 2 | 8.0 |
Neoplasm Proteins/*pharmacology | 2 | 15.0 |
Vindesine/administration & dosage | 3 | 23.0 |
Beclomethasone/*therapeutic use | 2 | 100.0 |
Leukocytes, Mononuclear/*cytology/immunology | 4 | 40.0 |
Cryptosporidium parvum/*immunology | 2 | 66.0 |
Interleukin-2/*administration & dosage/adverse effects/pharmacokinetics | 2 | 100.0 |
Carrier State/*virology | 2 | 50.0 |
Flaviviridae/*isolation & purification | 2 | 100.0 |
*Desensitization, Immunologic | 5 | 18.0 |
Pollen | 2 | 20.0 |
Rhinitis, Allergic, Perennial/immunology/therapy | 2 | 100.0 |
Dipeptides/metabolism | 2 | 15.0 |
Endocytosis/drug effects/*physiology | 2 | 9.0 |
Hela Cells/drug effects/metabolism | 2 | 10.0 |
Phorbol Esters/pharmacology | 4 | 3.0 |
Serine/*metabolism | 4 | 4.0 |
Vaccines, Synthetic/immunology | 7 | 22.0 |
Leukocytes, Mononuclear/immunology/transplantation | 2 | 66.0 |
T-Lymphocytes/immunology/*pathology/physiology | 3 | 100.0 |
HIV Envelope Protein gp120/chemistry/*metabolism | 11 | 84.0 |
Gold | 4 | 17.0 |
HIV Infections/diagnosis/*epidemiology | 2 | 100.0 |
Tuberculosis, Pulmonary/diagnosis/*epidemiology | 2 | 100.0 |
DNA-Binding Proteins/biosynthesis/*genetics | 2 | 1.0 |
Bisexuality/statistics & numerical data | 3 | 100.0 |
Health Behavior | 4 | 23.0 |
Lymphocytes/*immunology/metabolism | 4 | 18.0 |
Biological Assay/*methods | 3 | 7.0 |
T-Lymphocytes, Helper-Inducer/*cytology | 6 | 75.0 |
T-Lymphocytes/*drug effects/*immunology | 5 | 33.0 |
Gastric Mucosa/*immunology | 2 | 22.0 |
*Hepacivirus | 2 | 18.0 |
Drug Delivery Systems/*methods | 3 | 7.0 |
HIV-1/*metabolism/pathogenicity | 10 | 52.0 |
Cell Cycle Proteins/metabolism | 3 | 0.0 |
Staurosporine/pharmacology | 5 | 2.0 |
Asthma/*drug therapy | 2 | 10.0 |
Inflammation/drug therapy | 2 | 14.0 |
Colon/immunology/pathology | 5 | 50.0 |
Intestinal Mucosa/immunology/*pathology | 2 | 33.0 |
*Hematopoiesis | 8 | 4.0 |
Megakaryocytes/cytology/*metabolism | 2 | 33.0 |
T-Lymphocytes, Cytotoxic/immunology/*pathology | 3 | 100.0 |
Antigens, CD/genetics/*metabolism | 4 | 4.0 |
Genes, Reporter/genetics | 2 | 0.0 |
Receptors, Lymphocyte Homing | 4 | 11.0 |
Antibodies, Monoclonal/*metabolism | 4 | 10.0 |
Lymph Nodes/metabolism | 3 | 5.0 |
Thymus Gland/metabolism | 4 | 5.0 |
T-Lymphocytes, Cytotoxic/*drug effects/immunology | 2 | 22.0 |
Acquired Immunodeficiency Syndrome/drug therapy/immunology/*virology | 4 | 100.0 |
HIV/*drug effects | 11 | 45.0 |
Meningitis, Cryptococcal/*drug therapy/microbiology/mortality | 2 | 100.0 |
Carboxylic Ester Hydrolases/analysis | 3 | 21.0 |
Naphthol AS D Esterase/analysis | 2 | 33.0 |
Peroxidase/analysis | 3 | 4.0 |
HTLV-I Infections/*immunology | 8 | 50.0 |
Leukemia, Myeloid/*pathology | 2 | 3.0 |
*Predictive Value of Tests | 2 | 22.0 |
Membrane Proteins/metabolism/*physiology | 3 | 9.0 |
Tonsil/cytology/*immunology | 2 | 25.0 |
HIV Infections/*complications/*virology | 3 | 100.0 |
Peptide Fragments/chemistry/metabolism | 2 | 1.0 |
Proteins/physiology | 2 | 1.0 |
Receptors, Tumor Necrosis Factor/*physiology | 2 | 2.0 |
HIV Infections/complications/*immunology/*virology | 2 | 50.0 |
*Sex Factors | 2 | 14.0 |
Interferon Type II/*secretion | 5 | 26.0 |
Kidney Failure, Chronic/*therapy | 2 | 15.0 |
HIV-1/*classification/genetics/pathogenicity | 2 | 100.0 |
HIV Infections/pathology/virology | 2 | 100.0 |
Cell Nucleus/immunology/virology | 2 | 100.0 |
Cytoplasm/immunology/virology | 2 | 100.0 |
HIV-1/genetics/*immunology/*physiology | 4 | 100.0 |
Candidiasis, Oral/complications/epidemiology | 2 | 100.0 |
Mouth Diseases/*epidemiology/*etiology | 2 | 100.0 |
North Carolina/epidemiology | 2 | 11.0 |
Antigens, CD4/chemistry/genetics/*metabolism | 5 | 100.0 |
Peptide Fragments/chemistry/genetics/immunology | 2 | 40.0 |
HIV Seropositivity/immunology/*mortality | 2 | 100.0 |
Antibiotics, Antineoplastic/*therapeutic use | 3 | 12.0 |
Gene Products, nef/chemistry/*physiology | 3 | 75.0 |
Complement/immunology | 9 | 9.0 |
Platelet Activating Factor/pharmacology | 2 | 4.0 |
HIV-1 Reverse Transcriptase/antagonists & inhibitors | 3 | 60.0 |
HIV Antibodies/*therapeutic use | 4 | 100.0 |
Receptors, HIV/chemistry/physiology | 2 | 100.0 |
Multiple Sclerosis/*drug therapy/immunology | 5 | 35.0 |
Inosine Pranobex/*therapeutic use | 2 | 100.0 |
Lung/physiopathology | 2 | 7.0 |
Chemokines/*immunology | 5 | 26.0 |
Monocytes/cytology/*metabolism | 2 | 7.0 |
Affect/drug effects | 2 | 15.0 |
Burns/*immunology | 2 | 14.0 |
Interleukin-4/*metabolism | 4 | 10.0 |
HIV Core Protein p24/biosynthesis/immunology | 2 | 66.0 |
Antiviral Agents/pharmacology/therapeutic use | 4 | 66.0 |
HIV-1/drug effects/*pathogenicity | 4 | 80.0 |
Nonlinear Dynamics | 2 | 8.0 |
Crohn Disease/immunology/pathology/*therapy | 2 | 100.0 |
Oligopeptides/*therapeutic use | 4 | 23.0 |
Acquired Immunodeficiency Syndrome/pathology | 5 | 41.0 |
Glutamine/*administration & dosage | 5 | 71.0 |
Postoperative Complications/*immunology/prevention & control | 2 | 100.0 |
Thrombosis/blood/*complications | 2 | 66.0 |
Cytomegalovirus Infections/*drug therapy | 3 | 60.0 |
Nevirapine/administration & dosage | 3 | 100.0 |
Surface Properties | 7 | 3.0 |
Infectious Mononucleosis/*immunology | 5 | 26.0 |
Liver Diseases/*immunology | 2 | 10.0 |
Antigens, CD11/analysis | 3 | 10.0 |
Dental Plaque Index | 5 | 21.0 |
Leukocytes/*drug effects/immunology | 3 | 33.0 |
Periodontal Index | 7 | 14.0 |
Periodontal Pocket/pathology | 2 | 33.0 |
Allergens/*diagnostic use | 2 | 40.0 |
*Skin Tests | 6 | 35.0 |
*Laboratory Techniques and Procedures | 2 | 16.0 |
HIV-1/*genetics/pathogenicity/physiology | 5 | 62.0 |
Trypanosoma cruzi/isolation & purification | 3 | 100.0 |
AIDS-Related Opportunistic Infections/immunology/*radiography | 4 | 100.0 |
Tuberculosis, Pulmonary/immunology/*radiography | 2 | 100.0 |
Choline/metabolism | 2 | 5.0 |
Antibodies, Monoclonal/*chemistry | 2 | 5.0 |
Gene Expression Regulation, Viral/*immunology | 2 | 28.0 |
Antigens, CD28/*physiology | 4 | 4.0 |
Antigens, CD80/*physiology | 3 | 6.0 |
Avidin | 4 | 26.0 |
Immunohistochemistry/*methods | 4 | 4.0 |
Infrared Rays | 2 | 22.0 |
Lymphocytes/immunology/physiology | 2 | 28.0 |
Epitopes, T-Lymphocyte/chemistry/*immunology | 2 | 40.0 |
Drugs, Chinese Herbal/*pharmacology | 3 | 6.0 |
Cell Adhesion Molecules/biosynthesis | 5 | 6.0 |
T-Lymphocytes/drug effects/immunology/metabolism | 6 | 33.0 |
*Frozen Sections | 2 | 33.0 |
*Lasers | 2 | 9.0 |
Cell Nucleus/immunology | 3 | 13.0 |
Calibration | 8 | 5.0 |
Lymphoma, T-Cell/classification/immunology/*pathology | 2 | 100.0 |
Diagnostic Techniques, Ophthalmological | 2 | 28.0 |
Hepatitis, Viral, Human/*immunology | 3 | 33.0 |
Cell Differentiation/*drug effects | 2 | 1.0 |
Transfection/genetics | 4 | 2.0 |
HIV/*drug effects/*genetics | 2 | 66.0 |
Factor Analysis, Statistical | 3 | 7.0 |
Fluoxetine/*therapeutic use | 2 | 33.0 |
Patient Dropouts | 2 | 20.0 |
Psychiatric Status Rating Scales/statistics & numerical data | 3 | 33.0 |
Flaviviridae/genetics/*isolation & purification | 2 | 100.0 |
RNA, Viral/blood/*isolation & purification | 2 | 100.0 |
Antigens, CD26/*analysis | 2 | 40.0 |
Reverse Transcriptase Polymerase Chain Reaction/*methods | 2 | 3.0 |
Autoimmune Diseases/*immunology/pathology | 2 | 12.0 |
Epithelial Cells/immunology | 3 | 8.0 |
Inflammation/pathology | 9 | 15.0 |
Salivary Glands, Minor/*immunology/pathology | 2 | 100.0 |
Testis/*pathology | 2 | 15.0 |
Antigens, CD44/physiology | 2 | 9.0 |
Lymphocyte Function-Associated Antigen-1/physiology | 9 | 20.0 |
Receptors, Lymphocyte Homing/*physiology | 2 | 6.0 |
1-Phosphatidylinositol 3-Kinase/*metabolism | 2 | 0.0 |
*Aging | 8 | 4.0 |
*Bone Marrow Transplantation/adverse effects/immunology | 2 | 50.0 |
Epstein-Barr Virus Infections/immunology/prevention & control | 2 | 100.0 |
*Leukocyte Transfusion | 2 | 25.0 |
Cell Cycle/immunology | 8 | 25.0 |
Anemia/immunology | 3 | 100.0 |
Antigens, CD/biosynthesis/blood | 2 | 22.0 |
Fetal Blood/immunology | 8 | 11.0 |
Fetus/*immunology | 8 | 16.0 |
Rh Isoimmunization/*immunology | 2 | 50.0 |
Cell Survival/physiology | 2 | 1.0 |
T-Lymphocytes/immunology/*physiology | 12 | 22.0 |
CD8-Positive T-Lymphocytes/chemistry/*metabolism | 2 | 66.0 |
Cathepsin D/analysis | 3 | 8.0 |
Platelet Membrane Glycoproteins/analysis | 2 | 2.0 |
Serine Endopeptidases/analysis | 5 | 14.0 |
Clinical Trials/*statistics & numerical data | 3 | 60.0 |
Monte Carlo Method | 8 | 11.0 |
HIV Seropositivity/*complications/epidemiology/immunology | 2 | 100.0 |
Macrophages/cytology/*virology | 2 | 100.0 |
Stress | 2 | 3.0 |
Immunocompetence/drug effects | 3 | 60.0 |
Retroviridae Infections/drug therapy | 2 | 100.0 |
B-Lymphocytes/*metabolism | 13 | 6.0 |
Receptor-CD3 Complex, Antigen, T-Cell/*metabolism | 6 | 37.0 |
HIV Infections/*drug therapy/immunology/physiopathology | 6 | 100.0 |
Vaccines, Synthetic/administration & dosage/immunology | 2 | 40.0 |
Bacteremia/*prevention & control | 2 | 66.0 |
*Practice Guidelines | 2 | 7.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/*metabolism | 2 | 0.0 |
Mitogen-Activated Protein Kinase 1 | 5 | 3.0 |
Mitogen-Activated Protein Kinase Kinases | 3 | 8.0 |
*Mitogen-Activated Protein Kinases | 4 | 1.0 |
Protein Kinases/*metabolism | 6 | 1.0 |
Chondroitin Sulfates/metabolism | 2 | 6.0 |
Heparitin Sulfate/metabolism | 2 | 5.0 |
Macrophage Colony-Stimulating Factor/pharmacology | 4 | 5.0 |
Electrophoresis, Gel, Pulsed-Field | 2 | 0.0 |
*Minisatellite Repeats | 2 | 2.0 |
Allergens/administration & dosage | 4 | 26.0 |
*Methicillin Resistance | 2 | 28.0 |
Factor VIII/*therapeutic use | 5 | 29.0 |
Hemophilia A/complications/*drug therapy | 5 | 100.0 |
HIV Infections/epidemiology/*immunology/mortality | 2 | 100.0 |
Aging/immunology/*physiology | 2 | 66.0 |
RNA, Neoplasm/analysis | 6 | 2.0 |
Fibronectins/immunology | 2 | 25.0 |
Glycoproteins/*immunology | 3 | 3.0 |
Pneumonia, Pneumocystis/*immunology | 3 | 50.0 |
*Receptors, Antigen, T-Cell | 6 | 50.0 |
HIV/*chemistry | 3 | 75.0 |
HIV Envelope Protein gp120/chemistry | 2 | 28.0 |
Clone Cells/metabolism | 2 | 6.0 |
Steroids/pharmacology | 2 | 5.0 |
Multiple Myeloma/*immunology/pathology | 2 | 11.0 |
Cytomegalovirus Infections/*complications | 9 | 56.0 |
Arteriosclerosis/metabolism/pathology | 2 | 15.0 |
Pregnancy Complications/*pathology | 2 | 33.0 |
DNA-Binding Proteins/genetics/metabolism | 2 | 0.0 |
HIV-1/*drug effects/metabolism/pathogenicity | 2 | 66.0 |
Peptides/chemical synthesis/chemistry/*pharmacology | 2 | 40.0 |
Quality of Life/*psychology | 2 | 25.0 |
T-Lymphocyte Subsets/physiology | 6 | 66.0 |
*X Chromosome | 3 | 0.0 |
Drug Hypersensitivity/etiology | 2 | 33.0 |
Patient Education | 7 | 11.0 |
Pneumonia/chemically induced | 2 | 100.0 |
Genes, nef/genetics | 3 | 50.0 |
HIV Wasting Syndrome/*drug therapy | 2 | 100.0 |
Nutritional Status/physiology | 2 | 33.0 |
Skinfold Thickness | 2 | 2.0 |
AIDS-Related Opportunistic Infections/*therapy | 4 | 100.0 |
Protein Kinase C/antagonists & inhibitors | 11 | 8.0 |
Protein-Tyrosine Kinase/antagonists & inhibitors | 4 | 1.0 |
T-Lymphocyte Subsets/drug effects/immunology/*metabolism | 4 | 80.0 |
Interleukin-2/adverse effects/*therapeutic use | 3 | 16.0 |
*Sexual Partners | 6 | 66.0 |
Dapsone/*therapeutic use | 2 | 40.0 |
Pyrimethamine/*therapeutic use | 3 | 21.0 |
Toxoplasmosis/*prevention & control | 2 | 100.0 |
AIDS-Related Complex/*drug therapy/immunology | 7 | 50.0 |
AIDS-Related Opportunistic Infections/microbiology | 4 | 50.0 |
Bacteria/isolation & purification | 2 | 12.0 |
Diarrhea/*microbiology | 2 | 15.0 |
Carrier State/*immunology/pathology | 2 | 100.0 |
Clone Cells/*pathology | 2 | 15.0 |
HTLV-I Infections/*immunology/pathology | 2 | 66.0 |
Leukemia-Lymphoma, T-Cell, Acute, HTLV-I-Associated/immunology/pathology | 2 | 100.0 |
AIDS Vaccines/administration & dosage/adverse effects/*immunology | 2 | 100.0 |
Antigens, Surface/blood | 12 | 54.0 |
Eosinophils/cytology/immunology | 2 | 66.0 |
Integrins/blood | 3 | 60.0 |
Receptors, Lymphocyte Homing/blood | 2 | 50.0 |
Evoked Potentials | 2 | 3.0 |
Motor Neurons/physiology | 3 | 6.0 |
Neurologic Examination | 11 | 10.0 |
Autoimmunity/*drug effects | 2 | 33.0 |
Fluorometry | 3 | 4.0 |
Mycophenolic Acid/*analogs & derivatives/therapeutic use | 2 | 16.0 |
Spleen/cytology/drug effects/immunology | 2 | 40.0 |
Immunoglobulins, Fc/immunology | 4 | 16.0 |
Bone Marrow/chemistry | 2 | 6.0 |
Radiation Dosage | 6 | 6.0 |
*Ultraviolet Rays | 5 | 2.0 |
Receptors, Interleukin/metabolism | 2 | 3.0 |
*Agriculture | 2 | 20.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase | 5 | 13.0 |
G(M3) Ganglioside/*pharmacology | 2 | 66.0 |
Isoenzymes/*metabolism | 5 | 1.0 |
Serine | 3 | 3.0 |
Calcium/blood | 6 | 2.0 |
Parathyroid Hormone/blood | 2 | 1.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/*therapeutic use | 4 | 15.0 |
Receptors, Antigen, T-Cell, alpha-beta | 14 | 37.0 |
Receptors, Antigen, T-Cell, gamma-delta | 27 | 49.0 |
T-Lymphocytes/cytology/immunology | 15 | 22.0 |
Tanzania/epidemiology | 6 | 37.0 |
Molecular Probes | 2 | 3.0 |
Histocompatibility Antigens Class I/genetics | 3 | 3.0 |
Membrane Proteins/genetics | 4 | 1.0 |
Protein Sorting Signals/genetics | 5 | 6.0 |
Dendritic Cells/*cytology | 8 | 14.0 |
Genes, myc/genetics | 2 | 2.0 |
Tuberculosis/epidemiology | 3 | 100.0 |
Acquired Immunodeficiency Syndrome/therapy | 4 | 50.0 |
Antibodies, Monoclonal/*administration & dosage | 5 | 16.0 |
Islets of Langerhans Transplantation/*immunology | 2 | 22.0 |
Antigens, CD19/analysis/immunology | 2 | 66.0 |
B-Lymphocytes/chemistry/immunology | 2 | 25.0 |
DNA, Complementary | 11 | 0.0 |
Multiple Sclerosis/immunology | 2 | 4.0 |
Bisexuality/psychology | 2 | 100.0 |
*Disability Evaluation | 2 | 20.0 |
HIV Seropositivity/psychology | 2 | 100.0 |
Homosexuality, Male/psychology | 3 | 100.0 |
Kidney Transplantation/*adverse effects/immunology | 2 | 50.0 |
SIV/immunology/*physiology | 2 | 66.0 |
Herpesviridae Infections/*immunology | 3 | 30.0 |
Herpesvirus 7, Human/*pathogenicity | 2 | 100.0 |
Stavudine/pharmacology | 2 | 66.0 |
Lupus Erythematosus, Systemic/immunology | 4 | 3.0 |
*Circadian Rhythm | 12 | 5.0 |
Interleukin-2/*biosynthesis/genetics | 3 | 16.0 |
HIV Infections/*immunology/*therapy/virology | 3 | 100.0 |
*HIV-1/immunology/isolation & purification | 3 | 75.0 |
Surgical Procedures, Operative/*adverse effects | 3 | 23.0 |
Epinephrine/blood | 3 | 2.0 |
Norepinephrine/blood | 5 | 2.0 |
Decision Trees | 4 | 15.0 |
Pyrazinamide/administration & dosage | 2 | 66.0 |
Tuberculosis/*prevention & control | 3 | 75.0 |
Cell Transformation, Neoplastic/*genetics | 3 | 1.0 |
Genes, Structural | 13 | 1.0 |
Leukemia, T-Cell, Acute/*genetics | 2 | 5.0 |
*Multigene Family | 7 | 1.0 |
Acetylcysteine/*pharmacology | 3 | 13.0 |
Lipid Peroxidation | 2 | 1.0 |
Sulfhydryl Compounds | 2 | 8.0 |
Chimeric Proteins/chemistry/genetics/immunology | 2 | 33.0 |
Chemokines, CXC/genetics | 2 | 11.0 |
Genes, Dominant | 5 | 0.0 |
Ophthalmoscopy | 3 | 13.0 |
CD8-Positive T-Lymphocytes/*drug effects | 3 | 75.0 |
Cytomegalovirus/*genetics | 5 | 13.0 |
Cytomegalovirus Infections/*virology | 2 | 100.0 |
*Genes, Viral | 11 | 5.0 |
Viral Fusion Proteins/*genetics | 2 | 33.0 |
Sarcoma, Kaposi/*drug therapy/immunology/virology | 2 | 100.0 |
HIV/immunology/isolation & purification | 3 | 75.0 |
Retroviridae Proteins/immunology | 8 | 57.0 |
Sexually Transmitted Diseases/complications | 7 | 100.0 |
Kidney Failure, Chronic/complications/therapy | 2 | 7.0 |
Salmonella Infections/complications | 2 | 50.0 |
Autoimmune Diseases/immunology/pathology | 4 | 50.0 |
PUVA Therapy | 5 | 35.0 |
Lymphoma/diagnosis/immunology | 2 | 66.0 |
Thyroid Gland/*immunology | 7 | 11.0 |
*Prenatal Exposure Delayed Effects | 6 | 13.0 |
Respiratory Tract Diseases/etiology/immunology | 2 | 100.0 |
HIV Core Protein p24/*analysis | 6 | 85.0 |
Multiple Sclerosis/blood/*drug therapy/physiopathology | 2 | 100.0 |
Equipment Design | 2 | 1.0 |
Flow Cytometry/*instrumentation | 3 | 60.0 |
HN Protein/physiology | 2 | 100.0 |
HIV Infections/complications/diagnosis/*immunology | 4 | 100.0 |
Acquired Immunodeficiency Syndrome/*immunology/mortality | 2 | 100.0 |
Matched-Pair Analysis | 5 | 5.0 |
Calcitriol/analogs & derivatives/*pharmacology | 2 | 18.0 |
*Biological Assay | 2 | 9.0 |
Leukocytes, Mononuclear/immunology/pathology | 5 | 55.0 |
*Lymphocyte Subsets/immunology | 4 | 80.0 |
Carcinoma, Hepatocellular | 2 | 0.0 |
Liver Neoplasms | 2 | 0.0 |
Nocodazole/pharmacology | 2 | 1.0 |
Stochastic Processes | 11 | 28.0 |
Interleukin-6/immunology | 4 | 14.0 |
Mycobacterium leprae/*immunology | 2 | 6.0 |
Cytomegalovirus Infections/*complications/drug therapy | 2 | 100.0 |
Antigen Presentation/genetics | 3 | 13.0 |
Cell Adhesion/drug effects/immunology | 2 | 10.0 |
Transfection/immunology | 5 | 10.0 |
Antigens, CD18/analysis | 3 | 14.0 |
Pancreatitis/*pathology | 2 | 40.0 |
HIV Infections/blood/epidemiology/*virology | 2 | 66.0 |
Autoimmune Diseases/*therapy | 8 | 61.0 |
United States Food and Drug Administration | 4 | 30.0 |
Scotland | 4 | 10.0 |
C-Reactive Protein/metabolism | 4 | 1.0 |
DNA Probes | 17 | 1.0 |
Models, Theoretical | 8 | 6.0 |
European Continental Ancestry Group/*genetics | 4 | 1.0 |
*Hypersensitivity, Delayed | 4 | 66.0 |
Skin/*immunology/pathology | 7 | 36.0 |
Rectum/virology | 2 | 100.0 |
Bleomycin/administration & dosage | 12 | 16.0 |
Leucovorin/administration & dosage | 6 | 18.0 |
Neoplasm Proteins/*immunology | 4 | 11.0 |
Tetanus Toxoid/pharmacology | 9 | 37.0 |
Lymphocytes, Tumor-Infiltrating/*pathology | 3 | 42.0 |
Receptors, Complement 3d/analysis | 2 | 10.0 |
Tonsillitis/*immunology | 2 | 100.0 |
Gene Products, vpu/chemistry/genetics/*metabolism | 2 | 100.0 |
Microsomes/metabolism | 4 | 3.0 |
Radioimmunoprecipitation Assay | 11 | 45.0 |
Alkaline Phosphatase/metabolism | 2 | 1.0 |
Gene Products, env/genetics/metabolism | 8 | 57.0 |
Glycoproteins/genetics/*metabolism | 2 | 5.0 |
Octoxynol | 3 | 5.0 |
Virion/metabolism | 8 | 20.0 |
Antigens, CD3/*physiology | 4 | 23.0 |
Antigens, CD45/*physiology | 5 | 41.0 |
Blood Proteins/metabolism | 3 | 1.0 |
Interleukin-5/blood | 3 | 37.0 |
Prednisone/*therapeutic use | 6 | 22.0 |
Antigens, Differentiation, T-Lymphocyte/physiology | 23 | 28.0 |
HIV Infections/etiology/immunology/virology | 2 | 50.0 |
Clathrin/*metabolism | 3 | 7.0 |
Antigens, CD1/*metabolism | 3 | 9.0 |
HLA Antigens/metabolism | 5 | 15.0 |
Opportunistic Infections/*immunology | 3 | 50.0 |
*AIDS-Related Opportunistic Infections/diagnosis/drug therapy | 4 | 100.0 |
Phospholipase C/*metabolism | 4 | 3.0 |
*Cell Movement | 4 | 3.0 |
*Organic Chemicals | 2 | 7.0 |
Vagina/cytology/*immunology | 2 | 100.0 |
Fever of Unknown Origin | 2 | 100.0 |
Antigens, Bacterial | 7 | 25.0 |
HIV Infections/immunology/transmission/*virology | 3 | 100.0 |
*Ambulatory Care | 5 | 41.0 |
HIV Seropositivity/immunology/*metabolism | 2 | 100.0 |
Pleural Effusion/*immunology | 3 | 30.0 |
Tuberculosis, Pleural/*immunology | 2 | 100.0 |
Antibodies, Monoclonal/*diagnostic use | 22 | 10.0 |
Aerosols | 13 | 18.0 |
Cytomegalovirus Infections/complications/*drug therapy | 3 | 75.0 |
HIV Infections/*diagnosis/*immunology | 2 | 100.0 |
Neopterin/*blood | 3 | 37.0 |
T-Lymphocytes/metabolism/physiology | 2 | 66.0 |
X Chromosome/*genetics | 2 | 0.0 |
Cell Death/drug effects/physiology | 2 | 4.0 |
Gene Expression Regulation/drug effects/*physiology | 2 | 2.0 |
Membrane Glycoproteins/biosynthesis/*genetics | 2 | 6.0 |
Naphthalenes/pharmacology | 2 | 2.0 |
AIDS-Related Opportunistic Infections/microbiology/*radiography | 2 | 100.0 |
*Mycobacterium xenopi/isolation & purification | 2 | 100.0 |
Lung Diseases/immunology/*radiography | 2 | 100.0 |
Lung Neoplasms/immunology/*radiography | 2 | 100.0 |
Feces/microbiology | 3 | 4.0 |
Cell Adhesion Molecules/*biosynthesis | 10 | 11.0 |
Interleukin-6/genetics | 4 | 5.0 |
Titrimetry | 3 | 10.0 |
Mycosis Fungoides/*immunology/pathology | 3 | 75.0 |
Skin Neoplasms/*immunology/pathology | 7 | 35.0 |
Brain/*blood supply/*virology | 2 | 100.0 |
Endothelial Cells/virology | 2 | 100.0 |
Endothelium, Vascular/cytology/virology | 2 | 100.0 |
Proteoglycans/*metabolism | 3 | 4.0 |
Virion/*metabolism | 4 | 19.0 |
HIV Infections/drug therapy/*epidemiology | 2 | 100.0 |
Family Health | 8 | 0.0 |
Brain/metabolism/pathology | 2 | 1.0 |
HIV Infections/*epidemiology/immunology | 4 | 100.0 |
Mental Disorders/*epidemiology | 2 | 50.0 |
Membrane Glycoproteins/immunology/*metabolism | 2 | 4.0 |
HIV Infections/*blood/complications/drug therapy | 3 | 100.0 |
Acquired Immunodeficiency Syndrome/complications/diagnosis | 4 | 100.0 |
Candidiasis, Oral/etiology | 6 | 100.0 |
Leukoplakia, Hairy/etiology | 3 | 100.0 |
Mouth Diseases/*etiology | 3 | 100.0 |
Antibodies, Monoclonal/*analysis | 4 | 9.0 |
Cell Adhesion Molecules/analysis/immunology | 2 | 28.0 |
Crohn Disease/*immunology/pathology | 5 | 38.0 |
Epithelium/chemistry | 2 | 1.0 |
*Integrin beta Chains | 3 | 18.0 |
Integrins/*analysis | 2 | 8.0 |
Chemokines/*pharmacology | 3 | 11.0 |
Chemotaxis, Leukocyte/*drug effects | 6 | 9.0 |
Monocytes/*drug effects/metabolism | 2 | 2.0 |
HLA-A Antigens/*immunology | 3 | 3.0 |
Killer Cells, Natural/classification | 5 | 100.0 |
Candidiasis/epidemiology | 3 | 100.0 |
Receptors, Peptide/genetics/metabolism | 2 | 16.0 |
Integrins/biosynthesis/immunology | 2 | 66.0 |
Scalp | 3 | 15.0 |
T-Lymphocyte Subsets/*chemistry/metabolism | 2 | 100.0 |
*Intradermal Tests | 3 | 37.0 |
Receptors, Antigen, T-Cell, alpha-beta/*genetics/*immunology | 3 | 75.0 |
Thymus Gland/*cytology/*immunology | 3 | 50.0 |
HIV-1/classification/*immunology | 2 | 50.0 |
Antigens, CD4/*chemistry/immunology | 6 | 100.0 |
Behcet Syndrome/*immunology | 3 | 13.0 |
Nutrition Disorders/complications | 5 | 45.0 |
Dactinomycin/pharmacology | 6 | 1.0 |
Gonorrhea/complications/epidemiology | 2 | 100.0 |
Laparoscopy | 3 | 8.0 |
CD4-Positive T-Lymphocytes/drug effects/immunology/*physiology | 2 | 66.0 |
Tretinoin/*pharmacology | 5 | 1.0 |
Arthritis/*immunology | 4 | 16.0 |
HIV/*drug effects/physiology | 5 | 50.0 |
Population Dynamics | 2 | 25.0 |
Lung Diseases/*immunology/pathology | 2 | 66.0 |
Nuclear Proteins/metabolism | 3 | 0.0 |
Proto-Oncogene Proteins c-bcl-2/*metabolism | 3 | 1.0 |
CD8-Positive T-Lymphocytes/*chemistry | 6 | 66.0 |
Antigens/*analysis | 3 | 3.0 |
Cell Membrane Permeability/drug effects | 2 | 3.0 |
Ethanol/pharmacology | 2 | 3.0 |
Intracellular Fluid/immunology | 2 | 13.0 |
Saponins/pharmacology | 2 | 15.0 |
Guanine/*analogs & derivatives/pharmacology | 2 | 6.0 |
Purine-Nucleoside Phosphorylase/*antagonists & inhibitors | 2 | 100.0 |
AIDS-Related Opportunistic Infections/diagnosis | 4 | 66.0 |
Caregivers/*psychology | 2 | 66.0 |
Diarrhea/*etiology/pathology | 2 | 100.0 |
Interferons/analysis | 3 | 60.0 |
Diarrhea/*etiology | 2 | 20.0 |
Drug Eruptions | 2 | 100.0 |
AIDS-Related Opportunistic Infections/blood/*diagnosis/virology | 2 | 100.0 |
*Fluorescent Antibody Technique, Direct | 2 | 50.0 |
AIDS-Related Opportunistic Infections/*immunology/pathology | 3 | 100.0 |
Genes, Immunoglobulin | 15 | 8.0 |
Immunoglobulins, Heavy-Chain/genetics | 8 | 5.0 |
Immunoglobulins, Light-Chain/genetics | 3 | 8.0 |
Anti-Infective Agents/adverse effects | 2 | 66.0 |
Didanosine/adverse effects | 3 | 100.0 |
Zidovudine/adverse effects | 4 | 66.0 |
HIV Infections/complications/*microbiology | 4 | 66.0 |
Receptors, Tumor Necrosis Factor/analysis | 4 | 7.0 |
Antigens, CD/*biosynthesis | 20 | 10.0 |
Leukocytes, Mononuclear/drug effects/*immunology | 2 | 6.0 |
Antigens, CD19/drug effects | 2 | 100.0 |
Antigens, Surface/drug effects | 2 | 33.0 |
B-Lymphocytes/*drug effects | 6 | 31.0 |
HLA-DR Antigens/drug effects | 2 | 33.0 |
Receptors, Interleukin-2/drug effects | 4 | 40.0 |
Bronchi/*pathology | 8 | 34.0 |
Respiratory Mechanics | 2 | 11.0 |
Methylprednisolone/*therapeutic use | 2 | 20.0 |
Multiple Sclerosis/blood/*drug therapy | 2 | 66.0 |
Receptors, Lymphocyte Homing/biosynthesis | 2 | 11.0 |
HLA-DR Antigens/*blood | 3 | 15.0 |
Golgi Apparatus/*metabolism | 5 | 5.0 |
Peptide Fragments/immunology/*metabolism | 2 | 15.0 |
Receptors, Antigen, T-Cell, alpha-beta/immunology/*metabolism | 3 | 60.0 |
Granulocyte Colony-Stimulating Factor/*therapeutic use | 8 | 13.0 |
Thymus Gland/cytology/metabolism | 2 | 13.0 |
T-Lymphocytes/*immunology/metabolism/virology | 2 | 50.0 |
Allosteric Regulation | 3 | 4.0 |
Alkaline Phosphatase/genetics | 2 | 8.0 |
Nucleopolyhedrovirus/genetics | 2 | 9.0 |
Placenta/enzymology | 2 | 2.0 |
Recombinant Proteins/biosynthesis/genetics | 2 | 2.0 |
Spodoptera | 6 | 2.0 |
Vidarabine/*analogs & derivatives/therapeutic use | 5 | 55.0 |
Inflammation/*immunology/pathology | 2 | 66.0 |
Hemagglutinins/immunology | 2 | 22.0 |
HIV Infections/drug therapy/*genetics/immunology/virology | 2 | 100.0 |
HIV-1 Reverse Transcriptase/drug effects | 2 | 100.0 |
Diabetes Mellitus, Type 1/etiology/immunology | 2 | 66.0 |
Antibodies, Fungal/blood | 2 | 28.0 |
Hydrogen Peroxide/metabolism | 3 | 2.0 |
Immunodiffusion | 2 | 0.0 |
Acquired Immunodeficiency Syndrome/pathology/*physiopathology | 2 | 66.0 |
Graft vs Host Disease/prevention & control | 4 | 7.0 |
Lymphocyte Depletion/adverse effects | 2 | 100.0 |
Lymphopenia/etiology/*immunology | 2 | 100.0 |
Postoperative Complications/epidemiology | 3 | 6.0 |
DNA, Single-Stranded | 4 | 4.0 |
Antigen-Presenting Cells/drug effects/*immunology | 2 | 22.0 |
Autoimmunity/drug effects/immunology | 3 | 60.0 |
Immunoglobulin G | 4 | 3.0 |
Concanavalin A | 3 | 6.0 |
Lymphoma, T-Cell | 4 | 21.0 |
ras GTPase-Activating Proteins | 3 | 2.0 |
ras Proteins/*metabolism | 4 | 2.0 |
src-Family Kinases/*metabolism | 10 | 6.0 |
Colon/cytology | 3 | 20.0 |
Crohn Disease/immunology | 5 | 33.0 |
Integrins/analysis | 4 | 8.0 |
Intracellular Fluid/chemistry | 4 | 26.0 |
*CD4 Lymphocyte Count/methods | 3 | 100.0 |
Hemophilia A/*blood | 3 | 21.0 |
Genetic Vectors/*genetics/immunology | 2 | 50.0 |
Herpesvirus 3, Human/*isolation & purification | 2 | 100.0 |
Hepatitis C/complications | 3 | 13.0 |
Myocarditis/*pathology | 2 | 66.0 |
Intercellular Adhesion Molecule-1/*analysis | 2 | 10.0 |
Histiocytes/*pathology | 2 | 20.0 |
Lymphadenitis/*pathology | 2 | 50.0 |
T-Lymphocytes, Cytotoxic/*pathology | 2 | 66.0 |
Receptors, Virus/metabolism | 14 | 22.0 |
Cell Count/drug effects | 5 | 7.0 |
Cell Cycle/physiology | 4 | 1.0 |
HIV Protease Inhibitors/pharmacology | 4 | 30.0 |
*Forecasting | 2 | 14.0 |
Environmental Monitoring | 3 | 7.0 |
HIV Infections/*immunology/transmission | 4 | 57.0 |
Cell Fusion/physiology | 6 | 66.0 |
Guinea-Bissau | 4 | 80.0 |
HIV-2/*genetics/pathogenicity | 2 | 66.0 |
*Rural Population | 3 | 18.0 |
HIV-2/*genetics | 3 | 42.0 |
AIDS-Related Opportunistic Infections/diagnosis/therapy | 3 | 100.0 |
Hepatitis B Surface Antigens/analysis | 5 | 9.0 |
Anti-Infective Agents/adverse effects/therapeutic use | 2 | 100.0 |
HIV Infections/complications/drug therapy/*mortality | 2 | 100.0 |
Trimethoprim-Sulfamethoxazole Combination/adverse effects/therapeutic use | 2 | 100.0 |
Anus Neoplasms/*etiology | 2 | 100.0 |
Liver Transplantation/*immunology | 5 | 16.0 |
Mortality | 4 | 12.0 |
DNA-Binding Proteins/*genetics/metabolism | 2 | 0.0 |
Transcription Factors/*genetics/metabolism | 2 | 0.0 |
Erythema/etiology | 2 | 16.0 |
Hair Follicle/metabolism | 2 | 15.0 |
Epidermis/immunology | 4 | 19.0 |
Psoriasis/*immunology/pathology | 2 | 22.0 |
Receptors, Immunologic/metabolism | 4 | 2.0 |
Immunochemistry | 4 | 1.0 |
Antigens, Ly/genetics | 3 | 33.0 |
Receptors, Antigen, T-Cell/*biosynthesis/genetics | 3 | 50.0 |
Bladder Neoplasms/*therapy | 2 | 22.0 |
HIV Envelope Protein gp160/physiology | 2 | 100.0 |
CD4-Positive T-Lymphocytes/*cytology/drug effects/immunology | 2 | 66.0 |
Antibodies, Blocking/*pharmacology | 2 | 28.0 |
*Binding Sites, Antibody | 2 | 5.0 |
HIV Antibodies/*pharmacology | 3 | 75.0 |
Lymphoid Tissue/immunology/pathology | 4 | 50.0 |
Muramidase/immunology | 6 | 42.0 |
British Columbia | 8 | 80.0 |
Antigens, CD3/*analysis/genetics | 2 | 66.0 |
Antibodies, Helminth/blood | 3 | 15.0 |
Parasite Egg Count | 2 | 5.0 |
Fetal Blood/cytology/*immunology | 3 | 15.0 |
Osteosarcoma | 3 | 3.0 |
Acquired Immunodeficiency Syndrome/blood/*immunology | 13 | 56.0 |
Antigens, CD95/*biosynthesis | 3 | 16.0 |
Bone Marrow/*immunology | 9 | 15.0 |
Neoplasms/immunology/*therapy | 3 | 5.0 |
Alveolitis, Extrinsic Allergic/immunology | 2 | 40.0 |
Interleukin-8/biosynthesis | 2 | 1.0 |
Pulmonary Fibrosis/immunology | 4 | 57.0 |
Sarcoidosis/immunology | 5 | 33.0 |
Arthritis, Rheumatoid/*immunology/therapy | 4 | 80.0 |
Monocytes/*drug effects | 5 | 9.0 |
Receptors, Chemokine/*biosynthesis | 2 | 5.0 |
Kidney/metabolism | 2 | 0.0 |
Menstruation | 2 | 3.0 |
HIV Seropositivity/immunology/*physiopathology | 4 | 100.0 |
HIV Infections/immunology/physiopathology/*virology | 3 | 100.0 |
AIDS Vaccines/adverse effects/*immunology | 4 | 100.0 |
HIV Envelope Protein gp120/adverse effects/*immunology | 2 | 100.0 |
Anti-HIV Agents/*pharmacology/toxicity | 2 | 100.0 |
Antigens, CD4/genetics/*isolation & purification | 2 | 100.0 |
Cell Membrane/ultrastructure | 8 | 16.0 |
Nucleic Acid Conformation | 2 | 0.0 |
Staining and Labeling/*methods | 3 | 15.0 |
HIV-1/classification/genetics/*isolation & purification | 2 | 66.0 |
Monitoring, Physiologic/methods | 3 | 12.0 |
Antigens, Surface/physiology | 9 | 23.0 |
CD4-Positive T-Lymphocytes/physiology/*virology | 2 | 40.0 |
Cyclophosphamide/*administration & dosage | 5 | 23.0 |
Gene Products, nef/metabolism/*physiology | 2 | 100.0 |
Eosinophils | 5 | 13.0 |
Tuberculosis, Pulmonary/etiology | 2 | 66.0 |
Ciprofloxacin/pharmacology | 3 | 25.0 |
Tetracycline/pharmacology | 3 | 3.0 |
Urethra/*microbiology | 2 | 100.0 |
Eosinophils/*physiology | 3 | 7.0 |
Interleukin-5/*physiology | 2 | 22.0 |
Receptors, Interleukin/*physiology | 2 | 8.0 |
Antilymphocyte Serum/*immunology | 6 | 46.0 |
Infection/*etiology | 2 | 20.0 |
Receptors, HIV/biosynthesis/*metabolism | 2 | 100.0 |
Mycobacterium avium-intracellulare Infection/complications/*drug therapy | 3 | 100.0 |
Heroin Dependence/*immunology | 2 | 100.0 |
Substance Withdrawal Syndrome/*immunology | 3 | 100.0 |
Antigens, CD95/*biosynthesis/genetics | 2 | 28.0 |
Interleukin-7/*pharmacology | 7 | 17.0 |
Up-Regulation/*drug effects | 2 | 2.0 |
Leukemia, Lymphocytic, Chronic/*drug therapy/mortality | 2 | 66.0 |
Vidarabine/administration & dosage/*analogs & derivatives/therapeutic use | 2 | 100.0 |
CD4-Positive T-Lymphocytes/pathology/virology | 3 | 100.0 |
beta 2-Microglobulin/immunology | 4 | 11.0 |
BCG Vaccine/*administration & dosage | 2 | 33.0 |
Antigens, CD4/chemistry/genetics | 2 | 100.0 |
*Point Mutation | 6 | 0.0 |
Regulatory Sequences, Nucleic Acid | 4 | 0.0 |
Lung/microbiology | 5 | 29.0 |
Bladder Neoplasms/immunology/*therapy | 2 | 66.0 |
AIDS-Related Opportunistic Infections/*drug therapy/prevention & control | 2 | 66.0 |
Fluconazole/*administration & dosage | 2 | 40.0 |
Insulin/blood | 4 | 0.0 |
*Protein Biosynthesis | 4 | 0.0 |
Cytomegalovirus Retinitis/*immunology | 2 | 100.0 |
Leishmaniasis, Cutaneous/*immunology | 2 | 50.0 |
Protein Kinase Inhibitors | 3 | 2.0 |
Vanadates/pharmacology | 3 | 2.0 |
HIV Infections/*blood/*immunology | 4 | 100.0 |
Pregnancy Complications, Infectious/*diagnosis/virology | 2 | 100.0 |
Bladder Neoplasms/*immunology | 2 | 9.0 |
Codon/genetics | 7 | 2.0 |
Lamivudine/*pharmacology/therapeutic use | 2 | 100.0 |
B-Lymphocytes/drug effects/*metabolism | 2 | 9.0 |
Monocytes/drug effects/*metabolism | 2 | 1.0 |
Antifungal Agents/administration & dosage/therapeutic use | 4 | 100.0 |
Hemophilia A/complications/*therapy | 2 | 100.0 |
Cerebral Cortex/physiopathology | 2 | 8.0 |
Herpes Simplex/*immunology | 3 | 18.0 |
Lymphotoxin/metabolism | 2 | 20.0 |
HIV-2/metabolism/*physiology | 3 | 75.0 |
SIV/metabolism/*physiology | 2 | 66.0 |
Ribavirin/administration & dosage/therapeutic use | 2 | 50.0 |
Vidarabine/adverse effects/*analogs & derivatives/therapeutic use | 2 | 100.0 |
Measles Vaccine | 2 | 50.0 |
Immunosuppressive Agents/metabolism/*pharmacology | 2 | 66.0 |
Fixatives | 3 | 4.0 |
Membrane Proteins/*analysis | 8 | 11.0 |
Receptors, Antigen, T-Cell/*analysis | 29 | 55.0 |
Lymphocyte Function-Associated Antigen-1/blood | 2 | 50.0 |
*Chromosomes, Human, Pair 5 | 4 | 1.0 |
Fluconazole/administration & dosage/*therapeutic use | 7 | 100.0 |
Random Amplified Polymorphic DNA Technique | 2 | 8.0 |
Blood Chemical Analysis/methods | 2 | 16.0 |
HIV Envelope Protein gp41/genetics/immunology | 2 | 100.0 |
G2 Phase | 3 | 1.0 |
S Phase | 3 | 0.0 |
*Homosexuality | 26 | 65.0 |
Luteinizing Hormone/blood | 5 | 0.0 |
Weight Loss/*physiology | 5 | 15.0 |
Preoperative Care | 6 | 3.0 |
Respiratory Tract Infections/immunology | 2 | 50.0 |
Antibody Affinity/immunology | 3 | 18.0 |
Gene Products, vpu/*metabolism | 10 | 100.0 |
Repetitive Sequences, Nucleic Acid | 13 | 1.0 |
Serine/metabolism | 5 | 1.0 |
Ubiquitins/metabolism | 2 | 1.0 |
beta-Transducin Repeat-Containing Proteins | 2 | 16.0 |
DNA, Neoplasm/analysis/genetics | 4 | 4.0 |
Flow Cytometry/instrumentation/*methods | 3 | 42.0 |
Antigens, Neoplasm/*blood | 3 | 6.0 |
Leukemia, Myeloid/*immunology | 3 | 7.0 |
Rodentia | 2 | 2.0 |
Cytoplasm | 3 | 4.0 |
*Mitogen-Activated Protein Kinase Kinases | 4 | 4.0 |
Protein-Serine-Threonine Kinases/*metabolism | 8 | 1.0 |
Tumor Necrosis Factor-alpha/*genetics | 2 | 0.0 |
*Allergens | 3 | 18.0 |
*Pollen | 4 | 40.0 |
*ADP Ribose Transferases | 10 | 12.0 |
Interleukin-2/biosynthesis/pharmacology | 6 | 28.0 |
*Virulence Factors | 10 | 12.0 |
Receptors, CCR5/genetics/*physiology | 2 | 28.0 |
Receptors, Virus/genetics/*physiology | 2 | 40.0 |
Cholera Toxin/metabolism | 2 | 20.0 |
Heat-Shock Proteins/immunology | 6 | 40.0 |
*Peripheral Blood Stem Cell Transplantation | 4 | 22.0 |
Diabetes Mellitus, Type 1/*immunology/metabolism | 2 | 66.0 |
Cell Size | 4 | 1.0 |
HIV/*isolation & purification/pathogenicity | 2 | 100.0 |
HIV Infections/etiology | 4 | 40.0 |
HIV Infections/*epidemiology/*immunology | 2 | 100.0 |
HIV Infections/*drug therapy/immunology/*mortality | 3 | 100.0 |
Dermatitis, Seborrheic/etiology | 2 | 66.0 |
Skin Diseases/*etiology | 3 | 42.0 |
*Mistletoe | 3 | 75.0 |
Xenopus laevis | 2 | 0.0 |
Cell Movement/physiology | 7 | 3.0 |
Antigens, CD4/*chemistry/*physiology | 2 | 100.0 |
HIV Envelope Protein gp120/*chemistry/*physiology | 2 | 100.0 |
Receptor Aggregation | 14 | 14.0 |
Receptors, Virus/physiology | 10 | 40.0 |
HIV Antibodies/blood/immunology | 5 | 83.0 |
Suspensions | 6 | 30.0 |
*HIV-1/genetics/physiology | 2 | 50.0 |
B-Lymphocytes/cytology/immunology | 4 | 12.0 |
*Hyperthermia, Induced | 3 | 6.0 |
Monokines/*metabolism | 2 | 66.0 |
Retroviridae/*genetics | 5 | 3.0 |
Intestinal Mucosa/cytology/*immunology | 3 | 20.0 |
Interleukin-1/*physiology | 2 | 2.0 |
Interleukin-6/*biosynthesis | 4 | 3.0 |
CD4-Positive T-Lymphocytes/cytology/metabolism | 4 | 40.0 |
CD8-Positive T-Lymphocytes/cytology/metabolism | 3 | 60.0 |
Gene Rearrangement, beta-Chain T-Cell Antigen Receptor/immunology | 2 | 40.0 |
Multigene Family/*immunology | 2 | 8.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/therapeutic use | 3 | 11.0 |
HIV Infections/mortality/*physiopathology | 2 | 100.0 |
Aqueous Humor/cytology | 2 | 66.0 |
T-Lymphocytes, Helper-Inducer/*metabolism | 4 | 25.0 |
Hyaluronic Acid/*metabolism | 2 | 1.0 |
Recombinant Fusion Proteins/genetics/immunology/metabolism | 2 | 16.0 |
Lymphoma, AIDS-Related/*drug therapy | 2 | 100.0 |
Bacterial Vaccines/administration & dosage/*immunology | 2 | 50.0 |
HIV/immunology/physiology | 2 | 50.0 |
HIV Antibodies/*chemistry/immunology | 2 | 100.0 |
HIV-1/*chemistry/immunology | 7 | 77.0 |
Antigens, CD4/*chemistry/immunology/metabolism | 3 | 100.0 |
Cricetulus | 11 | 2.0 |
HIV Envelope Protein gp120/*chemistry/immunology/metabolism | 3 | 75.0 |
Acquired Immunodeficiency Syndrome/immunology/mortality/*therapy | 2 | 100.0 |
*Endoscopy | 2 | 10.0 |
AIDS-Related Opportunistic Infections/blood | 3 | 100.0 |
Acquired Immunodeficiency Syndrome/blood | 10 | 58.0 |
T-Lymphocyte Subsets/immunology/virology | 6 | 66.0 |
Brain/immunology/*virology | 2 | 66.0 |
*Chromosome Mapping | 2 | 0.0 |
Antigens, CD26/biosynthesis/*immunology | 3 | 100.0 |
Antigens, CD4/biosynthesis/*immunology | 4 | 100.0 |
Lymphotoxin/analysis | 3 | 25.0 |
DNA, Complementary/chemistry/isolation & purification | 2 | 4.0 |
Antigens, CD4/biosynthesis/genetics/*immunology | 3 | 100.0 |
Binding Sites, Antibody/drug effects | 3 | 25.0 |
Cytokines/antagonists & inhibitors/biosynthesis | 2 | 11.0 |
Interleukin-10/antagonists & inhibitors/secretion | 2 | 66.0 |
Receptors, Antigen, T-Cell/metabolism/*physiology | 5 | 55.0 |
Receptors, Fc/metabolism | 5 | 10.0 |
DMF Index | 2 | 18.0 |
DNA Footprinting | 3 | 1.0 |
Herpesvirus 8, Human/genetics/*isolation & purification | 2 | 28.0 |
*African Continental Ancestry Group | 6 | 5.0 |
HIV Infections/*epidemiology/immunology/transmission | 2 | 100.0 |
Sarcoma, Kaposi/*epidemiology/immunology | 2 | 100.0 |
Urban Population/*statistics & numerical data | 4 | 50.0 |
Interferons/administration & dosage/*therapeutic use | 2 | 50.0 |
Lymphoma, Large-Cell/immunology/*pathology | 2 | 40.0 |
Lymphoma, T-Cell, Cutaneous/immunology/*pathology | 2 | 66.0 |
Skin Neoplasms/immunology/*pathology | 5 | 19.0 |
*Bone Marrow Transplantation/adverse effects | 3 | 11.0 |
*Lymphocyte Transfusion/adverse effects | 2 | 66.0 |
Neoplasm, Residual | 2 | 2.0 |
Epithelium/metabolism/pathology | 3 | 4.0 |
Antigens, CD4/*chemistry/*metabolism/pharmacology | 2 | 100.0 |
Biotechnology | 4 | 14.0 |
Peptide Fragments/chemistry/metabolism/pharmacology | 2 | 25.0 |
Biological Assay | 6 | 2.0 |
Giant Cells/pathology/virology | 4 | 66.0 |
GTP-Binding Proteins/physiology | 3 | 4.0 |
Virulence Factors, Bordetella/pharmacology | 4 | 2.0 |
Gene Products, nef/physiology | 3 | 60.0 |
Gene Products, rev/physiology | 2 | 66.0 |
Membrane Proteins/chemistry | 3 | 6.0 |
Receptors, Interleukin-8B | 2 | 18.0 |
Acquired Immunodeficiency Syndrome/*complications/pathology | 5 | 55.0 |
Malaria/*complications/immunology | 2 | 100.0 |
*Exercise Therapy | 2 | 7.0 |
Histiocytes/pathology | 6 | 24.0 |
Galactosylceramides/analysis | 2 | 22.0 |
Arginine/*administration & dosage | 2 | 50.0 |
Fatty Acids, Omega-3/*administration & dosage | 2 | 15.0 |
Endocytosis/drug effects | 8 | 12.0 |
Oligonucleotides, Antisense/pharmacology | 3 | 1.0 |
Leupeptins/pharmacology | 5 | 3.0 |
Mycoplasma penetrans/*immunology | 2 | 66.0 |
Interleukin-2 | 4 | 23.0 |
Muromonab-CD3 | 2 | 25.0 |
*Plasmapheresis | 2 | 6.0 |
Lymphokines/immunology | 3 | 15.0 |
Zidovudine/economics/*therapeutic use | 3 | 100.0 |
Blood Cells/immunology | 3 | 9.0 |
Cell Aging/physiology | 2 | 6.0 |
Acquired Immunodeficiency Syndrome/*etiology | 11 | 78.0 |
Skin Neoplasms/immunology/pathology/*veterinary | 2 | 100.0 |
Lymphocytes/*drug effects/immunology/metabolism | 2 | 50.0 |
Receptors, Transferrin/metabolism | 8 | 11.0 |
HIV Seropositivity/virology | 3 | 60.0 |
AIDS-Related Opportunistic Infections/*epidemiology/immunology/virology | 2 | 100.0 |
*Selection (Genetics) | 3 | 4.0 |
Rifamycins/therapeutic use | 2 | 66.0 |
*Bereavement | 3 | 100.0 |
HIV Seropositivity/*immunology/*psychology | 3 | 100.0 |
Intervention Studies | 4 | 19.0 |
HIV Infections/*drug therapy/epidemiology/immunology | 2 | 66.0 |
Myelin Basic Proteins/*immunology | 3 | 1.0 |
Apoptosis/genetics/*immunology | 4 | 22.0 |
Interferons/biosynthesis | 2 | 13.0 |
Chromosomes, Human, Pair 7 | 2 | 1.0 |
Carrier Proteins/genetics/*metabolism | 2 | 0.0 |
Macrophages/immunology/pathology/*virology | 2 | 100.0 |
Antigens, CD4/*chemistry/physiology | 4 | 100.0 |
HIV Envelope Protein gp120/*chemistry/physiology | 2 | 50.0 |
Breast Neoplasms/*genetics | 2 | 0.0 |
*Genes, MDR | 2 | 5.0 |
Neoplasm Proteins/*analysis/genetics | 2 | 4.0 |
Receptor, Anaphylatoxin C5a | 2 | 10.0 |
Receptor-CD3 Complex, Antigen, T-Cell/*immunology | 3 | 23.0 |
Signal Transduction/drug effects/*immunology | 4 | 10.0 |
Los Angeles | 4 | 25.0 |
Lymphopenia/*complications/pathology | 2 | 100.0 |
Skin Neoplasms/*etiology | 2 | 33.0 |
Electrophoresis/methods | 2 | 2.0 |
Acquired Immunodeficiency Syndrome/epidemiology/immunology | 2 | 66.0 |
HIV Seropositivity/epidemiology/immunology | 3 | 100.0 |
Myasthenia Gravis/*immunology | 3 | 13.0 |
Chemokines, CXC/*physiology | 2 | 5.0 |
Erythrocyte Membrane/metabolism | 2 | 3.0 |
HIV Envelope Protein gp120/chemistry/immunology/*metabolism | 3 | 100.0 |
Peptide Fragments/chemistry/immunology/metabolism | 2 | 25.0 |
Leukocytes/drug effects/*physiology | 2 | 16.0 |
Microsporida/isolation & purification | 2 | 100.0 |
Hepatitis C/*complications/*virology | 2 | 100.0 |
Egypt | 3 | 6.0 |
*Repetitive Sequences, Nucleic Acid | 6 | 1.0 |
AIDS-Related Opportunistic Infections/blood/immunology/pathology | 2 | 100.0 |
HIV Infections/blood/immunology/*pathology | 2 | 100.0 |
Lymphocytosis/immunology/*pathology | 2 | 100.0 |
CD4 Lymphocyte Count/*instrumentation | 2 | 100.0 |
Louisiana | 5 | 25.0 |
Mutation, Missense | 5 | 0.0 |
Neovascularization, Pathologic | 2 | 0.0 |
T-Lymphocyte Subsets/cytology/*metabolism | 3 | 42.0 |
AIDS-Related Opportunistic Infections/diagnosis/*parasitology | 2 | 100.0 |
Blood Banks | 3 | 27.0 |
Withholding Treatment | 2 | 66.0 |
Viral Vaccines/immunology | 4 | 50.0 |
HIV Integrase Inhibitors/*pharmacology | 2 | 100.0 |
Quinolines/*pharmacology | 3 | 10.0 |
Laboratories | 3 | 15.0 |
Arthritis, Rheumatoid/drug therapy/*immunology | 4 | 28.0 |
Receptors, Chemokine/*blood | 3 | 50.0 |
Serum Amyloid A Protein/analysis | 2 | 5.0 |
T-Lymphocytes/chemistry | 5 | 16.0 |
Alkylating Agents/therapeutic use | 2 | 66.0 |
Victoria/epidemiology | 2 | 50.0 |
HIV Infections/blood/*complications/drug therapy | 3 | 100.0 |
Meningitis, Cryptococcal/*prevention & control | 3 | 100.0 |
Antilipemic Agents/*therapeutic use | 2 | 2.0 |
Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use | 2 | 4.0 |
Interleukins/*metabolism | 2 | 15.0 |
Human T-lymphotropic virus 1/genetics/*immunology | 2 | 33.0 |
HIV Core Protein p24/*immunology/pharmacology | 2 | 100.0 |
Nelfinavir/administration & dosage/*therapeutic use | 2 | 100.0 |
*Heat | 2 | 1.0 |
beta-Endorphin/blood | 3 | 8.0 |
Cysteine/blood | 2 | 40.0 |
Immunity, Natural/drug effects | 2 | 15.0 |
T-Lymphocytes/drug effects/*physiology | 8 | 57.0 |
Receptor-CD3 Complex, Antigen, T-Cell/metabolism | 3 | 27.0 |
Receptors, Interleukin-2/genetics/metabolism | 4 | 28.0 |
Interferon-alpha/*administration & dosage/adverse effects | 2 | 40.0 |
Anti-HIV Agents/adverse effects/*pharmacokinetics/*therapeutic use | 3 | 100.0 |
AIDS-Related Opportunistic Infections/*radiography | 6 | 100.0 |
Tuberculosis, Pulmonary/*radiography | 2 | 100.0 |
New South Wales/epidemiology | 3 | 20.0 |
AIDS-Related Opportunistic Infections/complications/*virology | 2 | 50.0 |
Herpesvirus 8, Human/*genetics | 2 | 12.0 |
Sarcoma, Kaposi/complications/*virology | 2 | 100.0 |
Interleukin-6/metabolism | 7 | 3.0 |
Antigens, CD44/*metabolism | 2 | 1.0 |
HIV Infections/immunology/metabolism | 4 | 44.0 |
Endometrium/immunology | 4 | 33.0 |
DNA, Protozoan/analysis | 2 | 11.0 |
Diarrhea/parasitology | 4 | 100.0 |
Carmustine/therapeutic use | 2 | 28.0 |
Cisplatin/therapeutic use | 2 | 5.0 |
Congo/epidemiology | 2 | 100.0 |
HIV Seropositivity/complications/*mortality | 2 | 100.0 |
Dendritic Cells/*immunology/pathology | 5 | 29.0 |
Irrigation | 5 | 8.0 |
Antibodies, Monoclonal/*adverse effects | 2 | 11.0 |
Electricity | 4 | 30.0 |
Neutropenia/etiology | 3 | 30.0 |
Biological Markers/blood/cerebrospinal fluid | 2 | 50.0 |
Meningitis/*immunology | 2 | 66.0 |
Multiple Sclerosis/*immunology | 8 | 7.0 |
Paraffin | 4 | 8.0 |
Carboxylesterase | 3 | 8.0 |
Asthma/*immunology/physiopathology | 3 | 50.0 |
DNA, Viral/genetics/isolation & purification | 12 | 46.0 |
Epithelium/ultrastructure/virology | 2 | 100.0 |
RNA, Viral/genetics/isolation & purification | 7 | 35.0 |
Macrophages/*immunology/microbiology | 3 | 18.0 |
T-Lymphocyte Subsets/*classification | 4 | 80.0 |
Acquired Immunodeficiency Syndrome/*complications/microbiology | 2 | 66.0 |
DNA, Bacterial/isolation & purification | 2 | 33.0 |
Mycobacterium avium-intracellulare Infection/*complications/microbiology | 2 | 100.0 |
Cytochalasin D/pharmacology | 3 | 3.0 |
HIV Envelope Protein gp120/*analysis | 4 | 80.0 |
Antigens, CD/*pharmacology | 2 | 18.0 |
Antigens, CD80/*pharmacology | 2 | 33.0 |
Immunoglobulins, Fc/pharmacology | 2 | 33.0 |
Interleukin-4/secretion | 10 | 24.0 |
Myelin Basic Proteins/immunology | 3 | 3.0 |
Recombinant Fusion Proteins/pharmacology | 5 | 5.0 |
G(M1) Ganglioside/immunology | 2 | 20.0 |
Mice, Mutant Strains | 13 | 1.0 |
Mice, Inbred AKR | 4 | 8.0 |
Herpesvirus 4, Human/genetics/*isolation & purification/pathogenicity | 2 | 66.0 |
Gene Products, tat/antagonists & inhibitors | 2 | 66.0 |
AIDS-Related Opportunistic Infections/diagnosis/immunology | 2 | 100.0 |
Escherichia coli | 5 | 1.0 |
HIV Infections/*blood/virology | 3 | 42.0 |
Hypergammaglobulinemia/*immunology | 3 | 33.0 |
CD4-Positive T-Lymphocytes/enzymology/immunology | 2 | 50.0 |
Leukocytes, Mononuclear/cytology/*virology | 2 | 66.0 |
HIV Infections/complications/immunology | 6 | 85.0 |
Hematologic Tests | 4 | 11.0 |
HIV Infections/*blood/epidemiology/immunology | 4 | 100.0 |
AIDS-Related Opportunistic Infections/blood/complications | 2 | 100.0 |
Antigen-Antibody Complex/*analysis | 2 | 1.0 |
Genes, rev | 3 | 25.0 |
*Viral Interference | 2 | 50.0 |
HIV-2/isolation & purification/*metabolism | 2 | 100.0 |
Defective Viruses/*genetics | 2 | 28.0 |
HIV Seropositivity/immunology/*virology | 6 | 75.0 |
Polymers/*metabolism | 2 | 14.0 |
Antitubercular Agents/administration & dosage | 2 | 50.0 |
Emigration and Immigration | 2 | 4.0 |
Cholecystectomy | 2 | 11.0 |
Interferon Alfa-2b/therapeutic use | 3 | 21.0 |
HLA-DQ Antigens/analysis | 7 | 14.0 |
Peptides/chemistry/immunology | 6 | 15.0 |
Chimeric Proteins | 10 | 11.0 |
Cysteine/chemistry | 3 | 2.0 |
Protein-Tyrosine Kinase/*physiology | 8 | 5.0 |
Receptors, Antigen, T-Cell/*chemistry | 3 | 60.0 |
Antigens, Differentiation/*physiology | 11 | 12.0 |
Interleukin-2/*secretion | 3 | 20.0 |
Antigens, CD/analysis/*physiology | 5 | 17.0 |
Antigens, Differentiation, T-Lymphocyte/analysis/*physiology | 2 | 22.0 |
CD8-Positive T-Lymphocytes/cytology/immunology/metabolism | 2 | 28.0 |
Genes, RAG-1/immunology | 2 | 66.0 |
Thymus Gland | 2 | 10.0 |
Protein Binding/genetics/immunology | 2 | 2.0 |
Herpes Genitalis/immunology/*virology | 2 | 100.0 |
Endothelium, Vascular/*immunology | 6 | 7.0 |
Lymphocytes/chemistry | 7 | 12.0 |
RNA, Viral/*isolation & purification | 5 | 83.0 |
Azithromycin/therapeutic use | 3 | 60.0 |
Adenocarcinoma/*immunology/pathology | 4 | 20.0 |
Receptors, Antigen, T-Cell, alpha-beta/*analysis | 14 | 56.0 |
Anus/pathology/virology | 2 | 100.0 |
Anus Neoplasms/epidemiology/*etiology/pathology | 3 | 100.0 |
Carcinoma in Situ/epidemiology/*etiology/pathology | 3 | 100.0 |
Neoplasms, Squamous Cell/epidemiology/*etiology/pathology | 2 | 100.0 |
Papillomavirus, Human | 4 | 10.0 |
AIDS-Related Opportunistic Infections/*complications/epidemiology | 4 | 100.0 |
Acquired Immunodeficiency Syndrome/*complications/epidemiology | 2 | 40.0 |
Sarcoma, Kaposi/complications/epidemiology | 2 | 100.0 |
*Graft Rejection | 11 | 12.0 |
Heart Transplantation/*pathology | 2 | 66.0 |
Bronchi/pathology | 3 | 15.0 |
Interleukin-10/*metabolism | 3 | 10.0 |
Pregnancy Complications, Infectious/virology | 6 | 60.0 |
Interleukin-6/immunology/metabolism | 2 | 40.0 |
Acquired Immunodeficiency Syndrome/*etiology/immunology/virology | 2 | 66.0 |
Antigens, CD4/genetics/physiology | 2 | 50.0 |
Cytoplasm/*immunology | 3 | 18.0 |
Fibronectins/*physiology | 4 | 28.0 |
Dendritic Cells/*cytology/immunology/metabolism | 2 | 25.0 |
Epithelial Cells/cytology/immunology | 2 | 15.0 |
*Communicable Disease Control | 2 | 20.0 |
HIV Infections/physiopathology/*therapy | 2 | 100.0 |
Filariasis/*immunology | 4 | 100.0 |
Wuchereria bancrofti/*immunology | 2 | 40.0 |
Coronary Disease/*immunology/pathology | 3 | 100.0 |
Blood/*microbiology | 2 | 28.0 |
Bone Marrow/*microbiology/pathology | 2 | 100.0 |
Histoplasma/isolation & purification | 3 | 100.0 |
Muscle, Skeletal/*immunology | 3 | 75.0 |
Indinavir/*pharmacology | 2 | 33.0 |
*Models, Theoretical | 3 | 5.0 |
Second Messenger Systems | 5 | 5.0 |
Lymph Nodes/pathology/*virology | 4 | 100.0 |
Jejunum/immunology | 3 | 42.0 |
T-Lymphocytes/classification/*immunology | 30 | 45.0 |
Tretinoin/pharmacology | 5 | 1.0 |
Monocytes/metabolism/*virology | 2 | 33.0 |
RANTES/metabolism/pharmacology | 2 | 25.0 |
Papillomavirus, Human/classification/genetics/isolation & purification | 2 | 66.0 |
Precancerous Conditions/epidemiology/*etiology/pathology | 2 | 100.0 |
HIV Seropositivity/*complications/immunology/virology | 2 | 100.0 |
Leukemia Virus, Murine/genetics | 3 | 21.0 |
Moloney murine leukemia virus/genetics | 5 | 17.0 |
Neurons/virology | 2 | 20.0 |
Lactoferrin/*pharmacology | 2 | 8.0 |
Singapore/epidemiology | 4 | 12.0 |
Palmitic Acid/metabolism | 3 | 17.0 |
Entropy | 2 | 10.0 |
RNA, Viral/*blood/drug effects | 2 | 66.0 |
Lymphocyte Subsets/*immunology/metabolism | 2 | 50.0 |
Sarcoma, Kaposi/epidemiology/*virology | 2 | 100.0 |
Chloroquine/pharmacology | 8 | 10.0 |
Antibodies, Monoclonal/*chemistry/immunology | 2 | 28.0 |
*Immunosuppressive Agents | 2 | 15.0 |
Lymphocyte Count/*methods | 2 | 100.0 |
HIV-1/drug effects/immunology/*physiology | 4 | 57.0 |
Aging/*blood/immunology | 2 | 66.0 |
Lymphocytes/immunology/*ultrastructure | 2 | 66.0 |
T-Lymphocytes/immunology/ultrastructure | 2 | 50.0 |
Anabolic Agents/*therapeutic use | 2 | 33.0 |
Antiviral Agents/*administration & dosage/adverse effects | 4 | 80.0 |
*Cytomegalovirus | 3 | 37.0 |
Receptors, Immunologic/physiology | 14 | 12.0 |
Transcription, Genetic/genetics | 3 | 0.0 |
Fluorescein | 2 | 8.0 |
*Fluorescent Dyes | 5 | 15.0 |
Eosinophils/cytology | 3 | 21.0 |
Lung Neoplasms/*drug therapy/mortality | 2 | 22.0 |
Sarcoma, Kaposi/*drug therapy/mortality | 2 | 100.0 |
Killer Cells, Lymphokine-Activated/*drug effects | 2 | 28.0 |
Neoplasms/*blood/therapy | 2 | 28.0 |
Decidua/*immunology | 2 | 11.0 |
Crohn Disease/*complications/immunology | 2 | 66.0 |
Peptide Fragments/*physiology | 2 | 7.0 |
Sarcoma, Kaposi/*drug therapy/etiology | 2 | 66.0 |
Scotland/epidemiology | 12 | 34.0 |
Survival Rate/trends | 2 | 33.0 |
Dermatitis, Atopic/immunology/*pathology | 2 | 100.0 |
Estradiol/blood | 7 | 1.0 |
Cancer Vaccines/*therapeutic use | 3 | 13.0 |
*Dendritic Cells | 4 | 36.0 |
Melanoma/*therapy | 2 | 25.0 |
Peptides/therapeutic use | 3 | 37.0 |
HIV Envelope Protein gp120/genetics/metabolism | 4 | 50.0 |
HIV-1/genetics/isolation & purification/*metabolism | 3 | 75.0 |
Bromodeoxyuridine/metabolism | 2 | 2.0 |
Mathematics | 5 | 2.0 |
*Enhancer Elements (Genetics) | 4 | 1.0 |
Cell Fusion/*physiology | 2 | 40.0 |
Blood Cells/metabolism | 2 | 6.0 |
Cell Division/drug effects/physiology | 2 | 0.0 |
Osmolar Concentration | 10 | 1.0 |
Uveal Neoplasms/*immunology/pathology | 2 | 50.0 |
Acylation | 2 | 2.0 |
Glycosylphosphatidylinositols/*metabolism | 3 | 5.0 |
Membrane Lipids/*metabolism | 3 | 9.0 |
Protein-Tyrosine Kinase/genetics/*metabolism | 5 | 3.0 |
HIV Infections/blood/diagnosis/*immunology | 3 | 100.0 |
Leukocytes, Mononuclear/cytology/metabolism | 3 | 18.0 |
Cytosol/metabolism | 5 | 0.0 |
Gene Products, vpu/genetics/*metabolism | 9 | 100.0 |
Acquired Immunodeficiency Syndrome/*mortality | 7 | 100.0 |
Decision Making | 5 | 7.0 |
Vitamin A/blood/*therapeutic use | 3 | 100.0 |
Fixatives/*pharmacology | 4 | 57.0 |
CD4-Positive T-Lymphocytes/enzymology/*immunology | 3 | 100.0 |
Cytoplasm/enzymology | 2 | 2.0 |
Interleukin-2/*blood | 3 | 13.0 |
Protein Kinase C/antagonists & inhibitors/*metabolism | 2 | 2.0 |
Dehydroepiandrosterone Sulfate/*blood | 2 | 14.0 |
Blood Cells/*immunology | 3 | 15.0 |
Arthritis, Rheumatoid/blood/*therapy | 2 | 66.0 |
Hematopoietic Stem Cells/*immunology | 12 | 8.0 |
Metaphase | 3 | 2.0 |
T-Lymphocytes/cytology/physiology | 2 | 22.0 |
Thymus Gland/cytology/*physiology | 3 | 33.0 |
*Chemokines, CXC | 5 | 7.0 |
Chemotactic Factors/*pharmacology | 4 | 11.0 |
T-Lymphocyte Subsets/cytology/*drug effects | 2 | 66.0 |
Open Reading Frames | 5 | 0.0 |
Pleura/pathology | 2 | 66.0 |
Variation (Genetics)/*genetics | 5 | 2.0 |
Glomerulonephritis, Membranous/*immunology/pathology | 2 | 66.0 |
Leukocytes/pathology | 2 | 6.0 |
*Clone Cells | 2 | 28.0 |
Lymphocytes/*cytology/immunology | 3 | 30.0 |
Clonal Anergy/physiology | 2 | 66.0 |
Chromosomes, Human, Pair 22/*genetics | 2 | 2.0 |
HIV Antibodies/*analysis | 9 | 42.0 |
Hepatitis B/*immunology | 4 | 12.0 |
Pneumonia, Pneumocystis/mortality | 2 | 100.0 |
Candida/immunology | 4 | 33.0 |
Diphtheria Toxoid/immunology | 2 | 25.0 |
*Evoked Potentials | 3 | 30.0 |
Carcinoma, Transitional Cell/*immunology/pathology | 2 | 66.0 |
Aqueous Humor/*immunology | 2 | 33.0 |
Keratinocytes/drug effects/*immunology/virology | 2 | 100.0 |
Viral Envelope Proteins/*biosynthesis | 4 | 80.0 |
HIV Seropositivity/blood/microbiology | 3 | 100.0 |
Transcription Factor AP-1/*metabolism | 2 | 1.0 |
Influenza A Virus, Human/immunology | 4 | 16.0 |
Thymoma | 2 | 22.0 |
HIV Envelope Protein gp160 | 91 | 86.0 |
HIV Infections/*immunology/therapy/virology | 2 | 100.0 |
Vaccines, Synthetic/immunology/therapeutic use | 2 | 100.0 |
Fatigue Syndrome, Chronic/*immunology | 3 | 37.0 |
Papillomavirus, Human/genetics/*isolation & purification | 2 | 13.0 |
Immunity, Active | 3 | 37.0 |
*Herpesviridae Infections | 2 | 66.0 |
*Herpesvirus 7, Human | 2 | 66.0 |
Receptors, Virus/genetics | 2 | 20.0 |
Immunization, Passive | 19 | 22.0 |
Lipoproteins, LDL/*metabolism | 2 | 1.0 |
Brain Neoplasms/*immunology | 4 | 30.0 |
Glioma/*immunology | 2 | 13.0 |
Interferon Type II/*physiology | 2 | 3.0 |
Monocytes/drug effects/*immunology/metabolism | 2 | 15.0 |
Lymphocytes/classification/*immunology | 4 | 21.0 |
Receptors, Cytokine/genetics/*metabolism | 5 | 16.0 |
Phosphatidylserines/*biosynthesis | 2 | 33.0 |
Phospholipids/metabolism | 3 | 1.0 |
*Plant Lectins | 17 | 16.0 |
HIV Seropositivity/immunology/*therapy | 2 | 100.0 |
HIV Seropositivity/*diagnosis/epidemiology | 2 | 100.0 |
Viremia/immunology/therapy | 2 | 100.0 |
*Chromosomes, Human, Pair 12 | 6 | 2.0 |
Dust | 3 | 10.0 |
P-Selectin/analysis | 2 | 10.0 |
Anti-Infective Agents/economics | 2 | 100.0 |
Diagnosis-Related Groups | 2 | 40.0 |
*Drug Costs | 3 | 100.0 |
Viral Load/*methods | 4 | 100.0 |
T-Lymphocytes, Cytotoxic/pathology | 10 | 62.0 |
RNA, Viral/chemistry/genetics | 2 | 25.0 |
Cell Adhesion Molecules/*blood | 7 | 11.0 |
Endothelin-1/blood | 2 | 11.0 |
Monocytes/chemistry/metabolism | 2 | 20.0 |
Saliva/immunology | 3 | 11.0 |
Liver/drug effects | 4 | 10.0 |
Leukoencephalopathy, Progressive Multifocal/*diagnosis | 2 | 50.0 |
AIDS-Related Opportunistic Infections/*drug therapy/pathology | 2 | 100.0 |
AIDS-Related Opportunistic Infections/*complications/microbiology | 3 | 75.0 |
Thalidomide/therapeutic use | 2 | 14.0 |
Candidiasis, Oral/epidemiology/etiology | 3 | 100.0 |
HIV Infections/*complications/diagnosis/epidemiology | 2 | 100.0 |
HIV Seropositivity/complications/epidemiology | 4 | 100.0 |
AIDS-Related Opportunistic Infections/epidemiology/*mortality | 2 | 100.0 |
Sarcoma, Kaposi/mortality | 2 | 100.0 |
Viremia/*drug therapy/immunology | 2 | 100.0 |
Eating | 6 | 4.0 |
Feeding Behavior | 2 | 8.0 |
Immunologic Surveillance | 4 | 15.0 |
Lymphocytes, Tumor-Infiltrating/*physiology | 4 | 50.0 |
False Positive Reactions | 3 | 1.0 |
Liver Diseases/immunology | 2 | 13.0 |
Acquired Immunodeficiency Syndrome/blood/*drug therapy/virology | 2 | 66.0 |
HIV-2/classification/*genetics/pathogenicity | 2 | 100.0 |
Plant Extracts/*pharmacology | 2 | 2.0 |
Viremia/diagnosis | 2 | 40.0 |
HIV Envelope Protein gp41/*chemistry/metabolism | 2 | 100.0 |
Lymphocyte Activation/drug effects/*physiology | 3 | 17.0 |
*Regulatory Sequences, Nucleic Acid | 4 | 1.0 |
HIV Envelope Protein gp120/drug effects | 2 | 33.0 |
HIV-1/*drug effects/enzymology | 2 | 66.0 |
Anti-Inflammatory Agents/administration & dosage | 3 | 18.0 |
Gamma-Globulins/analysis | 2 | 25.0 |
Pancreas/pathology | 2 | 5.0 |
Cytomegalovirus Infections/complications/diagnosis | 2 | 66.0 |
Histoplasmosis/complications/diagnosis | 2 | 100.0 |
Periodontitis/immunology | 2 | 28.0 |
Porphyromonas gingivalis/immunology | 2 | 40.0 |
Receptors, Antigen, T-Cell, alpha-beta/*analysis/genetics | 4 | 66.0 |
Membrane Proteins/chemistry/metabolism | 4 | 13.0 |
Methadone/*therapeutic use | 5 | 83.0 |
Antibodies, Protozoan/immunology | 4 | 26.0 |
Granuloma/immunology/pathology | 2 | 28.0 |
Leishmaniasis/*immunology | 2 | 40.0 |
Skin/*immunology/parasitology/pathology | 2 | 100.0 |
Acquired Immunodeficiency Syndrome/*blood/immunology | 9 | 45.0 |
Granulocytes/*immunology | 3 | 8.0 |
*Nucleic Acid Amplification Techniques | 2 | 15.0 |
HIV Infections/*complications/pathology/physiopathology | 2 | 66.0 |
Blood Coagulation Factors/therapeutic use | 2 | 100.0 |
Hemophilia A/*therapy | 2 | 22.0 |
Hepatitis, Viral, Human/transmission | 2 | 100.0 |
Acquired Immunodeficiency Syndrome/blood/*complications/drug therapy | 2 | 100.0 |
Colonoscopy | 8 | 18.0 |
Tuberculosis, Pulmonary/*complications/drug therapy | 2 | 66.0 |
Tuberculosis, Pulmonary/complications/*radiography | 2 | 100.0 |
Lymphocyte Function-Associated Antigen-1/*immunology | 2 | 10.0 |
Vitreous Body/pathology | 2 | 50.0 |
Carrier Proteins/*immunology | 5 | 11.0 |
Semen/immunology | 3 | 20.0 |
Spermatozoa/*immunology | 4 | 9.0 |
Chromosome Deletion | 8 | 1.0 |
Chromosomes, Human, Pair 11 | 3 | 0.0 |
Adrenal Cortex Hormones/adverse effects | 2 | 66.0 |
*Diabetes Complications | 2 | 3.0 |
Bacterial Infections/*complications | 2 | 15.0 |
Pneumonia, Bacterial/complications | 3 | 100.0 |
HIV Antigens/biosynthesis | 3 | 50.0 |
Diabetes Mellitus, Type 1/blood/*immunology | 2 | 16.0 |
Influenza Vaccines/adverse effects/*immunology | 2 | 100.0 |
Multigene Family | 8 | 0.0 |
World Health | 5 | 8.0 |
Acquired Immunodeficiency Syndrome/blood/*complications/immunology | 5 | 83.0 |
Military Personnel | 8 | 25.0 |
*Epitopes | 12 | 8.0 |
Gene Products, tat/*genetics | 2 | 5.0 |
RNA, Antisense | 2 | 3.0 |
Erythrocyte Indices | 2 | 3.0 |
Ferritin/blood | 3 | 1.0 |
Ammonium Chloride/pharmacology | 2 | 5.0 |
Brefeldin A | 6 | 12.0 |
Cyclopentanes/pharmacology | 6 | 12.0 |
Antigens, CD4/*genetics/*metabolism | 3 | 100.0 |
Factor Xa/*metabolism | 2 | 9.0 |
Leukemia/therapy | 4 | 10.0 |
Lymphoma, Non-Hodgkin/therapy | 3 | 12.0 |
Myelodysplastic Syndromes/therapy | 3 | 17.0 |
HIV Infections/*immunology/*transmission | 3 | 50.0 |
*Leukocytes | 2 | 10.0 |
Viral Vaccines/administration & dosage | 2 | 66.0 |
HIV-1/*genetics/isolation & purification/pathogenicity | 2 | 66.0 |
HIV-1/*genetics/*immunology/isolation & purification | 2 | 100.0 |
HIV Infections/*epidemiology/transmission | 5 | 100.0 |
Puerto Rico/epidemiology | 3 | 42.0 |
RNA, Viral/analysis/isolation & purification | 2 | 40.0 |
Cervix Uteri/immunology | 2 | 25.0 |
Antiviral Agents/administration & dosage/adverse effects/*therapeutic use | 6 | 100.0 |
Interleukin-2/immunology/*therapeutic use | 3 | 75.0 |
Heart Rate/physiology | 2 | 2.0 |
Acquired Immunodeficiency Syndrome/epidemiology/physiopathology | 3 | 100.0 |
Dependovirus/*genetics | 4 | 5.0 |
Brain/embryology | 2 | 4.0 |
Neuroglia/*cytology | 2 | 22.0 |
Gene Expression Regulation, Leukemic | 2 | 2.0 |
Filtration | 2 | 4.0 |
Leukocyte Count/*methods | 3 | 37.0 |
Hepatitis, Chronic/complications/*therapy | 3 | 75.0 |
Arthritis, Rheumatoid/*genetics/immunology | 2 | 4.0 |
Diseases in Twins | 2 | 4.0 |
Antigens, CD2/metabolism | 7 | 25.0 |
*Bronchoalveolar Lavage Fluid/cytology/microbiology | 2 | 100.0 |
HIV Infections/immunology/*mortality | 6 | 100.0 |
HIV-2/immunology | 3 | 50.0 |
HIV-1/*immunology/metabolism | 3 | 37.0 |
*Bayes Theorem | 3 | 37.0 |
HLA Antigens | 5 | 3.0 |
Erythropoietin/pharmacology | 3 | 2.0 |
Apoptosis/*radiation effects | 2 | 4.0 |
Clone Cells/*immunology | 3 | 42.0 |
Leukemia, B-Cell/*immunology | 2 | 11.0 |
Paraproteinemias/*immunology | 3 | 15.0 |
Vitamins/blood | 2 | 25.0 |
Zinc/blood | 4 | 20.0 |
Antigens, Differentiation/*blood | 2 | 11.0 |
Antibodies, Anti-Idiotypic/immunology | 6 | 15.0 |
Autoimmune Diseases/etiology | 3 | 17.0 |
CD8-Positive T-Lymphocytes/drug effects/metabolism | 3 | 42.0 |
HIV/genetics/immunology/*isolation & purification | 2 | 100.0 |
*Genes, Immunoglobulin | 7 | 3.0 |
Neurons/*physiology | 4 | 2.0 |
RNA, Messenger/*metabolism | 8 | 1.0 |
Microbial Sensitivity Tests/methods | 3 | 27.0 |
AIDS-Related Opportunistic Infections/diagnosis/*epidemiology/mortality | 2 | 100.0 |
*Mass Screening | 4 | 7.0 |
Immunoglobulins, Intravenous/*administration & dosage | 4 | 50.0 |
Amides/pharmacology | 3 | 5.0 |
Ammonium Compounds/pharmacology | 3 | 13.0 |
Peptide Fragments/pharmacology | 6 | 2.0 |
HIV Infections/*epidemiology/immunology/virology | 2 | 66.0 |
Leukocytes/*pathology | 4 | 25.0 |
Antigens, CD4/biosynthesis/*physiology | 10 | 100.0 |
Interleukins/secretion | 2 | 25.0 |
Lymphokines/*secretion | 6 | 14.0 |
Tumor Necrosis Factor-alpha/secretion | 7 | 6.0 |
Giant Cells/drug effects/virology | 2 | 66.0 |
RNA, Viral/analysis/blood/cerebrospinal fluid | 2 | 100.0 |
Protease Inhibitors/administration & dosage | 2 | 66.0 |
Herpesviridae Infections/epidemiology | 2 | 66.0 |
Lymphocyte Subsets/drug effects/*immunology | 3 | 60.0 |
Regeneration | 3 | 5.0 |
Tumor Virus Infections/epidemiology | 2 | 66.0 |
Autoantibodies/*biosynthesis | 5 | 8.0 |
Genital Diseases, Female/*immunology | 2 | 40.0 |
Immunoglobulin A, Secretory/analysis | 2 | 11.0 |
Eosinophilia/complications | 3 | 75.0 |
Antigens, Viral/metabolism | 4 | 18.0 |
Viral Matrix Proteins/metabolism | 3 | 16.0 |
*Medicine, Chinese Traditional | 3 | 12.0 |
Vaccines, Inactivated/therapeutic use | 3 | 100.0 |
Acquired Immunodeficiency Syndrome | 6 | 46.0 |
Gene Products, env/genetics/immunology | 5 | 100.0 |
Antibodies/metabolism | 2 | 2.0 |
*Chemokines, CC | 3 | 4.0 |
Common Variable Immunodeficiency/*immunology | 5 | 33.0 |
Arthritis, Rheumatoid/*drug therapy/*immunology | 2 | 28.0 |
Viremia/*drug therapy/virology | 2 | 100.0 |
Cytomegalovirus Infections/*complications/immunology | 2 | 40.0 |
Amylases/blood | 4 | 18.0 |
Baltimore/epidemiology | 7 | 87.0 |
Lipase/blood | 3 | 4.0 |
Receptors, Complement 3d/physiology | 2 | 40.0 |
RNA, Viral/*metabolism | 3 | 6.0 |
Arachidonic Acid/metabolism | 2 | 2.0 |
CD4-Positive T-Lymphocytes/drug effects/*enzymology | 2 | 66.0 |
Gene Products, env/*pharmacology | 4 | 50.0 |
Phosphatidylcholines | 3 | 8.0 |
SIV/*chemistry | 2 | 66.0 |
Immunity/*drug effects | 6 | 42.0 |
Insulin-Like Growth Factor I/metabolism | 4 | 2.0 |
Electrolytes/blood | 2 | 14.0 |
Cytomegalovirus/genetics/*isolation & purification | 2 | 50.0 |
T-Lymphocytes, Cytotoxic/*immunology/*virology | 2 | 100.0 |
Antigens, CD29/immunology | 4 | 44.0 |
Hypersensitivity, Delayed/diagnosis | 2 | 40.0 |
Candidiasis, Oral/drug therapy/*microbiology | 2 | 66.0 |
Carrier State/*microbiology | 2 | 25.0 |
Anti-Inflammatory Agents/*administration & dosage | 4 | 13.0 |
*DNA Replication | 3 | 1.0 |
Antigens, CD4/*analysis/genetics | 6 | 100.0 |
Antigens, CD8/*analysis/genetics | 3 | 60.0 |
Ribavirin/administration & dosage/*therapeutic use | 3 | 100.0 |
Vasculitis/pathology | 2 | 40.0 |
Endocytosis/*drug effects | 4 | 18.0 |
Rhabdomyosarcoma | 4 | 22.0 |
Stromal Cells/physiology | 2 | 3.0 |
Hodgkin Disease/*immunology/therapy | 2 | 50.0 |
Growth | 5 | 10.0 |
SIV/*genetics/pathogenicity | 2 | 40.0 |
Methylprednisolone/administration & dosage | 3 | 15.0 |
Prednisolone/*administration & dosage | 4 | 33.0 |
Methacrylates | 2 | 33.0 |
Antigens, CD/drug effects/metabolism | 2 | 18.0 |
Multiple Sclerosis/*therapy | 4 | 40.0 |
Carcinogens/pharmacology | 2 | 2.0 |
Skin/microbiology/pathology | 2 | 50.0 |
Tetradecanoylphorbol Acetate/immunology | 2 | 33.0 |
Pregnancy Trimester, First | 7 | 2.0 |
Antigens, Differentiation, B-Lymphocyte/blood | 2 | 20.0 |
Paris | 3 | 33.0 |
Serum Albumin/metabolism | 5 | 3.0 |
Markov Chains | 7 | 28.0 |
Receptors, HIV/immunology/*metabolism | 2 | 100.0 |
Thymus Gland/cytology/*virology | 4 | 66.0 |
Reverse Transcriptase Inhibitors/*pharmacokinetics/therapeutic use | 2 | 100.0 |
Prealbumin/analysis | 2 | 8.0 |
HIV Infections/drug therapy/immunology/*mortality | 2 | 100.0 |
AIDS Dementia Complex/complications | 2 | 100.0 |
Mycobacterium tuberculosis/*physiology | 3 | 42.0 |
Virus Activation/*drug effects | 2 | 18.0 |
Vitamin E/*blood | 2 | 9.0 |
Cytoskeleton/physiology | 4 | 5.0 |
HIV Envelope Protein gp160/*physiology | 2 | 100.0 |
Calcium/*physiology | 8 | 7.0 |
Inositol Phosphates/metabolism | 6 | 4.0 |
Phosphatidylinositols/*physiology | 4 | 25.0 |
Protein-Tyrosine Kinase/physiology | 8 | 6.0 |
HIV Core Protein p24/genetics/immunology | 2 | 100.0 |
Ontario/epidemiology | 3 | 12.0 |
Receptors, Tumor Necrosis Factor/immunology | 3 | 13.0 |
*Homeless Persons | 2 | 66.0 |
DNA, Viral/*analysis/blood | 2 | 66.0 |
HIV Infections/blood/*transmission/*virology | 2 | 100.0 |
Superoxides/metabolism | 8 | 2.0 |
Glioma | 3 | 4.0 |
T-Lymphocytes/drug effects/*virology | 3 | 60.0 |
Antibodies, Protozoan/analysis | 5 | 50.0 |
Cell Death/physiology | 4 | 5.0 |
HIV-1/growth & development/pathogenicity/*physiology | 3 | 100.0 |
Proviruses/growth & development | 3 | 75.0 |
Immunoglobulins, Intravenous/administration & dosage/*therapeutic use | 2 | 66.0 |
BCG Vaccine | 3 | 30.0 |
Hematopoietic Stem Cell Transplantation/*adverse effects/methods | 2 | 66.0 |
Immunologic Deficiency Syndromes/*etiology | 5 | 83.0 |
Transplantation Conditioning/methods | 4 | 18.0 |
Adenosine Deaminase/*metabolism | 3 | 37.0 |
Smoking/*immunology | 4 | 40.0 |
Myelofibrosis/*complications | 2 | 40.0 |
Cytoplasmic Granules | 2 | 33.0 |
Face/abnormalities | 2 | 3.0 |
Enhancer Elements (Genetics)/immunology | 3 | 25.0 |
Herpesvirus 7, Human/*immunology | 3 | 75.0 |
Membrane Glycoproteins/biosynthesis/immunology | 3 | 25.0 |
Regulatory Sequences, Nucleic Acid/immunology | 2 | 28.0 |
Contraceptives, Oral, Hormonal/*pharmacology | 2 | 16.0 |
DNA, Viral/*isolation & purification | 3 | 37.0 |
Vitamin A Deficiency/*virology | 2 | 100.0 |
Cytoplasm/physiology | 2 | 5.0 |
Down-Regulation/drug effects/physiology | 2 | 5.0 |
Arthritis, Infectious/complications | 2 | 66.0 |
Candidiasis/*complications/diagnosis/drug therapy | 2 | 100.0 |
Lymphoma, Non-Hodgkin/*complications | 2 | 40.0 |
Antigens, Surface/*drug effects | 2 | 66.0 |
B-Lymphocytes/drug effects | 4 | 22.0 |
Immunosuppressive Agents/*administration & dosage | 4 | 13.0 |
Aspergillus fumigatus/*isolation & purification | 2 | 50.0 |
Histocompatibility Antigens Class II/genetics | 5 | 4.0 |
*Ultraviolet Therapy | 4 | 44.0 |
Receptors, HIV/isolation & purification/*metabolism | 3 | 100.0 |
Anti-HIV Agents/*chemical synthesis/pharmacology | 2 | 28.0 |
Langerhans Cells/immunology/*pathology | 4 | 40.0 |
Papillomavirus, Human/*genetics/isolation & purification | 3 | 60.0 |
HIV Antigens/chemistry/*immunology | 3 | 50.0 |
Peptide Biosynthesis | 2 | 4.0 |
*Aryl Hydrocarbon Hydroxylases | 2 | 0.0 |
HIV Seropositivity/*metabolism | 7 | 87.0 |
*T-Lymphocytes, Helper-Inducer | 6 | 85.0 |
HIV Wasting Syndrome/diagnosis | 2 | 100.0 |
Toxoplasmosis/diagnosis | 2 | 66.0 |
Tuberculosis/diagnosis | 2 | 50.0 |
Antibodies, Blocking | 2 | 16.0 |
Receptors, CXCR4 | 21 | 55.0 |
Conjunctiva/*immunology | 2 | 40.0 |
Chimeric Proteins/biosynthesis | 4 | 8.0 |
Vagina | 2 | 25.0 |
HIV Infections/therapy/*virology | 3 | 100.0 |
Kidney/cytology | 2 | 1.0 |
Blood Proteins/*analysis | 2 | 1.0 |
Alternative Splicing | 3 | 0.0 |
Antigens, CD3/genetics/metabolism | 3 | 75.0 |
Protein-Tyrosine Kinase/genetics/metabolism | 3 | 4.0 |
Arthritis, Infectious/blood/*immunology/pathology | 2 | 100.0 |
Immunoglobulin Variable Region/genetics/immunology | 2 | 10.0 |
Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use | 2 | 5.0 |
*Hispanic Americans | 3 | 25.0 |
Drosophila melanogaster | 4 | 3.0 |
Monocytes/immunology/*microbiology | 8 | 66.0 |
DNA, Complementary/chemistry | 3 | 1.0 |
Receptors, HIV/*biosynthesis/genetics | 2 | 66.0 |
Proviruses/genetics/growth & development | 2 | 100.0 |
Virus Cultivation/methods | 3 | 50.0 |
Cell Fusion/*drug effects | 4 | 66.0 |
Dendritic Cells/classification/*cytology/immunology | 2 | 66.0 |
Appointments and Schedules | 2 | 28.0 |
Cytomegalovirus | 2 | 16.0 |
Gene Products, rev/*genetics | 2 | 40.0 |
Gene Products, tat | 2 | 10.0 |
Cell Membrane | 2 | 3.0 |
*Antigens, CD3 | 4 | 21.0 |
ATP-Binding Cassette Transporters/metabolism | 2 | 4.0 |
*Immunoglobulins | 3 | 10.0 |
T-Lymphocytes, Cytotoxic/*immunology/metabolism | 5 | 14.0 |
Cross-Linking Reagents/metabolism | 4 | 7.0 |
GTPase-Activating Proteins | 2 | 1.0 |
Tumor Necrosis Factor-alpha/*secretion | 3 | 3.0 |
Endothelium, Vascular/*cytology | 3 | 1.0 |
Antigens, CD19/immunology | 2 | 5.0 |
*B-Lymphocytes/immunology | 2 | 66.0 |
Receptors, Cytokine/biosynthesis | 2 | 11.0 |
HTLV-I Antibodies/analysis | 7 | 77.0 |
Dengue Virus/*immunology | 3 | 33.0 |
Herpesvirus 4, Human/physiology | 2 | 6.0 |
Histocompatibility Antigens Class I | 3 | 27.0 |
Antibodies, Monoclonal/adverse effects/*immunology/*therapeutic use | 2 | 66.0 |
Chimera | 8 | 4.0 |
Fusion Proteins, bcr-abl/genetics | 3 | 7.0 |
South Carolina/epidemiology | 3 | 75.0 |
Receptors, HIV/*genetics | 3 | 30.0 |
SIV/*genetics/pathogenicity/physiology | 2 | 100.0 |
Bulimia/*immunology/physiopathology | 2 | 100.0 |
Cell Degranulation | 2 | 4.0 |
Antigens, CD29/analysis | 2 | 9.0 |
Immunoglobulin Variable Region/chemistry | 2 | 25.0 |
src-Family Kinases/physiology | 2 | 6.0 |
Hematopoietic Stem Cells/*virology | 2 | 28.0 |
Plasma | 2 | 3.0 |
Endopeptidases/*metabolism | 2 | 1.0 |
Triiodothyronine/blood | 4 | 1.0 |
Tuberculosis/*complications/drug therapy/mortality | 2 | 100.0 |
Brain/radiography | 2 | 18.0 |
Antigens, CD4/immunology/*physiology | 10 | 90.0 |
Proto-Oncogene Proteins/biosynthesis | 3 | 1.0 |
Prednisone/*adverse effects | 3 | 37.0 |
CD4-Positive T-Lymphocytes/cytology/*metabolism/virology | 2 | 100.0 |
Protease Inhibitors/*pharmacology | 2 | 4.0 |
Interleukin-2/biosynthesis/*genetics | 2 | 11.0 |
Nasal Provocation Tests | 2 | 15.0 |
Neutrophils/enzymology | 3 | 4.0 |
Immunologic Deficiency Syndromes/*therapy | 2 | 28.0 |
Intensive Care | 2 | 11.0 |
Activities of Daily Living | 2 | 5.0 |
*Inversion, Chromosome | 2 | 2.0 |
Lymphopenia/*complications | 3 | 100.0 |
Ulcer/pathology | 2 | 50.0 |
Jejunum | 2 | 18.0 |
Monocytes/immunology/*virology | 7 | 58.0 |
Receptors, Cytokine/chemistry/genetics/*physiology | 2 | 50.0 |
Dextran Sulfate/*pharmacology | 3 | 37.0 |
Appetite/drug effects | 2 | 33.0 |
T-Lymphocytes, Helper-Inducer/cytology/immunology | 3 | 75.0 |
Acquired Immunodeficiency Syndrome/*blood/epidemiology/*immunology | 2 | 100.0 |
G1 Phase/immunology | 2 | 40.0 |
Recombinant Proteins/immunology/pharmacology | 3 | 12.0 |
Tumor Necrosis Factor-alpha/*immunology/pharmacology | 3 | 60.0 |
Erythropoietin, Recombinant/*therapeutic use | 2 | 5.0 |
Transferrin/metabolism | 2 | 1.0 |
Metabolic Clearance Rate | 4 | 1.0 |
Dehydroepiandrosterone/blood | 2 | 2.0 |
Antibodies, Bacterial/analysis | 5 | 14.0 |
AIDS-Related Opportunistic Infections/drug therapy/*microbiology | 3 | 50.0 |
Antibody-Dependent Cell Cytotoxicity/immunology | 3 | 23.0 |
Antigens, CD4/*immunology/*metabolism | 2 | 100.0 |
Complement Fixation Tests | 3 | 3.0 |
HIV/*genetics/immunology | 5 | 100.0 |
CDC2 Protein Kinase/metabolism | 2 | 1.0 |
Immunogenetics | 2 | 4.0 |
HIV Infections/blood/physiopathology/*virology | 2 | 100.0 |
HIV-1/classification/*genetics/pathogenicity | 3 | 100.0 |
RNA, Viral/biosynthesis/genetics | 2 | 22.0 |
Antigens, CD/biosynthesis/*physiology | 2 | 6.0 |
DNA, Viral/analysis/biosynthesis | 2 | 50.0 |
GTP-Binding Proteins/*physiology | 2 | 1.0 |
Acetylation | 4 | 0.0 |
Carboxylic Ester Hydrolases/metabolism | 3 | 15.0 |
*Viral Fusion Proteins | 2 | 66.0 |
Cysteine/metabolism | 4 | 5.0 |
Graft Rejection/*immunology/prevention & control | 2 | 28.0 |
Histiocytosis, Langerhans-Cell/*immunology/pathology | 2 | 40.0 |
Antigens, CD80/*biosynthesis | 2 | 5.0 |
Multiple Myeloma/*blood | 2 | 8.0 |
Enterotoxins/*pharmacology | 3 | 5.0 |
Superantigens/*pharmacology | 3 | 10.0 |
Erythrocytes/metabolism | 3 | 1.0 |
Hemoglobins | 2 | 6.0 |
Saccharomyces cerevisiae/*genetics | 2 | 1.0 |
Macrophages/*enzymology | 2 | 6.0 |
HIV Infections/*drug therapy/epidemiology/pathology | 2 | 100.0 |
Sural Nerve/pathology | 3 | 7.0 |
Neuroblastoma/*immunology | 2 | 22.0 |
Recovery of Function | 2 | 8.0 |
Microvilli/ultrastructure | 2 | 13.0 |
Lymphocyte Function-Associated Antigen-1/*metabolism | 4 | 14.0 |
*Pregnancy Complications, Infectious/epidemiology/immunology/therapy | 2 | 100.0 |
Dog Diseases/*immunology/pathology | 2 | 100.0 |
Antimetabolites/pharmacology | 3 | 9.0 |
Fluorouracil/*pharmacology | 2 | 5.0 |
Receptors, Interferon/drug effects/metabolism | 2 | 50.0 |
Receptors, Interleukin-2/drug effects/*metabolism | 2 | 40.0 |
Biopterin/analogs & derivatives/blood | 25 | 55.0 |
Neopterin | 48 | 49.0 |
Genetic Engineering | 2 | 2.0 |
Psoriasis/*immunology | 3 | 17.0 |
T-Lymphocytopenia, Idiopathic CD4-Positive/*complications | 5 | 100.0 |
Protein Kinase C/*physiology | 3 | 3.0 |
Receptors, Antigen, T-Cell, gamma-delta/metabolism | 2 | 15.0 |
CD4-CD8 Ratio/methods | 2 | 100.0 |
Receptors, Antigen, T-Cell/*analysis/genetics | 5 | 71.0 |
T-Lymphocytes, Helper-Inducer/pathology | 23 | 71.0 |
T-Lymphocytes, Suppressor-Effector/pathology | 18 | 60.0 |
Biometry | 2 | 13.0 |
HIV Seropositivity/blood/epidemiology/immunology | 2 | 100.0 |
Pregnancy Complications, Infectious/*pathology | 2 | 66.0 |
AIDS-Related Opportunistic Infections/*diagnosis/virology | 3 | 100.0 |
Myasthenia Gravis/*immunology/pathology | 2 | 40.0 |
Stem Cells/immunology | 3 | 9.0 |
Antigens, CD3/*blood | 5 | 62.0 |
CD4-Positive T-Lymphocytes/*metabolism/*ultrastructure | 2 | 100.0 |
Interleukin-2/*biosynthesis/blood | 2 | 40.0 |
Lymphocyte Activation/drug effects/physiology | 3 | 20.0 |
Mycobacterium Infections/*prevention & control | 2 | 100.0 |
DNA, Viral/blood/genetics | 2 | 40.0 |
Antiviral Agents/*pharmacology/therapeutic use | 4 | 36.0 |
HIV Infections/physiopathology | 4 | 57.0 |
HIV-2/growth & development | 2 | 100.0 |
Receptors, HIV/*chemistry/metabolism | 2 | 100.0 |
Membrane Glycoproteins/chemistry/*metabolism | 2 | 6.0 |
Heparan Sulfate Proteoglycan | 2 | 6.0 |
Heparin/pharmacology | 4 | 1.0 |
Heparitin Sulfate/*metabolism | 2 | 6.0 |
CD4-Positive T-Lymphocytes/*microbiology | 28 | 87.0 |
Cytoplasm/ultrastructure | 4 | 6.0 |
Recombinant Proteins/chemistry | 5 | 1.0 |
Graft Rejection/pathology | 4 | 50.0 |
Heart Transplantation/immunology/*pathology | 4 | 44.0 |
Monocytes/*pathology | 3 | 17.0 |
Transplantation, Homologous/immunology/pathology | 2 | 40.0 |
Kidney Transplantation/*immunology/*pathology | 3 | 60.0 |
Transplantation, Homologous/pathology | 2 | 50.0 |
HLA-D Antigens/chemistry/*metabolism | 2 | 66.0 |
Models, Structural | 15 | 9.0 |
Recombinant Proteins/biosynthesis/chemistry/metabolism | 5 | 5.0 |
Genetic Complementation Test | 9 | 1.0 |
Antibody Formation/drug effects/immunology | 2 | 33.0 |
Gene Products, env/biosynthesis | 3 | 37.0 |
Receptors, HIV/biosynthesis/*physiology | 2 | 100.0 |
AIDS-Related Opportunistic Infections/immunology/*prevention & control | 3 | 100.0 |
Acquired Immunodeficiency Syndrome/*drug therapy/mortality/virology | 2 | 100.0 |
Health Services/utilization | 2 | 66.0 |
Zalcitabine/administration & dosage/therapeutic use | 2 | 100.0 |
Immunoglobulin G/biosynthesis/*blood | 2 | 100.0 |
Antibodies, Monoclonal/adverse effects/pharmacokinetics/*therapeutic use | 2 | 20.0 |
Graft Rejection/immunology/*prevention & control | 5 | 26.0 |
T-Lymphocyte Subsets/*cytology/immunology | 4 | 44.0 |
Cell Communication/*drug effects | 2 | 10.0 |
Lymphocytes/enzymology | 3 | 3.0 |
Oncogene Proteins, Viral/metabolism | 3 | 15.0 |
Phosphoric Diester Hydrolases/metabolism | 2 | 7.0 |
T-Lymphocytes/*cytology/drug effects | 3 | 37.0 |
Computer Graphics | 8 | 15.0 |
Encephalomyelitis, Autoimmune, Experimental/immunology/physiopathology | 2 | 100.0 |
Epitopes/*chemistry | 2 | 11.0 |
Graft Survival/drug effects | 4 | 13.0 |
Graft vs Host Disease | 2 | 8.0 |
Isomerism | 3 | 1.0 |
Arousal/*physiology | 3 | 10.0 |
Antigens, CD40/*physiology | 2 | 5.0 |
Immunoglobulin M/physiology | 2 | 18.0 |
Carrier Proteins/immunology | 4 | 10.0 |
Receptors, Complement/immunology | 4 | 12.0 |
HIV Infections/diagnosis/*immunology/transmission | 3 | 100.0 |
Program Evaluation | 5 | 12.0 |
Prolactin/blood | 3 | 0.0 |
Burns/blood/*immunology | 2 | 66.0 |
HLA-D Antigens/biosynthesis | 2 | 18.0 |
*Genes, Reporter | 3 | 6.0 |
HIV Envelope Protein gp120/analysis | 6 | 75.0 |
Cell Membrane/*metabolism/ultrastructure | 4 | 15.0 |
Interleukin-1/*biosynthesis | 9 | 7.0 |
*Protein Folding | 3 | 2.0 |
Sarcoidosis, Pulmonary/*immunology | 5 | 29.0 |
Immunization/*methods | 2 | 25.0 |
Interferon Type II/biosynthesis/immunology | 2 | 12.0 |
Interleukin-4/biosynthesis/immunology | 3 | 60.0 |
Receptors, Interleukin-4 | 5 | 7.0 |
HIV Seropositivity/immunology/*pathology | 4 | 80.0 |
RNA-Binding Proteins/*analysis | 2 | 33.0 |
Delavirdine | 4 | 66.0 |
Acquired Immunodeficiency Syndrome/complications/*immunology | 18 | 75.0 |
Multiple Sclerosis/immunology/*therapy | 6 | 66.0 |
Immunoglobulin M/deficiency | 3 | 42.0 |
HIV Antibodies/*biosynthesis/blood | 2 | 50.0 |
Adipose Tissue | 4 | 7.0 |
Endocrine Glands/*physiopathology | 3 | 30.0 |
HIV-1/*chemistry/*genetics | 2 | 100.0 |
Cell Communication/physiology | 3 | 3.0 |
Herpesvirus 1, Human/*physiology | 2 | 15.0 |
Drug Monitoring/methods | 2 | 7.0 |
Viremia/blood | 4 | 80.0 |
Acquired Immunodeficiency Syndrome/immunology/*mortality/therapy | 2 | 100.0 |
Gene Products, gag/biosynthesis | 2 | 25.0 |
Escherichia coli/genetics | 7 | 1.0 |
Recombinant Proteins/chemistry/genetics/isolation & purification | 2 | 13.0 |
CD4-Positive T-Lymphocytes/cytology/metabolism/*virology | 3 | 75.0 |
Blood Grouping and Crossmatching | 2 | 2.0 |
*Blood Transfusion | 9 | 8.0 |
T-Lymphocytes, Cytotoxic/cytology | 2 | 40.0 |
T-Lymphocytes, Helper-Inducer/cytology | 2 | 22.0 |
Lymphoma/etiology | 2 | 40.0 |
Erythrocytes | 4 | 8.0 |
Cell Nucleus/ultrastructure | 4 | 3.0 |
Cytarabine/administration & dosage | 7 | 8.0 |
Lymphoma, High-Grade/*drug therapy/pathology | 2 | 100.0 |
Tumor Stem Cells/*drug effects | 2 | 18.0 |
Virion/*immunology | 2 | 40.0 |
Carcinoma, Squamous Cell/*immunology | 4 | 14.0 |
Head and Neck Neoplasms/*immunology | 3 | 27.0 |
DNA, Fungal/analysis | 2 | 10.0 |
Epidemiology, Molecular | 3 | 3.0 |
Mucous Membrane/microbiology | 2 | 50.0 |
Gene Products, vpu/genetics/*immunology | 2 | 100.0 |
Epitope Mapping/*methods | 2 | 14.0 |
Immunoglobulins, Heavy-Chain/chemistry | 2 | 20.0 |
Cyclosporine/blood/therapeutic use | 2 | 40.0 |
Lung Transplantation/immunology/*pathology | 2 | 100.0 |
AIDS-Related Opportunistic Infections/*mortality | 2 | 100.0 |
Antigens, CD5/immunology | 2 | 15.0 |
Interleukin-1/antagonists & inhibitors | 2 | 16.0 |
Tumor Necrosis Factor-alpha/*antagonists & inhibitors | 3 | 3.0 |
Antigens, Helminth/*immunology | 4 | 6.0 |
Lymphoma/immunology/pathology | 4 | 100.0 |
Intracellular Fluid/*metabolism | 2 | 10.0 |
Semen/*chemistry | 2 | 7.0 |
Macrophages/ultrastructure | 2 | 25.0 |
Neural Conduction/physiology | 2 | 5.0 |
Acquired Immunodeficiency Syndrome/immunology/*pathology | 5 | 50.0 |
Thromboplastin/analysis | 2 | 7.0 |
Methylprednisolone/*administration & dosage/therapeutic use | 2 | 33.0 |
Membrane Fusion/*immunology | 2 | 100.0 |
Pulmonary Surfactant-Associated Protein A | 3 | 9.0 |
Pulmonary Surfactant-Associated Proteins | 3 | 8.0 |
Anemia/complications | 3 | 50.0 |
HIV Infections/complications/epidemiology/*mortality | 2 | 100.0 |
Microscopy, Phase-Contrast | 3 | 3.0 |
Adenocarcinoma | 3 | 2.0 |
Desensitization, Immunologic | 2 | 14.0 |
T-Lymphocytes, Helper-Inducer/immunology/physiology | 3 | 60.0 |
Ribavirin/adverse effects/*therapeutic use | 3 | 75.0 |
Interleukin-7/*blood | 3 | 60.0 |
Sarcoma, Kaposi/*immunology/virology | 2 | 100.0 |
Cysteine Endopeptidases | 2 | 4.0 |
*Genes, pX | 3 | 27.0 |
HTLV-I Infections/immunology/*pathology | 2 | 66.0 |
Leukemia, T-Cell/immunology/*pathology | 2 | 66.0 |
Mouth Diseases/*epidemiology | 2 | 100.0 |
Periodontal Diseases/epidemiology | 2 | 100.0 |
Smoking/epidemiology | 3 | 4.0 |
Louisiana/epidemiology | 4 | 44.0 |
Viral Proteins/genetics | 2 | 3.0 |
Deuterium | 2 | 7.0 |
Antiretroviral Therapy, Highly Active/*adverse effects/methods | 3 | 100.0 |
Oligosaccharides/metabolism | 5 | 11.0 |
HLA-DR Antigens/*genetics/immunology | 3 | 5.0 |
Peptides/genetics/immunology/metabolism | 2 | 50.0 |
District of Columbia | 4 | 40.0 |
Receptors, Interleukin-2/*genetics | 2 | 7.0 |
Pyridines/adverse effects/blood/*therapeutic use | 2 | 100.0 |
Acquired Immunodeficiency Syndrome/immunology/*therapy | 7 | 63.0 |
DNA | 16 | 1.0 |
SIV/genetics/*metabolism | 2 | 33.0 |
Immunodominant Epitopes/*immunology | 3 | 10.0 |
Centers for Disease Control and Prevention (U.S.) | 14 | 56.0 |
Gene Products, gag/*genetics | 2 | 33.0 |
HIV Antigens/*genetics | 2 | 100.0 |
HIV-1/classification/*genetics/isolation & purification | 2 | 25.0 |
Herpesvirus 2, Saimiriine/*physiology | 2 | 22.0 |
Antigens, Differentiation | 16 | 21.0 |
Antigens, CD4/genetics/immunology/*physiology | 3 | 100.0 |
Antigens, Bacterial/*administration & dosage | 2 | 66.0 |
Antigens, CD45/*blood | 5 | 50.0 |
Pneumonia, Pneumocystis/pathology | 2 | 100.0 |
Antigens, Viral/*analysis | 10 | 20.0 |
Genes, vif | 2 | 66.0 |
HIV Core Protein p24/analysis/biosynthesis | 2 | 50.0 |
Recombinant Proteins/biosynthesis/immunology | 2 | 9.0 |
Influenza A virus/*immunology | 2 | 12.0 |
Immunity/*physiology | 6 | 27.0 |
Antigens, Differentiation, B-Lymphocyte/*metabolism | 6 | 16.0 |
*Bone Marrow Cells | 19 | 7.0 |
Hemoglobins/metabolism | 6 | 3.0 |
Immunologic Capping | 6 | 12.0 |
Rifabutin/adverse effects/*therapeutic use | 2 | 100.0 |
Neutropenia/chemically induced/*drug therapy | 2 | 100.0 |
Carnitine/*pharmacology | 2 | 40.0 |
CD4-Positive T-Lymphocytes/drug effects/immunology/pathology | 3 | 100.0 |
CD8-Positive T-Lymphocytes/drug effects/immunology/pathology | 2 | 100.0 |
Acquired Immunodeficiency Syndrome/complications/immunology/mortality | 3 | 100.0 |
Protein-Tyrosine Kinase/*biosynthesis | 2 | 8.0 |
Acetylcysteine/*analogs & derivatives/pharmacology | 2 | 4.0 |
Oncogenes | 4 | 1.0 |
Protein p53/metabolism | 2 | 0.0 |
Antigens, CD95/*biosynthesis/physiology | 2 | 100.0 |
Cyclic AMP-Dependent Protein Kinases/antagonists & inhibitors | 2 | 7.0 |
Isoquinolines/pharmacology | 11 | 9.0 |
*Sulfonamides | 3 | 5.0 |
HIV-1/*genetics/immunology/isolation & purification | 3 | 100.0 |
1-Phosphatidylinositol 3-Kinase | 5 | 3.0 |
Phosphotransferases (Alcohol Group Acceptor)/*metabolism | 4 | 4.0 |
Gene Products, nef/genetics/metabolism/*physiology | 2 | 100.0 |
BCG Vaccine/*immunology | 2 | 50.0 |
Bone Marrow/embryology | 2 | 8.0 |
Bone Marrow Cells | 38 | 8.0 |
Liver/cytology/*embryology | 2 | 20.0 |
Thymus Gland/transplantation | 3 | 42.0 |
Lectins/metabolism | 2 | 2.0 |
Macrophages/cytology/metabolism/*virology | 2 | 50.0 |
*Gene Therapy/methods | 2 | 12.0 |
HIV Infections/*genetics/*immunology/pathology | 2 | 100.0 |
Moloney murine leukemia virus/*genetics | 3 | 11.0 |
Leukemia, Erythroblastic, Acute | 3 | 3.0 |
Lymphoma, Large-Cell | 6 | 23.0 |
Candidiasis/complications | 4 | 80.0 |
Esophageal Diseases/complications | 2 | 100.0 |
Sarcoma, Kaposi/complications | 6 | 100.0 |
T-Lymphocytes/*ultrastructure | 3 | 50.0 |
*AIDS-Related Opportunistic Infections/diagnosis | 2 | 100.0 |
HTLV-I Infections/*complications/epidemiology | 2 | 100.0 |
Receptors, Antigen, T-Cell, alpha-beta/*genetics/immunology | 2 | 40.0 |
Lymphocytes/immunology/*physiology | 8 | 47.0 |
Peritoneal Cavity/cytology | 3 | 7.0 |
Recombinant Proteins/administration & dosage/pharmacology | 4 | 6.0 |
HIV Seropositivity/*therapy | 4 | 100.0 |
Malaria, Vivax/*immunology | 2 | 66.0 |
Plasmodium vivax/*immunology | 2 | 28.0 |
Arthritis, Rheumatoid/blood/*immunology/*therapy | 2 | 100.0 |
Acquired Immunodeficiency Syndrome/*etiology/immunology | 3 | 75.0 |
Inflammation Mediators/metabolism | 2 | 2.0 |
Radioallergosorbent Test | 5 | 10.0 |
Polymorphism, Genetic/immunology | 2 | 8.0 |
Receptors, Cytokine/*physiology | 3 | 11.0 |
Herpesvirus 4, Human/immunology/*isolation & purification | 3 | 50.0 |
Lymphoma, T-Cell/*virology | 2 | 100.0 |
Viremia/blood/drug therapy | 2 | 100.0 |
RNA-Directed DNA Polymerase | 5 | 4.0 |
Arthritis, Rheumatoid/genetics/immunology | 2 | 16.0 |
von Willebrand Factor/*genetics | 2 | 2.0 |
Peptide Fragments/chemical synthesis/chemistry/*pharmacology | 3 | 100.0 |
Sarcoidosis/blood/*immunology | 2 | 66.0 |
Biopterin/*analogs & derivatives/blood | 12 | 54.0 |
beta 2-Microglobulin/*metabolism | 3 | 7.0 |
HIV Infections/*blood/drug therapy/virology | 3 | 100.0 |
Immunologic Deficiency Syndromes/*immunology | 7 | 20.0 |
Hodgkin Disease/*immunology/pathology | 5 | 31.0 |
Antibodies, Heterophile/*biosynthesis | 2 | 50.0 |
Antigens, Heterophile/immunology | 3 | 30.0 |
Gene Products, nef/*genetics/physiology | 2 | 100.0 |
Dermatitis, Contact/immunology | 2 | 20.0 |
Interferons/pharmacology | 3 | 4.0 |
*Receptors, Cytokine | 2 | 1.0 |
Rats, Inbred ACI | 2 | 13.0 |
Hemophilia A/immunology/*therapy | 3 | 75.0 |
HIV Seropositivity/*epidemiology/immunology | 3 | 100.0 |
Mumps/immunology | 2 | 100.0 |
T-Lymphocytes, Helper-Inducer/*immunology/pathology | 3 | 75.0 |
Histocompatibility Antigens Class II/genetics/metabolism | 2 | 40.0 |
Ovalbumin/pharmacology | 2 | 25.0 |
Peptides/immunology/*pharmacology | 2 | 66.0 |
Dyspnea/etiology | 2 | 25.0 |
Leukemia, Lymphocytic, Acute, L1/drug therapy/*immunology | 3 | 37.0 |
*Bystander Effect | 2 | 100.0 |
Gene Products, nef/*immunology | 4 | 40.0 |
Receptors, HIV/*antagonists & inhibitors | 2 | 28.0 |
Oropharynx/*virology | 2 | 100.0 |
Specimen Handling/methods | 2 | 15.0 |
Chloroquine/*pharmacology | 2 | 18.0 |
Methionine/metabolism | 5 | 3.0 |
Infant Mortality | 4 | 26.0 |
Antiretroviral Therapy, Highly Active/adverse effects/*methods | 5 | 100.0 |
Pregnancy Complications, Infectious/*epidemiology | 3 | 60.0 |
Antigens, Viral/administration & dosage | 2 | 40.0 |
Langerhans Cells/immunology/pathology | 3 | 50.0 |
Virus Replication/radiation effects | 2 | 66.0 |
*beta-Glucans | 3 | 25.0 |
Hepatitis B Antigens/blood | 2 | 50.0 |
Leukemia, Promyelocytic, Acute | 5 | 8.0 |
Nasal Mucosa/*immunology | 6 | 66.0 |
Rhinitis, Allergic, Perennial/*immunology | 6 | 46.0 |
Didanosine/administration & dosage/adverse effects/*therapeutic use | 8 | 80.0 |
Inflammation/etiology | 2 | 5.0 |
Interleukin-8/blood | 2 | 2.0 |
Endothelium, Vascular/cytology/metabolism | 2 | 1.0 |
Genes, Tumor Suppressor | 2 | 0.0 |
Histocompatibility Antigens | 9 | 56.0 |
*AIDS-Related Opportunistic Infections/diagnosis/therapy | 2 | 100.0 |
DNA, Viral/analysis/blood | 2 | 66.0 |
Lymph Nodes/immunology/*pathology | 6 | 40.0 |
Paraproteinemias/*pathology | 2 | 33.0 |
AIDS-Related Opportunistic Infections/pathology | 2 | 50.0 |
Forehead/pathology | 2 | 100.0 |
Headache/chemically induced | 3 | 23.0 |
Hematologic Diseases/chemically induced | 4 | 40.0 |
Sarcoma, Kaposi/etiology/immunology/*therapy | 3 | 100.0 |
Lymphocytes/immunology/*metabolism | 5 | 20.0 |
Monocytes/immunology/*metabolism | 3 | 6.0 |
Bronchi/*immunology/pathology | 3 | 37.0 |
Callithrix | 5 | 7.0 |
Apgar Score | 2 | 8.0 |
Sarcoma, Kaposi/etiology/therapy | 2 | 100.0 |
Bacterial Infections/*immunology/microbiology | 3 | 60.0 |
Bacterial Vaccines/immunology | 5 | 50.0 |
Trans-Activators/genetics | 2 | 0.0 |
Enzyme Activation/drug effects | 3 | 0.0 |
Receptors, IgG/*metabolism | 3 | 4.0 |
HLA-DR Antigens/genetics/immunology | 5 | 15.0 |
*Haplotypes | 3 | 1.0 |
Zidovudine/administration & dosage/*pharmacology | 2 | 100.0 |
HIV Infections/*drug therapy/*transmission | 2 | 100.0 |
HIV Antibodies/*biosynthesis/*immunology | 2 | 100.0 |
Killer Cells, Lymphokine-Activated/drug effects | 5 | 45.0 |
Lymphokines/*pharmacology | 4 | 1.0 |
Antigen-Antibody Complex/immunology | 9 | 15.0 |
Antibodies, Monoclonal/administration & dosage | 3 | 10.0 |
Mice, Mutant Strains/*immunology | 2 | 66.0 |
Glutathione/*metabolism | 2 | 3.0 |
HIV Seropositivity/*metabolism/physiopathology | 2 | 100.0 |
Pulmonary Diffusing Capacity | 3 | 42.0 |
AIDS-Related Opportunistic Infections/*diagnosis/immunology | 2 | 66.0 |
Tuberculin Test/*methods | 4 | 57.0 |
Protein Precursors/analysis | 3 | 7.0 |
Transglutaminases/analysis | 3 | 8.0 |
Bronchoalveolar Lavage Fluid | 8 | 17.0 |
Acquired Immunodeficiency Syndrome/complications/*diagnosis | 4 | 100.0 |
HIV-2/immunology/physiology | 2 | 100.0 |
Cell Survival/radiation effects | 3 | 3.0 |
Autoantibodies | 3 | 9.0 |
Immune Sera | 5 | 1.0 |
Cytomegalovirus/classification/*genetics/isolation & purification | 2 | 100.0 |
Genitalia, Female/*virology | 2 | 100.0 |
Vitamin A Deficiency/*complications | 2 | 66.0 |
Hay Fever/*immunology | 6 | 46.0 |
Mutation/immunology | 3 | 23.0 |
Antigens, CD4/immunology/*metabolism/pharmacology | 2 | 100.0 |
Proto-Oncogene Proteins c-raf | 5 | 4.0 |
Urea | 2 | 9.0 |
*T-Lymphocytes, Cytotoxic | 2 | 28.0 |
CD8-Positive T-Lymphocytes/cytology/physiology | 2 | 100.0 |
Transplantation, Homologous/physiology | 2 | 66.0 |
Interferon Type I, Recombinant/*therapeutic use | 3 | 25.0 |
Oxidants/pharmacology | 2 | 3.0 |
T-Lymphocytes/metabolism/virology | 3 | 25.0 |
Recombinant Proteins/adverse effects/immunology | 3 | 100.0 |
Antibodies/analysis/immunology | 2 | 28.0 |
Antigens, CD27/metabolism | 2 | 15.0 |
Acquired Immunodeficiency Syndrome/immunology/*mortality | 3 | 100.0 |
Calcium/immunology | 3 | 30.0 |
Leukocytes/*metabolism | 4 | 4.0 |
Leprosy/*complications | 2 | 50.0 |
Sexually Transmitted Diseases/complications/epidemiology | 2 | 100.0 |
Condoms/utilization | 2 | 50.0 |
Wegener's Granulomatosis/immunology/*therapy | 2 | 66.0 |
*Cell Adhesion Molecules/physiology | 2 | 100.0 |
Tritium/metabolism | 2 | 12.0 |
B-Lymphocyte Subsets | 2 | 16.0 |
*B-Lymphocytes | 5 | 17.0 |
*Hematopoietic Stem Cells | 2 | 4.0 |
Immunoglobulin Isotypes/biosynthesis | 3 | 25.0 |
Antigens, CD15/analysis | 2 | 7.0 |
Antigens, Thy-1/analysis | 2 | 14.0 |
Luteolysis/*immunology | 2 | 100.0 |
Ovary/immunology | 2 | 33.0 |
Cross-Linking Reagents/pharmacology | 3 | 2.0 |
Gene Products, env/biosynthesis/*immunology | 2 | 100.0 |
Transplantation, Heterologous/immunology | 2 | 11.0 |
CD4-Positive T-Lymphocytes/cytology/*radiation effects | 2 | 100.0 |
Bone Marrow/*drug effects | 2 | 7.0 |
Sarcoidosis/*pathology | 2 | 40.0 |
Mycobacterium avium-intracellulare Infection/*microbiology | 2 | 100.0 |
Filgrastim/*administration & dosage | 2 | 40.0 |
Cell Membrane/metabolism/*virology | 2 | 100.0 |
Hypersensitivity, Immediate/*complications | 2 | 66.0 |
*Seasons | 2 | 5.0 |
Arthritis, Rheumatoid/metabolism/pathology | 2 | 11.0 |
Herpesvirus 2, Human/*physiology | 2 | 40.0 |
*Chromosomes, Human, Pair 16 | 2 | 0.0 |
*Chromosomes, Human, Pair 17 | 2 | 0.0 |
Gene Products, gag/genetics/immunology | 2 | 100.0 |
Reaction Time/physiology | 5 | 5.0 |
Leukoplakia, Hairy/*complications | 2 | 100.0 |
Histocompatibility Antigens Class I/*analysis | 7 | 14.0 |
Laryngeal Neoplasms/*immunology | 2 | 22.0 |
HIV-2/*drug effects/physiology | 3 | 60.0 |
Kidney Failure, Chronic/*complications/therapy | 2 | 10.0 |
Immunosuppression/*adverse effects | 3 | 25.0 |
Intercellular Adhesion Molecule-1/physiology | 4 | 16.0 |
Oligodeoxyribonucleotides/genetics | 3 | 3.0 |
HIV-1/*growth & development/pathogenicity | 2 | 100.0 |
Hemophilia A/*virology | 2 | 100.0 |
Peptide Mapping | 12 | 2.0 |
Phosphotransferases/metabolism | 2 | 4.0 |
HIV Envelope Protein gp120/immunology/metabolism | 13 | 86.0 |
B-Lymphocytes/virology | 2 | 15.0 |
Antibodies/immunology/metabolism | 2 | 11.0 |
*Nutrition Assessment | 2 | 13.0 |
Acquired Immunodeficiency Syndrome/*complications/*diagnosis | 3 | 100.0 |
Lung Diseases, Interstitial/immunology | 2 | 66.0 |
Mediastinum | 2 | 33.0 |
Sarcoidosis/*immunology | 8 | 36.0 |
CD4-Positive T-Lymphocytes/secretion | 2 | 100.0 |
Interleukin-5/secretion | 2 | 25.0 |
Interferons/*pharmacology | 2 | 2.0 |
Drainage | 2 | 10.0 |
Blood Cell Count/drug effects | 6 | 28.0 |
Interleukin-6/*therapeutic use | 2 | 33.0 |
Antidepressive Agents/pharmacology/*therapeutic use | 2 | 40.0 |
Sertraline | 3 | 30.0 |
Meglumine/therapeutic use | 2 | 100.0 |
Organometallic Compounds/therapeutic use | 2 | 33.0 |
Spouses | 2 | 20.0 |
Ganciclovir/*therapeutic use | 2 | 33.0 |
Survival | 3 | 8.0 |
Androgens/*blood | 4 | 3.0 |
Muscles/pathology | 4 | 10.0 |
HIV Core Protein p24/*genetics | 2 | 66.0 |
Leukoencephalopathy, Progressive Multifocal/*drug therapy | 2 | 100.0 |
Cimetidine/*therapeutic use | 3 | 60.0 |
HIV Antigens/analysis | 27 | 71.0 |
HIV Seropositivity/physiopathology | 2 | 50.0 |
DNA Methylation | 2 | 0.0 |
Tetrachlorodibenzodioxin/*toxicity | 3 | 6.0 |
Antigens, Helminth/immunology | 3 | 9.0 |
Echinococcosis, Hepatic/*immunology | 2 | 100.0 |
Lupus Erythematosus, Systemic/*metabolism | 2 | 13.0 |
Cyclophosphamide/administration & dosage/adverse effects | 4 | 18.0 |
Doxorubicin/administration & dosage/adverse effects | 3 | 20.0 |
Etoposide/administration & dosage/adverse effects | 3 | 15.0 |
Macrophages, Alveolar/immunology | 5 | 31.0 |
Glycosylphosphatidylinositols | 6 | 11.0 |
Phospholipase C/pharmacology | 2 | 5.0 |
Antigens/*immunology | 12 | 15.0 |
Tetanus Toxin/immunology | 2 | 50.0 |
AIDS Dementia Complex/*psychology | 2 | 100.0 |
Hybrid Cells/*metabolism | 2 | 16.0 |
Antitubercular Agents/adverse effects/therapeutic use | 2 | 100.0 |
*HIV-1/genetics/growth & development | 2 | 66.0 |
Simplexvirus/*immunology | 5 | 14.0 |
HLA Antigens/biosynthesis/genetics | 2 | 40.0 |
Antigens, Bacterial/chemistry/*immunology | 2 | 28.0 |
Peptide Fragments/chemistry/*immunology | 2 | 16.0 |
Gene Expression Regulation, Leukemic/drug effects | 3 | 12.0 |
Signal Transduction/drug effects/physiology | 2 | 0.0 |
Cryptosporidiosis/epidemiology/etiology/*mortality | 2 | 100.0 |
Patient Admission | 2 | 16.0 |
Patient Discharge | 2 | 25.0 |
Glutathione Disulfide | 3 | 18.0 |
HIV Seropositivity/*blood/complications | 3 | 100.0 |
Hemophilia A/*blood/complications | 2 | 100.0 |
Gangliosides/*immunology | 2 | 10.0 |
Zalcitabine/adverse effects/*therapeutic use | 9 | 100.0 |
Hypothalamo-Hypophyseal System/*physiopathology | 2 | 3.0 |
Pituitary-Adrenal System/*physiopathology | 3 | 12.0 |
HIV Envelope Protein gp120/*chemistry/immunology | 3 | 60.0 |
Bacteremia/*microbiology | 2 | 50.0 |
Pseudomonas aeruginosa/isolation & purification | 4 | 40.0 |
beta 2-Microglobulin/*immunology | 2 | 8.0 |
Blood Cells/cytology | 3 | 17.0 |
*Skin Transplantation | 3 | 15.0 |
Hydrogen Peroxide/*metabolism | 2 | 5.0 |
*Lymphocyte Count/economics | 3 | 100.0 |
Antigens, CD95 | 5 | 12.0 |
2',5'-Oligoadenylate Synthetase/metabolism | 2 | 16.0 |
Histocompatibility Antigens/analysis | 20 | 32.0 |
HIV Core Protein p24/*blood/immunology | 2 | 100.0 |
T-Lymphocytes/*drug effects/*metabolism | 2 | 20.0 |
Lymphoma, T-Cell, Cutaneous/*immunology | 2 | 66.0 |
Mycosis Fungoides/immunology | 2 | 33.0 |
Receptors, Interleukin-7 | 3 | 17.0 |
Sezary Syndrome/immunology | 2 | 33.0 |
Intestines/immunology | 2 | 16.0 |
Substance Abuse, Intravenous/complications/virology | 2 | 100.0 |
Tuberculosis, Pulmonary/radiography | 2 | 100.0 |
HIV Seropositivity/*physiopathology | 6 | 75.0 |
Antigens, CD3/*chemistry | 2 | 66.0 |
Detergents | 3 | 2.0 |
Sarcoma, Kaposi/*therapy | 3 | 100.0 |
Heart Transplantation/immunology | 2 | 11.0 |
HIV-1/immunology/isolation & purification/*physiology | 2 | 100.0 |
Nasal Mucosa/*immunology/pathology | 2 | 66.0 |
*In Situ Hybridization | 2 | 14.0 |
1-Deoxynojirimycin/*analogs & derivatives/pharmacology | 3 | 75.0 |
Lipid Bilayers | 2 | 4.0 |
Fibroblasts/*virology | 2 | 50.0 |
Cations, Divalent/pharmacology | 3 | 7.0 |
T-Lymphocyte Subsets/chemistry | 3 | 50.0 |
*HIV-1/pathogenicity/physiology | 2 | 100.0 |
Genes, vpu | 3 | 75.0 |
Proviruses/genetics/immunology | 5 | 83.0 |
Interferons/blood | 3 | 33.0 |
Monocytes/*immunology/metabolism | 5 | 13.0 |
Hodgkin Disease/*immunology/virology | 2 | 100.0 |
Opportunistic Infections/prevention & control | 5 | 71.0 |
Alveolar Bone Loss/pathology | 2 | 100.0 |
Periodontal Attachment Loss/pathology | 3 | 100.0 |
Antigens, CD4/chemistry/*physiology | 3 | 75.0 |
Biopsy/*methods | 2 | 33.0 |
Pregnancy Complications, Parasitic/*immunology | 2 | 33.0 |
Spleen/immunology/metabolism | 2 | 18.0 |
HIV/growth & development | 2 | 33.0 |
T-Lymphocytes/chemistry/*metabolism | 2 | 33.0 |
Social Class | 3 | 8.0 |
Dipeptidyl Peptidases/*analysis | 2 | 66.0 |
HIV Infections/drug therapy/mortality/*virology | 2 | 100.0 |
Antigens/*blood | 3 | 12.0 |
HIV Antigens/blood | 12 | 75.0 |
Immunity, Natural/genetics/immunology | 2 | 33.0 |
src-Family Kinases/*physiology | 2 | 5.0 |
Acquired Immunodeficiency Syndrome/*complications/*virology | 2 | 100.0 |
HIV Envelope Protein gp120/immunology/physiology | 2 | 100.0 |
Phagocytosis/*physiology | 2 | 4.0 |
Attitude to Health | 2 | 4.0 |
National Institutes of Health (U.S.) | 4 | 16.0 |
Bacteremia/*etiology | 2 | 100.0 |
Streptokinase/immunology | 2 | 100.0 |
Cell Membrane/physiology/ultrastructure | 2 | 8.0 |
*Genes, vpu | 2 | 66.0 |
Protein Sorting Signals/*genetics | 2 | 5.0 |
Thymus Gland/*metabolism | 2 | 11.0 |
RNA Probes | 5 | 3.0 |
Lacrimal Apparatus/*immunology/pathology | 2 | 66.0 |
Mice, Inbred NOD/*immunology | 2 | 40.0 |
Collagenases/*pharmacology | 2 | 100.0 |
Endopeptidases/*pharmacology | 2 | 28.0 |
Peptide Fragments/chemical synthesis/pharmacology | 3 | 37.0 |
Pokeweed Mitogens/immunology | 6 | 46.0 |
Tumor Necrosis Factor-alpha/*biosynthesis/immunology | 2 | 15.0 |
Protein-Tyrosine Kinase/chemistry/metabolism | 2 | 12.0 |
Heart Transplantation/*immunology/pathology | 3 | 17.0 |
RNA-Directed DNA Polymerase/*genetics | 5 | 62.0 |
Retroviridae Proteins/*genetics | 2 | 16.0 |
Herpesvirus 2, Human/isolation & purification | 2 | 66.0 |
Lymphoma, AIDS-Related/complications | 4 | 100.0 |
Organ Transplantation | 3 | 25.0 |
Drug Resistance/genetics | 3 | 1.0 |
T-Lymphocyte Subsets/immunology/*pathology | 8 | 72.0 |
Neoplasms/epidemiology | 2 | 18.0 |
Acquired Immunodeficiency Syndrome/*etiology/therapy | 2 | 100.0 |
Angiotensin-Converting Enzyme Inhibitors/*therapeutic use | 2 | 0.0 |
Kidney/*pathology | 4 | 7.0 |
Breast Implants/*adverse effects | 4 | 44.0 |
*Immunoglobulin A | 2 | 14.0 |
Stem Cell Factor | 3 | 3.0 |
Cytochalasin B/pharmacology | 4 | 4.0 |
Convalescence | 3 | 9.0 |
Graft vs Host Disease/epidemiology | 3 | 25.0 |
RNA, Viral/*blood/genetics | 2 | 66.0 |
HTLV-II Infections/*complications | 2 | 100.0 |
Bleomycin/administration & dosage/adverse effects | 2 | 18.0 |
Proto-Oncogene Proteins c-bcl-2 | 8 | 4.0 |
Antigens, Differentiation, B-Lymphocyte/*blood | 2 | 66.0 |
Antigens, CD4/analysis/*biosynthesis | 2 | 100.0 |
Antibiotics, Antifungal/pharmacology | 2 | 16.0 |
Immunotoxins/*pharmacology | 12 | 28.0 |
*Macrolides | 3 | 8.0 |
Antigens, CD4/chemistry/*pharmacology | 3 | 100.0 |
Antiviral Agents/chemistry/*pharmacology | 4 | 40.0 |
Peptide Fragments/chemistry/*pharmacology | 3 | 10.0 |
Neoplasm Proteins/*metabolism | 3 | 0.0 |
Antigens, CD4/*chemistry/genetics | 2 | 100.0 |
RNA-Directed DNA Polymerase/metabolism | 34 | 50.0 |
Antigens, CD18/physiology | 2 | 16.0 |
CD4-Positive T-Lymphocytes/*secretion | 2 | 100.0 |
Leukemia, T-Cell | 7 | 20.0 |
HIV/drug effects/genetics/physiology | 2 | 66.0 |
*Protein Processing, Post-Translational | 9 | 3.0 |
Recombinant Fusion Proteins/*pharmacology | 3 | 13.0 |
Carrier State/*immunology | 2 | 22.0 |
Antimony Sodium Gluconate/therapeutic use | 3 | 100.0 |
*Hospitalization | 3 | 30.0 |
HIV Infections/*complications/microbiology | 3 | 50.0 |
Outpatient Clinics, Hospital | 5 | 38.0 |
Neutrophils/drug effects | 4 | 7.0 |
Methadone/therapeutic use | 4 | 40.0 |
CD4 Lymphocyte Count/economics/*methods | 4 | 80.0 |
Antiviral Agents/*adverse effects/therapeutic use | 3 | 100.0 |
Gene Products, vpu/physiology | 2 | 100.0 |
Microscopy | 4 | 15.0 |
Antibodies, Anticardiolipin/*blood | 2 | 13.0 |
Crohn Disease/*complications | 2 | 28.0 |
Oligodeoxyribonucleotides/chemistry | 15 | 7.0 |
Tumor Necrosis Factor-alpha | 4 | 2.0 |
RNA, Messenger/analysis/biosynthesis | 2 | 0.0 |
Proto-Oncogenes | 3 | 1.0 |
Calcineurin | 2 | 10.0 |
Opportunistic Infections/*complications/immunology | 3 | 75.0 |
Ganciclovir/pharmacology/therapeutic use | 2 | 100.0 |
Interleukin-15 | 2 | 22.0 |
Brain/*pathology | 6 | 3.0 |
HIV Infections/*enzymology | 4 | 66.0 |
*Nebulizers and Vaporizers | 3 | 15.0 |
Pentamidine/*administration & dosage | 4 | 80.0 |
HIV-1 Reverse Transcriptase | 42 | 67.0 |
Myristic Acid | 2 | 8.0 |
Myristic Acids/metabolism | 2 | 14.0 |
Endothelium, Vascular/metabolism | 2 | 0.0 |
Didanosine/*administration & dosage/adverse effects/therapeutic use | 2 | 66.0 |
Antibodies/*therapeutic use | 2 | 10.0 |
Cell Adhesion Molecules/*physiology | 7 | 6.0 |
Interleukin-1/physiology | 3 | 3.0 |
Gene Products, gag | 4 | 40.0 |
HIV Antigens/*biosynthesis | 2 | 100.0 |
Antiviral Agents/adverse effects/pharmacokinetics/*therapeutic use | 5 | 100.0 |
Zalcitabine/adverse effects/*analogs & | 2 | 100.0 |
Glycoproteins/physiology | 2 | 6.0 |
Macrophages/chemistry/virology | 2 | 100.0 |
Protein Precursors/*metabolism | 9 | 11.0 |
Protein Precursors/genetics/*metabolism | 2 | 6.0 |
RNA, Transfer, Met/genetics | 2 | 100.0 |
Saquinavir | 4 | 80.0 |
Erythema/chemically induced | 2 | 33.0 |
Lymphocyte Function-Associated Antigen-1/metabolism | 7 | 15.0 |
Exudates and Transudates/cytology | 2 | 40.0 |
Tuberculosis, Pleural/blood/*immunology | 2 | 100.0 |
Hepatitis B Surface Antigens/*analysis | 2 | 6.0 |
Receptors, Somatotropin/chemistry | 2 | 40.0 |
Histocompatibility Testing/*methods | 3 | 1.0 |
Lymphocytes, Tumor-Infiltrating/*immunology/pathology | 4 | 50.0 |
Lymphokines/metabolism | 6 | 2.0 |
Antigens, CD36/analysis | 3 | 20.0 |
Fibroblasts/cytology | 4 | 1.0 |
Receptor, Epidermal Growth Factor/analysis | 2 | 1.0 |
Vimentin/analysis | 2 | 0.0 |
Plasma Cells/immunology | 3 | 11.0 |
Sexually Transmitted Diseases/epidemiology | 2 | 100.0 |
Esophagitis/*complications/diagnosis/drug therapy | 2 | 100.0 |
Candidiasis, Oral/complications/*drug therapy | 2 | 100.0 |
Lymphocytes, Tumor-Infiltrating/immunology/*pathology | 3 | 37.0 |
Sarcoma, Kaposi/etiology/*therapy | 6 | 100.0 |
Antibodies, Neoplasm/*immunology | 3 | 13.0 |
Antigens, CD/*genetics/immunology | 2 | 11.0 |
Graft Rejection/*prevention & control | 8 | 19.0 |
Smoking/blood | 2 | 4.0 |
Casein Kinase II | 3 | 2.0 |
Protein Precursors/genetics/metabolism | 5 | 16.0 |
Antigens, Differentiation, Myelomonocytic/*metabolism | 4 | 7.0 |
Antiviral Agents/pharmacokinetics/*therapeutic use | 2 | 66.0 |
Arginine/therapeutic use | 2 | 28.0 |
Food, Formulated | 3 | 10.0 |
*Food, Fortified | 2 | 15.0 |
RNA/therapeutic use | 2 | 100.0 |
Receptors, Tumor Necrosis Factor/*analysis | 3 | 9.0 |
Weight Gain/*physiology | 2 | 33.0 |
Leukopenia/chemically induced | 3 | 16.0 |
Vidarabine Phosphate/*analogs & derivatives/therapeutic use | 2 | 100.0 |
Human T-lymphotropic virus 1/*physiology | 3 | 10.0 |
*Heat-Shock Proteins | 3 | 4.0 |
Glutathione/metabolism | 5 | 2.0 |
Interferon Alfa-2b/*pharmacology | 2 | 9.0 |
G(M1) Ganglioside/metabolism | 2 | 10.0 |
Antigens, Differentiation/*analysis/immunology | 4 | 36.0 |
Antigens, Ly/analysis | 3 | 33.0 |
Liver/embryology | 4 | 12.0 |
N-Glycosyl Hydrolases/*analysis/immunology | 2 | 100.0 |
Killer Cells, Natural/classification/*immunology | 2 | 33.0 |
Antigen-Antibody Complex/*metabolism | 2 | 2.0 |
Virion/immunology/*metabolism | 2 | 40.0 |
Virus Integration/immunology | 2 | 66.0 |
DNA, Viral/immunology | 2 | 40.0 |
Liver/*immunology | 5 | 13.0 |
Acquired Immunodeficiency Syndrome/complications/*epidemiology/immunology | 3 | 75.0 |
Gene Products, env/analysis | 2 | 66.0 |
HIV Infections/*immunology/*pathology | 3 | 60.0 |
B-Lymphocytes/chemistry/*metabolism | 2 | 40.0 |
Thymus Gland/immunology/*pathology | 6 | 75.0 |
Ascitic Fluid/*immunology/pathology | 2 | 66.0 |
Virology/*methods/statistics & numerical data | 2 | 40.0 |
Lymphoma, AIDS-Related | 3 | 100.0 |
Pulmonary Ventilation | 2 | 13.0 |
Tumor Necrosis Factor-alpha/immunology/*metabolism | 2 | 13.0 |
Antigens, CD31 | 5 | 13.0 |
Chromatography, Liquid | 3 | 2.0 |
Trans-Activators/biosynthesis | 2 | 5.0 |
Viral Matrix Proteins/analysis | 3 | 21.0 |
Pancreatitis/*immunology | 2 | 18.0 |
Tuberculosis, Pulmonary/*etiology | 2 | 100.0 |
Fibrosis/pathology | 2 | 14.0 |
G(M1) Ganglioside/pharmacology | 4 | 57.0 |
Lectins/*pharmacology | 5 | 13.0 |
Histocompatibility Antigens Class II/*physiology | 7 | 31.0 |
T-Lymphocytes/classification/*immunology/metabolism | 6 | 50.0 |
Neoplasm Proteins/*blood | 3 | 5.0 |
Transforming Growth Factor beta/*blood | 2 | 7.0 |
Chimeric Proteins/biosynthesis/immunology | 2 | 28.0 |
Intercellular Adhesion Molecule-1/immunology/metabolism | 2 | 22.0 |
Carrier State/immunology | 2 | 13.0 |
Human T-lymphotropic virus 1/immunology | 3 | 50.0 |
Aging/*genetics/*immunology | 2 | 100.0 |
Base Pair Mismatch/genetics/immunology | 2 | 100.0 |
Cell Aging/genetics/immunology | 2 | 66.0 |
DNA Repair/genetics/immunology | 2 | 100.0 |
Hematopoietic Stem Cells/pathology | 4 | 10.0 |
Skin Neoplasms/metabolism/*pathology | 2 | 5.0 |
Lectins, C-Type/*physiology | 2 | 50.0 |
HIV-2/growth & development/immunology/*physiology | 2 | 100.0 |
Gene Products, vpu/*physiology | 6 | 100.0 |
Interferon-alpha/administration & dosage/adverse effects/*therapeutic use | 3 | 75.0 |
Interleukin-12/*immunology | 3 | 20.0 |
Immunoglobulins, Intravenous/*pharmacology | 3 | 37.0 |
AIDS-Related Opportunistic Infections/*etiology/mortality | 2 | 100.0 |
Phosphotyrosine | 22 | 8.0 |
Isoniazid/*therapeutic use | 2 | 40.0 |
Globins/genetics | 3 | 2.0 |
Chromosomes, Human, Pair 12 | 3 | 1.0 |
Venezuela | 2 | 6.0 |
Alcoholism/*immunology | 2 | 25.0 |
Psychomotor Performance | 2 | 6.0 |
Papillomavirus, Human/*isolation & purification | 7 | 25.0 |
Tuberculosis, Pulmonary/immunology | 4 | 44.0 |
Dermatitis, Atopic/*immunology/pathology | 2 | 40.0 |
Anesthetics, Inhalation/pharmacology | 2 | 28.0 |
Isoflurane/pharmacology | 2 | 40.0 |
Aurintricarboxylic Acid/pharmacology | 4 | 44.0 |
Blood Platelets/cytology | 3 | 12.0 |
Dental Plaque/microbiology | 2 | 14.0 |
Gingivitis/immunology/microbiology | 2 | 100.0 |
Periodontitis/immunology/microbiology | 2 | 100.0 |
Asthma/drug therapy/*immunology/*physiopathology | 2 | 100.0 |
Langerhans Cells/pathology | 7 | 41.0 |
Macrophages/*pathology | 5 | 9.0 |
Cell Membrane/enzymology | 5 | 2.0 |
beta Carotene | 5 | 31.0 |
Sarcoma, Kaposi/complications/*drug therapy/mortality | 2 | 100.0 |
Neutrophils/virology | 2 | 100.0 |
Membrane Fluidity | 3 | 8.0 |
*Immunophenotyping/methods | 3 | 42.0 |
Fetal Blood/chemistry | 2 | 3.0 |
T-Lymphocytes, Cytotoxic/classification/*immunology/metabolism | 2 | 66.0 |
HIV Infections/diagnosis | 3 | 60.0 |
Interleukin-3/*pharmacology | 3 | 2.0 |
*Immunologic Capping | 3 | 33.0 |
Erythropoiesis | 2 | 2.0 |
HIV Infections/blood/*pathology | 2 | 100.0 |
Lymphoma/pathology | 2 | 7.0 |
T-Lymphocytes, Helper-Inducer/metabolism | 5 | 31.0 |
Receptors, Complement/*physiology | 3 | 5.0 |
Tonsil | 3 | 14.0 |
Conjunctiva/immunology | 2 | 40.0 |
Hemophilia A | 2 | 50.0 |
Leukocytes, Mononuclear/classification | 3 | 75.0 |
Silicones/*adverse effects | 3 | 60.0 |
Antifungal Agents/administration & dosage/pharmacology/*therapeutic use | 2 | 100.0 |
Hepatitis, Chronic/*immunology | 5 | 31.0 |
*Immunity, Maternally-Acquired | 3 | 23.0 |
*Neoplasms, Multiple Primary | 3 | 25.0 |
Skin Diseases/*pathology | 2 | 8.0 |
Gingival Hemorrhage/pathology | 3 | 75.0 |
Mouth Diseases/*immunology/pathology | 4 | 100.0 |
Periodontitis/pathology | 2 | 100.0 |
CD4-Positive T-Lymphocytes/classification | 4 | 100.0 |
T-Lymphocytes/*immunology/ultrastructure | 10 | 66.0 |
HIV Envelope Protein gp120/genetics/physiology | 2 | 50.0 |
Viremia/complications | 2 | 100.0 |
AIDS Dementia Complex/*metabolism | 2 | 50.0 |
Creatine/metabolism | 2 | 14.0 |
*Oncogenes | 3 | 0.0 |
Endocytosis/*immunology | 2 | 22.0 |
1-Phosphatidylinositol 4-Kinase | 5 | 23.0 |
HIV-1/enzymology/*immunology | 2 | 100.0 |
*Cell Compartmentation | 2 | 7.0 |
Actins/genetics | 3 | 2.0 |
Antigens, CD4/biosynthesis/*genetics | 7 | 100.0 |
Lymph Nodes | 2 | 13.0 |
Thymus Gland/*cytology/growth & development | 3 | 75.0 |
Cell Movement/*drug effects | 2 | 2.0 |
Interleukin-16 | 8 | 100.0 |
Protein Kinase C/antagonists & inhibitors/*physiology | 3 | 10.0 |
T-Lymphocytes/drug effects/enzymology/*immunology | 3 | 60.0 |
Polyploidy | 2 | 5.0 |
Recombinant Proteins/drug effects/metabolism | 2 | 8.0 |
HIV Seropositivity/microbiology | 6 | 60.0 |
Multiple Myeloma/immunology/therapy | 2 | 50.0 |
Transplantation, Autologous/*immunology | 2 | 66.0 |
*Anesthesia, Epidural | 2 | 18.0 |
Drug Resistance, Viral/*physiology | 2 | 100.0 |
Viremia/epidemiology | 2 | 66.0 |
T-Lymphocytes/*immunology/*microbiology | 2 | 66.0 |
Chlorambucil/therapeutic use | 3 | 42.0 |
Oligodeoxyribonucleotides | 16 | 1.0 |
Receptors, Antigen, T-Cell, alpha-beta/biosynthesis | 4 | 18.0 |
Alkaloids/pharmacology | 9 | 8.0 |
Staurosporine | 10 | 10.0 |
T-Lymphocytes/*immunology/physiology/ultrastructure | 2 | 100.0 |
Thymopentin/*therapeutic use | 2 | 100.0 |
Cell Fusion/immunology | 4 | 57.0 |
Genes, env/genetics | 3 | 25.0 |
Pregnancy Complications, Infectious/*blood/immunology | 2 | 100.0 |
Acquired Immunodeficiency Syndrome/*complications/diagnosis/epidemiology | 2 | 100.0 |
Hypersensitivity, Delayed/*immunology/pathology | 2 | 66.0 |
Spectrophotometry, Atomic | 3 | 6.0 |
B-Lymphocytes/*drug effects/enzymology/immunology | 2 | 100.0 |
Molecular Mimicry/immunology | 3 | 50.0 |
Menstrual Cycle | 2 | 1.0 |
Smoking/immunology | 3 | 42.0 |
*Exertion | 3 | 1.0 |
Movement | 3 | 5.0 |
Antigens, Tumor-Associated, Carbohydrate/*immunology | 2 | 10.0 |
Immunoglobulins/pharmacology | 2 | 50.0 |
SIV/*metabolism/pathogenicity | 2 | 100.0 |
Ritonavir | 3 | 75.0 |
Thiazoles/*therapeutic use | 4 | 36.0 |
Valine/*analogs & derivatives/therapeutic use | 2 | 66.0 |
*Eosinophils | 3 | 37.0 |
CD4-Positive T-Lymphocytes/*drug effects/pathology | 2 | 100.0 |
Recombinant Proteins/*therapeutic use | 3 | 13.0 |
Hemophilia A/*complications/therapy | 3 | 75.0 |
Interleukin-8/*biosynthesis | 2 | 3.0 |
*Clinical Medicine | 3 | 75.0 |
Hematopoietic Stem Cells/*cytology/drug effects | 2 | 2.0 |
Antibodies, Monoclonal/immunology/*pharmacology | 2 | 4.0 |
HIV Infections/blood/immunology/*therapy | 3 | 100.0 |
Dermatitis/immunology | 2 | 50.0 |
Rats, Nude | 2 | 4.0 |
Muromonab-CD3/*immunology | 3 | 75.0 |
Carrier Proteins/*physiology | 2 | 0.0 |
Interferons/physiology | 2 | 8.0 |
Vaccinia virus/*genetics | 3 | 15.0 |
Colonic Neoplasms/*immunology | 2 | 8.0 |
Cell Adhesion Molecules/immunology/metabolism | 3 | 37.0 |
Superantigens/physiology | 2 | 50.0 |
Receptors, Lymphocyte Homing/physiology | 3 | 13.0 |
Acyclovir/administration & dosage/therapeutic use | 2 | 66.0 |
HIV-2/genetics/*pathogenicity | 3 | 75.0 |
Lupus Erythematosus, Systemic/blood/*immunology | 2 | 5.0 |
Encephalitis/etiology/*prevention & control | 2 | 100.0 |
Interferon Alfa-2a/*therapeutic use | 6 | 30.0 |
T-Lymphocytes, Suppressor-Effector/*drug effects | 2 | 100.0 |
Hypersensitivity/complications | 2 | 22.0 |
Cyclosporine/*pharmacology/therapeutic use | 2 | 50.0 |
Th1 Cells/drug effects/immunology | 2 | 20.0 |
Antiviral Agents/immunology/*pharmacology | 2 | 100.0 |
Graves' Disease/*immunology | 7 | 8.0 |
Isoelectric Focusing | 3 | 0.0 |
HIV-1/immunology/metabolism | 3 | 60.0 |
Graft vs Host Disease/*immunology/pathology | 2 | 50.0 |
Interferon Alfa-2b/*administration & dosage | 3 | 42.0 |
Immunoglobulins, Heavy-Chain/biosynthesis/genetics | 2 | 22.0 |
Blood Cells/*physiology | 2 | 22.0 |
*Magnetics | 4 | 16.0 |
Histocompatibility Antigens Class II/biosynthesis/genetics | 2 | 33.0 |
Receptors, Antigen, T-Cell/immunology/metabolism | 3 | 27.0 |
Crohn Disease/immunology/*therapy | 2 | 40.0 |
Tetanus/prevention & control | 2 | 50.0 |
Mannans/pharmacology | 2 | 16.0 |
Hemophilia A/complications/*immunology | 12 | 85.0 |
RNA-Directed DNA Polymerase/*metabolism | 2 | 50.0 |
*Antibody Formation/drug effects | 2 | 40.0 |
Endometrium/*cytology | 2 | 10.0 |
Dinoprostone/biosynthesis | 2 | 3.0 |
Proteins/*genetics/immunology | 2 | 22.0 |
HIV/*drug effects/isolation & purification | 3 | 100.0 |
HIV Envelope Protein gp120/chemistry/genetics/immunology | 2 | 100.0 |
Antigen-Presenting Cells/immunology/physiology | 2 | 50.0 |
Proteins/*immunology | 2 | 11.0 |
Wiskott-Aldrich Syndrome/*immunology | 2 | 18.0 |
Treponema pallidum/*immunology | 2 | 25.0 |
HIV Infections/*complications/immunology/*mortality | 2 | 100.0 |
Heart Transplantation | 3 | 7.0 |
*Hospitals | 2 | 50.0 |
Dehydroepiandrosterone/analogs & derivatives/blood | 2 | 3.0 |
Dehydroepiandrosterone Sulfate | 4 | 4.0 |
HIV Seropositivity/*blood/*immunology | 2 | 100.0 |
Muscle, Smooth/pathology | 2 | 9.0 |
Sarcoma, Kaposi/drug therapy | 2 | 50.0 |
Allergens/diagnostic use | 2 | 28.0 |
Hypersensitivity, Delayed/immunology/pathology | 2 | 50.0 |
Arm | 2 | 6.0 |
Muscle, Skeletal/pathology | 2 | 3.0 |
DNA, Viral/*genetics | 6 | 8.0 |
Interferon-gamma, Recombinant/*therapeutic use | 3 | 25.0 |
Lymphoma, T-Cell, Cutaneous/*drug therapy | 2 | 100.0 |
*Blood Vessel Prosthesis | 2 | 6.0 |
HIV Envelope Protein gp120/*biosynthesis | 2 | 100.0 |
HIV Envelope Protein gp41/*biosynthesis | 2 | 100.0 |
Synaptic Transmission/*physiology | 2 | 5.0 |
AIDS-Related Opportunistic Infections/drug therapy | 3 | 60.0 |
Stress, Mechanical | 2 | 0.0 |
Killer Cells, Natural/drug effects/*immunology | 3 | 8.0 |
Calmodulin/physiology | 2 | 13.0 |
Th2 Cells/*drug effects/immunology/metabolism | 2 | 66.0 |
Antigens, CD4/biosynthesis/chemistry/*metabolism | 4 | 100.0 |
Adenoma/*immunology/pathology | 2 | 40.0 |
HLA Antigens/*analysis | 8 | 1.0 |
Receptors, Fc/biosynthesis | 4 | 25.0 |
Parathyroid Hormone-Related Protein | 3 | 3.0 |
Pneumococcal Infections/prevention & control | 3 | 100.0 |
Vaccines, Conjugate/immunology | 2 | 28.0 |
Interferon-gamma, Recombinant/*pharmacology | 6 | 4.0 |
Rural Population/statistics & numerical data | 2 | 28.0 |
Antifungal Agents/*pharmacology | 2 | 4.0 |
Fluconazole/*pharmacology | 3 | 20.0 |
Eosinophilia/immunology | 2 | 40.0 |
Interleukin-5/analysis | 2 | 15.0 |
Antigens, CD2/*genetics | 2 | 25.0 |
Leukemia, T-Cell, Acute/*immunology | 3 | 27.0 |
Gene Targeting/*methods | 2 | 9.0 |
Virion/chemistry | 2 | 22.0 |
Ploidies | 3 | 1.0 |
Herpesvirus 6, Human/genetics/*isolation & purification | 2 | 100.0 |
Autoantibodies/biosynthesis | 2 | 5.0 |
Autoimmune Diseases/*etiology | 3 | 27.0 |
Receptors, IgG/genetics | 3 | 17.0 |
Isoniazid/administration & dosage | 2 | 40.0 |
Myocardium/immunology/pathology | 2 | 16.0 |
Receptors, Immunologic/biosynthesis | 5 | 16.0 |
Simian virus 40 | 2 | 4.0 |
Dapsone/therapeutic use | 4 | 36.0 |
Pneumonia, Pneumocystis/*drug therapy | 2 | 66.0 |
HIV-1/*genetics/*isolation & purification | 3 | 75.0 |
Polymerase Chain Reaction/*methods/statistics & numerical data | 3 | 27.0 |
Leukemia/immunology | 3 | 9.0 |
Interleukin-5/*biosynthesis | 2 | 20.0 |
Lymphoma, Non-Hodgkin/*immunology | 3 | 13.0 |
Antigens, CD/*analysis/metabolism | 2 | 28.0 |
Immunoglobulin M/metabolism | 4 | 4.0 |
Cell Adhesion Molecules/analysis | 15 | 9.0 |
Hematopoietic Stem Cells/*pathology | 2 | 2.0 |
Technetium/*diagnostic use | 3 | 12.0 |
Cervix Neoplasms/immunology/*pathology | 2 | 25.0 |
Milk, Human/*virology | 4 | 80.0 |
HIV Seropositivity/*immunology/transmission | 2 | 100.0 |
Recombinant Proteins/biosynthesis/metabolism | 4 | 2.0 |
Acquired Immunodeficiency Syndrome/immunology/transmission/*virology | 2 | 100.0 |
Leukocytes, Mononuclear/*physiology | 4 | 16.0 |
Methotrexate/pharmacology | 2 | 2.0 |
HLA-DQ Antigens | 2 | 6.0 |
Hepacivirus/immunology | 2 | 11.0 |
*Genetic Techniques | 2 | 3.0 |
Interleukin-2/*immunology/pharmacology | 3 | 42.0 |
Calmodulin/antagonists & inhibitors | 2 | 10.0 |
Cell Membrane/*immunology | 5 | 29.0 |
Mutagenesis/genetics | 2 | 5.0 |
Sulfonamides/pharmacology | 3 | 2.0 |
HIV-1/*genetics/*pathogenicity/physiology | 3 | 100.0 |
HIV Seropositivity/*immunology/pathology | 3 | 100.0 |
DNA, Viral/blood/*genetics | 2 | 100.0 |
HIV Infections/transmission/virology | 3 | 100.0 |
Monocytes/cytology/immunology | 2 | 5.0 |
Receptors, Interleukin-2/analysis/*immunology | 2 | 66.0 |
Hypertension/complications | 2 | 3.0 |
Blood Pressure/drug effects | 2 | 0.0 |
Allergens/adverse effects | 2 | 28.0 |
Cyanates/*adverse effects | 2 | 40.0 |
Cough/etiology | 2 | 50.0 |
Diarrhea/etiology | 7 | 38.0 |
Bone Marrow/metabolism | 2 | 1.0 |
Lymphoma, AIDS-Related/immunology/*pathology | 2 | 66.0 |
AIDS-Related Complex/drug therapy | 6 | 75.0 |
T-Lymphocyte Subsets/immunology/metabolism/ultrastructure | 2 | 66.0 |
Immunologic Deficiency Syndromes/enzymology/*genetics | 2 | 40.0 |
Receptors, Antigen, T-Cell/*deficiency | 2 | 66.0 |
AIDS-Related Opportunistic Infections/drug therapy/*parasitology | 3 | 100.0 |
Albendazole/*therapeutic use | 3 | 60.0 |
Anthelmintics/*therapeutic use | 2 | 50.0 |
Microsporidiosis/drug therapy/*parasitology | 2 | 100.0 |
Rhodamine 123 | 4 | 16.0 |
Malaysia | 3 | 7.0 |
Carcinoma/immunology/*pathology | 2 | 28.0 |
HIV Infections/complications/pathology/*physiopathology | 2 | 100.0 |
Epithelium/immunology/metabolism | 3 | 10.0 |
Periodontitis/*immunology | 4 | 22.0 |
Keratinocytes/immunology/pathology | 2 | 33.0 |
Measles Vaccine/immunology | 3 | 60.0 |
Pyridines/*therapeutic use | 3 | 20.0 |
HIV Seropositivity/blood/immunology/*physiopathology | 4 | 100.0 |
AIDS-Related Opportunistic Infections/epidemiology/*immunology | 3 | 100.0 |
*Pyrroles | 2 | 50.0 |
Proto-Oncogene Proteins/*biosynthesis/immunology | 2 | 50.0 |
Cytokines/biosynthesis/drug effects | 2 | 15.0 |
Enterotoxins/*immunology/pharmacology | 3 | 37.0 |
Superantigens/*immunology/pharmacology | 2 | 50.0 |
Interleukin-4/*secretion | 2 | 50.0 |
HTLV-II Infections/*immunology | 3 | 50.0 |
Neoplasms/*drug therapy/immunology/pathology | 2 | 40.0 |
Reaction Time | 5 | 4.0 |
*Health Services Accessibility | 3 | 17.0 |
Health Services Needs and Demand | 3 | 27.0 |
Chloramphenicol O-Acetyltransferase/biosynthesis | 3 | 2.0 |
Epitopes/*analysis | 18 | 11.0 |
Daunorubicin/administration & dosage | 3 | 8.0 |
Antigens, CD4/analysis/biosynthesis | 3 | 100.0 |
B-Lymphocytes/classification | 4 | 66.0 |
Antibodies, Bispecific/*immunology | 4 | 21.0 |
Lymph Nodes/microbiology/pathology | 2 | 66.0 |
Blast Crisis | 2 | 5.0 |
Hepatitis C Antibodies/*blood | 3 | 33.0 |
Hemagglutinin Glycoproteins, Influenza Virus | 2 | 11.0 |
Interleukin-2/pharmacology/secretion | 3 | 37.0 |
Proto-Oncogene Proteins/biosynthesis/genetics | 2 | 2.0 |
Androstenedione/blood | 2 | 1.0 |
Anus/*pathology | 3 | 100.0 |
Killer Cells/pathology | 2 | 66.0 |
Lymph Node Excision | 2 | 2.0 |
DNA, Viral/*biosynthesis | 6 | 30.0 |
Protein-Tyrosine Kinase/*deficiency/genetics | 2 | 33.0 |
Severe Combined Immunodeficiency/genetics/*immunology | 2 | 28.0 |
HIV-1/drug effects/*growth & development | 5 | 62.0 |
RNA-Directed DNA Polymerase/analysis | 15 | 55.0 |
Cell Line/metabolism | 2 | 8.0 |
HIV Antibodies/*biosynthesis | 4 | 30.0 |
Antigens, CD/chemistry/*metabolism | 2 | 5.0 |
Receptors, Interleukin-2/chemistry/metabolism | 2 | 33.0 |
Antigens, CD4/drug effects/*physiology | 2 | 66.0 |
Duodenum/immunology | 2 | 50.0 |
Proviruses/genetics/*physiology | 2 | 100.0 |
RNA, Viral/*biosynthesis | 2 | 9.0 |
AIDS-Related Complex/immunology | 12 | 32.0 |
Viral Fusion Proteins/genetics/*metabolism | 2 | 66.0 |
Opsonins | 4 | 9.0 |
Polysaccharides, Bacterial/administration & dosage/*immunology | 2 | 40.0 |
Craniocerebral Trauma/complications/*immunology | 4 | 100.0 |
Injury Severity Score | 3 | 8.0 |
Cell Adhesion/drug effects/physiology | 2 | 3.0 |
HIV/pathogenicity/*physiology | 3 | 100.0 |
HIV Antigens/*blood | 3 | 60.0 |
Mitomycin/pharmacology | 4 | 4.0 |
*Phenotype | 3 | 1.0 |
Trace Elements/*blood | 4 | 36.0 |
Antineoplastic Combined Chemotherapy Protocols/adverse effects | 2 | 20.0 |
Macrophages/immunology/virology | 4 | 44.0 |
Bronchoalveolar Lavage Fluid/*microbiology | 3 | 50.0 |
Leukemia, T-Cell/*immunology/pathology | 2 | 66.0 |
*Health Personnel | 2 | 40.0 |
Pentamidine/administration & dosage/*therapeutic use | 2 | 100.0 |
Pneumonia, Pneumocystis/etiology/*prevention & control | 3 | 100.0 |
Acquired Immunodeficiency Syndrome/epidemiology/*physiopathology | 2 | 100.0 |
Blood Component Transfusion | 2 | 12.0 |
Hemophilia A/therapy | 2 | 40.0 |
AIDS-Related Complex/physiopathology | 2 | 50.0 |
Laparoscopy/*adverse effects | 2 | 22.0 |
Piperazines/*pharmacology | 3 | 5.0 |
Drugs, Chinese Herbal/therapeutic use | 2 | 50.0 |
Thyroid Function Tests | 5 | 6.0 |
Lung Neoplasms/*complications | 2 | 22.0 |
*Cost of Illness | 2 | 25.0 |
Face | 2 | 8.0 |
HIV-Associated Lipodystrophy Syndrome/*drug therapy | 2 | 100.0 |
Papillomavirus Infections/*complications | 2 | 33.0 |
HIV/genetics/immunology | 2 | 66.0 |
Th2 Cells/*cytology/drug effects | 2 | 100.0 |
Major Histocompatibility Complex/genetics | 4 | 7.0 |
Serum Albumin/immunology | 3 | 14.0 |
Diarrhea/*drug therapy | 2 | 100.0 |
Bone Marrow/immunology/pathology | 3 | 8.0 |
Immunoglobulins, lambda-Chain/biosynthesis | 2 | 40.0 |
Enterotoxins/*immunology | 6 | 8.0 |
RNA, Neoplasm/genetics | 4 | 1.0 |
Antigens, CD4/*drug effects | 4 | 80.0 |
G(M1) Ganglioside/*pharmacology | 7 | 87.0 |
Immunoglobulin M/*metabolism | 2 | 5.0 |
alpha-Glucosidases/*antagonists & inhibitors | 3 | 21.0 |
Tonsil/immunology/pathology | 2 | 28.0 |
Ki-67 Antigen | 8 | 3.0 |
HIV Antibodies/biosynthesis/*immunology | 4 | 66.0 |
AIDS-Related Opportunistic Infections/epidemiology/prevention & control | 2 | 66.0 |
Endosomes/*metabolism | 2 | 1.0 |
Vidarabine/administration & dosage/*analogs & derivatives | 2 | 28.0 |
Lymphocytes/microbiology | 7 | 46.0 |
Northwestern United States | 2 | 33.0 |
Antigens, Polyomavirus Transforming/*genetics | 3 | 11.0 |
Receptors, Antigen, T-Cell/genetics/*physiology | 4 | 80.0 |
Flow Cytometry/veterinary | 4 | 57.0 |
Antioxidants/*analysis | 2 | 14.0 |
Erythrocyte Membrane/chemistry | 2 | 10.0 |
Fatty Acids/*blood | 3 | 10.0 |
Selenium/blood | 3 | 27.0 |
HLA-DR Antigens/physiology | 4 | 36.0 |
Acquired Immunodeficiency Syndrome/blood/drug therapy/*metabolism | 2 | 100.0 |
Vitamin B 12/*blood | 2 | 6.0 |
Burkitt Lymphoma | 5 | 5.0 |
Palmitic Acid | 2 | 12.0 |
*Proto-Oncogene Proteins | 3 | 0.0 |
Lymphocytes/*classification/immunology | 4 | 40.0 |
Flow Cytometry/economics/*methods | 2 | 100.0 |
Statistics/methods | 3 | 33.0 |
Hepatitis B/complications/immunology | 2 | 66.0 |
Hepatitis B Antibodies/analysis | 4 | 22.0 |
C-Peptide/blood | 3 | 1.0 |
Concanavalin A/immunology | 4 | 22.0 |
Feline Acquired Immunodeficiency Syndrome/*immunology | 2 | 50.0 |
*Immunodeficiency Virus, Feline | 2 | 66.0 |
Substance Abuse, Intravenous/complications/epidemiology | 2 | 100.0 |
Antigens, CD/immunology/physiology | 3 | 18.0 |
Antigens, CD40 | 6 | 10.0 |
Leukemia, Lymphocytic, Acute/diagnosis | 2 | 40.0 |
Tumor Markers, Biological/*immunology | 2 | 8.0 |
Antigens, CD58 | 9 | 6.0 |
HLA-DR1 Antigen/*immunology | 2 | 22.0 |
DNA Replication/physiology | 3 | 9.0 |
Chimeric Proteins/pharmacology | 2 | 11.0 |
Gene Products, env/*genetics/metabolism | 3 | 50.0 |
Hybrid Cells | 5 | 0.0 |
Histocompatibility Antigens Class II/immunology/*metabolism | 3 | 37.0 |
CD4-CD8 Ratio/*drug effects | 3 | 100.0 |
Recombinant Proteins/adverse effects/pharmacology/therapeutic use | 2 | 66.0 |
Trypanosoma cruzi/immunology | 2 | 18.0 |
Virology/methods | 2 | 40.0 |
Adrenal Cortex/physiopathology | 2 | 28.0 |
Protein-Tyrosine Kinase/biosynthesis | 3 | 12.0 |
Dietary Fats/*administration & dosage | 2 | 2.0 |
Phosphotransferases/*metabolism | 2 | 5.0 |
T-Lymphocytes, Suppressor-Effector | 26 | 70.0 |
Crohn Disease/*pathology | 2 | 50.0 |
Urine/parasitology | 2 | 100.0 |
AIDS-Related Complex/complications | 7 | 36.0 |
Leukocytosis/*etiology | 2 | 40.0 |
Mouth Mucosa/*immunology | 2 | 16.0 |
AIDS-Related Opportunistic Infections/*complications/diagnosis/therapy | 2 | 100.0 |
Antigens, CD/biosynthesis/physiology | 2 | 22.0 |
AIDS-Related Complex/*drug therapy/virology | 2 | 100.0 |
Antigens, CD5 | 29 | 11.0 |
Antigens, CD7 | 17 | 14.0 |
RNA, Viral/*blood/isolation & purification | 2 | 100.0 |
Antigens, CD44 | 2 | 1.0 |
T-Lymphocytes/secretion | 2 | 25.0 |
Transforming Growth Factor beta/*analysis | 2 | 13.0 |
Immune Tolerance/drug effects/immunology | 3 | 27.0 |
Stress, Psychological/*complications/immunology | 2 | 66.0 |
Hemagglutinins, Viral/*immunology | 3 | 25.0 |
*Serine | 2 | 5.0 |
T-Lymphocytes/enzymology/immunology | 5 | 41.0 |
Antilymphocyte Serum/*administration & dosage | 2 | 66.0 |
Graft Enhancement, Immunologic/*methods | 2 | 40.0 |
Hematology/*instrumentation | 2 | 66.0 |
Antigens, CD29/metabolism | 2 | 3.0 |
Asthma/*genetics/*immunology | 2 | 50.0 |
Glial Fibrillary Acidic Protein/biosynthesis | 2 | 10.0 |
Antibodies, Neoplasm/therapeutic use | 3 | 42.0 |
Immunocompetence/physiology | 3 | 100.0 |
*Mortality | 2 | 8.0 |
Toxoplasmosis/*immunology | 3 | 30.0 |
Antigen-Presenting Cells/drug effects/immunology | 4 | 36.0 |
HTLV-I Infections/*metabolism | 2 | 40.0 |
Complement 3c/analysis | 2 | 20.0 |
Selenium/pharmacology | 2 | 33.0 |
Zinc/pharmacology | 2 | 3.0 |
Lymphocyte Subsets/*chemistry | 2 | 40.0 |
Drug Hypersensitivity | 2 | 28.0 |
Antigens, CD/biosynthesis/chemistry/*metabolism | 2 | 28.0 |
Toxoplasmosis/complications | 3 | 100.0 |
Interleukin-2/biosynthesis/physiology | 3 | 42.0 |
*Cell Aging | 2 | 3.0 |
Erythrocyte Membrane/*immunology | 3 | 6.0 |
N-Acetylneuraminic Acid | 2 | 5.0 |
*Social Support | 4 | 36.0 |
AIDS-Related Opportunistic Infections/pathology/*radiography | 2 | 100.0 |
DNA/*analysis | 2 | 0.0 |
Lymph Nodes/*immunology/pathology | 4 | 30.0 |
Arthritis, Rheumatoid/*pathology | 2 | 10.0 |
Blood Cells/*pathology | 2 | 40.0 |
Carcinoma, Squamous Cell/*immunology/pathology/therapy | 2 | 66.0 |
Antigens, Differentiation, T-Lymphocyte/immunology | 68 | 37.0 |
Calcium/analysis | 2 | 6.0 |
Antigens, CD/*analysis/biosynthesis/genetics | 2 | 66.0 |
Leukemia, Myelocytic, Acute/genetics/immunology/*pathology | 2 | 33.0 |
Antibodies, Monoclonal/*biosynthesis/chemistry | 2 | 50.0 |
Pulmonary Fibrosis/etiology | 2 | 40.0 |
CD4-Positive T-Lymphocytes/*immunology/*secretion | 2 | 100.0 |
Lymphokines/immunology/*secretion | 2 | 100.0 |
Brain/pathology/*physiopathology | 2 | 28.0 |
*Magnetic Resonance Spectroscopy | 2 | 4.0 |
Cystic Fibrosis Transmembrane Conductance Regulator | 2 | 1.0 |
*Sequence Homology, Nucleic Acid | 2 | 2.0 |
Cell Adhesion Molecules/immunology/*physiology | 2 | 20.0 |
Giant Cells/immunology | 8 | 66.0 |
Adenoviruses, Human/*genetics | 2 | 1.0 |
Protein-Tyrosine Kinase/isolation & purification/*metabolism | 5 | 25.0 |
Autoradiography | 7 | 1.0 |
Trimethoprim-Sulfamethoxazole Combination/*administration & dosage/advers | 3 | 100.0 |
HLA Antigens/analysis/immunology | 2 | 40.0 |
Receptors, IgG/analysis/immunology | 2 | 66.0 |
Glycoproteins/immunology/*isolation & purification/metabolism | 2 | 100.0 |
Antigens, CD3/*immunology/metabolism | 2 | 66.0 |
Eosinophils/*cytology | 2 | 15.0 |
Actins/biosynthesis | 2 | 4.0 |
Plasma/*virology | 2 | 100.0 |
Monocytes/*metabolism/secretion | 2 | 100.0 |
Adenoids/*immunology | 2 | 40.0 |
Immunoglobulin A/*analysis | 3 | 5.0 |
*AIDS Serodiagnosis | 4 | 66.0 |
Bacterial Proteins/administration & dosage/*immunology | 2 | 100.0 |
Haemophilus Vaccines/administration & dosage/*immunology | 3 | 75.0 |
Immunoglobulin G/*biosynthesis | 5 | 13.0 |
Cold/*adverse effects | 2 | 16.0 |
Urticaria/*etiology/immunology | 2 | 100.0 |
Leukemia, Monocytic, Acute/blood | 2 | 66.0 |
Leukemia, Myelocytic, Acute/blood | 3 | 50.0 |
Leukemia, Myelomonocytic, Acute/blood | 2 | 66.0 |
Leukemia, Promyelocytic, Acute/blood | 2 | 66.0 |
*Dialysis Solutions | 2 | 40.0 |
*Gene Expression Regulation/drug effects | 3 | 1.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/biosynthesis/*genetics | 2 | 50.0 |
Eosinophils/cytology/*metabolism | 2 | 33.0 |
Sputum/*microbiology | 5 | 41.0 |
Lymphokines/biosynthesis | 15 | 13.0 |
Antigens, CD/immunology/*metabolism | 4 | 8.0 |
Antigens, CD59 | 2 | 1.0 |
Complement/physiology | 4 | 8.0 |
*Reverse Transcriptase Inhibitors | 4 | 50.0 |
Receptors, Fc/*physiology | 9 | 25.0 |
HIV Infections/*classification/mortality | 2 | 100.0 |
Down-Regulation/*genetics | 2 | 11.0 |
Gene Products, nef/genetics/physiology | 2 | 100.0 |
HIV-1/genetics/*metabolism/physiology | 2 | 28.0 |
Polyethylene Glycols/*chemistry | 2 | 15.0 |
Proviruses/*physiology | 2 | 100.0 |
Superinfection | 2 | 50.0 |
Polysaccharide-Lyases/metabolism | 2 | 22.0 |
Mycobacterium Infections, Atypical/*complications/microbiology | 3 | 100.0 |
Immunoglobulin E/*immunology | 2 | 8.0 |
Lymphokines/physiology | 2 | 2.0 |
*src-Family Kinases | 3 | 7.0 |
Antigens, CD3/genetics/*metabolism | 2 | 100.0 |
RANTES | 2 | 22.0 |
Dideoxynucleosides/*administration & dosage | 2 | 100.0 |
Africa, Southern | 2 | 18.0 |
Anti-Retroviral Agents/adverse effects/therapeutic use | 2 | 100.0 |
Astrocytes/virology | 2 | 66.0 |
Sequence Analysis, Protein | 2 | 1.0 |
Swine/immunology | 2 | 25.0 |
Bosnia-Herzegovina | 2 | 50.0 |
Depression/*immunology | 2 | 66.0 |
Interferon Type I, Recombinant/*pharmacology | 5 | 10.0 |
*Receptors, Antigen, T-Cell, gamma-delta | 2 | 50.0 |
T-Lymphocyte Subsets/immunology/*virology | 2 | 40.0 |
*Eating | 3 | 5.0 |
Methimazole/therapeutic use | 2 | 25.0 |
Simian Acquired Immunodeficiency Syndrome/immunology/*therapy/virology | 2 | 100.0 |
Antibodies, Anti-Idiotypic/*biosynthesis | 2 | 40.0 |
Antibodies, Monoclonal/*biosynthesis | 3 | 8.0 |
Injections, Intralymphatic | 4 | 57.0 |
HIV-1/genetics/metabolism | 2 | 22.0 |
Tuberculosis/*complications/microbiology | 2 | 100.0 |
*HIV Antibodies/blood | 2 | 100.0 |
HIV Infections/immunology/therapy | 2 | 66.0 |
HIV-1/*drug effects/pathogenicity/physiology | 3 | 60.0 |
Reverse Transcriptase Inhibitors | 14 | 70.0 |
Mutagenesis, Insertional | 3 | 1.0 |
Recombinant Proteins/genetics/immunology | 2 | 5.0 |
Graft Rejection/*pathology | 2 | 33.0 |
Protein-Tyrosine Kinase/immunology/*metabolism | 3 | 15.0 |
T-Lymphocytopenia, Idiopathic CD4-Positive/*etiology | 2 | 100.0 |
Blood Platelets/*immunology | 2 | 2.0 |
HIV Seropositivity/blood/complications/*immunology | 2 | 100.0 |
Rheumatoid Factor/*blood | 2 | 11.0 |
Genes, Structural, Viral/genetics | 2 | 28.0 |
HIV Envelope Protein gp120/immunology/metabolism/*physiology | 2 | 100.0 |
Biopterin/analogs & derivatives/analysis | 2 | 28.0 |
Interleukin-2/*pharmacology/therapeutic use | 3 | 27.0 |
Tumor Cells, Cultured/drug effects | 5 | 0.0 |
Chicago/epidemiology | 5 | 83.0 |
Chromatography, Ion Exchange | 4 | 1.0 |
Interleukin-7/*immunology | 2 | 33.0 |
Receptors, Antigen, T-Cell | 18 | 45.0 |
Acquired Immunodeficiency Syndrome/blood/*etiology/immunology | 2 | 100.0 |
Keratinocytes/*metabolism | 2 | 2.0 |
Receptors, Antigen, T-Cell, gamma-delta/physiology | 2 | 40.0 |
Pentamidine/administration & dosage/adverse effects/*therapeutic use | 3 | 100.0 |
Histocompatibility Antigens Class II/*blood | 2 | 66.0 |
Immunocompetence/immunology | 4 | 80.0 |
HIV Infections/*epidemiology/physiopathology | 3 | 100.0 |
Viral Interference | 3 | 42.0 |
Killer Cells, Natural/immunology/physiology | 2 | 66.0 |
Vascular Cell Adhesion Molecule-1 | 6 | 7.0 |
Energy Transfer | 2 | 3.0 |
Photochemistry | 3 | 5.0 |
Genes, pol/*genetics | 2 | 40.0 |
Complement/pharmacology | 3 | 27.0 |
1-(5-Isoquinolinesulfonyl)-2-methylpiperazine | 7 | 12.0 |
Antigens, CD/biosynthesis/*metabolism | 3 | 27.0 |
Piperazines/pharmacology | 8 | 7.0 |
Graft Rejection/*immunology/pathology | 2 | 14.0 |
Methylprednisolone/therapeutic use | 2 | 4.0 |
Lymphocytosis/immunology | 2 | 50.0 |
Hematopoietic Cell Growth Factors/pharmacology | 4 | 5.0 |
Tumor Stem Cells/chemistry/drug effects/*pathology | 2 | 100.0 |
Thioguanine/administration & dosage | 2 | 22.0 |
Tumor Stem Cell Assay | 2 | 1.0 |
Leukemia, Myelocytic, Acute/*immunology | 3 | 8.0 |
Mycobacterium Infections/complications | 2 | 100.0 |
Mycobacterium avium-intracellulare Infection/complications | 3 | 60.0 |
Mycoses/complications | 2 | 100.0 |
Virus Diseases/complications | 3 | 25.0 |
Radioimmunoassay/methods | 3 | 1.0 |
CD4 Immunoadhesins/adverse effects/*therapeutic use | 2 | 100.0 |
HLA-D Antigens/*metabolism | 9 | 42.0 |
Cryptosporidiosis/epidemiology | 2 | 100.0 |
Giardiasis/epidemiology | 2 | 100.0 |
Killer Cells, Natural/immunology/*physiology | 2 | 50.0 |
Lactates/blood | 3 | 4.0 |
Oxygen Consumption/physiology | 4 | 5.0 |
T-Lymphocytes, Suppressor-Effector/cytology | 5 | 62.0 |
Haemophilus Infections/prevention & control | 2 | 100.0 |
HIV Seropositivity/drug therapy/immunology | 2 | 100.0 |
Toxoplasmosis, Cerebral/prevention & control | 2 | 100.0 |
T-Lymphocytes/*enzymology | 7 | 11.0 |
Gluten/*immunology | 2 | 50.0 |
Adenosine Deaminase/*blood | 2 | 18.0 |
Asbestos/*adverse effects | 2 | 14.0 |
Pulmonary Fibrosis/*etiology/immunology | 2 | 100.0 |
Enzyme Induction | 4 | 0.0 |
Interleukin-1/genetics | 2 | 2.0 |
Leukocytes, Mononuclear/cytology/*immunology | 2 | 22.0 |
Lymphoma, AIDS-Related/genetics/*pathology | 2 | 66.0 |
Candidiasis, Oral/*drug therapy/etiology | 3 | 100.0 |
Dacarbazine/administration & dosage | 2 | 16.0 |
Procarbazine/administration & dosage | 3 | 21.0 |
Antigens, CD57 | 14 | 21.0 |
Trophoblasts/*immunology | 2 | 6.0 |
Immunoconjugates/*therapeutic use | 2 | 16.0 |
*Immunologic Tests | 2 | 28.0 |
Hematologic Diseases/*immunology | 2 | 33.0 |
Tunisia | 2 | 4.0 |
Oncogene Proteins, Viral/*metabolism | 3 | 8.0 |
CD4-Positive T-Lymphocytes/*immunology/ultrastructure | 4 | 80.0 |
*HLA-D Antigens | 2 | 28.0 |
HIV-1/*drug effects/pathogenicity | 4 | 80.0 |
Diabetes Mellitus, Type 1/immunology | 2 | 11.0 |
*RNA, Small Cytoplasmic | 2 | 7.0 |
Sjogren's Syndrome/*immunology/pathology | 2 | 25.0 |
Receptors, Immunologic/*physiology | 15 | 8.0 |
Acquired Immunodeficiency Syndrome/genetics/*therapy | 2 | 66.0 |
Acquired Immunodeficiency Syndrome/blood/immunology/*therapy | 2 | 40.0 |
Acquired Immunodeficiency Syndrome/*complications/immunology/pathology | 2 | 66.0 |
Autoimmune Diseases/*pathology | 2 | 28.0 |
HIV/drug effects/genetics/*physiology | 5 | 71.0 |
Liver Neoplasms/immunology/secondary | 2 | 66.0 |
Microcirculation/cytology | 2 | 10.0 |
Gene Products, gag/analysis | 17 | 73.0 |
Intestinal Diseases, Parasitic/*epidemiology/parasitology | 2 | 100.0 |
Isospora | 2 | 100.0 |
Sexual Behavior/statistics & numerical data | 2 | 100.0 |
Lymphoproliferative Disorders/complications | 2 | 28.0 |
Chromatography, Gel | 4 | 0.0 |
Partial Thromboplastin Time | 2 | 1.0 |
Aging/blood | 2 | 3.0 |
Lymphocyte Activation/radiation effects | 4 | 36.0 |
*Power Plants | 2 | 13.0 |
Exotoxins/*pharmacology | 6 | 24.0 |
RNA, Viral/genetics/metabolism | 2 | 8.0 |
Immunoglobulins, Light-Chain/chemistry | 2 | 28.0 |
Receptors, Antigen, T-Cell/analysis/genetics | 4 | 80.0 |
Immunoglobulins, Intravenous/*immunology | 2 | 28.0 |
Duodenum/parasitology | 2 | 66.0 |
Microsporida/*isolation & purification | 7 | 100.0 |
Amino Acids/analysis | 5 | 1.0 |
CD4-Positive T-Lymphocytes/enzymology | 2 | 100.0 |
Killer Cells, Natural/*physiology | 5 | 10.0 |
Diabetes Mellitus, Type 1/complications | 2 | 11.0 |
Antigens, CD4/*blood/immunology | 2 | 100.0 |
Erythroid Progenitor Cells/*cytology | 2 | 10.0 |
*Erythropoiesis | 2 | 2.0 |
*Cognitive Therapy | 2 | 28.0 |
Antibodies, Anticardiolipin/blood | 3 | 11.0 |
Placenta Diseases/*immunology | 2 | 100.0 |
Pregnancy Complications/*immunology | 2 | 15.0 |
T-Lymphocytes/immunology/physiology | 5 | 29.0 |
Dendritic Cells/*immunology/metabolism | 5 | 11.0 |
Immunologic Memory/radiation effects | 2 | 100.0 |
Hepatitis C/immunology | 2 | 20.0 |
Drug Evaluation, Preclinical/methods | 4 | 12.0 |
Lung Neoplasms/*immunology | 5 | 10.0 |
Microscopy, Fluorescence/methods | 3 | 9.0 |
Antibodies, Bacterial/immunology | 2 | 4.0 |
Antigens, CD/genetics/immunology | 2 | 10.0 |
Membrane Proteins/immunology | 3 | 5.0 |
*Gene Products, env | 3 | 100.0 |
*Liposomes | 3 | 8.0 |
Immunologic Deficiency Syndromes/genetics/*immunology | 2 | 18.0 |
Basophils/*immunology | 2 | 9.0 |
Receptors, IgE/metabolism | 2 | 6.0 |
Antigens, Surface/analysis/immunology | 3 | 18.0 |
Intestine, Large/*immunology | 2 | 66.0 |
Antibody Formation/*drug effects | 3 | 15.0 |
*Antiviral Agents | 5 | 35.0 |
CD4-Positive T-Lymphocytes/microbiology | 13 | 86.0 |
HLA-D Antigens/*genetics | 2 | 1.0 |
Immunologic Deficiency Syndromes/complications/immunology | 2 | 66.0 |
HIV-2/metabolism | 3 | 42.0 |
Leishmania major/*immunology | 2 | 28.0 |
HLA-D Antigens/analysis | 14 | 25.0 |
Alveolitis, Extrinsic Allergic/*immunology | 4 | 36.0 |
*Cocaine | 2 | 33.0 |
Pneumonia, Pneumocystis/*complications | 3 | 100.0 |
Protein Precursors/*immunology | 8 | 53.0 |
Biological Factors/*physiology | 2 | 15.0 |
Multiple Myeloma | 3 | 15.0 |
Leukemia, Hairy Cell/*immunology | 2 | 15.0 |
*Survival Rate | 2 | 66.0 |
Bacterial Infections/complications/immunology | 2 | 66.0 |
Escherichia coli/immunology | 2 | 2.0 |
HLA-D Antigens/*chemistry/immunology | 2 | 100.0 |
Virus Diseases/complications/immunology | 2 | 33.0 |
Hepatitis C/complications/*therapy | 2 | 50.0 |
Hepatitis B/*therapy | 2 | 100.0 |
Leukemia/immunology/therapy | 3 | 50.0 |
E-Selectin | 7 | 8.0 |
Antigens, CD55 | 6 | 3.0 |
Complement 3/*metabolism | 3 | 1.0 |
*Complement Activation | 3 | 0.0 |
Complement Pathway, Classical | 2 | 1.0 |
Cisplatin/administration & dosage/adverse effects | 3 | 12.0 |
Leukocyte Count/*drug effects | 5 | 55.0 |
Antibiotics, Antineoplastic/*pharmacology | 2 | 1.0 |
Proto-Oncogene Protein pp60(c-src)/metabolism | 2 | 5.0 |
Estradiol/*pharmacology | 3 | 1.0 |
Receptors, Antigen, T-Cell, alpha-beta/analysis/genetics | 3 | 60.0 |
Y Chromosome | 2 | 2.0 |
Factor VIII/isolation & purification/*therapeutic use | 3 | 100.0 |
Lymphocytosis/*immunology | 3 | 50.0 |
Interferons/*biosynthesis | 2 | 16.0 |
Cell Differentiation/drug effects/physiology | 5 | 5.0 |
Receptors, Cell Surface/immunology | 2 | 5.0 |
Leukemia, Myelocytic, Acute/*pathology | 2 | 5.0 |
Receptors, Antigen, T-Cell, alpha-beta/analysis/*genetics | 2 | 100.0 |
Antigen-Antibody Complex/blood | 6 | 19.0 |
Hydrogen Peroxide/pharmacology | 2 | 0.0 |
Capsid/immunology | 2 | 20.0 |
Rabies virus/*immunology | 3 | 37.0 |
Intestinal Diseases, Parasitic/diagnosis/*epidemiology | 2 | 100.0 |
Microsporidiosis/diagnosis/*epidemiology | 2 | 100.0 |
Gene Products, nef/genetics/immunology | 2 | 100.0 |
Thalidomide/*pharmacology | 3 | 17.0 |
Fibromyalgia/*immunology | 2 | 100.0 |
*Hyperbaric Oxygenation | 2 | 12.0 |
Acquired Immunodeficiency Syndrome/*immunology/physiopathology | 3 | 60.0 |
Immune System/*drug effects/immunology | 2 | 100.0 |
Embryonic and Fetal Development | 3 | 0.0 |
Genes, fos | 2 | 1.0 |
Mammals | 2 | 0.0 |
Ricin/*therapeutic use | 3 | 37.0 |
Receptors, Very Late Antigen/analysis | 2 | 25.0 |
T-Lymphocytes, Helper-Inducer/*drug effects/immunology | 2 | 40.0 |
Antigens, CD29 | 36 | 59.0 |
Retinitis/*immunology | 2 | 66.0 |
Heparin/*pharmacology | 3 | 2.0 |
Vitronectin | 2 | 5.0 |
Receptors, Antigen, B-Cell/*metabolism | 2 | 2.0 |
Tyrosine/analogs & derivatives/metabolism | 16 | 13.0 |
Doxorubicin/pharmacology | 2 | 0.0 |
Acquired Immunodeficiency Syndrome/diagnosis/*epidemiology | 2 | 100.0 |
Acquired Immunodeficiency Syndrome/*prevention & control/transmission | 2 | 100.0 |
Respiratory Hypersensitivity/etiology/*immunology | 2 | 100.0 |
Simplexvirus/isolation & purification | 2 | 50.0 |
Peru | 3 | 6.0 |
Trimethoprim-Sulfamethoxazole Combination/pharmacology | 2 | 28.0 |
HLA-A Antigens/genetics/immunology | 2 | 10.0 |
Antibodies, Neoplasm/*therapeutic use | 2 | 18.0 |
Antigens, CD4/blood/immunology | 2 | 100.0 |
Melanoma | 3 | 3.0 |
Leukocytes, Mononuclear/microbiology | 14 | 73.0 |
Macrophages/microbiology | 8 | 36.0 |
Cell Membrane/metabolism/microbiology | 2 | 66.0 |
Histiocytosis, Langerhans-Cell/*pathology | 2 | 20.0 |
Langerhans Cells/*pathology | 5 | 38.0 |
Binding Sites, Antibody/immunology | 3 | 20.0 |
Genistein | 4 | 5.0 |
Isoflavones/pharmacology | 4 | 6.0 |
CA-15-3 Antigen | 5 | 5.0 |
Budesonide | 2 | 20.0 |
Antigens, CD26 | 8 | 29.0 |
Giant Cells/cytology | 6 | 60.0 |
Physical Examination | 2 | 7.0 |
Substance Abuse, Intravenous/*complications/psychology/rehabilitation | 2 | 100.0 |
Receptors, Very Late Antigen/*biosynthesis | 2 | 66.0 |
Human T-lymphotropic virus 1/genetics/isolation & purification | 2 | 100.0 |
*Major Histocompatibility Complex | 6 | 2.0 |
Blood Proteins/immunology | 2 | 10.0 |
Parathyroid Hormone/*blood | 2 | 2.0 |
Hay Fever/*immunology/pathology | 2 | 40.0 |
*Cardiopulmonary Bypass | 3 | 3.0 |
Chimeric Proteins/*metabolism | 2 | 16.0 |
Glycosylphosphatidylinositols/*physiology | 2 | 13.0 |
Antigens, CD20 | 15 | 21.0 |
Epithelium/microbiology | 4 | 19.0 |
Suramin/*pharmacology | 3 | 14.0 |
Protein Precursors/immunology | 6 | 46.0 |
*Artifacts | 2 | 9.0 |
Antigens, CD4/*analysis/genetics/immunology | 3 | 100.0 |
Benzyl Compounds/pharmacology | 2 | 25.0 |
Dipeptides/*pharmacology | 2 | 11.0 |
Antigens, Differentiation, Myelomonocytic/*blood | 2 | 11.0 |
HLA-D Antigens/*biosynthesis | 3 | 60.0 |
Antigens, CD3/analysis/physiology | 2 | 50.0 |
Candida albicans/*immunology | 2 | 10.0 |
Monocytes/*cytology/immunology | 3 | 15.0 |
Antigen-Antibody Reactions/immunology | 3 | 33.0 |
Arthritis, Rheumatoid/therapy | 2 | 33.0 |
Collagen/*immunology | 2 | 10.0 |
RNA, Neoplasm/*analysis | 3 | 6.0 |
Gingivitis/*immunology/pathology | 2 | 40.0 |
T-Lymphocyte Subsets/*immunology/metabolism/ultrastructure | 2 | 100.0 |
Antigens, CD/analysis/*immunology | 4 | 10.0 |
Chemistry, Physical | 2 | 1.0 |
Antigens, CD11 | 20 | 24.0 |
Intercellular Adhesion Molecule-1 | 36 | 15.0 |
HIV Seropositivity/blood/*microbiology | 2 | 100.0 |
HIV Seropositivity/blood/*diagnosis | 2 | 100.0 |
Ketoconazole/therapeutic use | 4 | 57.0 |
Acquired Immunodeficiency Syndrome/epidemiology/*etiology/immunology | 3 | 60.0 |
Factor VIII/standards/*therapeutic use | 3 | 100.0 |
Antigens, Differentiation, T-Lymphocyte/*analysis/immunology | 5 | 33.0 |
Receptors, Immunologic/*analysis/immunology | 2 | 66.0 |
Acquired Immunodeficiency Syndrome/complications/*epidemiology/mortality | 3 | 100.0 |
Thrombocytopenia/complications | 2 | 20.0 |
Aspergillosis/*complications/diagnosis/drug therapy | 2 | 100.0 |
Lung Diseases, Fungal/*complications/diagnosis/drug therapy | 2 | 100.0 |
Hemophilia A/complications/immunology/*therapy | 3 | 100.0 |
Immunosorbent Techniques | 8 | 2.0 |
Lymphocytes/drug effects/*metabolism | 2 | 8.0 |
Polysaccharides/*pharmacology | 3 | 13.0 |
HIV Envelope Protein gp120/*drug effects/*metabolism | 2 | 100.0 |
HIV-1/*isolation & purification/pathogenicity | 2 | 66.0 |
Mycobacterium bovis/immunology | 4 | 16.0 |
Cell Membrane/metabolism/ultrastructure | 3 | 5.0 |
HIV Envelope Protein gp120/biosynthesis | 2 | 66.0 |
HIV Envelope Protein gp120/*immunology/ultrastructure | 3 | 100.0 |
Pleural Effusion, Malignant/immunology/*pathology | 2 | 66.0 |
Interleukin-12 | 4 | 23.0 |
Myristates/metabolism | 2 | 66.0 |
Peptide Fragments | 3 | 4.0 |
Microscopy, Electron/methods | 3 | 5.0 |
Indomethacin/pharmacology | 4 | 1.0 |
Receptors, Cholinergic/*immunology | 2 | 10.0 |
Rheumatic Diseases/*immunology | 2 | 12.0 |
T-Lymphocytes/*drug effects/physiology | 2 | 25.0 |
Genomic Library | 3 | 0.0 |
Introns | 3 | 0.0 |
Semen/microbiology | 3 | 75.0 |
Tissue Preservation/*methods | 2 | 25.0 |
Acquired Immunodeficiency Syndrome/complications/*immunology/therapy | 2 | 66.0 |
Genes, nef/*physiology | 3 | 75.0 |
T-Lymphocytes, Suppressor-Inducer/*immunology | 2 | 66.0 |
Anti-HIV Agents/*chemistry/metabolism | 2 | 100.0 |
Receptors, CCR5/antagonists & inhibitors/metabolism | 2 | 66.0 |
Ribavirin/adverse effects | 2 | 100.0 |
Antigens, CD2/immunology | 2 | 6.0 |
Eosinophilia/*immunology | 2 | 20.0 |
Receptors, Cell Surface/metabolism | 4 | 0.0 |
CD4-Positive T-Lymphocytes/drug effects/*physiology | 2 | 100.0 |
Membrane Potentials/drug effects/physiology | 2 | 2.0 |
Gene Products, env/*biosynthesis/genetics/immunology | 2 | 100.0 |
HIV Envelope Protein gp120/biosynthesis/genetics/immunology | 2 | 100.0 |
*Complement Inactivators | 2 | 2.0 |
Ethiopia/ethnology | 2 | 40.0 |
HIV Infections/*immunology/metabolism/virology | 2 | 66.0 |
DNA Nucleotidyltransferases/genetics | 2 | 18.0 |
Integrases | 2 | 22.0 |
Micronucleus Tests | 2 | 4.0 |
Giant Cells/microbiology | 11 | 100.0 |
HIV Infections/*drug therapy/immunology/*microbiology | 2 | 100.0 |
Monocytes/cytology/microbiology | 2 | 66.0 |
Central Nervous System Diseases/diagnosis/*microbiology/therapy | 2 | 100.0 |
Protein p53/biosynthesis | 2 | 1.0 |
Fluconazole/administration & dosage | 2 | 66.0 |
Antigens, Differentiation, B-Lymphocyte/analysis/immunology | 4 | 40.0 |
Acquired Immunodeficiency Syndrome/microbiology | 11 | 52.0 |
Biopterin/analogs & derivatives/urine | 2 | 50.0 |
Factor VIII/therapeutic use | 4 | 26.0 |
Sulfhydryl Compounds/metabolism | 2 | 5.0 |
Horses/*immunology | 2 | 33.0 |
Herpesviridae Infections/*metabolism | 2 | 100.0 |
Oligonucleotides | 2 | 3.0 |
CD4-Positive T-Lymphocytes/metabolism/microbiology | 2 | 100.0 |
Proto-Oncogene Proteins/physiology | 4 | 3.0 |
*Virus Replication/genetics | 2 | 40.0 |
CD4-CD8 Ratio/radiation effects | 2 | 100.0 |
Arthritis, Psoriatic/*immunology | 2 | 40.0 |
Acquired Immunodeficiency Syndrome/*complications/diagnosis/immunology | 2 | 100.0 |
Multiple Myeloma/immunology | 2 | 11.0 |
Interferon-beta/pharmacology | 2 | 4.0 |
Liver/cytology | 2 | 3.0 |
Antigen-Antibody Complex/analysis | 6 | 5.0 |
Vaccinia virus/genetics/metabolism | 2 | 33.0 |
RNA/biosynthesis | 3 | 3.0 |
Precancerous Conditions/*immunology | 2 | 20.0 |
Antigens, CD/*immunology/metabolism | 2 | 6.0 |
HIV-1/enzymology/genetics/*physiology | 3 | 75.0 |
RNA-Directed DNA Polymerase/biosynthesis | 6 | 60.0 |
Receptors, Transferrin/analysis | 4 | 11.0 |
T-Lymphocyte Subsets/cytology/metabolism | 6 | 85.0 |
Interleukin-7/administration & dosage/*pharmacology | 2 | 100.0 |
Fibroblasts/immunology | 6 | 8.0 |
Infusions, Parenteral | 5 | 3.0 |
Bacteremia/*complications/drug therapy/microbiology | 2 | 100.0 |
Clavulanic Acid | 2 | 100.0 |
Peptides/pharmacology | 4 | 2.0 |
Receptors, Fc/*metabolism | 4 | 11.0 |
Insulin/pharmacology | 3 | 1.0 |
HIV Infections/blood/drug therapy/*metabolism | 2 | 50.0 |
Myocardium/metabolism | 3 | 1.0 |
B-Lymphocytes/immunology/microbiology | 2 | 66.0 |
T-Lymphocytes/immunology/microbiology | 7 | 63.0 |
HLA-DR Antigens/*physiology | 3 | 42.0 |
Carcinoma, Renal Cell/*immunology/therapy | 2 | 50.0 |
Kidney Neoplasms/*immunology/therapy | 2 | 50.0 |
*Nephrectomy | 2 | 11.0 |
Myelodysplastic Syndromes/*immunology | 3 | 60.0 |
Sarcoidosis/*immunology/pathology | 2 | 28.0 |
*HIV Antibodies | 4 | 66.0 |
*Cytotoxicity Tests, Immunologic | 2 | 20.0 |
Leukemia | 6 | 8.0 |
Opportunistic Infections/*etiology | 2 | 50.0 |
Ethanol/*toxicity | 2 | 6.0 |
Acquired Immunodeficiency Syndrome/immunology/pathology | 3 | 100.0 |
HIV Infections/blood/complications/*physiopathology | 2 | 100.0 |
Nucleosides/*pharmacology | 2 | 40.0 |
Levamisole/*pharmacology | 2 | 25.0 |
Antigens, CD/analysis/physiology | 2 | 16.0 |
Antigens, Differentiation, T-Lymphocyte/analysis/physiology | 6 | 50.0 |
Tenascin | 2 | 18.0 |
*Neutralization Tests | 2 | 33.0 |
Bone Marrow Transplantation/*immunology/pathology | 2 | 25.0 |
Leukocytes, Mononuclear/*microbiology | 7 | 53.0 |
Receptors, Immunologic/analysis/*physiology | 2 | 40.0 |
Antigens, Differentiation, T-Lymphocyte/immunology/*physiology | 8 | 38.0 |
Protein Array Analysis | 2 | 6.0 |
Tumor Necrosis Factor-alpha/biosynthesis/genetics | 2 | 3.0 |
Antibodies/chemistry | 2 | 9.0 |
Antiretroviral Therapy, Highly Active/*adverse effects/utilization | 2 | 100.0 |
Protein Structure, Tertiary/genetics | 2 | 0.0 |
Bile Ducts/immunology | 2 | 40.0 |
Leukocytes, Mononuclear/*pathology | 5 | 38.0 |
Interleukin-1/*blood | 2 | 3.0 |
Fibronectins/pharmacology | 2 | 4.0 |
Integrins/*immunology | 2 | 12.0 |
Melanoma/*metabolism | 2 | 3.0 |
Micelles | 2 | 4.0 |
Rhode Island | 2 | 66.0 |
Antigens, Bacterial/administration & dosage | 2 | 50.0 |
Gene Products, nef/*pharmacology | 2 | 40.0 |
Rectum/*immunology/pathology | 2 | 66.0 |
Bloodletting | 2 | 16.0 |
HIV Seropositivity/complications/*microbiology | 2 | 66.0 |
HIV-1/genetics/*immunology/pathogenicity | 3 | 100.0 |
Boston/epidemiology | 2 | 33.0 |
Leukocytes, Mononuclear/*chemistry | 2 | 12.0 |
Epstein-Barr Virus Nuclear Antigens | 5 | 11.0 |
*Gene Expression Regulation, Neoplastic | 3 | 0.0 |
CD4-Positive T-Lymphocytes/*immunology/microbiology | 10 | 83.0 |
*Antigens, CD8 | 3 | 42.0 |
Arousal | 2 | 40.0 |
Lymphocytes/classification | 18 | 62.0 |
Giant Cells/*microbiology | 3 | 100.0 |
HIV Infections/*microbiology/*physiopathology | 2 | 100.0 |
Dendritic Cells/*immunology/ultrastructure | 3 | 50.0 |
Leishmania donovani/immunology | 2 | 66.0 |
Human T-lymphotropic virus 1 | 4 | 30.0 |
Membrane Glycoproteins/*blood/genetics | 2 | 66.0 |
AIDS-Related Complex/immunology/*pathology | 3 | 75.0 |
Recombinant Proteins/*immunology | 2 | 10.0 |
Antigens, CD36 | 3 | 2.0 |
Macrophages/immunology/*pathology | 5 | 27.0 |
Psoriasis/immunology/*pathology | 3 | 37.0 |
T-Lymphocytes, Suppressor-Effector/metabolism | 5 | 55.0 |
HLA Antigens/*metabolism | 2 | 6.0 |
Antigen-Antibody Reactions/drug effects | 2 | 14.0 |
Herpesvirus 7, Human/*metabolism | 2 | 100.0 |
Sarcoma, Kaposi/etiology/*immunology | 3 | 100.0 |
Leukemia, B-Cell, Chronic/*immunology/pathology | 3 | 18.0 |
Homosexuality/statistics & numerical data | 2 | 100.0 |
AIDS-Related Opportunistic Infections/complications/prevention & control | 2 | 100.0 |
Leukemia, Lymphocytic, Acute/*immunology | 4 | 14.0 |
Antigens, CD4/analysis/*biosynthesis/genetics | 3 | 100.0 |
Gene Products, nef/analysis | 3 | 100.0 |
Gene Products, env/chemistry/*metabolism | 2 | 100.0 |
Protein Precursors/chemistry/*metabolism | 2 | 25.0 |
Receptors, Fc/analysis | 13 | 21.0 |
HIV-1/*growth & development/isolation & purification | 3 | 75.0 |
HIV Envelope Protein gp41/genetics | 2 | 40.0 |
Hela Cells/microbiology | 3 | 23.0 |
T-Lymphocytes/microbiology | 13 | 56.0 |
Iron/*pharmacology | 2 | 13.0 |
Retroviridae Infections/immunology | 2 | 40.0 |
Wechsler Scales | 2 | 12.0 |
S100 Proteins/*analysis | 4 | 8.0 |
Measles/epidemiology/*immunology | 2 | 100.0 |
Endothelium, Vascular/cytology/*metabolism | 2 | 1.0 |
Nephrotic Syndrome/*immunology | 4 | 50.0 |
Eosinophils/immunology/*pathology | 2 | 50.0 |
Cryptococcosis/complications | 2 | 100.0 |
Lung Diseases, Fungal/complications | 3 | 100.0 |
Depressive Disorder/*drug therapy/etiology/psychology | 2 | 100.0 |
Acquired Immunodeficiency Syndrome/immunology/*microbiology | 4 | 50.0 |
HIV Seropositivity/immunology/*microbiology | 2 | 100.0 |
Viremia/immunology/microbiology | 2 | 100.0 |
Viremia/microbiology | 2 | 50.0 |
Viral Matrix Proteins/*analysis | 2 | 25.0 |
Sheep/immunology | 2 | 8.0 |
Pneumonia/pathology | 2 | 50.0 |
Imidazoles/pharmacology | 3 | 1.0 |
Arthritis, Rheumatoid/blood/immunology/*therapy | 2 | 50.0 |
Receptors, Immunologic/analysis | 16 | 18.0 |
*B-Lymphocyte Subsets/immunology | 2 | 100.0 |
Neprilysin/analysis | 2 | 3.0 |
Rabbits/immunology | 3 | 3.0 |
Pentamidine/*administration & dosage/adverse effects | 2 | 100.0 |
Neoplasms/blood/*drug therapy | 2 | 15.0 |
*Papillomavirus, Human/immunology | 2 | 100.0 |
Antilymphocyte Serum/*immunology/therapeutic use | 2 | 66.0 |
Leucine/chemistry | 2 | 5.0 |
Leukemia, T-Cell/*immunology | 4 | 23.0 |
Metalloendopeptidases/*metabolism | 2 | 2.0 |
Bone Marrow/*microbiology | 2 | 66.0 |
Rhinitis, Allergic, Perennial/*pathology | 2 | 100.0 |
Acquired Immunodeficiency Syndrome/complications/*pathology | 2 | 33.0 |
Arthritis, Rheumatoid/*therapy | 6 | 33.0 |
Recombinant Proteins/*biosynthesis | 3 | 8.0 |
Carrier Proteins/genetics/*immunology | 2 | 22.0 |
Retinal Vessels/*pathology | 2 | 20.0 |
AIDS-Related Complex/prevention & control | 2 | 100.0 |
CD4-Positive T-Lymphocytes/immunology/radiation effects | 2 | 100.0 |
HIV Infections/complications/immunology/*therapy | 4 | 100.0 |
T-Lymphocytes/immunology/*radiation effects | 3 | 50.0 |
Macrophages, Alveolar/*classification | 2 | 100.0 |
Arthritis, Juvenile Rheumatoid/*immunology | 5 | 25.0 |
L-Selectin | 9 | 14.0 |
*Mutagenesis | 2 | 3.0 |
*Blood Specimen Collection | 2 | 25.0 |
*Self Tolerance | 2 | 20.0 |
T-Lymphocytes/transplantation | 2 | 25.0 |
Antigens, Differentiation, B-Lymphocyte/*physiology | 3 | 8.0 |
Cloning, Molecular/methods | 2 | 1.0 |
Escherichia coli/*metabolism | 2 | 7.0 |
Reticulocytes/metabolism | 2 | 2.0 |
CD4-Positive T-Lymphocytes/metabolism/*microbiology | 4 | 80.0 |
Hexosaminidases/metabolism | 2 | 13.0 |
DNA/*biosynthesis | 2 | 2.0 |
AIDS-Related Complex/blood/immunology | 2 | 50.0 |
Tumor Necrosis Factor-alpha/*biosynthesis/genetics | 2 | 2.0 |
Cell Fusion/drug effects/*physiology | 3 | 100.0 |
SIV/*immunology/pathogenicity | 2 | 100.0 |
Mice, SCID/*immunology | 2 | 50.0 |
Lymphoma/*immunology | 4 | 12.0 |
Sympathetic Nervous System/physiopathology | 2 | 8.0 |
Arthritis, Rheumatoid/*radionuclide imaging | 3 | 100.0 |
*Radioimmunodetection | 2 | 16.0 |
Technetium/diagnostic use | 2 | 7.0 |
Kidney Neoplasms/*immunology | 3 | 11.0 |
Indicator Dilution Techniques | 2 | 10.0 |
Stem Cells/physiology | 2 | 3.0 |
Antibodies, Monoclonal/*immunology/metabolism | 2 | 10.0 |
Antigen-Antibody Reactions/*drug effects | 2 | 50.0 |
Interleukin-6/biosynthesis/genetics | 2 | 5.0 |
Autoimmune Diseases/*complications/immunology | 2 | 66.0 |
T-Lymphocytes, Suppressor-Effector/physiology | 6 | 50.0 |
Antigens, CD18 | 9 | 9.0 |
T-Lymphocytes/chemistry/pathology/ultrastructure | 2 | 66.0 |
Immune Tolerance/physiology | 2 | 20.0 |
Lymphoproliferative Disorders/genetics | 2 | 50.0 |
Phosphatidylinositols/metabolism | 5 | 4.0 |
*Antigens, Differentiation, B-Lymphocyte | 2 | 13.0 |
HIV-1/drug effects/immunology/*pathogenicity | 2 | 100.0 |
Immunotoxins/metabolism/*therapeutic use | 2 | 66.0 |
Aging/metabolism | 2 | 1.0 |
Rats, Inbred WF | 3 | 14.0 |
Hepatitis B Core Antigens/*blood | 2 | 100.0 |
Hepatitis B Surface Antigens/*blood | 2 | 22.0 |
Antibodies, Monoclonal/diagnostic use/immunology | 5 | 18.0 |
Cell Count/methods | 2 | 3.0 |
Evoked Potentials, Auditory/*physiology | 2 | 5.0 |
Leukocytes/immunology/*physiology | 2 | 50.0 |
AIDS-Related Complex/*immunology | 7 | 23.0 |
Macrophages/*microbiology | 9 | 30.0 |
HIV Seropositivity/complications/*metabolism | 2 | 100.0 |
Ovarian Neoplasms/immunology/*therapy | 3 | 60.0 |
Immunoglobulin A, Secretory/*biosynthesis | 2 | 28.0 |
Electrocardiography | 4 | 1.0 |
Attention/physiology | 2 | 6.0 |
Mediastinal Neoplasms/*pathology | 2 | 40.0 |
Hodgkin Disease/therapy | 3 | 42.0 |
*Phorbol 12,13-Dibutyrate | 2 | 100.0 |
Cytokines/*secretion | 5 | 8.0 |
Graves' Disease/immunology/*pathology | 2 | 50.0 |
Lymphocyte Subsets/immunology/pathology | 2 | 50.0 |
Thyroid Gland/immunology/*pathology | 2 | 100.0 |
Interleukins/immunology | 3 | 17.0 |
Receptors, Leukocyte-Adhesion/immunology | 2 | 16.0 |
Leukocytes/immunology/pathology | 3 | 37.0 |
Pancytopenia/chemically induced | 2 | 66.0 |
CD4-Positive T-Lymphocytes/immunology/microbiology | 7 | 77.0 |
HIV-1/drug effects/*isolation & purification | 2 | 100.0 |
Blood Component Transfusion/*adverse effects | 2 | 28.0 |
HIV Core Protein p24/*analysis/blood | 2 | 100.0 |
Models, Neurological | 2 | 1.0 |
Myelin Sheath/*physiology | 2 | 6.0 |
Antibodies, Viral | 4 | 16.0 |
Peroxidase/immunology | 2 | 5.0 |
Neoplasms/pathology/*therapy | 2 | 14.0 |
Autoimmune Diseases/*drug therapy/immunology | 4 | 57.0 |
Democratic Republic of the Congo | 2 | 14.0 |
Neoplasms/*therapy | 2 | 1.0 |
*CD4-CD8 Ratio/drug effects | 2 | 100.0 |
Pulmonary Surfactants/metabolism | 2 | 16.0 |
Endoplasmic Reticulum/immunology | 2 | 50.0 |
Golgi Apparatus/immunology | 2 | 33.0 |
Cell Adhesion Molecules/biosynthesis/genetics | 2 | 12.0 |
Pentostatin/therapeutic use | 2 | 100.0 |
Thyroglobulin/*immunology | 2 | 2.0 |
Bone Marrow Transplantation/*pathology | 3 | 25.0 |
Cell Nucleus | 2 | 2.0 |
Receptors, IgG/*immunology | 2 | 6.0 |
Lomustine/administration & dosage | 2 | 22.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/blood | 2 | 13.0 |
B-Lymphocytes/classification/immunology | 2 | 33.0 |
Killer Cells, Natural/classification/immunology | 3 | 60.0 |
Syphilis/*immunology | 2 | 50.0 |
T-Lymphocytes/classification/immunology | 7 | 41.0 |
Methotrexate/pharmacology/*therapeutic use | 2 | 100.0 |
Gene Products, rev/genetics/metabolism | 2 | 66.0 |
Gene Products, tat/genetics/metabolism | 2 | 13.0 |
RNA/genetics/isolation & purification | 2 | 1.0 |
Antigens, CD/*analysis/*biosynthesis | 2 | 40.0 |
Interleukin-3/pharmacology | 2 | 0.0 |
Antigens, CD/*chemistry | 2 | 7.0 |
Immunoglobulins/*chemistry | 2 | 13.0 |
Immunoglobulins, kappa-Chain/chemistry | 2 | 66.0 |
Mice, Transgenic/*immunology | 2 | 28.0 |
Recombinant Proteins/isolation & purification | 3 | 7.0 |
Gene Products, env/pharmacology | 2 | 66.0 |
Protein Precursors/pharmacology | 2 | 28.0 |
Smoking/pathology | 2 | 28.0 |
HIV Infections/complications/immunology/*microbiology | 2 | 100.0 |
Pokeweed Mitogens/*pharmacology | 4 | 57.0 |
Hypersensitivity, Delayed/immunology/physiopathology | 2 | 100.0 |
Thymus Extracts/*therapeutic use | 5 | 71.0 |
Protein Precursors/genetics/immunology | 2 | 66.0 |
Animals, Domestic/*immunology | 2 | 66.0 |
Bacterial Proteins/genetics | 2 | 2.0 |
DNA Replication | 12 | 3.0 |
*Genome, Viral | 3 | 4.0 |
*Trans-Activators | 2 | 0.0 |
Receptors, IgE/*analysis | 2 | 22.0 |
Herpes Zoster/*complications | 3 | 100.0 |
AIDS-Related Complex/complications/*drug therapy | 3 | 100.0 |
HIV Seropositivity/complications/*drug therapy | 2 | 100.0 |
Calcium/analysis/metabolism | 2 | 22.0 |
DNA/analysis/metabolism | 2 | 22.0 |
Myelodysplastic Syndromes/*genetics | 3 | 4.0 |
Tumor Cells, Cultured/*pathology | 2 | 10.0 |
Immunoglobulins/chemistry | 3 | 12.0 |
Stress/metabolism | 2 | 22.0 |
Blood Cells/immunology/*pathology | 3 | 100.0 |
Epidermis/*immunology | 2 | 16.0 |
Trinitrobenzenes/immunology | 2 | 16.0 |
Antigens, Thy-1 | 10 | 34.0 |
Leukemia, Lymphocytic, Acute | 3 | 25.0 |
Antigens, CD4/biosynthesis/metabolism/*physiology | 2 | 100.0 |
T-Lymphocytes/*cytology/*immunology | 4 | 22.0 |
Measles-Mumps-Rubella Vaccine | 3 | 60.0 |
Lung Neoplasms/*complications/epidemiology/pathology | 2 | 100.0 |
Retroviridae/genetics/*immunology | 2 | 66.0 |
AIDS-Related Complex/blood/*drug therapy/immunology | 4 | 100.0 |
Antigens, CD4/*toxicity | 2 | 100.0 |
Leukocytes/drug effects/immunology | 2 | 25.0 |
Recombinant Proteins/*toxicity | 2 | 25.0 |
Cardiomyopathy, Dilated/*immunology/pathology | 2 | 100.0 |
Lymphocytes/*microbiology | 5 | 50.0 |
Simian Acquired Immunodeficiency | 2 | 50.0 |
Arthritis, Rheumatoid/physiopathology/*therapy | 2 | 40.0 |
Chimeric Proteins/therapeutic use | 3 | 25.0 |
HIV Infections/*complications/immunology/*transmission | 2 | 100.0 |
Neoplasms/drug therapy | 2 | 3.0 |
Transglutaminases/*analysis | 3 | 17.0 |
Macrophages/immunology/*microbiology | 4 | 100.0 |
Antigens, CD4/*pharmacology | 4 | 40.0 |
Rifabutin | 4 | 100.0 |
Dermatomyositis/immunology | 2 | 33.0 |
HLA-D Antigens/*analysis | 3 | 4.0 |
T-Lymphocyte Subsets/drug effects/immunology/*pathology | 2 | 100.0 |
Bone Marrow Transplantation/*adverse effects/immunology | 2 | 18.0 |
Cytomegalovirus Infections/*etiology | 3 | 50.0 |
Chemotactic Factors/biosynthesis | 2 | 28.0 |
AIDS-Related Opportunistic Infections/complications/pathology | 2 | 100.0 |
Gene Products, env/biosynthesis/*metabolism | 2 | 50.0 |
Peritoneal Cavity/*cytology | 2 | 16.0 |
Arrestin | 3 | 16.0 |
Uveitis/immunology | 2 | 50.0 |
Lipoproteins, LDL/pharmacology | 2 | 4.0 |
Receptors, Immunologic/*biosynthesis | 3 | 13.0 |
Agammaglobulinemia/*immunology | 4 | 33.0 |
Hepatitis B Surface Antigens/blood | 4 | 15.0 |
T-Lymphocytes, Suppressor-Effector/*physiology | 5 | 38.0 |
Shock, Septic/*immunology | 2 | 14.0 |
Antigens, CD4/chemistry/genetics/*immunology | 2 | 100.0 |
Tyrosine/*analogs & derivatives/metabolism | 2 | 3.0 |
Macrophages/cytology/*microbiology | 2 | 66.0 |
T-Lymphocytes, Suppressor-Effector/*cytology | 2 | 66.0 |
Acquired Immunodeficiency Syndrome/blood/*epidemiology | 3 | 100.0 |
T-Lymphocytes/*immunology/microbiology | 7 | 63.0 |
Lymphocyte Subsets/physiology | 2 | 22.0 |
Interleukin-2/*genetics/metabolism | 4 | 40.0 |
5'-Nucleotidase/analysis | 2 | 40.0 |
Membrane Proteins/genetics/isolation & purification/*metabolism | 2 | 20.0 |
Recombinant Fusion Proteins/isolation & purification/metabolism | 2 | 2.0 |
Acquired Immunodeficiency Syndrome/*microbiology | 10 | 47.0 |
HIV Infections/*drug therapy/microbiology | 2 | 100.0 |
Monocytes/metabolism/*microbiology | 2 | 50.0 |
*Bronchoalveolar Lavage Fluid | 2 | 25.0 |
Antibodies/therapeutic use | 2 | 11.0 |
Pentamidine/*therapeutic use | 2 | 100.0 |
HIV/isolation & purification/*physiology | 2 | 66.0 |
Antigens, CD4/metabolism/*pharmacology | 2 | 100.0 |
Cryosurgery | 2 | 40.0 |
Hepatitis Antibodies/*analysis | 2 | 28.0 |
Hepatitis C Antibodies | 2 | 16.0 |
Lymphocytes/immunology/metabolism | 6 | 19.0 |
*Emigration and Immigration | 2 | 16.0 |
Jews | 2 | 2.0 |
Capsid/*metabolism | 3 | 25.0 |
Morphogenesis | 3 | 1.0 |
Virion/ultrastructure | 3 | 23.0 |
Antigens, Viral/genetics | 2 | 11.0 |
Receptors, Glucocorticoid/metabolism | 3 | 5.0 |
Langerhans Cells/*immunology/ultrastructure | 3 | 33.0 |
Concanavalin A/*pharmacology | 2 | 7.0 |
Antigens, CD4/drug effects/immunology/*metabolism | 2 | 100.0 |
Gene Products, nef/*biosynthesis/genetics | 3 | 100.0 |
Receptors, Antigen, T-Cell, alpha-beta/genetics/*physiology | 2 | 100.0 |
Pokeweed Mitogens | 6 | 54.0 |
Mice, Inbred BALB C/immunology | 3 | 9.0 |
Epidermis/pathology | 6 | 19.0 |
Lichen Planus/*pathology | 2 | 50.0 |
Bone Marrow Purging/*methods | 2 | 5.0 |
*Drug Resistance | 2 | 4.0 |
Lymphoma/immunology | 2 | 6.0 |
Acquired Immunodeficiency Syndrome/drug therapy/mortality | 2 | 66.0 |
CD4-Positive T-Lymphocytes/immunology/*microbiology | 6 | 85.0 |
Synovial Fluid/*cytology | 2 | 12.0 |
HIV Infections/*blood/epidemiology | 2 | 66.0 |
Antigens, CD4/analysis/genetics/*metabolism | 2 | 100.0 |
HIV Envelope Protein gp41/*genetics | 4 | 100.0 |
*T-Lymphocytes/immunology | 4 | 57.0 |
Viruses/immunology | 2 | 40.0 |
Disulfides/analysis | 2 | 11.0 |
DNA/genetics/isolation & purification | 2 | 0.0 |
Complement Pathway, Alternative | 2 | 1.0 |
Glycoproteins/metabolism | 3 | 1.0 |
Receptors, Complement 3d/*metabolism | 2 | 10.0 |
Dinoprostone/blood | 2 | 28.0 |
Macrophage-1 Antigen/*immunology | 2 | 18.0 |
Pneumonia, Pneumocystis/complications/*prevention & control | 4 | 100.0 |
Synovial Fluid/cytology/*immunology | 4 | 28.0 |
HIV Infections/*immunology/microbiology | 2 | 66.0 |
HIV-1/*physiology/ultrastructure | 3 | 60.0 |
Silver Staining | 2 | 2.0 |
Skin/*microbiology | 2 | 33.0 |
Immunoglobulin A/analysis/immunology | 2 | 66.0 |
Lung Diseases/*immunology | 4 | 33.0 |
Receptors, CCR5/blood | 2 | 66.0 |
Protein-Tyrosine Kinase/analysis | 2 | 8.0 |
*T-Lymphocytes, Suppressor-Effector | 6 | 75.0 |
Thymus Gland/*embryology | 3 | 75.0 |
Complement/metabolism/*physiology | 2 | 50.0 |
HIV Antibodies/*physiology | 3 | 75.0 |
Immunoglobulin Constant Region/analysis | 2 | 66.0 |
Receptors, Complement/analysis | 6 | 11.0 |
Neutrophils/*physiology | 2 | 1.0 |
HIV Envelope Protein gp120/drug effects/metabolism | 2 | 33.0 |
Zalcitabine/pharmacology | 2 | 66.0 |
Graft vs Host Disease/*pathology | 3 | 50.0 |
*Bronchial Provocation Tests | 2 | 18.0 |
Polysaccharides/pharmacology | 2 | 13.0 |
AIDS-Related Complex/epidemiology/immunology | 2 | 100.0 |
AIDS-Related Complex/immunology/*therapy | 2 | 40.0 |
HIV/*immunology/physiology | 2 | 50.0 |
Opsonins/immunology | 2 | 10.0 |
RNA/analysis | 7 | 3.0 |
Membrane Glycoproteins/chemistry/immunology | 2 | 50.0 |
Viral Envelope Proteins/chemistry/*immunology | 2 | 66.0 |
Protein Kinase C/antagonists & inhibitors/metabolism | 3 | 3.0 |
T-Lymphocytes/immunology/metabolism/*microbiology | 5 | 100.0 |
*Gene Rearrangement | 3 | 1.0 |
Leukemia, Myeloid, Chronic/genetics/*pathology | 2 | 15.0 |
Leukemia, Myeloid, Philadelphia-Negative/*pathology | 2 | 66.0 |
HTLV-I Infections/complications/*immunology | 2 | 100.0 |
Substance Abuse, Intravenous/complications/*immunology | 2 | 100.0 |
Receptors, Fc | 2 | 13.0 |
Antisense Elements (Genetics) | 2 | 3.0 |
Lymphoid Tissue/*pathology | 2 | 14.0 |
Monocytes/cytology/*microbiology | 2 | 50.0 |
Azides/pharmacology | 2 | 8.0 |
Calcium/*pharmacology | 2 | 2.0 |
Mouth Mucosa/cytology/*immunology | 2 | 40.0 |
Autoimmune Diseases/therapy | 2 | 20.0 |
Sarcoma, Kaposi/immunology/*therapy | 2 | 100.0 |
Antibodies, Monoclonal/analysis/immunology | 3 | 23.0 |
DNA/analysis/genetics | 2 | 1.0 |
AIDS-Related Complex/*drug therapy | 9 | 56.0 |
Antigens, Differentiation, T-Lymphocyte/*analysis/genetics | 4 | 40.0 |
*Genes, Homeobox | 2 | 0.0 |
Hematopoietic Stem Cells/physiology | 2 | 4.0 |
Histoplasmosis/complications | 2 | 100.0 |
Immunologic Deficiency Syndromes/complications | 2 | 28.0 |
Opportunistic Infections/*complications | 5 | 100.0 |
Pneumonia, Pneumocystis/drug therapy/*immunology | 2 | 100.0 |
Leukemia, Lymphocytic, Acute/diagnosis/*immunology/pathology | 2 | 100.0 |
Lipid Peroxidation/drug effects | 3 | 5.0 |
*Fetal Tissue Transplantation | 2 | 8.0 |
Brucella abortus/*immunology | 3 | 60.0 |
Mexico | 2 | 2.0 |
Neoplasms/*complications | 2 | 5.0 |
Hepatitis, Chronic/*drug therapy/immunology | 2 | 100.0 |
Immunoglobulin G/genetics/immunology | 2 | 50.0 |
Hemophilia A/blood/*complications/immunology | 2 | 66.0 |
Hemoglobins/drug effects | 3 | 20.0 |
Enzyme Inhibitors/therapeutic use | 3 | 4.0 |
Vaccines, Conjugate/administration & dosage | 2 | 66.0 |
HLA-D Antigens/metabolism | 6 | 33.0 |
Celiac Disease/*immunology/pathology | 2 | 50.0 |
*Flow Cytometry/instrumentation | 2 | 100.0 |
Antigens, Differentiation, T-Lymphocyte/*physiology | 32 | 21.0 |
Cryptosporidiosis/complications | 3 | 100.0 |
Exotoxins/*toxicity | 2 | 33.0 |
Bronchoalveolar Lavage Fluid/*pathology | 9 | 81.0 |
Pleura | 2 | 66.0 |
Aerospace Medicine | 2 | 8.0 |
Protein-Tyrosine-Phosphatase/metabolism | 2 | 1.0 |
Antibodies, Monoclonal/pharmacology/*therapeutic use | 3 | 27.0 |
Psoriasis/*therapy | 2 | 28.0 |
Nuclear Proteins/analysis | 2 | 1.0 |
Lung Diseases/*pathology | 2 | 25.0 |
Monocytes/immunology/*pathology/physiology | 2 | 100.0 |
Friend murine leukemia virus | 2 | 28.0 |
Axilla | 2 | 3.0 |
Leucine/analogs & derivatives/pharmacology | 2 | 11.0 |
Antigens, Differentiation/*analysis/physiology | 2 | 66.0 |
*Tyrosine | 2 | 4.0 |
Calcitriol/blood | 3 | 6.0 |
Colonic Neoplasms/*immunology/pathology | 2 | 22.0 |
Leukemia, T-Cell, Acute/immunology | 2 | 16.0 |
*Adhesins, Bacterial | 2 | 11.0 |
Bacterial Proteins/*toxicity | 2 | 40.0 |
Receptors, Very Late Antigen/*physiology | 3 | 25.0 |
Human T-lymphotropic virus 2/isolation & purification | 3 | 100.0 |
HIV/immunology/*metabolism | 3 | 75.0 |
Picibanil/*therapeutic use | 2 | 13.0 |
HIV Seropositivity/*transmission | 2 | 40.0 |
Antigens, CD30 | 9 | 32.0 |
C-Reactive Protein/*analysis | 2 | 0.0 |
Bronchi/immunology | 2 | 20.0 |
Kidney Tubules/pathology | 2 | 18.0 |
Arthritis, Rheumatoid/immunology/pathology | 2 | 22.0 |
Carcinoma/*immunology | 3 | 10.0 |
Spinal Cord/pathology | 2 | 2.0 |
Herpesviridae Infections/*drug therapy | 2 | 50.0 |
Hepatitis B/*complications/immunology | 2 | 40.0 |
Lymphatic Diseases/genetics/*pathology | 2 | 66.0 |
*Bacterial Physiology | 2 | 50.0 |
Paraparesis, Tropical Spastic/*pathology | 2 | 66.0 |
Endocardium/pathology | 2 | 22.0 |
Membrane Glycoproteins/genetics | 3 | 1.0 |
Nelfinavir/adverse effects/*therapeutic use | 4 | 100.0 |
Muromonab-CD3/metabolism | 2 | 66.0 |
Protein-Tyrosine Kinase/antagonists & inhibitors/physiology | 2 | 15.0 |
Blood Cells/*cytology/immunology | 2 | 40.0 |
Receptors, Interleukin-6 | 2 | 2.0 |
Uremia/*immunology | 3 | 60.0 |
Immunoglobulins, kappa-Chain/genetics | 3 | 9.0 |
Immunologic Capping/*physiology | 2 | 66.0 |
Protein-Tyrosine Kinase/*analysis | 2 | 6.0 |
Opportunistic Infections/complications/*immunology | 2 | 100.0 |
Sarcoma, Kaposi/complications/*immunology | 2 | 66.0 |
Graft vs Host Reaction/immunology | 2 | 40.0 |
Rhodamines/metabolism | 2 | 9.0 |
HIV Envelope Protein gp41/analysis | 2 | 66.0 |
Graft vs Host Reaction | 2 | 18.0 |
Antigens, CD15/*biosynthesis | 2 | 40.0 |
Hepatitis, Chronic/immunology/*therapy | 2 | 66.0 |
AIDS-Related Complex/blood | 3 | 42.0 |
Antigens, Differentiation, Myelomonocytic/biosynthesis | 2 | 4.0 |
Lymphoma, Large-Cell/*immunology | 2 | 40.0 |
Antiviral Agents/immunology | 3 | 75.0 |
Suppressor Factors, Immunologic/*immunology | 2 | 66.0 |
Trypanosoma cruzi/*immunology | 2 | 9.0 |
Eye Proteins/*immunology | 2 | 33.0 |
Receptors, Virus/immunology/*metabolism | 3 | 50.0 |
Leukemia, T-Cell, Chronic/*immunology | 2 | 40.0 |
Acquired Immunodeficiency Syndrome/*complications/*mortality | 2 | 100.0 |
Receptors, Antigen, T-Cell/*genetics/immunology | 3 | 33.0 |
*Transplantation, Heterologous | 3 | 4.0 |
Receptors, Fc/physiology | 2 | 8.0 |
Antigens, Neoplasm/*biosynthesis | 2 | 6.0 |
Tumor Cells, Cultured/microbiology | 2 | 50.0 |
Human T-lymphotropic virus 1/genetics | 2 | 13.0 |
Receptors, Fc/*immunology | 3 | 9.0 |
Mouth Diseases/*pathology | 2 | 20.0 |
Multiple Sclerosis/*immunology/*pathology | 2 | 33.0 |
Leukocytes/cytology/*immunology | 3 | 50.0 |
HIV Infections/drug therapy/*immunology/*mortality | 2 | 100.0 |
RNA/metabolism | 3 | 0.0 |
Antigenic Modulation | 4 | 50.0 |
Immunoglobulin Joining Region/genetics | 2 | 9.0 |
Lymphoma, Non-Hodgkin/*genetics/pathology | 2 | 14.0 |
Plasma Cells/*pathology | 2 | 10.0 |
Receptors, Tumor Necrosis Factor | 4 | 1.0 |
Antigens, CD27 | 7 | 16.0 |
Cyclic AMP/biosynthesis | 2 | 1.0 |
Fibronectins/*chemistry | 2 | 33.0 |
Leukemia, Myeloid, Philadelphia-Positive/genetics/immunology/*pathology | 2 | 100.0 |
Tumor Cells, Cultured/pathology | 2 | 3.0 |
Keratinocytes/*immunology | 2 | 11.0 |
Lichen Planus/*immunology/pathology | 3 | 75.0 |
Microcirculation/pathology | 2 | 2.0 |
*Cardiac Surgical Procedures | 2 | 4.0 |
Syphilis Serodiagnosis | 2 | 66.0 |
HIV-1/genetics/*physiology/ultrastructure | 2 | 66.0 |
Leukocytes/microbiology | 2 | 66.0 |
HIV Infections/immunology/transmission | 2 | 66.0 |
*Cloning, Molecular | 5 | 1.0 |
Protein Precursors/biosynthesis | 2 | 9.0 |
HIV Infections/*drug therapy/immunology/microbiology | 3 | 100.0 |
Zidovudine/*pharmacology/*therapeutic use | 2 | 100.0 |
Pancreatic Neoplasms/immunology | 2 | 28.0 |
Acquired Immunodeficiency Syndrome/*epidemiology/etiology | 2 | 100.0 |
Antigens, Neoplasm/*metabolism | 2 | 2.0 |
Prostaglandin-Endoperoxide Synthase/metabolism | 2 | 2.0 |
Gangliosides/*pharmacology | 5 | 38.0 |
Myeloid Cells/*immunology | 3 | 30.0 |
Antiviral Agents/adverse effects | 2 | 100.0 |
Peptides/chemical synthesis/chemistry/immunology | 2 | 40.0 |
Amphotericin B/administration & dosage/therapeutic use | 2 | 100.0 |
T-Lymphocyte Subsets/*immunology/microbiology | 3 | 60.0 |
T-Lymphocytes, Helper-Inducer/*drug effects | 2 | 28.0 |
Placenta/*microbiology | 2 | 100.0 |
Trophoblasts/microbiology | 2 | 100.0 |
Acquired Immunodeficiency Syndrome/*drug therapy/*mortality | 2 | 100.0 |
Lung Transplantation/*immunology/pathology | 2 | 33.0 |
Antibodies, Viral/*analysis | 9 | 14.0 |
Colchicine/pharmacology | 2 | 3.0 |
Cytochalasins/pharmacology | 4 | 40.0 |
Monensin/pharmacology | 3 | 5.0 |
Phorbol 12,13-Dibutyrate/*pharmacology | 3 | 17.0 |
HIV Infections/pathology | 3 | 60.0 |
Mannose-Binding Lectins | 3 | 6.0 |
Giant Cells/drug effects/microbiology | 2 | 100.0 |
Recombinant Proteins/genetics | 2 | 1.0 |
Sulfates/*pharmacology | 2 | 33.0 |
Synovial Membrane/*pathology | 2 | 10.0 |
Xerostomia/complications/physiopathology | 2 | 100.0 |
Immunoglobulin Variable Region/physiology | 2 | 100.0 |
Leukemia-Lymphoma, T-Cell, Acute, HTLV-I-Associated/pathology | 2 | 100.0 |
Luminescent Measurements | 2 | 2.0 |
Leukocyte Count/*instrumentation | 2 | 40.0 |
Interferon Alfa-2a/therapeutic use | 2 | 28.0 |
*Immunoglobulin Idiotypes | 3 | 75.0 |
Receptors, Virus/*immunology | 8 | 72.0 |
Opportunistic Infections/complications/*prevention & control | 5 | 100.0 |
*Chromosomes, Human, Pair 11 | 3 | 0.0 |
Recombinant Proteins/*pharmacology | 10 | 11.0 |
Pertussis Toxin/pharmacology | 2 | 3.0 |
*Sulfones | 2 | 20.0 |
Oxidants/metabolism | 2 | 11.0 |
*Oxidative Stress | 3 | 1.0 |
Stem Cell Transplantation/*methods | 2 | 11.0 |
Korea | 3 | 1.0 |
Acquired Immunodeficiency Syndrome/*epidemiology/transmission | 2 | 50.0 |
HLA-DR1 Antigen/chemistry/*immunology | 2 | 66.0 |
Lymphokines/*genetics | 4 | 1.0 |
Receptors, Interleukin-2/biosynthesis/drug effects | 2 | 40.0 |
Transcription, Genetic/*drug effects | 3 | 0.0 |
Proviruses/immunology | 2 | 100.0 |
HLA-D Antigens/genetics | 2 | 5.0 |
*Patient Education | 4 | 10.0 |
T-Lymphocytes/*drug effects/immunology/ultrastructure | 2 | 100.0 |
Dacarbazine/administration & dosage/*therapeutic use | 2 | 100.0 |
Arthritis, Rheumatoid/blood/*drug therapy/immunology | 2 | 40.0 |
Interleukin-2/administration & dosage/adverse effects/*therapeutic use | 2 | 40.0 |
Endoplasmic Reticulum/*immunology | 2 | 66.0 |
Antigens, CD4/*administration & dosage | 3 | 75.0 |
Semen/*physiology | 2 | 20.0 |
Macrophages, Alveolar/*microbiology | 2 | 100.0 |
Acquired Immunodeficiency Syndrome/*genetics | 2 | 16.0 |
Receptors, Complement/*analysis | 3 | 3.0 |
Membrane Proteins/isolation & purification/*metabolism | 2 | 16.0 |
T-Lymphocytes, Helper-Inducer/metabolism/*microbiology | 2 | 100.0 |
Histocompatibility Antigens/immunology | 4 | 23.0 |
Psoriasis/immunology/*therapy | 2 | 40.0 |
Melanoma/*immunology/pathology | 2 | 8.0 |
Antibody-Producing Cells/*immunology | 3 | 18.0 |
Peyer's Patches/immunology | 3 | 33.0 |
Opportunistic Infections/complications/*microbiology | 2 | 100.0 |
Interferon-gamma, Recombinant/*immunology | 2 | 33.0 |
Cimetidine/*pharmacology | 3 | 20.0 |
T-Lymphocyte Subsets/drug effects/*physiology | 3 | 75.0 |
Leukemia, Lymphocytic, Acute/*complications/drug therapy/surgery/*therapy | 2 | 100.0 |
Arthritis, Infectious/*immunology | 4 | 80.0 |
HTLV-I Antibodies/*immunology | 2 | 100.0 |
Melanoma/*complications/pathology | 2 | 50.0 |
Sarcoma, Kaposi/complications/pathology | 2 | 66.0 |
Skin Neoplasms/*complications/pathology | 3 | 60.0 |
Blood Glucose/*metabolism | 2 | 0.0 |
C-Peptide/*blood | 2 | 5.0 |
Diabetes Mellitus, Type 1/*drug therapy/immunology | 2 | 100.0 |
Hemoglobin A, Glycosylated/*analysis | 2 | 0.0 |
Insulin/*therapeutic use | 2 | 2.0 |
*Insulin Infusion Systems | 2 | 4.0 |
HIV Infections/complications/*immunology/virology | 2 | 100.0 |
Thymus Gland/physiology | 2 | 20.0 |
Vitiligo/*pathology | 2 | 66.0 |
Oligonucleotides/chemistry | 3 | 2.0 |
Breast Neoplasms/immunology/pathology/therapy | 2 | 100.0 |
Killer Cells, Lymphokine-Activated/immunology/*transplantation | 2 | 100.0 |
Thymidine Kinase/metabolism | 2 | 6.0 |
Antineoplastic Agents/pharmacology | 3 | 0.0 |
Receptors, Complement/metabolism | 2 | 3.0 |
Receptors, Complement 3b | 6 | 1.0 |
Antigens, Differentiation, T-Lymphocyte/biosynthesis/immunology | 2 | 28.0 |
HLA-DR Antigens/*analysis/genetics | 2 | 8.0 |
Histocompatibility Antigens/*analysis | 14 | 28.0 |
Antigens, CD4/*blood/metabolism | 2 | 100.0 |
Herpesvirus 3, Human/*pathogenicity | 2 | 100.0 |
Tumor Cells, Cultured/drug effects/metabolism/pathology | 2 | 5.0 |
Histocompatibility Antigens Class II/chemistry/*metabolism | 2 | 33.0 |
HIV Envelope Protein gp41/chemistry/genetics/*metabolism | 2 | 100.0 |
Brain/immunology/*microbiology | 2 | 66.0 |
Autoimmune Diseases/immunology/*therapy | 3 | 25.0 |
Immunoglobulins, Surface/analysis | 6 | 12.0 |
Peroxidase/*analysis | 2 | 10.0 |
Papillomavirus | 2 | 25.0 |
Chromosomes, Human, Pair 1 | 2 | 0.0 |
HIV-1/classification/*pathogenicity/physiology | 2 | 100.0 |
Staphylococcal Protein A/metabolism | 2 | 12.0 |
Immunoglobulins, Fab | 4 | 7.0 |
Maternal-Fetal Exchange/*immunology | 2 | 11.0 |
Psoriasis/immunology | 2 | 13.0 |
Bacterial Proteins/immunology | 3 | 14.0 |
Skin Transplantation | 3 | 11.0 |
Malaria/*immunology | 4 | 20.0 |
Multiple Myeloma/*pathology | 2 | 3.0 |
Leukemia, Lymphocytic/*immunology/pathology | 2 | 18.0 |
Histocompatibility Antigens/*physiology | 5 | 41.0 |
Dimethyl Sulfoxide/*pharmacology | 2 | 8.0 |
*Alkaline Phosphatase | 2 | 66.0 |
Carotenoids/*therapeutic use | 2 | 50.0 |
DNA, Recombinant | 6 | 3.0 |
GTP-Binding Proteins/genetics | 2 | 4.0 |
Phorbol 12,13-Dibutyrate/pharmacology | 3 | 5.0 |
Antiretroviral Therapy, Highly Active/statistics & numerical data | 3 | 100.0 |
Mice, Inbred ICR | 2 | 0.0 |
*Guideline Adherence | 2 | 28.0 |
Gastritis/*pathology | 2 | 66.0 |
Immunoglobulin Idiotypes/*immunology | 6 | 15.0 |
Blood Bactericidal Activity | 2 | 2.0 |
Receptors, Immunologic/immunology/metabolism | 2 | 28.0 |
T-Lymphocytes/immunology/*metabolism/ultrastructure | 2 | 100.0 |
Placenta/cytology/*immunology | 2 | 28.0 |
Plasma/immunology | 2 | 22.0 |
Tuberculosis/*complications | 3 | 60.0 |
Hemophilia A/immunology | 3 | 37.0 |
HIV Infections/drug therapy/*mortality/transmission | 2 | 100.0 |
Protein Kinase C/*antagonists & inhibitors | 2 | 6.0 |
Glucosidases/*antagonists & inhibitors | 2 | 40.0 |
HIV-1/*drug effects/metabolism/physiology | 2 | 20.0 |
Protein Engineering | 2 | 2.0 |
Macrophages/cytology/*immunology | 2 | 11.0 |
Receptors, Fc/*analysis | 3 | 13.0 |
Radiation-Protective Agents/*pharmacology | 2 | 10.0 |
Thymus Gland/*cytology/embryology | 2 | 28.0 |
Isoantibodies/immunology | 3 | 7.0 |
CD4-Positive T-Lymphocytes/*microbiology/pathology | 2 | 100.0 |
Hemophilia A/blood/*complications | 2 | 100.0 |
Antiviral Agents | 3 | 33.0 |
Transferrin/pharmacology | 2 | 7.0 |
AIDS-Related Complex/*blood | 3 | 42.0 |
Immunotoxins/*toxicity | 2 | 15.0 |
Acquired Immunodeficiency Syndrome/metabolism/*microbiology | 2 | 66.0 |
Receptors, Virus/drug effects | 2 | 66.0 |
T-Lymphocytes/metabolism/microbiology | 2 | 33.0 |
Stomach Neoplasms/immunology/*therapy | 2 | 33.0 |
Antigens, Differentiation, T-Lymphocyte/*genetics | 5 | 9.0 |
Hepatitis B/*drug therapy/immunology | 2 | 66.0 |
Serine/physiology | 2 | 100.0 |
*Patient Acceptance of Health Care | 2 | 25.0 |
Hydrogen Bonding | 2 | 1.0 |
T-Lymphocytes, Suppressor-Effector/drug effects | 4 | 44.0 |
Leprosy/*immunology | 2 | 8.0 |
Receptors, IgE | 2 | 3.0 |
Family | 3 | 0.0 |
Prediabetic State/*immunology | 2 | 100.0 |
Histocompatibility Antigens/*analysis/immunology | 2 | 50.0 |
Antineoplastic Combined Chemotherapy Protocols/*adverse effects | 2 | 4.0 |
Cefotaxime/*analogs & derivatives/pharmacology | 2 | 100.0 |
Ovarian Neoplasms/*immunology/pathology | 2 | 25.0 |
Antigens, CD4/*immunology/*therapeutic use | 2 | 100.0 |
Immunoglobulin G/*therapeutic use | 2 | 5.0 |
Breast Neoplasms/immunology/*radiotherapy | 2 | 100.0 |
Lymphocyte Subsets/*radiation effects | 3 | 100.0 |
T-Lymphocytes/*radiation effects | 2 | 40.0 |
Thymus Gland/embryology/*immunology | 2 | 66.0 |
*Trisomy | 2 | 1.0 |
Osteoarthritis/immunology/pathology | 2 | 33.0 |
Monocytes/immunology/microbiology | 3 | 75.0 |
Receptors, Complement 3d | 7 | 5.0 |
AIDS-Related Complex/blood/*drug therapy | 3 | 100.0 |
Dermatitis/complications | 2 | 100.0 |
Drug Contamination | 3 | 12.0 |
Leucine/*analogs & derivatives/therapeutic use | 5 | 100.0 |
Acquired Immunodeficiency Syndrome/blood/complications/*immunology | 2 | 66.0 |
Zalcitabine/*administration & dosage/adverse effects/pharmacokinetics | 2 | 100.0 |
Antibodies, Helminth/immunology | 2 | 15.0 |
Neurons/*microbiology | 3 | 50.0 |
Antineoplastic Agents, Phytogenic/adverse effects/*therapeutic use | 2 | 40.0 |
Myocardium/*immunology | 2 | 11.0 |
Cytomegalovirus Infections/drug therapy/immunology | 2 | 100.0 |
Paraparesis, Tropical Spastic/*immunology | 2 | 28.0 |
Schistosoma mansoni/*immunology | 3 | 4.0 |
Schistosomiasis mansoni/*immunology | 2 | 5.0 |
Lymphocyte Subsets/cytology/*immunology | 5 | 83.0 |
Hybridomas/*immunology | 4 | 13.0 |
Immune Sera/*immunology | 3 | 13.0 |
Histocompatibility Antigens/*metabolism | 3 | 37.0 |
Bacterial Toxins/*immunology | 2 | 25.0 |
Helicobacter pylori/*immunology | 3 | 15.0 |
Hexadimethrine/pharmacology | 2 | 66.0 |
Endotoxins/pharmacology | 2 | 2.0 |
Macrophages/*physiology | 2 | 2.0 |
Platelet Membrane Glycoproteins/metabolism | 2 | 2.0 |
Opportunistic Infections/complications/*diagnosis | 2 | 100.0 |
*Antigens, CD4/genetics | 3 | 75.0 |
Epitopes/analysis/*immunology | 3 | 42.0 |
Rats, Inbred Strains/immunology | 2 | 100.0 |
Receptors, Fibronectin | 2 | 16.0 |
Gene Rearrangement/*genetics | 2 | 5.0 |
Mutagenesis, Insertional/genetics | 2 | 8.0 |
Leprosy/immunology | 3 | 50.0 |
Antibodies, Monoclonal/*administration & dosage/immunology | 2 | 25.0 |
Hemophilia A/complications/drug therapy/*immunology | 2 | 100.0 |
Cholera Toxin/pharmacology | 2 | 2.0 |
Myocardium/immunology/*pathology | 2 | 40.0 |
Liver/cytology/immunology | 2 | 22.0 |
Skin/cytology/immunology | 2 | 11.0 |
Heart Catheterization | 2 | 3.0 |
Receptors, Antigen, T-Cell/genetics/immunology | 2 | 15.0 |
Monocytes/drug effects/*microbiology | 4 | 66.0 |
Chickens/*immunology | 2 | 22.0 |
AIDS-Related Complex | 3 | 100.0 |
Neprilysin | 3 | 4.0 |
Viral Core Proteins/analysis | 17 | 77.0 |
Chloramphenicol O-Acetyltransferase/genetics/metabolism | 2 | 1.0 |
HIV-1/growth & development/*metabolism | 2 | 66.0 |
T-Lymphocytes/cytology/*immunology/ultrastructure | 2 | 66.0 |
Genes, MHC Class II/*genetics | 2 | 2.0 |
Antilymphocyte Serum | 2 | 14.0 |
Exotoxins/*immunology | 2 | 18.0 |
HIV Infections/*physiopathology/psychology | 2 | 100.0 |
Leukemia-Lymphoma, T-Cell, Acute, HTLV-I-Associated/*complications | 2 | 100.0 |
Viral Core Proteins/blood | 10 | 76.0 |
Colitis, Ulcerative/*immunology | 3 | 8.0 |
Ileum/immunology | 2 | 28.0 |
Doxorubicin/administration & dosage/adverse effects/*therapeutic use | 2 | 66.0 |
Scleroderma, Systemic/immunology/*pathology | 2 | 100.0 |
Receptors, HIV | 50 | 98.0 |
Acquired Immunodeficiency Syndrome/*drug therapy/etiology/immunology | 2 | 100.0 |
Bacterial Infections/*immunology | 2 | 6.0 |
1-Deoxynojirimycin | 2 | 25.0 |
Carbohydrates/analysis | 2 | 3.0 |
*Antigens, Differentiation, T-Lymphocyte | 20 | 62.0 |
Macrophage-1 Antigen | 5 | 10.0 |
Antigens, CD4/*antagonists & inhibitors | 3 | 100.0 |
Phosphatidylinositols/*metabolism | 2 | 2.0 |
Peptides/chemical synthesis/immunology | 3 | 6.0 |
Neuroblastoma | 2 | 1.0 |
Antilymphocyte Serum/analysis | 3 | 21.0 |
Epidermis/cytology | 2 | 5.0 |
Antigens, Differentiation, B-Lymphocyte/genetics | 2 | 8.0 |
*Genes, Structural, Viral | 2 | 15.0 |
T-Lymphocytes, Cytotoxic/*physiology | 2 | 16.0 |
Lymphoproliferative Disorders/*immunology | 3 | 21.0 |
Insulin/*immunology | 3 | 25.0 |
Hela Cells/immunology | 7 | 50.0 |
Leukocyte Count/methods | 5 | 62.0 |
Leg | 2 | 4.0 |
Body Constitution | 2 | 1.0 |
Hypoglycemic Agents/*therapeutic use | 2 | 3.0 |
*CD4 Lymphocyte Count/economics | 2 | 100.0 |
Immunity, Cellular/drug effects/*immunology | 2 | 100.0 |
HIV-1/*drug effects/enzymology/genetics/physiology | 2 | 100.0 |
Phosphoprotein Phosphatase/*metabolism | 3 | 3.0 |
Stress, Psychological | 2 | 7.0 |
Mouth Mucosa/pathology | 2 | 8.0 |
Interferon Type I/*administration & dosage/adverse effects | 2 | 100.0 |
Skin Neoplasms/immunology/*therapy | 2 | 100.0 |
Histocompatibility Antigens/physiology | 2 | 25.0 |
Herpesvirus 6, Human/*genetics | 2 | 25.0 |
Colonic Neoplasms/immunology/*therapy | 2 | 50.0 |
Antibodies, Anti-Idiotypic/analysis | 3 | 11.0 |
Opportunistic Infections/complications/prevention & control | 2 | 66.0 |
Combined Modality Therapy/adverse effects | 2 | 28.0 |
Antigens, CD4/analysis/genetics/*physiology | 2 | 100.0 |
Antigens, Differentiation, T-Lymphocyte/analysis/genetics/*physiology | 2 | 66.0 |
Minor Lymphocyte Stimulatory Antigens | 2 | 100.0 |
Antigens, Differentiation, T-Lymphocyte/genetics/*immunology | 4 | 22.0 |
Glycoproteins/genetics/*immunology | 2 | 28.0 |
Immunoglobulin E/metabolism | 2 | 9.0 |
Anemia, Aplastic/blood/*immunology | 2 | 100.0 |
T-Lymphocytes/immunology/*microbiology/ultrastructure | 2 | 100.0 |
Hematopoietic Stem Cells/drug effects | 2 | 3.0 |
Fluoresceins/diagnostic use | 2 | 16.0 |
Giant Cells/*immunology | 2 | 28.0 |
Herpesvirus 4, Human/*genetics | 3 | 4.0 |
Herpesviridae Infections/microbiology | 3 | 75.0 |
Calcitriol/*pharmacology | 7 | 3.0 |
Cyclosporins/pharmacology | 4 | 10.0 |
Protozoa/isolation & purification | 2 | 100.0 |
Stomach Neoplasms/*immunology/pathology | 2 | 33.0 |
Cyclosporins/*therapeutic use | 3 | 12.0 |
Sulfonamides/adverse effects | 2 | 66.0 |
Bacterial Proteins/pharmacology | 2 | 9.0 |
Viral Envelope Proteins/genetics/*immunology | 2 | 14.0 |
Interleukins/*blood | 2 | 8.0 |
Interferon Type I/adverse effects/*therapeutic use | 2 | 66.0 |
Acquired Immunodeficiency Syndrome/genetics/*immunology/pathology | 2 | 100.0 |
Kidney Failure, Chronic/*immunology | 2 | 14.0 |
Receptors, Interleukin-2/drug effects/metabolism | 3 | 30.0 |
Thionucleotides/*pharmacology | 2 | 11.0 |
Macrophages/immunology/*ultrastructure | 2 | 100.0 |
Catecholamines/blood | 2 | 4.0 |
Wound Healing/*immunology | 3 | 42.0 |
Hela Cells/immunology/metabolism | 2 | 66.0 |
*Diseases in Twins | 2 | 6.0 |
Wounds and Injuries/*immunology | 2 | 33.0 |
HIV-1/drug effects/*immunology/isolation & purification | 2 | 66.0 |
Lymphoma | 2 | 5.0 |
Receptors, Gastrointestinal Hormone/metabolism | 2 | 20.0 |
Receptors, Vasoactive Intestinal Peptide | 2 | 3.0 |
Inositol Phosphates/biosynthesis | 4 | 16.0 |
Deltaretrovirus Infections/*immunology | 2 | 40.0 |
Clindamycin/*therapeutic use | 2 | 66.0 |
Receptors, Interleukin-2/physiology | 5 | 10.0 |
Iodine Radioisotopes/diagnostic use | 2 | 0.0 |
Pulmonary Fibrosis/pathology | 2 | 33.0 |
T-Lymphocyte Subsets/immunology/*microbiology | 2 | 100.0 |
Dexamethasone/diagnostic use | 2 | 5.0 |
Synovial Membrane/drug effects/*pathology | 2 | 100.0 |
Alkaloids/*pharmacology | 2 | 3.0 |
Lactones/*pharmacology | 2 | 6.0 |
Receptors, HIV/biosynthesis/*drug effects | 2 | 100.0 |
Antigens, Differentiation, T-Lymphocyte/*genetics/immunology | 3 | 60.0 |
Densitometry | 2 | 1.0 |
Interferon Type I/administration & dosage | 2 | 100.0 |
Antigens, CD4/immunology/physiology | 2 | 66.0 |
Recombinant Proteins/pharmacology/therapeutic use | 2 | 5.0 |
Physical Education and Training | 2 | 8.0 |
*Fluorescent Antibody Technique | 3 | 12.0 |
Myocardial Infarction/*etiology/*prevention & control | 2 | 66.0 |
Troponin I/analysis | 2 | 66.0 |
*Preoperative Care | 2 | 10.0 |
Urine/*cytology | 2 | 22.0 |
Leukemia/*immunology | 3 | 7.0 |
Gene Products, gag/*analysis | 4 | 66.0 |
Viral Core Proteins/*analysis | 3 | 60.0 |
Neoplasms/drug therapy/*immunology | 2 | 25.0 |
Monocytes/immunology/*microbiology/physiology | 2 | 66.0 |
Mexico/ethnology | 2 | 7.0 |
Synovitis/immunology/pathology | 2 | 66.0 |
Antigens, Differentiation, B-Lymphocyte | 2 | 5.0 |
HLA-D Antigens/*physiology | 2 | 50.0 |
Antiviral Agents/administration & dosage/*pharmacology | 2 | 66.0 |
*N-Glycosyl Hydrolases | 2 | 3.0 |
Plant Proteins/administration & dosage/*pharmacology | 2 | 66.0 |
Receptors, Virus/*analysis | 2 | 18.0 |
Lectins/*immunology | 3 | 11.0 |
Interferon Alfa-2a/*pharmacology | 2 | 18.0 |
Tumor Cells, Cultured/drug effects/immunology | 3 | 27.0 |
Opportunistic Infections/complications/*epidemiology | 2 | 100.0 |
Ileum/cytology | 2 | 100.0 |
HLA-DQ Antigens/*immunology | 4 | 28.0 |
L Cells (Cell Line)/immunology | 3 | 20.0 |
Glycolipids/*physiology | 2 | 25.0 |
Receptors, Virus/drug effects/*physiology | 3 | 100.0 |
Thiocyanates | 7 | 30.0 |
Antigens, CD4/*metabolism/ultrastructure | 2 | 100.0 |
Trypsin | 3 | 1.0 |
Mannose/metabolism | 5 | 17.0 |
HIV Infections/*drug therapy/metabolism/virology | 2 | 66.0 |
Lymphoid Tissue/*metabolism/virology | 2 | 100.0 |
Stromal Cells/metabolism | 2 | 2.0 |
Antigens, Differentiation, T-Lymphocyte/analysis/*immunology | 7 | 31.0 |
Receptors, Antigen, T-Cell/analysis/*immunology | 4 | 66.0 |
Sarcoma, Kaposi/*drug therapy/etiology/immunology | 2 | 100.0 |
Physician-Patient Relations | 2 | 7.0 |
Neutrophils/*microbiology | 2 | 66.0 |
Heat-Shock Proteins/*immunology | 3 | 25.0 |
Synovial Fluid/cytology/immunology | 3 | 15.0 |
Chromatography, Affinity/methods | 2 | 2.0 |
Bacterial Toxins/*pharmacology | 2 | 6.0 |
Arizona | 2 | 6.0 |
Meningitis/complications | 2 | 50.0 |
Antigens, Differentiation, T-Lymphocyte/antagonists & inhibitors | 2 | 100.0 |
Muscles/*pathology | 2 | 8.0 |
Bleomycin/*therapeutic use | 2 | 40.0 |
Dextran Sulfate | 6 | 27.0 |
*HIV-1/drug effects/physiology | 2 | 100.0 |
DNA, Viral/*genetics/isolation & purification | 2 | 50.0 |
Interferon Type I/blood | 2 | 50.0 |
Splenic Neoplasms/genetics/*pathology | 2 | 50.0 |
Lymphocytes/immunology/microbiology | 2 | 66.0 |
Acquired Immunodeficiency Syndrome/complications/microbiology | 2 | 100.0 |
Protein Precursors/*genetics | 2 | 1.0 |
Autoantibodies/metabolism | 2 | 10.0 |
Immunoglobulins, Thyroid-Stimulating | 2 | 8.0 |
Leukocytes, Mononuclear/drug effects/*metabolism | 2 | 5.0 |
Antibodies, Monoclonal/analysis/*immunology | 2 | 16.0 |
Membrane Microdomains/*immunology | 2 | 28.0 |
Apoptosis/drug effects/physiology | 2 | 2.0 |
Cell Survival/drug effects/physiology | 2 | 2.0 |
Colitis, Ulcerative/*immunology/pathology | 2 | 14.0 |
*Intensive Care Units | 2 | 25.0 |
Multiple Trauma/*immunology | 2 | 50.0 |
Leukemia Virus, Murine/*genetics | 2 | 13.0 |
Immunoglobulins, Heavy-Chain/*therapeutic use | 2 | 100.0 |
Ribonucleosides/*therapeutic use | 3 | 42.0 |
Lymphatic Diseases/etiology | 2 | 28.0 |
Gingiva/*immunology | 3 | 37.0 |
Multiple Sclerosis/*immunology/pathology | 2 | 16.0 |
T-Lymphocytes/analysis/*immunology | 2 | 40.0 |
HIV/drug effects/*genetics | 2 | 50.0 |
Ricin/*pharmacology | 3 | 18.0 |
Ions | 2 | 2.0 |
Lymphocyte Function-Associated Antigen-1 | 17 | 22.0 |
AIDS-Related Complex/complications/immunology | 2 | 100.0 |
Indium Radioisotopes/diagnostic use | 2 | 11.0 |
Monocytes/*immunology/microbiology | 3 | 23.0 |
Opportunistic Infections | 3 | 42.0 |
HLA-DR Antigens/genetics/*immunology | 3 | 9.0 |
*Dental Implants | 2 | 25.0 |
Granuloma/etiology/*immunology/pathology | 2 | 100.0 |
Tumor Cells, Cultured/*immunology | 3 | 13.0 |
Antigens, Differentiation, T-Lymphocyte/genetics/*metabolism | 2 | 25.0 |
Receptors, Transferrin/immunology | 3 | 37.0 |
Ovary | 6 | 14.0 |
Peptide Fragments/isolation & purification | 2 | 3.0 |
Antibodies, Viral/analysis/biosynthesis | 2 | 100.0 |
Myoblasts/*immunology/transplantation | 2 | 100.0 |
Kidney/*immunology | 3 | 21.0 |
Transplants | 2 | 15.0 |
Esterases/metabolism | 2 | 10.0 |
Opportunistic Infections/epidemiology | 4 | 100.0 |
Cerebrospinal Fluid/*immunology | 2 | 40.0 |
Stomach Neoplasms/blood/*immunology/pathology | 2 | 66.0 |
Macrophages/immunology/ultrastructure | 2 | 40.0 |
Leukemia-Lymphoma, T-Cell, Acute, HTLV-I-Associated/immunology/*therapy | 2 | 100.0 |
Mycobacterium leprae/immunology | 2 | 9.0 |
Interferon Type I, Recombinant/*administration & dosage | 2 | 50.0 |
T-Lymphocytes, Suppressor-Effector/cytology/immunology | 2 | 100.0 |
HIV Antigens/metabolism | 3 | 30.0 |
Transaminases/blood | 2 | 11.0 |
Freeze Fracturing | 4 | 17.0 |
*HLA-DR Antigens | 2 | 14.0 |
Plasmodium falciparum | 2 | 5.0 |
Endothelium, Vascular/immunology/*physiology | 2 | 28.0 |
*Cytotoxicity, Immunologic/drug effects | 5 | 19.0 |
Dietary Proteins/*administration & dosage | 2 | 7.0 |
Jejunum/*immunology | 2 | 50.0 |
Escherichia coli/*genetics | 2 | 2.0 |
Antigens, Surface/*genetics | 4 | 6.0 |
Lymphoma/genetics/*immunology/pathology | 2 | 50.0 |
Interleukins/*physiology | 2 | 6.0 |
Glycoproteins/*analysis | 3 | 4.0 |
Peptide Fragments/*analysis | 2 | 4.0 |
Hyperplasia/immunology/pathology | 2 | 33.0 |
Pericardial Effusion/etiology | 2 | 66.0 |
Receptors, Leukocyte-Adhesion/*physiology | 2 | 16.0 |
Dysgerminoma/complications | 2 | 100.0 |
Hemangiosarcoma/complications | 2 | 100.0 |
AIDS-Related Complex/*drug therapy/mortality | 2 | 100.0 |
HIV/*pathogenicity/physiology | 2 | 100.0 |
*Neovascularization, Pathologic | 2 | 0.0 |
Sus scrofa | 2 | 18.0 |
Immunity/drug effects | 3 | 23.0 |
Remission Induction/methods | 2 | 8.0 |
Salvage Therapy/methods | 2 | 50.0 |
Lymphocytes/analysis | 2 | 13.0 |
Brain Neoplasms | 2 | 14.0 |
Granuloma/*immunology | 2 | 18.0 |
Hypersensitivity, Immediate/immunology/pathology | 2 | 100.0 |
HLA-DR Antigens/analysis/*immunology | 2 | 18.0 |
Complement 3b/metabolism | 2 | 1.0 |
Diagnosis, Computer-Assisted | 2 | 13.0 |
Antigens, Neoplasm/genetics/immunology/metabolism | 2 | 100.0 |
Receptors, Leukocyte-Adhesion/*immunology | 3 | 37.0 |
Growth Substances/pharmacology | 4 | 2.0 |
T-Lymphocytes, Suppressor-Effector/immunology/pathology | 2 | 66.0 |
Chemistry | 3 | 1.0 |
T-Lymphocytes, Helper-Inducer/analysis/*immunology | 2 | 100.0 |
Retroviridae Proteins/*immunology | 3 | 50.0 |
HIV/immunology/*metabolism/ultrastructure | 2 | 100.0 |
Neoplasms/immunology/pathology/*therapy | 2 | 40.0 |
Receptors, HIV/*ultrastructure | 2 | 100.0 |
*Genes, Structural | 3 | 0.0 |
Zinc/*pharmacology | 2 | 6.0 |
Hodgkin Disease/immunology/*pathology | 2 | 20.0 |
Epithelium/analysis/immunology | 2 | 50.0 |
T-Lymphocytes/*analysis | 7 | 50.0 |
B-Lymphocytes/analysis | 2 | 15.0 |
Lymphocytes/*analysis | 2 | 28.0 |
T-Lymphocytes, Helper-Inducer/analysis | 4 | 66.0 |
T-Lymphocytes, Suppressor-Effector/analysis | 3 | 100.0 |
Antigens, Surface/*immunology/isolation & purification | 2 | 25.0 |
Pentamidine/*administration & dosage/therapeutic use | 2 | 66.0 |
Lymphoid Tissue/pathology | 3 | 33.0 |
Brain/*microbiology | 2 | 33.0 |
Acetone | 2 | 40.0 |
*Piperidines | 2 | 40.0 |
Government Programs | 2 | 33.0 |
Leukocytes, Mononuclear/*drug effects/immunology | 2 | 13.0 |
Polytetrafluoroethylene | 2 | 6.0 |
Retroviridae Proteins/analysis | 7 | 58.0 |
HIV/*analysis | 5 | 83.0 |
T-Lymphocytes, Suppressor-Effector/classification/*immunology | 4 | 80.0 |
Protein-Tyrosine-Phosphatase | 3 | 17.0 |
Intestine, Small/pathology | 2 | 11.0 |
Cytoplasm/analysis | 2 | 9.0 |
Viral Envelope Proteins/*analysis/genetics | 2 | 50.0 |
Colon/*immunology | 3 | 13.0 |
Colony-Stimulating Factors/genetics | 2 | 33.0 |
Growth Substances/genetics | 2 | 3.0 |
Receptors, Virus/genetics/immunology/*metabolism | 2 | 40.0 |
Retroviridae Proteins/immunology/*metabolism | 2 | 100.0 |
Dextrans/*pharmacology | 3 | 25.0 |
IgG Deficiency | 3 | 42.0 |
Lymphocytes/classification/immunology | 6 | 50.0 |
Antigens, Differentiation, T-Lymphocyte/*analysis/*physiology | 2 | 50.0 |
T-Lymphocytes/*classification/immunology | 19 | 67.0 |
Lymphoma/diagnosis/immunology/*pathology | 2 | 66.0 |
*Histocompatibility Antigens | 2 | 2.0 |
Sarcoma, Kaposi/immunology | 3 | 37.0 |
Acquired Immunodeficiency Syndrome/*immunology/microbiology | 2 | 40.0 |
T-Lymphocytes/classification/*pathology | 2 | 66.0 |
Clone Cells/classification/immunology | 2 | 28.0 |
Leukemia, Erythroblastic, Acute/immunology | 2 | 25.0 |
Lymphocytes/analysis/*classification | 2 | 100.0 |
Carcinoma, Squamous Cell/*immunology/metabolism/pathology | 2 | 100.0 |
Viral Envelope Proteins/*pharmacology | 2 | 40.0 |
Flow Cytometry/standards | 2 | 33.0 |
Lymphocytes/*classification | 11 | 64.0 |
Antibodies, Monoclonal/physiology | 11 | 15.0 |
Ethers/pharmacology | 4 | 21.0 |
T-Lymphocytes/classification/immunology/*metabolism | 2 | 33.0 |
*Antigens, Differentiation, T-Lymphocyte/analysis | 4 | 80.0 |
*Receptors, Antigen, T-Cell/analysis | 2 | 100.0 |
Receptors, Antigen, T-Cell/analysis/*genetics | 2 | 100.0 |
Influenza A virus/immunology | 2 | 15.0 |
Killer Cells, Natural/*classification/immunology/ultrastructure | 2 | 100.0 |
T-Lymphocytes/classification | 17 | 51.0 |
Retroviridae Proteins/metabolism | 10 | 76.0 |
Complement 1/metabolism | 2 | 5.0 |
Complement 1q | 2 | 1.0 |
Complement Activating Enzymes/metabolism | 2 | 7.0 |
T-Lymphocytes/*analysis/classification/immunology | 2 | 66.0 |
Peptide Fragments/*therapeutic use | 2 | 11.0 |
Graft vs Host Disease/etiology | 2 | 3.0 |
T-Lymphocytes/*classification/immunology/metabolism | 2 | 50.0 |
Antibodies, Anti-Idiotypic | 2 | 9.0 |
Retroviridae Proteins/metabolism/*pharmacology | 2 | 100.0 |
Cyclosporins/*pharmacology | 2 | 5.0 |
*T-Lymphocytes/classification/immunology | 2 | 100.0 |
Viral Envelope Proteins/genetics/*physiology | 2 | 22.0 |
*Histocompatibility Antigens Class I | 2 | 18.0 |
Staphylococcal Protein A | 2 | 13.0 |
T-Lymphocytes, Helper-Inducer/*classification | 4 | 100.0 |
T-Lymphocytes, Suppressor-Effector/*classification | 2 | 66.0 |
T-Lymphocytes, Helper-Inducer/classification | 4 | 100.0 |
T-Lymphocytes, Suppressor-Effector/classification/immunology | 2 | 66.0 |
T-Lymphocytes/classification/cytology/*immunology | 2 | 25.0 |
Kidney Glomerulus/*immunology | 2 | 8.0 |
*Phytohemagglutinins | 2 | 50.0 |
T-Lymphocytes/analysis/immunology/*metabolism | 2 | 100.0 |
Pneumonia/*immunology | 2 | 40.0 |
Retroviridae Proteins/*immunology/metabolism | 3 | 100.0 |
Acquired Immunodeficiency Syndrome/*immunology/metabolism | 3 | 75.0 |
Receptors, Virus | 3 | 25.0 |
Immunotoxins/pharmacology | 2 | 16.0 |
Retroviridae/physiology | 2 | 33.0 |
Retroviridae Proteins/*analysis | 2 | 100.0 |
Zalcitabine | 2 | 33.0 |
*Antigens, Differentiation, T-Lymphocyte/immunology | 2 | 33.0 |
T-Lymphocytes, Helper-Inducer/*immunology/physiology | 2 | 100.0 |
Anti-Retroviral Agents/economics | 2 | 100.0 |
HIV Infections/*diagnosis/drug therapy/economics/transmission | 2 | 100.0 |
Mass Screening/*economics | 2 | 66.0 |
Immune System/*cytology/growth & development | 2 | 100.0 |
Coronary Artery Bypass | 2 | 3.0 |
Guideline Adherence | 2 | 22.0 |
Immunomagnetic Separation/methods | 2 | 18.0 |
Tumor Necrosis Factor-alpha/adverse effects/*therapeutic use | 2 | 22.0 |
HIV/isolation & purification/physiology | 2 | 100.0 |
T-Lymphocytes/immunology/*ultrastructure | 2 | 100.0 |
CD4 Lymphocyte Count/statistics & numerical data | 5 | 100.0 |
*Likelihood Functions | 2 | 50.0 |
HIV Infections/diagnosis/epidemiology/*immunology | 2 | 100.0 |
Lymphocytes, Null/immunology | 2 | 100.0 |
AIDS-Related Complex/*therapy | 2 | 40.0 |
Retroviridae Proteins/*pharmacology | 3 | 60.0 |
Lymphocytes/*classification/pathology | 2 | 100.0 |
T-Lymphocytes, Suppressor-Effector/classification | 3 | 100.0 |
Immune System/immunology | 2 | 25.0 |
T-Lymphocytes/analysis/*classification | 2 | 100.0 |
T-Lymphocytes/analysis | 3 | 13.0 |
T-Lymphocytes/analysis/classification | 2 | 66.0 |
Microtomy | 2 | 13.0 |
T-Lymphocytes, Helper-Inducer/*microbiology | 2 | 66.0 |
Receptors, Virus/analysis | 2 | 28.0 |
Oligosaccharides/analysis | 2 | 8.0 |
Retroviridae Proteins/*physiology | 2 | 66.0 |
Viral Envelope Proteins/*physiology | 2 | 11.0 |
IgA Deficiency | 2 | 28.0 |
Immunosuppressive Agents/physiology | 2 | 28.0 |
T-Lymphocytes, Helper-Inducer/*classification/immunology | 2 | 100.0 |
Oxazines/administration & dosage | 2 | 100.0 |
Antiretroviral Therapy, Highly Active/*statistics & numerical data | 2 | 100.0 |
Membrane Proteins/immunology/*metabolism | 2 | 7.0 |
Gamma-Globulins/therapeutic use | 2 | 33.0 |
Hippocampus/cytology | 2 | 5.0 |
Zidovudine | 8 | 80.0 |
Antigens/analysis | 2 | 1.0 |
Microsomes/*immunology | 2 | 13.0 |
Colony-Stimulating Factors/biosynthesis | 2 | 28.0 |
Retroviridae Proteins/genetics/immunology/*metabolism | 2 | 66.0 |
Inositol 1,4,5-Trisphosphate | 2 | 11.0 |
T-Lymphocytes/microbiology/*physiology | 3 | 60.0 |
Antilymphocyte Serum/*pharmacology | 2 | 22.0 |
*T-Lymphocytes/classification | 2 | 100.0 |
T-Lymphocytes, Helper-Inducer/classification/*immunology | 2 | 33.0 |
Phosphoserine/metabolism | 2 | 2.0 |
Chemokines, CXC/biosynthesis/physiology | 2 | 100.0 |
Erythroid Progenitor Cells/immunology | 2 | 33.0 |
Deltaretrovirus/*physiology | 2 | 100.0 |
Hybrid Cells/*immunology | 3 | 23.0 |
Interferon Type I/pharmacology | 2 | 4.0 |
Antibodies, Monoclonal/*administration & dosage/physiology | 2 | 100.0 |
Immunologic Deficiency Syndromes/immunology | 3 | 17.0 |
5'-Nucleotidase | 3 | 13.0 |
Nucleotidases/*deficiency | 2 | 50.0 |
Peptides/chemistry/metabolism | 3 | 6.0 |
Monophenol Monooxygenase/metabolism | 2 | 10.0 |
Antibodies, Neoplasm/immunology | 2 | 5.0 |
Retroviridae Proteins/physiology | 2 | 100.0 |
T-Lymphocytes, Suppressor-Effector/analysis/*immunology | 2 | 100.0 |
Antibodies, Monoclonal/*physiology | 2 | 5.0 |
T-Lymphocytes, Cytotoxic/analysis | 3 | 100.0 |
Diglycerides/*pharmacology | 2 | 15.0 |
Receptors, Cyclic AMP/metabolism | 2 | 66.0 |
Recombinant Fusion Proteins/metabolism/*pharmacology | 4 | 44.0 |
Neoplasms, Multiple Primary/*pathology | 2 | 12.0 |
HLA-B Antigens | 2 | 0.0 |
T-Lymphocytes/classification/pathology | 2 | 50.0 |
T-Lymphocyte Subsets/*immunology/*metabolism | 2 | 7.0 |
Lectins, C-Type/*immunology | 2 | 33.0 |
Bacterial Vaccines | 2 | 40.0 |
T-Lymphocytes/*classification/pathology | 2 | 100.0 |
DNA Restriction Enzymes | 6 | 1.0 |
HIV/genetics/immunology/physiology | 2 | 100.0 |
HIV Infections/complications/*drug therapy/immunology/*virology | 2 | 100.0 |
Antigens, CD56/*biosynthesis | 2 | 22.0 |
*Ploidies | 2 | 2.0 |
Deoxycytidine/*analogs & derivatives/pharmacology | 2 | 8.0 |
Thymidine/*analogs & derivatives/pharmacology | 2 | 66.0 |
Hospitals, Public/statistics & numerical data | 2 | 100.0 |
Substance-Related Disorders/blood/*complications | 2 | 100.0 |
Pulsatile Flow | 2 | 4.0 |
Killer Cells, Natural/*classification/immunology | 2 | 66.0 |
*Algorithms | 2 | 3.0 |
Myositis/*immunology | 3 | 42.0 |
HIV/*growth & development/immunology | 2 | 100.0 |
Chromatography, High Pressure Liquid/methods | 2 | 1.0 |
Macrophage Inflammatory Protein-1/analysis | 2 | 33.0 |
Growth Substances/biosynthesis | 2 | 10.0 |
CD8-Positive T-Lymphocytes/drug effects/physiology | 2 | 66.0 |
Mitosis/physiology | 3 | 3.0 |
Central Nervous System/pathology | 2 | 9.0 |
Lymphoma, AIDS-Related/*drug therapy/immunology/mortality | 2 | 100.0 |
Sulfates/*metabolism | 2 | 6.0 |
Cysteine Endopeptidases/metabolism | 2 | 0.0 |
Ubiquitin/metabolism | 2 | 0.0 |
T-Lymphocytes/cytology/*drug effects/immunology | 2 | 28.0 |
Stomach Neoplasms/*immunology/*surgery | 2 | 100.0 |
Indinavir/blood/*therapeutic use | 2 | 66.0 |
Hepatitis, Viral, Human/*complications | 2 | 50.0 |
Cervical Intraepithelial Neoplasia/epidemiology/virology | 2 | 100.0 |
Radiotherapy | 2 | 6.0 |
HIV Infections/*complications/*drug therapy/immunology/virology | 3 | 100.0 |
Eosinophils/metabolism | 2 | 7.0 |
Heart-Assist Devices/*adverse effects | 2 | 40.0 |
HIV Protease Inhibitors/adverse effects | 2 | 66.0 |
Transforming Growth Factor beta/secretion | 2 | 25.0 |
T-Lymphocyte Subsets/*cytology/*immunology/metabolism | 3 | 25.0 |
HIV Infections/*drug therapy/metabolism/radiography | 2 | 100.0 |
Coronary Angiography | 4 | 1.0 |
Herpesvirus 6, Human | 2 | 100.0 |
Saquinavir/*administration & dosage | 3 | 100.0 |
*Linear Models | 2 | 50.0 |
Lymphocytes/radiation effects | 2 | 18.0 |
Mycobacterium tuberculosis/immunology/*physiology | 2 | 100.0 |
Gingivitis/pathology | 2 | 50.0 |
Lectins, C-Type/metabolism | 2 | 13.0 |
Antigens, CD3/immunology/*metabolism | 2 | 66.0 |
Receptors, CCR5/chemistry/*genetics | 2 | 66.0 |
Interferon Type II/antagonists & inhibitors/secretion | 2 | 100.0 |
Tumor Necrosis Factor-alpha/antagonists & inhibitors/secretion | 2 | 15.0 |
T-Lymphocyte Subsets/*immunology/transplantation | 2 | 66.0 |
Immunoglobulin G/administration & dosage | 2 | 16.0 |
Epidemiologic Studies | 2 | 4.0 |
CD4-Positive T-Lymphocytes/*chemistry/*cytology | 2 | 100.0 |
Mouth Diseases/*epidemiology/immunology | 2 | 100.0 |
Clonal Deletion/*physiology | 2 | 66.0 |
Viral Envelope Proteins/chemistry/*metabolism | 2 | 40.0 |
Antibodies/blood/immunology | 2 | 20.0 |
Infant Food | 2 | 8.0 |
Tablets | 2 | 5.0 |
*Health Care Costs | 2 | 33.0 |
Nelfinavir/administration & dosage/adverse effects/therapeutic use | 2 | 100.0 |
Indinavir/*administration & dosage/adverse effects/*therapeutic use | 2 | 100.0 |
Ritonavir/*administration & dosage/adverse effects/*therapeutic use | 2 | 100.0 |
Interleukin-10/biosynthesis/genetics | 2 | 13.0 |
Gene Expression Regulation/physiology | 2 | 0.0 |
*Outcome and Process Assessment (Health Care) | 3 | 33.0 |
*Renal Dialysis/standards/statistics & numerical data | 3 | 100.0 |
Nutritional Requirements | 2 | 6.0 |
Tuberculosis, Pulmonary/immunology/prevention & control | 2 | 100.0 |
beta 2-Microglobulin/*blood | 2 | 20.0 |
Probiotics/*administration & dosage | 2 | 25.0 |
HIV Infections/drug therapy/immunology/*metabolism/virology | 2 | 100.0 |
Delirium/complications/*diagnosis/nursing | 2 | 50.0 |
Nursing Assessment/*methods | 2 | 33.0 |
Pain/complications/*diagnosis/nursing | 2 | 50.0 |
Postanesthesia Nursing/*methods | 2 | 50.0 |
Psychomotor Agitation/*etiology | 2 | 50.0 |
AIDS Vaccines/therapeutic use | 2 | 50.0 |
HIV-1/*classification/*genetics | 2 | 33.0 |
